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INTRODUCTION TO THE THESIS
In the Netherlands, over 100.000 people are diagnosed with cancer each year and more than 42.000 of these 
patients succumb to this disease as shown by the data of the Dutch cancer registry over 20141. The mainstay of 
treatment for most types of advanced cancer remains cytoreductive surgery, often combined with chemotherapy 
and radiation therapy. Innovations and adaptations of these conventional therapeutic approaches over the past 
decades have steadily improved clinical outcome in many types of cancer2. Further, the development of new 
targeted cancer therapeutics, in particular antibody-based drugs, has further improved the outcome for patients 
in many types of cancer3.
Despite this obvious progress, the overall 5-year survival rate of all patients diagnosed with cancer in the 
Netherlands has only moderately increased from 51% in 1995 to 62% in 20131. This picture is even bleaker for 
hard-to-treat cancers such as pancreatic cancer, ovarian cancer and colon cancer, for which the 5-year survival 
rate has hardly improved in the past decades. Various factors contribute to the low survival rates for these hard-to-
treat malignancies, including the often advanced stage of disease at time of diagnosis. In addition, intrinsic and/
or acquired resistance to therapy limits the efficacy of currently used drugs, which results in unresponsiveness to 
therapy and relapses after initial successful treatment. Furthermore, the risk for unwanted side effects increases 
as higher doses of the therapeutic drugs are needed to obtain clinical responses. Of note, therapy resistance is 
generally caused by oncogenic mutations which induce defects in cell death pathways (e.g. apoptotic cell death 
pathway) or over activate cell growth signaling (e.g. Mitogen-Activated Protein Kinase (MAPK) pathway)4. Hence, 
novel therapeutic agents which act via different cell death pathways, or can interfere with oncogenic signaling, 
are needed to improve cancer therapy and overcome therapy resistance. 
More recently, it has also become evident that the patient’s immune system is an interesting target for cancer 
therapy. Normally, the immune system prevents tumor formation by surveilling for  deregulated cells, which are 
destroyed before they can form a tumor mass5. However, due to oncogenic mutations, cancer cells can grow too 
fast to be eliminated by the immune system, and/ or start to express molecules which have immune suppressing 
activity. Therefore, stimulating anticancer immune responses using so called ‘cancer immunotherapy’, is a 
promising approach towards curative anti-cancer therapy6.
In this thesis, we aimed to develop new therapeutic strategies which meet one or more criteria needed to 
obtain improved anti-cancer therapeutics, i.e. being more tumor selective, able to overcome drug resistance, or 
able to promote anti-cancer immune responses. Part I of this thesis (chapters 2 to 5) details studies dedicated to 
the use of fusion proteins which selectively target the pro-apoptotic tumoricidal protein Tumor Necrosis Factor-
related Apoptosis-Inducing Ligand (TRAIL) to immune cells by virtue of their antibody fragment. This approach 
enhances the tumoricidal potential of various types of immune effector cells by arming them with TRAIL. Part II of 
this thesis (chapters 6 to 9) details studies on elucidating the therapeutic potential of the (immunomodulatory) 
glycan-binding protein Galectin-9 (Gal-9). In particular, we studied its use to overcome therapy resistance in 
different human cancers and investigated its role in modulating the immune response.
Part I: Targeted delivery of TRAIL for cancer immune therapy
TRAIL is a member of the tumor necrosis (TNF) superfamily that is normally expressed as type II transmembrane 
protein on the surface of certain immune cell types, i.e. natural killer (NK) cells, T-cells and NKT-cells [reviewed 
by7. On these immune cells, TRAIL serves as a key effector molecule in cancer immunosurveillance. Specifically, 
mice deficient for TRAIL have an increased risk of developing tumors and metastatic disease8 and treatment 
of wild-type tumor-bearing mice with a TRAIL-neutralizing antibody increases the number of metastasis9. 
In addition, TRAIL is acquired for optimal graft-versus-tumor activity during allogeneic hematopoietic-cell 
transplantation10, a therapy whereby blood cells from a healthy donor are infused into cancer patients, in a 
mouse model of leukemia. Thus, TRAIL is involved in the ongoing fight of the immune system against cancer 
cells and is an attractive effector domain for cancer immunotherapy. Indeed, TRAIL gained much attention 




different human cancer cell types, without affecting normal nonmalignant cells11. TRAIL induces apoptotic cell 
death in cancer cells by binding to its agonistic receptors TRAILR-1 (death receptor 4; DR4) or TRAILR-2 (DR5) 
and concomitant activation of caspase dependent apoptotic cell death12. Furthermore, membrane TRAIL can 
be proteolytically cleaved, yielding soluble TRAIL (sTRAIL)13. This sTRAIL retains apoptotic activity and has been 
evaluated as a recombinant protein drug in cancer therapy11. Based on a host of promising preclinical data, 
‘first generation’ TRAIL therapeutic agents such as recombinant sTRAIL (dulanermin) and TRAIL-R1 or TRAIL-R2 
targeting agonistic antibodies have entered clinical trials. In these clinical studies TRAIL-based therapeutics 
proved to be safe, having no dose-limiting toxicity, but also essentially lacked clinical activity (reviewed by14). 
To improve the efficacy of TRAIL-based therapy, our laboratory has developed a class of TRAIL-based 
antibody immunotherapeutics in which sTRAIL is genetically fused to a tumor-targeting antibody fragment 
(scFv) (Reviewed by15) This antibody fragment binds with high affinity to a pre-selected target antigen over-
expressed on tumor cells, enabling selective accretion of scFv:TRAIL to tumor cells. This tumor selectivity is of 
particular importance since TRAIL receptors are widely expressed on healthy cells in the human body16, which 
creates a ‘sink’ that potentially reduces tumor accretion of conventional sTRAIL. Further, once bound to its target 
antigen the scFv:TRAIL fusion protein is essentially a membrane-bound TRAIL that crosslinks and activates 
apoptotic signaling through TRAIL-R1 but also TRAIL-R2. In contrast, sTRAIL does not effectively activate TRAIL-R2 
without secondary crosslinking17. Finally, by incorporating an agonistic or antagonistic scFv antibody fragment a 
TRAIL fusion protein can be equipped with additional therapeutic activity. For instance, the use of an epidermal 
growth factor receptor (EGFR)-blocking antibody fragment simultaneously inhibited oncogenic EGFR-signaling 
and triggered TRAIL-mediated apoptotic cell death18.
In part I of this thesis we adapted this established approach by targeting TRAIL to the surface of T cells 
(effector cells of the adaptive system) in chapter 2 and to granulocytes (effector cells of the innate immune 
system) in chapter 3. Hereby, these effector cells are coated with high levels of TRAIL that are designed to 
enhance their tumoricidal activity. 
T cells are key effector cells of the adaptive immune system that are involved in the elimination of malignant 
cells. Indeed, high levels of T cell infiltration in the tumor is correlated with increased survival in various types of 
cancer19-22, and various immunomodulatory strategies that reactivate T cells can achieve cure in advanced stage 
cancer patients, especially melanoma patients23. To augment the cytolytic activity of such T cells, we in chapter 
2 delivered TRAIL to the cell surface of T-cells using a CD3- and/or CD7-targeted TRAIL fusion protein (designated 
hereafter as scFvCD3:sTRAIL and K12:sTRAIL, respectively). Indeed, treatment of T-cells with scFvCD3:sTRAIL or 
K12:sTRAIL increased the tumoricidal activity of T cells ~500-fold in vitro. Furthermore, both scFvCD3:TRAIL and 
K12:TRAIL inhibited the outgrowth of carcinoma xenografts in a mouse model of human colorectal cancer. Thus, 
equipping immune cells with TRAIL enhances their intrinsic tumoricidal potential.
In chapter 3, we expanded this ‘arming’ strategy to myeloid effector cells, particularly granulocytes, using 
fusion protein scFvCLL1:sTRAIL. Granulocytes comprise about 60% of all leukocytes in the human blood and are 
important effector cells during treatment of cancer patients with anticancer antibodies24. Cancer cells opsonized 
by anticancer antibodies are subject to antibody-dependent cellular phagocytosis (ADCP) and/or antibody-
dependent cell-mediated cytotoxicity (ADCC) (reviewed by25). In this respect, granulocytes are effective at ADCP, 
but are relatively inefficient in ADCC. To enhance the cytotoxic potential of granulocytes, we designed fusion 
protein scFvCLL1:sTRAIL which arms granulocytes with TRAIL by binding to membrane-expressed C-type lectin-
like molecule-1 (CLL-1). Treatment with scFvCLL1:TRAIL indeed increased the intrinsic cytotoxic potential of 
granulocytes towards tumor cells. Furthermore, since apoptotic cells are more easily engulfed than viable cells26, 
scFvCLL1:sTRAIL enhanced the efficacy of phagocytosis as induced by clinically used therapeutic anticancer 
antibodies like rituximab (anti-CD20; B-cell leukemia) and cetuximab (anti-EGFR; colorectal cancer, head/neck 
cancer).
However, providing granulocytes with pro-phagocytic signals is not always sufficient to induce (cancer) cell 
phagocytosis. In this respect, pro-phagocytic signals are counterbalanced by signals that negatively regulate 
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phagocytosis. To further shift the balance towards tumoricidal activity of granulocytes, we in chapter 4 
incorporated an antagonistic antibody fragment toward CD47 in our fusion protein construct. CD47 is a major 
negative regulator of phagocytosis that is expressed on virtually all cells in the body and serves to inhibit 
untimely phagocytosis by binding to signal regulatory protein α (SIRPα) expressed on phagocytes27. Importantly, 
both solid and hematological cancers hijack this inhibitory pathway to evade from the immune system by 
overexpressing CD4728-31. Hence, blocking the CD47-SIRPα signaling pathway on cancer cells using CD47 blocking 
antibodies potentiates the tumoricidal effects of anticancer antibodies, as has been published for myeloma32 
and lymphoma28,33. In line with this, scFvCD47:sTRAIL enhanced the phagocytic activity of phagocytes when co-
treated with the CD20-targeting therapeutic antibody rituximab. Furthermore, scFvCD47:TRAIL directly induced 
apoptosis in lymphoma cell lines and patient-derived tumor cells via its TRAIL domain. Since apoptotic cells are 
more easily engulfed then alive cells26, this cell death inducing potential of scFvCD47:sTRAIL may contribute 
to phagocytic removal of cancer cells. Thus, scFvCD47:sTRAIL has multifunctional therapeutic activity that may 
be of general use for optimizing antibody-based cancer therapy and serves as proof of concept for combining 
CD47-blockade with alternate effector principles to further potentiate anticancer activity.
In chapter 5, a comprehensive overview of the phagocyte-inhibitory receptor CD47 and the pro-phagocytic 
molecule calreticulin is provided, specifically in the context of TRAIL-based immunotherapy. Whereas CD47 
provides the dominant ‘don’t eat me’ signal on cancer cells, this signal is counterbalanced by calreticulin, a 
dominant ‘eat me’ signal that can be expressed on the cell membrane of e.g. dying cells. Calreticulin normally 
resides in the endoplasmic reticulum (ER) where it regulates calcium homeostasis and protein folding34. 
However, during apoptotic cell death induced by certain cancer therapeutics, i.e. anthracyclines and radiation, 
calreticulin can be translocated to the cell membrane where it interacts with phagocytes to promote engulfment 
of the dying cell. This calreticulin translocation is an important prerequisite for the induction of ‘immunogenic 
cell death’, i.e. the induction of cancer cell death that triggers an immune response toward malignant cells35. 
Calreticulin and CD47 are both important molecules in the context of TRAIL-based immunotherapy, with CD47 
inhibition maximizing the therapeutic of TRAIL-mediated apoptosis induction, as demonstrated in chapter 4. 
Further, as illustrated in chapter 5 we recently identified that treatment with TRAIL triggered the cell surface 
association of calreticulin with TRAIL and the TRAIL-R2 Death Inducing Signaling Complex in melanoma cells. 
These data build on earlier reports of TRAIL-induced surface translocation of calreticulin36 and the reported 
interaction of TRAIL and other members of the TNF superfamily with calreticulin in an ELISA-type assay37. Hence, 
calreticulin recruitment to TRAIL, and possibly other TNF members, may regulate (cancer) cell phagocytosis.
Part II: Evaluation of Galectin-9 as novel agent for cancer therapy
In the second part of the thesis, I detail the result of our search for a new therapeutic effector molecule for 
cancer therapy. Hereto, we focused on the interesting yet under-investigated area of glycobiology. Glycosylation 
of lipids and proteins is the most prevalent post-translational modification and is not template-driven (unlike 
DNA/ RNA/ protein). The branched nature of glycosylation yields enormous functional and antigenic diversity. By 
now it has been well-established that cancer cells can have markedly aberrant glycosylation patterns that allows 
for selective targeting of cancer cells (38). For instance, underglycosylation of the protein Mucin-1, has been 
successfully targeted with a monoclonal antibody for the treatment of ovarian cancer39. 
Among the naturally occurring ligands that recognize glycosylated proteins/ lipids is the galectin family of 
carbohydrate binding proteins, which has gained prominence in cancer therapy. In our studies, we focused on 
Galectin-9 (Gal-9), a so called ‘tandem-repeat’ galectin that has two different carbohydrate recognition domains 
(CRDs) separated by an inter-domain linker (reviewed by40). Gal-9 is best known for its immunomodulatory role in 
innate and adaptive immunity. In brief, Gal-9 was originally discovered as a potent eosinophil chemoattractant41 
and has since been most prominently studied for its T-cell immunomodulatory effects. Specifically, Gal-9 was 
reported to induce apoptosis in Th1 and Th17 cells by binding to the T-cell Immunoglobulin Mucin 3 (TIM-3) 




to negatively regulate epithelial cell adhesion to components of the extracellular matrix (ECM)44. Here, by 
inhibiting cellular adhesion, Gal-9 prevents colon cancer and melanoma metastasis as has been shown in a 
mouse model. In addition, Gal-9 seems to have more tumor suppressor like functions as its expression is lost 
during disease progression in melanoma, breast, cervix, gastric and colon cancer45-49. Thus, Gal-9 is a versatile 
protein which has many different functions as well as potential implications for cancer (immuno)therapy, which 
is reviewed in chapter 6. 
In chapter 7, we followed-up on the reported anti-metastatic activity of Gal-9 in melanoma. Specifically, it 
was found that murine melanoma cells that were transfected with a secretable form of Gal-9 lost their metastatic 
potential, resulting in reduced lung metastases when injected into mice44. In contrast, mock-transfected or 
melanoma cells transfected with a non-secretable form of Gal-9 formed a large number of metastatic foci in this 
mouse model. This suggests that Gal-9 has tumoricidal anti-metastatic activity, especially when it is present at 
the outside of a cell. Therefore, we hypothesized that Gal-9 treatment, via exogenous addition of Gal-9, of human 
melanoma cells has anti-cancer activity. As described in chapter 7, we indeed identified that Gal-9 treatment 
(using a recombinant form of Gal-9 containing a truncated linker for enhanced stability) inhibits the in vitro 
adhesion of human melanoma cell lines as well as primary patient-derived melanoma cells to the ECM protein 
collagen-I. However, we discovered that this reduced adhesion was most likely attributable to induction of 
cancer cell death upon Gal-9 treatment rather than a primary effect on adhesion. This hitherto unrecognized 
direct cytotoxic effect of Gal-9 toward melanoma cells was restricted to malignant cells and not detected on 
normal melanocytes. Hence, Gal-9 has therapeutic potential for the treatment of human metastatic melanoma.
We next explored whether Gal-9 also had cytotoxic effects toward other cancer types. In chapter 8, we 
report that this is indeed the case for colorectal cancer cells, one of the most prevalent types of cancer in the 
Netherlands. Treatment with Gal-9 induced the formation of large vacuoles in colon cancer cell lines as well as 
patient derived colon cancer cells, which eventually resulted into cell death. In contrast, healthy colon epithelial 
cells were not affected by Gal-9 treatment. In line with these tumoricidal effects, Gal-9 also strongly inhibited 
the growth of colon cancer tumors in mice, whereby their survival time was significantly increased. Interestingly, 
colon cancer cell lines which harbor the oncogenic k-Ras (Kirsten rat sarcoma viral oncogene homolog) mutation 
were uniquely sensitive to Gal-9 treatment. This is of particular interest since these k-Ras mutations are found in 
30-45% of all colorectal cancer patients, and are predictive for resistance toward EGFR-targeted therapy (50) and 
associate with poor prognosis51,52. In these k-Ras mutated cells, Gal-9 was found to inhibit the complete execution 
of autophagy by halting this process at the stage of autophagosome/ lysosome fusion, eventually leading to cell 
death. Thus, Gal-9 is a potential new therapeutic agent for the treatment of k-Ras mutant colorectal cancer. 
Besides its functions in epithelial cells, Gal-9 is also known for its versatile immunomodulatory activity that 
affects both innate and adaptive immune responses. On the one hand, Gal-9 is known to have strong anti-
inflammatory effects and can be used to ameliorate inflammatory autoimmune diseases43,53. In contrast, Gal-9 
treatment generated Th1 cells in ex vivo activated human T-cells in a study on food allergy (54), and stimulated 
antitumor T-cell immune responses in a sarcoma mouse model55. Thus, Gal-9 can have diametric effects on T-cell 
immunity likely depending on experimental conditions and the balance of immunity in specific disease settings 
and micro-environments. Nevertheless, in the context of using Gal-9 for (cancer) therapy, it is of importance 
to carefully characterize the immunomodulatory effects of Gal-9 on human T-cells. In chapter 9, we therefore 
aimed to delineate the immunomodulatory effect of Gal-9 on resting and (ex vivo) activated human Peripheral 
Blood Lymphocytes (PBLs). To this end, we treated PBLs using increasing concentrations of Gal-9 and evaluated 
its effects on T-cells in time for up to 7 days, including changes in T-cell viability, T-cell proliferation and T-cell 
phenotype. We showed that after initial cell death, a part of the Gal-9-treated T-cells survived and eventually 
expanded and differentiated into central memory T-cells with a typical Th1 phenotype. Thus, Gal-9 has diverse 
immunomodulatory effects depending on concentration and skewing signals available and is therefore likely to 
have a disease-specific role that needs to be evaluated in depth for both autoimmunity and cancer.
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In conclusion, this thesis describes a number of studies aimed at establishing new TRAIL-based immunostimulatory 
therapeutics and Galectin-9 as drugs that may be used to overcome current problems encountered in the clinic 
like off-target side-effects and therapy resistance. A summary of this work and the perspectives is presented in 
chapter 10.
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Purpose: Adoptive T-cell therapy generally fails to induce meaningful anticancer responses in patients with solid 
tumors. Here, we present a novel strategy designed to selectively enhance the tumoricidal activity of T cells by 
targeted delivery of TNF-related apoptosis-inducing ligand (TRAIL) to the T-cell surface.
Experimental Design: We constructed two recombinant fusion proteins, anti-CD3:TRAIL and K12:TRAIL. 
Tumoricidal activity of T cells in the presence of these fusion proteins was assessed in solid tumor cell lines, 
primary patient-derived malignant cells, and in a murine xenograft model.
Results: When added to T cells, K12:TRAIL and anti-CD3:TRAIL selectively bind to the T-cell surface antigens CD3 
and CD7, respectively, leading to cell surface accretion of TRAIL. Subsequently, anti-CD3:TRAIL and K12:TRAIL 
increased the tumoricidal activity of T cells toward cancer cell lines and primary patient-derived malignant 
cells by more than 500-fold. Furthermore, T-cell surface delivery of TRAIL strongly inhibited tumor growth and 
increased survival time of xenografted mice more than 6-fold.
Conclusions: Targeted delivery of TRAIL to cell surface antigens of T cells potently enhances the tumoricidal 
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TRANSLATIONAL RELEVANCE
Because adoptive T-cell strategies generally fail to trigger clinically relevant anticancer immunity in patients 
with solid tumors, new strategies that optimize adoptive T-cell transfer are warranted. Here, we present a novel 
strategy that aims to selectively and safely enhance the antitumor activity of T cells by targeted delivery of 
human TNF-related apoptosis-inducing ligand (TRAIL) to the cell surface, whereby T cells can utilize TRAIL as an 
additional cytotoxic effector. This approach strongly enhances the antitumor activity of T cells toward a panel 
of cancer cell lines and primary patient-derived cancer cells. In addition, targeted delivery of TRAIL to the T-cell 
surface significantly extended the survival time of tumor-bearing mice. The approach reported here could also 
be easily integrated in current adoptive T-cell strategies.
INTRODUCTION
While efficacious in certain virus-mediated cancers, adoptive T-cell therapy generally fails to induce meaningful 
anticancer responses in patients with solid tumors. The cause for this lack of clinical efficacy is multifactorial by 
nature and includes the intrinsic or acquired resistance of malignant cells to cytotoxic T-cell effector mechanisms 
such as granzyme/perforin-mediated lysis1-5 and Fas-mediated killing6,7. To overcome or circumvent this potential 
pitfall of adoptive T-cell therapy, we propose to selectively expand the T-cell armamentarium with additional 
tumoricidal effector molecules, in particular with the TNF-related apoptosis-inducing ligand (TRAIL).
TRAIL is a type II transmembrane protein normally expressed on natural killer (NK) cells, where it is essential for 
NK cell–mediated tumor immune surveillance8,9. In contrast, the expression of TRAIL on resting T cells is typically 
very low10,11. Nevertheless, a slight induction of TRAIL expression on T cells, by ectopic expression of TRAIL or by ex 
vivo costimulation with anti-CD3 and IFN-α, already potently increases their tumoricidal activity11,12. Furthermore, 
T-cell–expressed TRAIL is essential for graft-versus-tumor (GVT) activity during allogeneic hematopoietic cell 
transplantation (AHCT; ref. 10). Importantly, T-cell–expressed TRAIL does not contribute to deleterious GVHD 
activity10. Taken together, these findings suggest that T cells should gain additional tumoricidal potential when 
equipped with TRAIL at the cell surface.
Previously, we and others have reported on an approach that may be particularly useful in this respect. In 
brief, recombinant soluble TRAIL (sTRAIL) was genetically linked to a tumor cell–selective antibody fragment 
(scFv). The resultant recombinant scFv:sTRAIL fusion protein has the following properties: By virtue of the 
antibody fragment, the scFv:TRAIL fusion protein selectively delivers TRAIL to the cell surface of tumor cells. 
Subsequently, cell surface bound scFv:TRAIL can activate TRAIL receptor apoptotic signaling in tumor cells 
(reviewed in ref. 13). Here, we utilized and adapted this approach for the selective delivery of high levels of TRAIL 
to the cell surface of T cells, with the aim of expanding the cytotoxic armament of these T cells with TRAIL (for 
schematic, see Figure 1).
This approach was preclinically evaluated using 2 novel recombinant fusion proteins, designated anti-CD3:TRAIL 
and K12:TRAIL, that selectively bind to the T-cell surface antigen CD3 and CD7, respectively. Fusion protein anti-
CD3:TRAIL contains a CD3 stimulatory antibody fragment, whereas K12:TRAIL contains a soluble form of the CD7 
ligand K12. Anti-CD3:TRAIL and K12:TRAIL strongly potentiated the tumoricidal activity of T cells toward a panel 
of cancer cell lines, primary patient-derived malignant cells, and in a murine xenograft model. This strategy may 




Anti-CD7 mAb TH-69 competes with K12:TRAIL for binding to CD7 and was a gift from Prof. Dr. Martin Gramatzki 
(University of Kiel, Kiel, Germany). TRAIL-neutralizing mAb 2E5 was purchased from Kordia Life Sciences, FasL-
neutralizing mAb Alf2.1 was purchased from Sigma-Aldrich, and TNF-α–neutralizing fusion protein Enbrel was 
purchased from Wyeth. Phycoerythrin (PE)-labeled anti-TRAIL mAb B-S23 was purchased from Diaclone SAS and 
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PE-labeled anti-CD69 mAb was purchased from IQ products. Anti-TRAILR antibodies HS-201, HS-202, HS-203, 
and HS-204 and soluble TRAIL receptors TRAILR1-Fc, TRAILR2-Fc, TRAILR3-Fc, and TRAILR4-Fc were purchased 
from Alexis. TRAIL ELISA was purchased from Diaclone and Cytokine ELISA was from SA Biosciences. DiI, DiO, 
and FLUO-3-AM were purchased from Invitrogen. DiOC6 was purchased from Molecular Probes. Actinomycin D, 
valproic acid (VPA), and cycloheximide were purchased from Sigma-Aldrich. Pan-caspase inhibitor zVAD-FMK, 
caspase-8 inhibitor zLEHD-FMK, and caspase-9 inhibitor zIETD-FMK were purchased from Calbiochem. Anti-CD3 
mAb and recombinant interleukin (IL) 2 were purchased from ImmunoTools. TNF-α was purchased from Abcam. 
FasL-Fc was a kind gift from Prof. Dr. Harald Wajant (University of Würzburg, Würzburg, Germany). RhTRAIL was 
purchased from R&D Technologies.
Production of K12:TRAIL and anti-CD3:TRAIL
Fusion protein K12:TRAIL and anti-CD3:TRAIL were constructed by cloning the cDNA of soluble human K12 (aa 
29–143) or the anti-CD3 antibody fragment scFvUCHT-1v9 in frame with human soluble TRAIL into previously 
described vector pEE14, yielding plasmids pEE14-K12:TRAIL and pEE14-anti-CD3:TRAIL, respectively. Fusion 
proteins K12:TRAIL and anti-CD3:TRAIL were produced in CHO-K1 cells essentially using previously described 
methods14. Culture medium containing K12:TRAIL or anti-CD3:TRAIL was cleared by centrifugation (10,000 
Figure 1. Cell surface delivery of TRAIL to augment the tumoricidal activity of T cells. Fusion proteins K12:TRAIL 
and anti-CD3:TRAIL were designed to selectively bind to T-cell markers CD7 and CD3, respectively, and enhance levels 
of TRAIL on the surface of T cells. Tumoricidal activity of T cells should be augmented by virtue of TRAIL-TRAILR–
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× g, 10 minutes), filter sterilized, and stored at −80°C until further use. Fusion proteins were purified via the 
N-terminal hemagglutinin (HA) tag using anti-HA affinity chromatography. Fusion protein anti-MCSP:TRAIL is 
a fusion protein that is essentially identical to anti-CD3:TRAIL except that it contains an anti-MCSP scFv instead 
of an anti-CD3 scFv. Melanoma-associated chondroitin sulfate proteoglycan (MCSP) is expressed on cells of the 
melanocyte lineage but not on T cells or carcinoma cells.
Cell lines
SK-OV-3, OvCAR-3, A2780, HCT-8, HT29, A375M, A2058, SK-MEL-28, HEP3B, PLC-PRF-5, FADU, PC-3M, HK-2, and 
Ramos were obtained from the American Tissue Culture Collection and characterized by short tandem repeat 
profiling, karyotyping, and isoenzyme analysis. A375M.FADD-DED cells were generated by transfection of 
parental A375M cells with a dominant-negative FADD-DED construct using Fugene (Roche BV). A375M.FADD-
DED cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and 500 μg/mL 
Geneticin. HCT-116–luc was from Caliper Biosciences (Xenogen). NHDF-juv cells were from Promocell. Human 
umbilical vein endothelial cells (HUVEC) were isolated as described previously. Unless otherwise indicated, cells 
were cultured in standard RPMI (Cambrex BioScience) supplemented with 10% FCS.
Isolation of primary patient-derived tumor cells, T cells and activation of T cells
Experiments were approved by the local Medical Ethical Committee and patients/healthy volunteers signed for 
informed consent. Tumor tissues and ascitic fluids were obtained during surgery procedures and if necessary 
minced, after which adherent cells were cultured. Experiments were carried out before passage number 5. 
Samples with a background apoptosis more than 30% were excluded from analysis. Normal fibroblast cultures 
originating from tumor tissue/ascitis were essentially established as described above for primary cancer cell 
cultures. Tumor-infiltrating T cells were isolated from the primary tumor cultures using ammonium chloride lysis. 
Peripheral blood lymphocytes (PBL) from blood of healthy donors were isolated using standard density gradient 
centrifugation (Lymphoprep; Axis-Shield PoC As). Activated T cells were generated by culturing PBLs with anti-
CD3 mAb (0.5 μg/mL; 72 hours) and IL-2 (100 ng/mL; 48 hours).
Analysis of fusion protein binding and TRAILR expression
The presence of cell surface bound TRAIL was assessed by incubating cells with PE-conjugated anti-TRAIL mAb 
B-S23 (Diaclone SAS) for 60 minutes at 4°C followed by 3 washes. Cells were subsequently measured on an Accuri 
C6 flow cytometer. Cell surface display of TRAIL in time was determined by incubating cells with 50 pg per T cell 
K12:TRAIL or anti-CD3:TRAIL for 60 minutes at 4°C followed by 3 washes in PBS. Cells were then incubated at 
37°C for the time points indicated and TRAIL expression was determined by flow cytometry using PE-labeled 
mAb B-S23. The amount of K12:TRAIL or anti-CD3:TRAIL bound to an individual T cell was determined using 
TRAIL ELISA. Briefly, 1 × 105 T cells were incubated with increasing concentrations of K12:TRAIL or anti-CD3:TRAIL 
for 1 hour. Subsequently, cells were centrifuged and supernatants used for TRAIL ELISA. Loss of K12:TRAIL and 
anti-CD3:TRAIL from the supernatant was calculated using the same concentration range of K12:TRAIL and anti-
CD3:TRAIL in the absence of T cells as a reference. Expression of TRAIL receptors was determined by incubating 
cells with mAb HS-201, HS-202, HS-203, or HS-204 for 60 minutes at 4°C followed by 3 washes with PBS and 
incubation with PE-labeled goat anti-mouse Ab for 60 minutes at 4°C. Cells were subsequently washed 3 more 
times with PBS and TRAILR expression was determined using an Accuri C6 flow cytometer.
Analysis of cell death
For cell death assays, cancer cells were labeled with red fluorescent membrane label DiI (Invitrogen) in serum-
free medium for 15 minutes followed by 3 washes in serum containing medium and subsequent culture in a 
48-well plate (3.0 × 104 cells per well). After 24 hours, cancer cells were treated for 16 hours with T cells (activated 
or resting) at the indicated ratios in the presence or absence of K12:TRAIL (50 pg per T cell), anti-CD3:TRAIL (50 
24
Chapter II
pg per T cell), or anti-MCSP:TRAIL (50 pg per T cell) after which apoptosis was assessed in tumor cells by loss of 
mitochondrial membrane potential (Δψ), as previously described14 using an Accuri C6 flow cytometer. Where 
indicated, caspase inhibitors were used at a final concentration of 10 μmol/L. Actinomycin D was used at a final 
concentration of 2 μg/mL. Anti-TRAIL (2E5)- and anti-FasL (Alf2.1)-neutralizing mAbs and TNF-α–neutralizing 
fusion protein Enbrel were used at a final concentration of 5 μg/mL. For experiments involving VPA, tumor 
cells were pretreated for 24 hours with 1 mmol/L of VPA prior to addition of T cells at the indicated ratios. For 
experiments involving concanamycin A (CMA), T cells were treated with the indicated concentrations of CMA for 
2 hours prior to addition to tumor cells. Tumor cells were subsequently treated with these T cells for 4 hours in 
the presence of CMA after which induction of apoptosis was assessed. For outgrowth experiments using patient 
ascitic fluid, anti-CD3:TRAIL, anti-CD3 mAb, or rhTRAIL were added at a final concentration of 100 ng/mL to a 
mixture of ascitic fluid and normal culture medium (50% v/v).
Time lapse confocal microscopy
Tumor cells were labeled with membrane label DiO (green) by incubation of 1 × 106 cells with 5 μL DiO in serum-
free RPMI 1640 for 15 minutes at 37°C. Cells were then washed 3 times with RPMI 1640 + 10% FCS and DiO-
labeled tumor cells were cultured in a glass coverslide (3.0 × 104 cells per well). After 24 hours, T cells labeled with 
DiI (red) using the same procedure were added to the tumor cells at the indicated effector-to-target (E:T) ratios. 
Time lapse confocal microscopy was carried out on a Solamere Nipkow Disk CLSM equipped with temperature/
CO2-controlled cabinet and multicell track table.
Mechanical stimulation of CD3 signaling and calcium flux
Glass coverslides in Petri dishes were coated overnight with 10 μg/mL TRAILR1-Fc, TRAILR2-Fc, TRAILR3-Fc, or 
TRAILR4-Fc. Coverslides were subsequently washed with PBS and blocked with normal human serum for 1 hour. 
T cells were labeled with FLUO-3-AM by incubating the cells with 5 μmol/L FLUO-3-AM ester in 100 μL PBS for 
15 minutes at 20°C, followed by addition of 400 μL PBS with 10% FCS and 45 minutes of incubation at 37°C. 
Next, FLUO-3-AM labeled T cells were added to the TRAIL-R1-, TRAIL-R2-, TRAIL-R3-, or TRAIL-R4–coated glass 
slides. T cells were mechanically stimulated by using a micropipette, as previously described15. Calcium flux was 
measured and quantified on a TILL iMIC fluorescence microscope equipped with temperature/CO2-controlled 
cabinet. Calcium flux is depicted as the mean fluorescent intensity (MFI) at any given time point (MFIT)/the MFI 
at T = 0 (MFI0).
Cytokine ELISA
T cells were incubated with tumor cells for 16 hour at an E:T ratio of 5:1 in the presence or absence of 50 pg per T 
cell anti-CD3:TRAIL. Where indicated, mAb 2E5 was added to block TRAIL–TRAILR interaction. Alternatively, T cells 
were treated with anti-CD3 mAb for 16 hours to elicit T-cell activation and cytokine release. Cell supernatants 
were subsequently harvested, centrifuged, and used for cytokine ELISA according to the manufacturer’s 
instructions.
HCT-116–luc xenograft mouse model
Experiments were approved by the Committee for Research and Animal Ethics of the UMCG. Male athymic 
mice (Harlan) were intraperitoneally inoculated with HCT-116–luc (1 × 106 cells). Animals were subsequently 
treated with a single intraperitoneal dose of 5 × 106 T cells and about 150 μg/kg K12:TRAIL or anti-CD3:TRAIL, as 
indicated. Tumor growth was monitored by luminescent imaging of mice from the ventral abdominal side using 
an IVIS Spectrum (Xenogen) optical imager. Animals were sacrificed by cervical dislocation when bioluminescent 
signal was increased 10-fold compared with day of inoculation. For localization of T cells, T cells were labeled 
with CellVue NIR815 membrane labeling kit according to the manufacturer’s instructions. Specific fluorescent 
signal was determined by subtracting the fluorescent signal from saline-treated mice.
25
| Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T-cells
II
Statistical analysis
Data reported are mean values ± SD of 3 independent experiments. Data was analyzed by 1-way ANOVA followed 
by Tukey–Kramer post test or, where appropriate, by 2-sided unpaired Student’s t test. Where indicated, *, P < 
0.05; **, P < 0.01; ***, P < 0.001.
RESULTS
Tumoricidal activity of T cells is potently augmented by delivery of TRAIL to the T-cell surface
To selectively deliver TRAIL to the cell surface of T cells, the CD3-targeted fusion protein anti-CD3:TRAIL and the 
CD7-targeted fusion protein K12:TRAIL were generated. In line with literature, ex vivo activated T cells obtained 
from healthy volunteers did not detectably express TRAIL (Figure 2A). Incubation of these TRAIL-negative T cells 
with anti-CD3:TRAIL or K12:TRAIL lead to the display of high levels of TRAIL on the T-cell surface (Figure 2A). A 
subsequent TRAIL ELISA showed that 1 × 105 T cells bind about 50 pg of K12:TRAIL and/or about 4 pg of anti-
CD3:TRAIL. This T-cell binding by anti-CD3:TRAIL or K12:TRAIL was selectively blocked by anti-CD3 or anti-CD7 
mAb, respectively (data not shown) and did not induce reciprocal T-cell death (Supplementary Figure S1A).
Importantly, T-cell–selective binding by anti-CD3:TRAIL and K12:TRAIL did potentiate the tumoricidal activity of 
activated T cells toward cancer cells, with more than 90% apoptosis at an E:T ratio of 2:1 (Figure 2B). Activated T 
cells alone failed to induce apoptosis at these E:T ratios, with only about 40% apoptosis at an E:T ratio of 100:1 
(Figure 2B). Addition of an analogous TRAIL fusion protein that cannot bind T cells did not augment cell death in 
OvCAR-3 cells (Supplementary Figure S1B).
This enhanced tumoricidal activity toward OvCAR-3 was dose dependent (Supplementary Figure S1C and 
D), apparent within 2 hours and progressed to a maximum effect within 16 hours (Figure 2C and Supplementary 
Videos S1 and 2). In addition, while the display of K12:TRAIL and anti-CD3:TRAIL on the T-cell surface was 
reduced over time (Supplementary Figure S1E and F, respectively), T cells preincubated with excess K12:TRAIL or 
anti-CD3:TRAIL prior to addition to tumor cells (up to 48 hours) fully retained their enhanced apoptotic activity 
(Supplementary Figure S1G). This indicates that in the presence of normal receptor turnover, sufficient K12:TRAIL 
or anti-CD3:TRAIL remain displayed on the T-cell surface. Importantly, the potentiating effect of anti-CD3:TRAIL 
and K12:TRAIL on the tumoricidal activity of T cells was detected in a panel of 14 solid tumor cell lines (Figure 2D) 
and in an extensive panel of short-term cultures of primary patient-derived cancer cell samples (Figure 2E and 
F; anti-CD3:TRAIL and K12:TRAIL, respectively). In these patient-derived malignant cell cultures, treatment with 
anti-CD3:TRAIL or K12:TRAIL and T cells, completely disrupted the monolayer within 5 hours as exemplified for 
K12:TRAIL in Figure 2G and Supplementary Videos S3 and 4.
To assess for possible effects of TRAIL receptor expression on the sensitivity of tumor cells to the potentiating 
effect of K12:TRAIL and anti-CD3:TRAIL on T-cell activity, TRAILR expression levels were determined in a panel of 
cell lines (see Table 1). There was no correlation between TRAILR expression and sensitivity to K12:TRAIL-mediated 
T-cell cytotoxicity (Supplementary Figure S2A–D). Interestingly, there was a weak negative correlation (r2 = 0.48) 
with TRAIL-R4 expression in terms of sensitivity to anti-CD3:TRAIL–mediated T-cell cytotoxicity (Supplementary 
Figure S2D) but no correlation with TRAIL-R1, TRAIL-R2, and TRAIL-R3 (Supplementary Figure S2A–C).
Taken together, anti-CD3:TRAIL and K12:TRAIL both potently augment the tumoricidal activity of activated T 
cells toward cancer cell lines and patient-derived malignant cells by about 500-fold.
Anti-CD3:TRAIL induces tumoricidal activity by activation of resting T cells
Anti-CD3:TRAIL comprises a T-cell–stimulating CD3 antibody fragment. By virtue of this antibody fragment, 
anti-CD3:TRAIL might also be able to activate intrinsic cytotoxic effector mechanisms of T cells. In line with this 
hypothesis, resting T cells that lacked activity in coculture experiments with OvCAR-3 gained potent cytotoxic 
activity in the presence of anti-CD3:TRAIL (Figure 3A, 100% apoptosis at E:T ratio of 10:1). In contrast, resting T 
cells remained ineffective in the presence of K12:TRAIL, with no cytotoxicity even at the highest E:T ratio tested 
(Figure 3A). Furthermore, anti-CD3:TRAIL consistently reduced long-term outgrowth by more than 50% in ascitic 
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Figure 2. Tumoricidal activity of T cells is potently augmented by delivery of TRAIL to the T-cell surface. (A) TRAIL expression 
on anti-CD3 + IL-2–activated T cells was assessed by incubation of T cells with PE-conjugated anti-TRAIL mAb (thin line). Cell surface 
TRAIL expression after binding of K12:TRAIL or anti-CD3:TRAIL was determined by preincubating T cells with K12:TRAIL (hashed 
line) or anti-CD3:TRAIL (solid line). Shaded gray area represents fluorescence of PE-labeled isotype control. (B) Activated T cells were 
incubated with OvCAR-3 cells in the presence or absence of K12:TRAIL (50 pg per T cell) or anti-CD3:TRAIL (50 pg per T cell) for 16 hours 
at the indicated E:T ratios and apoptosis was assessed in OvCAR-3 cells. (C) Activated T cells were incubated with OvCAR-3 cells in the 
presence or absence of K12:TRAIL (50 pg per T cell) or anti-CD3:TRAIL (50 pg per T cell) at an E:T ratio of 10:1 for the indicated time 
points and apoptosis was assessed in OvCAR-3 cells. (D) Cancer cell lines SK-OV-3, OvCAR-3, A2780, HCT-116, HCT-8, HT29, A375M, 
A2058, SK-MEL-28, HEP3B, PLC-PRF-5, FADU, PC-3M, and Ramos were treated for 16 hours with activated T cells at an E:T ratio of 5:1 
in the presence or absence of K12:TRAIL (50 pg per T cell) or anti-CD3:TRAIL (50 pg per T cell) and apoptosis was assessed. (E) and (F), 
primary ovarian cancer (OC) cells were treated as indicated at an E:T ratio of 5:1 for 16 hours and apoptosis was assessed. (G), primary 
tumor cells were fluorescently labeled using membrane label DiO (green) and incubated with DiI (red)-labeled activated T cells in the 
presence or absence of K12:TRAIL (50 pg per T cell) at an E:T ratio of 10:1. Subsequently, cells were used for live fluorescent imaging (5 
hours) to observe morphologic changes. For purpose of clarity, only cancer cells are depicted. See also Supplementary Videos S1–S4. 
n.s., nonsignificant.
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fluid from ovarian cancer patients that contains both primary malignant cells and autologous T cells (Figure 
3B and Supplementary Figure S3A). Neither an anti-CD3 stimulatory mAb nor an untargeted soluble rhTRAIL 
preparation alone inhibited cancer cell outgrowth (Figure 3B).
In line with these activating properties, anti-CD3:TRAIL induced a rapid calcium flux in T cells cocultured with 
OvCAR-3 cells (Supplementary Figure S3B) which was followed in time by an increase in the number of T cells 
positive for the activation marker CD69 (Supplementary Figure S3C) and the release of proinflammatory T-cell 
cytokines (Supplementary Figure S3D). Interestingly, preventing cellular contact between T cells and tumor 
cells abolished T-cell activation induced by anti-CD3:TRAIL (Supplementary Figure S3E), as did the addition of 
TRAIL-neutralizing and TRAILR-blocking antibodies (Supplementary Figure S3C). In contrast, caspase inhibition 
did not block activation of anti-CD3:TRAIL–armed T cells (Supplementary Figure S3C) but did block induction 
of apoptosis by rhTRAIL (Supplementary Figure S5A). Further analysis using T cells mechanically manipulated 
using a micropipette (Supplementary Figure S4A for schematic representation) indicated that anti-CD3:TRAIL–
mediated T-cell activation was likely because of shear stress upon simultaneous binding of anti-CD3:TRAIL to 
CD3 on T cells and TRAILR2 on tumor cells (Supplementary Figure S4A–C).
K12:TRAIL and anti-CD3:TRAIL enhance tumoricidal activity of resting T cells via distinct mechanisms
On the basis of these activating properties, T-cell cytotoxicity induced by anti-CD3:TRAIL may, at least partly, 
be attributable to stimulation of intrinsic T-cell cytotoxicity. Indeed, the potentiating effect on T-cell activity by 
anti-CD3:TRAIL, but not by K12:TRAIL, was dose dependently blocked by the granzyme/perforin release inhibitor 
CMA (Figure 3C and Supplementary Figure S5B). In addition, A375M cells overexpressing a mutant form of the 
TRAILR adaptor protein FADD (FADD-DED) that inhibits TRAILR-mediated caspase activation, remained sensitive 
to treatment with T cells + anti-CD3:TRAIL but not to T cells + K12:TRAIL (Figure 3D). Inhibition of other typical 
cytotoxic T-cell effectors, such as the tumoricidal proteins FasL and TNF-α, failed to inhibit apoptotic activity 
of anti-CD3:TRAIL/K12:TRAIL toward OvCAR-3 cells (Figure 3E). Apoptotic activity of anti-CD3:TRAIL/K12:TRAIL–
armed T cells was abrogated by a pan-caspase inhibitor (Figure 3E) and by inhibition of caspase-8 or caspase-9 
(Figure 3E). Of note, the potentiating effect of anti-CD3:TRAIL on tumoricidal T-cell activity closely resembled that 
of T cells redirected with the bispecific antibody Bis-1 (anti-CD3:anti-EpCAM), which was also abrogated by CMA 
(Supplementary Figure S5C). Therefore, the mode of action of anti-CD3:TRAIL appears to be largely dependent 
Table 1. FIs for TRAILR expression levels determined on a panel of cancer cell lines
Cell line TRAILR expression (MFI)
TRAIL-R1 TRAIL-R2 TRAIL-R3 TRAIL-R4
OvCAR-3 1,722 22,076 1,851 4,879
A2780 3,559 33,519 4,207 1,586
SK-OV-3 3,023 14,192 0 0
HCT-116 37,441 34,970 13,132 1,488
HCT-8 7,173 26,162 0 0
HT29 10,207 4,890 1,034 26,458
A375M 687 9,468 858 584
A2058 884 3,022 2,099 316
SK-MEL-28 2,786 8,895 1,559 805
HEP3B 4,039 8,112 4,878 1,474
PLC-PRF-5 22,977 26,123 1,847 1,934
FADU 0 12,784 72 215
PC-3M 2,724 12,631 8,062 2,907
Ramos 5,437 4,618 0 8,371
NOTE: Values are representative from 3 independent experiments.
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on granzyme/perforin-mediated lysis, whereas K12:TRAIL functions via activation of initiator caspase-8/-9 
and effector caspases. Furthermore, the inhibitory effect of caspase-9 blockade suggests that mitochondrial 
amplification of the caspase-8 apoptotic signal is required for effective tumoricidal activity.
K12:TRAIL and anti-CD3:TRAIL inhibit growth of colorectal carcinoma in vivo
The potent in vitro effects of K12:TRAIL and anti-CD3:TRAIL prompted us to evaluate activity against tumor cells in 
vivo. To this end, we xenografted colorectal carcinoma cell line HCT-116–luc intraperitoneally in mice as a model 
for advanced metastatic colon carcinoma. HCT-116–luc cells rapidly established tumor nodules throughout the 
abdominal cavity, resulting in a median survival of only 7 days (Figure 4B and C). Importantly, growth of HCT-
116–luc in vivo was significantly suppressed by cotreatment with K12:TRAIL and activated T cells, compared 
with treatment with either K12:TRAIL or T cells alone. Indeed, median survival was increased 6-fold and 1 mouse 
survived for the duration of the experiment (70 days) with minimal residual disease (Figure 4A and B; 42 vs. 7 
days). Of note, cotreatment with K12:TRAIL and T cells did not have obvious off-target toxicity in these mice, with 
Figure 3. K12:TRAIL and anti-CD3:TRAIL enhance tumoricidal activity of resting T cells via distinct mechanisms. (A) OvCAR-3 
cells were treated with resting T cells at the indicated E:T ratios for 48 hours in the presence or absence of K12:TRAIL (50 pg per T cell) or 
anti-CD3:TRAIL (50 pg per T cell) and apoptosis was assessed. (B) Ascitic fluid (n = 5) was mixed with culture medium at a 1:1 ratio and 
treated with anti-CD3:TRAIL (50 pg per T cell), anti-CD3 mAb (2 μg/mL), or rhTRAIL (100 ng/mL) for 12 days after which cell viability 
was assessed. (C) OvCAR-3 cells were incubated for 4 hours at an E:T of 10:1 with activated T cells ± K12:TRAIL (50 pg per T cell) or anti-
CD3:TRAIL (50 pg per T cell) in the presence of the indicated concentrations of CMA and apoptosis was assessed. (D) A375M or A375M.
FADD-DED cells were treated rhTRAIL (100 ng/mL), act T cells (5:1) ± K12:TRAIL (50 pg per T cell), or anti-CD3:TRAIL (50 pg per T cell) for 
16 hours and apoptosis was assessed. E, OvCAR-3 cells were treated for 16 hours with activated T cells ± K12:TRAIL (50 pg per T cell) 
or anti-CD3:TRAIL (50 pg per T cell) at an E:T ratio of 10:1 in the presence or absence of TRAIL-neutralizing mAb 2E5, FasL-neutralizing 
mAb Alf2.1, TNF-α–neutralizing fusion protein Enbrel, pan-caspase inhibitor zVAD-fmk, caspase-8 inhibitor zIETD-fmk, or caspase-9 
inhibitor zLEHD-fmk and apoptosis was assessed.
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Figure 4. K12:TRAIL and anti-CD3:TRAIL inhibit growth of colorectal carcinoma in vivo. (A) Male athymic mice were injected 
intraperitoneally with 1 × 106 HCT-116–luc cells followed by intraperitoneal injection with saline, activated T cells (5 × 106), K12:TRAIL 
(0.25 mg/kg), anti-CD3:TRAIL (0.25 mg/kg), activated T cells + K12:TRAIL, or activated T cells + anti-CD3:TRAIL and tumor growth was 
monitored by bioluminescence. Mice were sacrificed when tumor size reached a 10-fold increase compared with initial tumor load. 
Representative images of mice from all treatment groups on days 3 and 14 after tumor cell injection are depicted. (B) mice survival 
following treatment with act. T cells, K12:TRAIL, or act. T cells + K12:TRAIL, as determined by a 10-fold increase in tumor size compared 
with start of treatment, was plotted in a Kaplan–Meier curve. (C) Mice survival following treatment with act. T cells, anti-CD3:TRAIL, 
or act. T cells + anti-CD3:TRAIL, as determined by a 10-fold increase in tumor size compared with start of treatment, was plotted in a 
Kaplan–Meier curve. (D) Male athymic mice were injected intraperitoneally with 1×106 HCT-116–luc cells followed by intraperitoneal 
injection with saline, activated T cells (1×106), activated T cells + K12:TRAIL (0.25 mg/kg), or activated T cells + anti-CD3:TRAIL (0.25 mg/
kg). T-cell localization was subsequently monitored at the indicated time points using fluorescence together with tumor localization 
using bioluminescence. See also Supplementary Videos S5 and 6.
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Figure 5. K12:TRAIL and anti-CD3:TRAIL are compatible with experimental strategies to ameliorate GVHD and optimize GVT. 
(A) OvCAR-3 cells were pretreated with VPA (1 nmol/L) for 1 day and subsequently treated for 16 hours with activated T cells at the 
indicated E:T ratios. (B) OvCAR-3 cells pretreated with VPA for 1 day were treated for 16 hours with K12:TRAIL-armed T cells (50 pg per 
T cell) at the indicated E:T ratios. (C) OvCAR-3 cells pretreated with VPA for 1 day were treated for 16 hours with anti-CD3:TRAIL–armed 
T cells (50 pg per T cell) at the indicated E:T ratios. (D) Primary cancer cells (n = 2) were pretreated with VPA (1 nmol/L) for 1 day and 
subsequently treated for another 16 hours with activated T cells or K12:TRAIL/anti-CD3:TRAIL–armed T cells (50 pg per T cell) at an 
E:T ratio of 5:1. (E) Activated T cells were double stained for CD3 and CD69, whereupon CD69low, CD69medium, and CD69high populations 
were sorted from the CD3-positive cells. (F) OvCAR-3 cells were treated with CD69low, CD69medium, and CD69high and corresponding 
K12:TRAIL/anti-CD3:TRAIL–armed T-cell populations (50 pg per T cell) for 16 hours at an E:T ratio of 1:1. (G) Activated T cells were 
separated into CD4 and CD8 populations, whereupon OvCAR-3 cells were treated with the different T-cell populations and K12:TRAIL/
anti-CD3:TRAIL–loaded populations (50 pg per T cell) for 16 hours at an E:T ratio of 5:1.
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no apparent weight loss (data not shown). In addition, fibroblasts (NHDF-juv), normal kidney cells (HK-2), and 
endothelial cells (HUVEC) were resistant to cotreatment with K12:TRAIL and T cells (Supplementary Figure S5D). 
Similarly, cotreatment of mice with T cells and anti-CD3:TRAIL resulted in a striking increase in median survival 
with 4 of 5 mice remaining tumor free for the duration of the experiment (Figure 4A and C). Treatment with anti-
CD3:TRAIL alone had no effect on animal survival (Figure 4C). Of note, while no deleterious effects on animal 
well being were observed during the course of the experiment, the in vitro treatment of NHDF-juv, HK-2, and 
HUVECs with T cells and anti-CD3:TRAIL did trigger an increase in the percentage of apoptosis (Supplementary 
Figure S5D). To determine whether T cells localized to the intraperitoneally growing tumor cells, fluorescently 
labeled T cells were followed up to 5 days in an intraperitoneal tumor model with HCT-116–luc (Figure 4D). 
Treatment with activated T cells or activated T cells + anti-CD3:TRAIL resulted in colocalization of bioluminescent 
(tumor) and fluorescent (T cell) signal in tumor nodes in the abdominal cavity after 2 days but not after 5 days 
(Figure 4D). Upon treatment with activated T cells + K12:TRAIL (Figure 4D), the T cells were found to colocalize 
with tumor signal until tumor cells were eliminated (Figure 4D). Taken together, K12:TRAIL and anti-CD3:TRAIL 
potently enhance antitumor activity of T cells and inhibit growth of colorectal xenografts in vivo.
K12:TRAIL and anti-CD3:TRAIL are compatible with experimental strategies to ameliorate GVHD and 
optimize GVT
Earlier studies have shown that TRAIL expression on T cells is required for optimal GVT activity during AHCT but 
does not exacerbate GVHD. Therefore, it was examined whether K12:TRAIL could be used in conjunction with 
therapies currently being evaluated for optimizing AHCT. In particular, the so-called histone deacytelase inhibitors 
(HDACi) inhibit GVHD in preclinical settings16,17 but are also well known to synergize with the proapoptotic 
activity of TRAIL18,19. Of note, HDACi do not potentiate the GVT effect. In line with this, pretreatment with HDACi 
VPA did not enhance the tumoricidal activity of T cells alone (Figure 5A). In contrast, pretreatment of OvCAR-3 
cells with VPA strongly optimized the potentiating effect of K12:TRAIL and anti-CD3:TRAIL on tumoricidal T-cell 
activity, with approximately 30% and 50% cell death in OvCAR-3 at E:T ratio of 1:50, respectively (Figure 5A–C). 
Interestingly, VPA enhanced the antitumor effect of K12:TRAIL, but not anti-CD3:TRAIL, toward 2 patient-derived 
tumor samples (Figure 5D).
Various other strategies have been developed to selectively enhance GVT or ameliorate GVHD without 
affecting GVT. These strategies include the selective depletion of a population of alloreactive CD69high T cells 
before infusion20 or selectively transferring only CD4+, CD8+, or CD25+ cells21. K12:TRAIL and anti-CD3:TRAIL 
potentiated the tumoricidal activity of isolated CD69low, CD69medium, or CD69high T-cell populations to a similar 
degree (Figure 5F). Similarly, K12:TRAIL and anti-CD3:TRAIL potentiated the tumoricidal activity of sorted CD4+ 
and CD8+ T cells to a level similar to that observed in nonsorted T cells (Figure 5G). Therefore, K12:TRAIL and anti-
CD3:TRAIL appear suitable for integration in existing strategies for optimizing AHCT.
DISCUSSION
Here, we report on the preclinical evaluation of a new strategy designed to deliver high levels of the proapoptotic 
effector molecule TRAIL to the surface of T cells and thereby safely augment antitumor T-cell activity. Arming T 
cells with anti-CD3:TRAIL or K12:TRAIL resulted in a more than 500-fold increase in tumoricidal activity toward 
both cancer cell lines and primary patient-derived malignant cells. In addition, cotreatment with anti-CD3:TRAIL 
or K12:TRAIL and T cells significantly prolonged survival time of xenografted mice.
K12:TRAIL enhanced the tumoricidal activity of T cells by activation of proapoptotic TRAIL receptor 
signaling in tumor cells. Surprisingly, the potentiating activity of anti-CD3:TRAIL was found to be predominantly 
because of granzyme/perforin signaling, analogous to the activity of T-cell–redirecting bispecific antibodies. In 
line with this mechanism of redirected lysis, anti-CD3:TRAIL triggered CD3-mediated calcium flux because of 
mechanical stress acting on the anti-CD3:TRAIL–CD3 complex. These findings corroborate with a recent report 
that suggests that CD3 in the T-cell receptor complex functions as a mechanoreceptor translating shear stresses 
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into signaling15,22. In this way, the function of anti-CD3:TRAIL appears analogous to artificial antigen-presenting 
complexes or native major histocompatibility complex molecules. In view of these activating properties, anti-
CD3:TRAIL may be particularly suited for ex vivo tumor cell purging of bone marrow. In addition, anti-CD3:TRAIL 
may be used in patients that suffer from malignant disease that is restricted to an anatomically confined 
region. Of interest in this respect are peritonitis carcinomatosis patients that undergo heated intraperitoneal 
chemotherapy (HIPEC), an operation in which anti-CD3:TRAIL may easily be incorporated.
Applicability of K12:TRAIL is likely not limited to a specific kind of T-cell immunotherapy but may be applied 
to ex vivo expanded tumor infiltrating lymphocytes, engineered T cells, T-cell bodies, as well as in GVT activity 
during AHCT. Indeed, perhaps the most obvious application of T-cell–specific delivery of TRAIL using K12:TRAIL 
would be in the context of AHCT. Alloreactive donor T cells are the primary mediators of GVT activity as well 
as GVHD. Earlier studies have shown that TRAIL expression on T cells was required for optimal GVT, whereas 
TRAIL did not contribute to GVHD10. Although not investigated here, the data of the current study suggest 
that targeted delivery of TRAIL to donor T cells using K12:TRAIL may be of value to selectively enhance GVT. 
Interestingly, novel GVHD inhibitors, such as HDACi16,17 or rapamycin23, are also known to sensitize cancer cells 
to TRAIL-induced apoptosis18,19. In line with this, our experiments show further optimization of the potentiating 
effect of K12:TRAIL by pretreatment of tumor cells with the HDACi VPA. Thus, rationally designed combinatorial 
strategies that include K12:TRAIL may well yield optimal GVT activity with no/minimal GVHD.
The here described immunotherapeutic approach to optimize T-cell immunotherapy may be further 
explored using TRAIL fusion proteins that incorporate other immunomodulatory scFvs or ligands that would 
simultaneously provide stimulatory signals to T cells and add TRAIL signaling to the T-cell armamentarium. 
Likely combinations to this effect include stimulatory anti-CD28 scFvs24 or inhibitory scFvs directed against 
cytotoxic T-lymphocyte antigen 4 (CTLA-4; ref. 25). In this respect, targeted activation of CTLA-4 signaling using 
a fusion protein CTLA-4:TRAIL has been shown to limit T-cell activity and ameliorate autoimmunity in preclinical 
models26. Reversely, inhibition of CTLA-4 signaling may potentiate antitumor T-cell activity.
In conclusion, cell surface delivery of TRAIL to T cells potently augments the antitumor activity of T cells in 
vitro and in vivo and might be widely applicable in current/experimental T-cell–based strategies to optimize 
anticancer efficacy.
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Figure S1. (A) Anti-CD3 + IL-2 activated T-cells were treated with 50 pg/T-cell K12:TRAIL, 50 pg/T-cell anti-CD3:TRAIL or 2 μg/ml 
actinomycin D for 16h, after which cell death was quantified by flow cytometry. (B) Activated T-cells were incubated with OvCAR-3 
cells in the presence or absence of anti-MCSP:TRAIL (50 pg/T-cell) for 16h at the indicated E:T ratios and apoptosis was assessed in 
OvCAR-3 cells. (C) Activated T-cells were incubated with OvCAR-3 cells for 16h in the presence or absence of increasing concentrations 
of K12:TRAIL or (D) anti-CD3:TRAIL at an E:T ratio of 1:1 and apoptosis was assessed in OvCAR-3 cells. (E) T-cells were incubated 
with K12:TRAIL (50 pg/T-cells) or (F) anti-CD3:TRAIL (50 pg/T-cell) for 1h and washed three times with PBS. TRAIL expression was 
subsequently determined at the indicated time-points using a PE-conjugated anti-TRAIL mAb. (G) T-cells were pre-incubated with 
K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 pg/T-cell) for 0, 24 or 48h prior to addition to tumor cells. Tumor cells were subsequently 
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Figure S2. Expression of (A) TRAILR1 (B) TRAILR2 (C) TRAILR3 (D) TRAILR4 was determined on SK-OV-3, OvCAR-3, A2780, HCT-116, HCT-
8, HT29, A375M, A2058, SK-MEL-28, HEP3B, PLC-PRF-5, FADU, PC-3M and RAMOS and plotted against the Fold increase in apoptosis 
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Left: Figure S3. (A) Tumor cells and Lymphocytes derived from OC patient ascitic fluid were treated for 16h with anti-CD3:TRAIL (50 
pg/T-cell) and CD69 expression on lymphocytes was determined by flow cytometry using anti-CD3 as a T-cell marker. (B) T-cells were 
labeled with FLUO-3-AM and added to OvCAR-3 cells grown on glass inserts in a Petri dish. Subsequently, anti-CD3:TRAIL (50 pg/T-
cell) was added and Ca-flux was measured in T-cells (n=19).  (C) Resting T-cells were incubated ± tumor cells and anti-CD3:TRAIL (50 
pg/T-cell) in the presence or absence of TRAIL-neutralizing mAb 2E5, TRAILR blocking antibodies or pan-caspase inhibitor zVAD-fmk 
for 16h and CD69 expression on T-cells was assessed by flow cytometry. (D) Resting T-cells were co-incubated with tumor cells for 16h 
in the presence or absence of anti-CD3:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL+anti-TRAIL mAb. Alternatively, T-cells were treated with 
anti-CD3 mAb (2μg/mL). T-cell supernatants were harvested and relative cytokine levels in culture supernatant were determined by 
ELISA. (E) OvCAR-3 cells were coated in the top well of a trans-well system and resting T-cells were added to the top and bottom well. 
Subsequently, cells were treated with anti-CD3:TRAIL (50 pg/T-cell) or anti-CD3 mAb (2μg/mL) for 16h and CD69 expression on T-cells 
was assessed. 
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Figure S4. (A) Schematic representation of mechanical CD3-mediated Ca-flux. In brief, FLUO-3-AM labeled T-cells are added to TRAILR-
coated wells, after which a micropipette is used to induce mechanical shear stress and fluorescent intensity is monitored by microscopy. 
(B) Ca-Flux induced in anti-CD3:TRAIL-loaded T-cells on TRAIL-R1, -R2, -R3 or -R4 coated wells. (C) representative images of Ca-flux 




















































Figure S5. (A) OvCAR-3 cells were treated with rhTRAIL (100ng/mL) ±pan-caspase inhibitor zVAD-fmk, Cyclohexamide/TNF-α±Enbrel 
or FasL-Fc±anti-FasL mAb Alf2.1 and inhibition of apoptosis was assessed. (B) A375M cells were incubated for 4h at an E:T of 10:1 
with activated T-cells ± anti-CD3:TRAIL (50 pg/T-cell) in the presence of the indicated concentrations of concanamycin A. (C) OvCAR-3 
cells were treated with activated T-cells, anti-CD3:TRAIL-armed T-cells or activated T-cells redirected using bispecific antibody anti-
CD3xanti-EpCAM in the presence or absence of 10nM concanamycin A and apoptosis was assessed. (D) NHDF-juv, HK-2 and HUVEC 
cells were treated for 16h with activated T-cells ± K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 pg/T-cell) and apoptosis was assessed. 
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The therapeutic effect of anti-cancer monoclonal antibodies stems from their capacity to opsonize targeted 
cancer cells with subsequent phagocytic removal, induction of antibody-dependent cell-mediated cytotoxicity 
(ADCC) or induction of complement-mediated cytotoxicity (CDC). The major immune effector cells involved in 
these processes are natural killer (NK) cells and granulocytes. The latter and most prevalent blood cell population 
contributes to phagocytosis, but is not effective in inducing ADCC. Here, we report that targeted delivery of 
the tumoricidal protein tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to granulocyte marker 
C-type lectin-like molecule-1 (CLL1), using fusion protein CLL1:TRAIL, equips granulocytes with high levels of 
TRAIL. Upon CLL1-selective binding of this fusion protein, granulocytes acquire additional TRAIL-mediated 
cytotoxic activity that, importantly, potentiates antibody-mediated cytotoxicity of clinically used therapeutic 
antibodies (e.g., rituximab, cetuximab). Thus, CLL1:TRAIL could be used as an adjuvant to optimize the clinical 
potential of anticancer antibody therapy by augmenting tumoricidal activity of granulocytes.
Key words:
Leukocyte, Granulocyte, CLL1, TRAIL, ADCC, antibody-therapy
Abbreviations:
ADCC: antibody-dependent cell-mediated cytotoxicity, ADCP: antibody-dependent cellular phagocytosis, CLL1: 
C-type lectin-like molecule-1, scFv: single-chain variable fragment, TRAIL: TNF-related apoptosis-inducing ligand
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INTRODUCTION
Therapeutic anti-cancer antibodies have become part of clinical practice and have significantly contributed 
towards improved patient survival in various malignancies1,2. Nevertheless, the efficacy of antibody-based 
anti-cancer approaches is still hampered by various mechanisms, including relapses of target antigen-negative 
disease, as well as intrinsic or acquired resistance to cytotoxic immune effector mechanisms3. Therefore, 
strategies that further augment the efficacy of antibody-based anti-cancer approaches are warranted. 
The therapeutic effect of anti-cancer antibodies can derive from inhibition of target antigen-signaling 
and from their capacity to opsonize targeted cancer cells with subsequent phagocytic removal, induction of 
antibody-dependent cell-mediated cytotoxicity (ADCC) or induction of complement-mediated cytotoxicity 
(CDC). Immune effector cells involved in these processes are natural killer (NK) cells, monocytes/macrophages 
and granulocytes. Granulocytes, the most prevalent white blood cell, comprise ~60% of all leukocytes in human 
blood. Granulocytes are professional phagocytes and efficiently remove target cells upon interaction of target 
cell-bound antibodies with their high affinity Fc receptors (FcR)2,4. However, granulocytes are relatively weak 
inducers of (tumor) cell lysis via ADCC, especially when compared to NK cells. 
Previously, we demonstrated that the tumoricidal activity of immune cells, specifically T cells, can be 
enhanced using the tumoricidal protein tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)5. TRAIL 
is expressed as type II transmembrane protein on NK-cells, where it is essential for NK cell–mediated immune 
surveillance of cancer cells6,7. Proteolytic processing of the extracellular domain of TRAIL generates a soluble 
form of TRAIL (sTRAIL) that retains prominent tumor-selective pro-apoptotic activity. Hence, recombinant sTRAIL 
is a promising effector molecule that is currently undergoing clinical evaluation8. By genetic fusion of sTRAIL 
to a T-cell selective antibody fragment, we previously showed that high levels of TRAIL could be delivered to 
the surface of T cells, hereby increasing their tumoricidal activity up to 500-fold5. In addition, a recent report 
demonstrated that coating leukocytes with TRAIL could trigger killing of cancer cells in the blood stream9. In line 
with this, we recently demonstrated that antibody fragment-mediated targeting of TRAIL to CD47 could improve 
the pro-phagocytic and apoptotic activity of leukocytes10.
Here, we propose to augment the tumoricidal activity of granulocytes by surface delivery of high levels of 
TRAIL to C-type lectin-like molecule-1 (CLL1) using a CLL1-specific scFv antibody fragment. CLL1 is highly an 
selectively expressed on granulocytes, monocytes and dendritic cells, whereas other normal human cell types 
do not express CLL111. Therefore, we hypothesized that CLL1:TRAIL would potentiate the tumoricidal activity 




Antibodies for flow cytometry used in this study were: PE-conjugated anti-TRAIL (Diaclone SAS, Besancon, 
France), anti-CD14-APC, anti-CD16-PE-Dy647, anti-CD16-FITC (Immunotools). Reagents used in this study where: 
TRAIL-neutralizing mAb 2E5 (Alexis, Kordia Life Sciences, Leiden, The Netherlands), recombinant human sTRAIL 
was from R&D systems (Oxon, UK), zIETDfmk was purchased from Calbiochem® (Merck Millipore). Cetuximab, 
rituximab, alemtuzumab were obtained from the hospital pharmacy. A CD38-targeted Daratumumab analogue 
was generated in-house (see below).
Construction and production of CLL-1 minibody and Daratumumab analogue
A DNA insert encoding scFvCLL-1 and scFvDaratumumab was synthesized based on published VH and VL DNA 
sequence data by DNA2.0 (Menlo Park, USA). Chimeric anti-CLL-1 and daratumumab minibodies were generated 
using the previously published anti-EpCAM minibody containing plasmid pEE14-MOC-Fc26. Briefly, the anti-
EpCAM scFvMOC31 was swapped for scFvCLL-1 or scFvDaratumumab using unique SfiI and NotI restriction sites. 
Recombinant proteins were produced essentially as described before27.
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Cell lines and leukocytes
Leukemia cell lines U-937 (AML, CLL1+) and Ramos (B-CLL, CLL1-) were purchased from the ATCC (Manassas, 
USA). Carcinoma cell lines DLD-1 (colon), FaDu (hypopharyngeal), were also from ATCC. All cell lines were 
cultured in RPMI-1640 (Cambrex, New Jersey, New Hampshire, USA), supplemented with 10% (v/v) FCS. Primary 
human keratinocytes were cultured in serum free keratinocyte culture medium (BioWhittaker Europe SPRL, 
Belgium), human fibroblasts (NHDFjuv) were cultured in DMEM (Cambrex, New Jersey, New Hampshire, USA), 
supplemented with 10% (v/v) FCS, and primary human melanocytes were cultured in melanocyte growth 
medium (Cell applications, Inc.)  CLL1+ transfectant Ramos cells (Ramos.CLL1) were generated by electroporation 
with eukaryotic expression plasmid pCLL-1-IRIS2-EGFP. All above described cells were maintained at 37ºC/5% 
CO2.
After written informed consent, human leukocytes were obtained from venous blood from healthy 
volunteers using ammonium chloride lysis. Leukocytes were subsequently stimulated with IFN-γ (10 ng/ml, 
Immunotools) at a concentration of 1x106/ml for 1h at 37oC. Isolated granulocytes were obtained by negative 
selection using MACS with anti-CD14/anti-CD3/anti-CD56/anti-CD19 microbead cocktail (Miltenyi Biotec).
Immunoblot analysis of CLL1:TRAIL
CLL1:TRAIL (1μg) was separated by non-reducing SDS/PAGE (12% acrylamide) under reduing (β-mercaptoethanol 
and sample boiling) or nonreducing (without β-mercaptoethanol and sample boiling) and was subsequently 
electroblotted to nitrocellulose. Detection of CLL:TRAIL was performed by incubation with horseradish 
peroxidase-conjugated HA-tag antibody (Genscript), after which specific binding was visualized using 
chemoluminescence (WestDura Thermoscientific). Antibody incubation was performed at room temperature 
in PBS/5% skim milk for 1,5 h and followed by 3 washes with PBS/0,1%TWEEN. Coomassie blue staining of the 
gel was performed via standard protocol. In brief, the gel was stained with coomassie blue (Biorad) for 2h, and 
subsequently destained  (5% methanol, 7% Acetic acid in H2O). 
Size-exclusion FPLC of CLL1:TRAIL
The solution behavior of CLL1:TRAIL was analyzed by size exclusion (SE) FPLC using a calibrated HiLoad 26/60 
Superdex 200 Prep grade column (Amersham Biosciences AB, Upsala, Sweden). CLL1:TRAIL (5 ml) was loaded 
onto the column after which individual samples were collected at 1-minute intervals. All samples were analyzed 
for their capacity to induce apoptosis using the CLL1-positive and TRAIL sensitive cell line U937.
Flow cytometric analysis of cell surface TRAIL
For binding analysis of CLL1:TRAIL, CLL1 negative Ramos and Ramos.CLL1 cells were incubated with CLL1:TRAIL 
in the presence or absence of 10-fold molar excess of epitope-blocking CLL1 minibody, whereupon membrane 
expression of TRAIL was determined by incubating cells with anti-TRAIL-PE antibody at 4oC for 45 minutes. This 
was followed by 2 washes with excess PBS, after which binding was analyzed by flow cytometry on an Accuri C6 
flow cytometer (BD biosciences). To analyze loading of TRAIL on the surface of specific leukocyte populations, 
leukocytes were incubated with CLL1:TRAIL and stained with anti-TRAIL-PE. In addition, anti-CD16 and anti-
CD14 staining was performed to separately analyze TRAIL staining in granulocytes and monocytes, respectively. 
Assessment of induction of cell death/ loss of cell viability
Experiments were performed by mixing 3x104 tumor cells with leukocytes and/or fusion protein simultaneously 
in the E:T ratio/ concentrations as indicated. Of note, the E:T ratio of granulocytes and tumor cells was determined 
by flow cytometry based on FCS/SCC. Ratios were calculated by, after mixing leukocytes with tumor cell, gating 
on the granulocyte (Effector) and tumor cell (Target) populations (Supplementary Figure S1B). Thus, although 
all different leukocyte populations were present, the ratio was based on the number of granulocytes. Where 
indicated, competing CLL-1 minibody, anti-TRAIL mAb 2E5 or caspase-8 inhibitor zIETD-fmk or the various 
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therapeutic antibodies were added to the mixed culture 30 min. prior to treatment with CLL1:TRAIL. After 24 h 
treatment, cell death was assessed by determining phosphatidylserine (PS) exposure on the outer membrane. 
PS on the outer membrane was analyzed by flow cytometry using AnnexinV-FITC (Immunotools, Friesoythe, 
Germany). In brief, all cells were harvested and washed with cold calcium binding buffer and resuspended in 
calcium buffer containing Annexin-V-FITC. After 10 min incubation at 4˚C, PS-exposure was analyzed by flow 
cytometry using a BD Accuri C6 flow cytometer (BD Biosciences) and accessory CFlow Plus analysis software. 
Of note, tumor cells were gated based on FCS/ SCC, and AnnexinV-FITC binding was determined within this 
population. Correct separation was confirmed by fluorescent labeling of tumor cells, which enabled exclusion of 
granulocytes based on fluorescence (Supplementary Figure S1C) and, additionally, by labeling of granulocytes 
with CD16 antibody (Supplementary Figure S2). In brief, tumor cells were DiD labeled (Vybrant® DiD cell-labeling 
solution, Life technologies) by incubating 1x106 cells/ ml in serum free media with 5 μM DiD for 10 minutes at 
37oC. Cells were washed to remove excess dye. 
Loss of mitochondrial membrane potential (∆y) was analyzed by flow cytometry using the cell-permeant 
green-fluorescent lipophilic dye DiOC6 (Molecular Probes, Eugene, USA). In brief, all cells were harvested and 
incubated for 20 min with DiOC6 (0.1 μM in medium) at 37°C. After washing, cells were resuspended in PBS and 
assessed by flow cytometry. Similar gating strategies as described for the determination of PS-exposure were 
used. Cell viability was measured using MTS according manufacturers protocol (CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay, Promega). In brief, 20% (v/v) MTS+PMS was added to culture medium of 
treated cells, and absorbance was measured at 490 nM after 1-2 hours of incubation at 37oC. Cells treated with 
70% ethanol were included as a background control whereby the obtained absorbance was subtracted from 
all experimental conditions. Of note, tumor cells were carefully washed (3x) with PBS to remove the leukocytes 
before performing the MTS assay. 
In addition, cell viability was determined using LDH-release assay (CytoTox 96® Non-Radioactive Cytotoxicity 
Assay, Promega) following manufacturers protocol. In brief, supernatants were collected, centrifuged to remove 
the death tumor cells and leukocytes, after which 50μl was tranfered to a 96-wells plate. Subsequently, 50μl 
of substrate mix was added to each sample and incubated for 30 min at room temperature. The reaction was 
stopped using 50μl stop solution, and absorbance was measured at 490 nM. Of note, for each experiment 
appropriate controls were included (maximum release control, spontaneous release control, effector cell release 
control).
Formation and treatment of 3D-tumor spheres
3D-tumor spheres were generated by culture of 3x106 cells in low adherent culture flasks (Costar) for 72 hours. 
Subsequently, spheres were collected and separated from the medium by gravity, and the spheres were then 
used in similar experiments as described for single cell experiments. To assess the induction of cell death in the 
3D-tumor spheres, spheres were harvested and washed with PBS. Subsequently, cells were dissociated using 10x 
trypsin-EDTA (Gibco) and then stained with DioC6 as described for single cell experiments.
Statistical analysis




Construction of fusion protein CLL1:TRAIL was performed using the previously reported eukaryotic expression 
plasmid pEE14scFv:sTRAIL. This vector exploits the strong CMV promoter to drive recombinant protein expression 
and contains the murine kappa light-chain leader peptide, the hemagglutinin (HA) affinity tag and 2 multiple 
cloning sites (MCSs) separated by a 26 amino acid in-frame linker sequence (for vector map see Figure 1A). In 
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the first MCS, a 729 base pair DNA fragment encoding scFvCLL-1 (scFv-357) was directionally inserted using the 
unique SfiI and NotI restriction enzyme sites. The second MCS contained a PCR-truncated 593 base pair DNA 
fragment encoding the extracellular domain of human TRAIL (sTRAIL) (for sequence and features see Figure 1B). 
The pEE14 vector encodes for the glutamine synthetase (GS) selection gene for protein expression in Chinese 
hamster ovary cells. This production platform produces and secretes correctly folded trimeric scFv:TRAIL fusion 
protein into the supernatant12 and was here exploited for the production of CLL1:TRAIL at a concentration of 5.3 
mg/L (for schematic representation of CLL1:TRAIL see Figure 1C). Coomassie staining and immunoblot analysis 
of purified CLL1:TRAIL revealed a single band close to the predicted molecular weight of 51kDa  after reducing 
SDS-PAGE (Figure 1D), whereas in non-reducing conditions (non-reducing SDS-PAGE without sample boiling) 
CLL1:TRAIL predominantly migrated at a MW corresponding to that of trimeric CLL1:TRAIL (Figure 1D). Further, 
size exclusion FPLC of CLL1:TRAIL was performed, after which separate fractions were tested for apoptotic 
Figure 1. Construction of CLL1:TRAIL. (A) Vector map of scFvCLL1:TRAIL, designated CLL1:TRAIL. (B) Amino acid sequence of 
CLL1:TRAIL. (C) Schematic diagram of CLL1:TRAIL components and active CLL1:TRAIL trimer. (D) Gel stained with coomassie blue of 
reduced CLL1:TRAIL (β-mercaptoethanol and sample boiling) and corresponding immunoblot (IB) stained with anti-HA-HRP, as well 
as immunoblot analysis of CLL1:TRAIL (anti-HA-HRP) under nonreducing conditions without sample boiling. Size exclusion FPLC was 
performed, after which all collected fractions were tested for their potential to induce cytotoxicity in CLL1+ U937 cells. Apoptosis was 
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activity on CLL1-positive U937 cells (Figure 1D). This analysis confirmed that the apoptotic activity of CLL1:TRAIL 
is found in fractions that match a molecular weight closely corresponding to that of trimeric CLL1:TRAIL, with no 
evidence of CLL1:TRAIL protein aggregates (Figure 1D).
CLL1-resticted binding and apoptotic activity of CLL1:TRAIL
In earlier studies, it was shown that scFv:TRAIL fusion proteins bind via the scFv-domain to the target antigen 
of choice, whereupon membrane-associated TRAIL is capable of triggering apoptosis of target cells. CLL1:TRAIL 
was analogously designed to selectively bind to CLL1, leading to display of membrane-bound TRAIL on the 
surface, and subsequently to activation of TRAIL-receptor mediated cancer cell apoptosis. To verify this mode 
of action, we used a model system composed of parental CLL1-negative Ramos cells and CLL1 transfectant 
Ramos.CLL1 cells. Incubation of parental Ramos cells with CLL1:TRAIL (250ng/ml) did not lead to detectable 
surface binding as evaluated by flow cytometric analysis with anti-TRAIL-PE antibody (Figure 2A, left panel). 
However, incubation of Ramos.CLL1 cells with CLL1:TRAIL (250ng/ml) at 0˚C led to strongly increased fluorescent 
intensity upon TRAIL-PE staining, indicating high levels of surface-bound CLL1:TRAIL. Binding of CLL1:TRAIL was 
strongly inhibited by pre-incubation with epitope-competing CLL1 minibody (Figure 2A, right panel, 2,5μg/
ml). In line with the lack of binding of CLL1:TRAIL to Ramos, treatment of these cells for 24 h with up to 500 
ng/ml CLL1:TRAIL did not significantly induce apoptosis (Figure 2B, EC50 >500ng/ml). In contrast, treatment 
of Ramos.CLL1 cells with CLL1:TRAIL potently induced apoptosis, with a maximum apoptotic effect of 97% at 
500ng/ml (Figure 2B, EC50 59.8ng/ml). Further, on CLL1-positive U937 acute myeloid leukemia cells, CLL1:TRAIL 
triggered apoptosis that was abrogated by the presence of anti-CLL1 minibody or TRAIL-neutralizing antibody 
2E5 (Figure 2C, EC50 36ng/ml). Subsequently, CLL1:TRAIL was serum and temperature stable since it retained 
CLL1-restricted activity after storage at different temperatures (-20oC, 4oC, 37oC) in 5% FCS (Figure 2D). Thus, 
CLL1:TRAIL specifically binds to the CLL1 target antigen, whereupon the surface-associated TRAIL domain 
induced cancer cell apoptosis.
CLL1:TRAIL selectively binds to and augments tumoricidal activity of granulocytes
CLL1:TRAIL was produced with the aim of selectively equipping granulocytes with surface TRAIL to augment 
the cytotoxic potential of granulocytes. In line with literature, freshly isolated granulocytes expressed only 
minimal amounts of full-length trans-membrane TRAIL on the cell surface (Figure 3A). However, incubation with 
CLL1:TRAIL (250ng/ml) markedly up-regulated TRAIL surface levels on granulocytes, an increase blocked by co-
incubation with epitope-competing anti-CLL1 minibody (Figure 3A, 2.5 μg/ml). Further analysis revealed that 
CLL1:TRAIL enhanced the display of TRAIL on the surface of CD16+ granulocytes, but also to a lesser extent on 
the surface of CD14+ monocytes (Figure 3B). 
In line with the reported limited cytotoxic potential of granulocytes, mixing of DLD-1 cells with leukocytes 
only minimally affected DLD-1 viability after 24 h, with only 20% reduction in cell viability at the highest effector 
(E; leukocyte) to target (T; tumor cell) ratio evaluated (E:T-ratio=10:1, Figure 3C). Treatment of CLL1-negative DLD-
1 cells with CLL1:TRAIL (200 ng/ml) alone did not reduce cell viability (Figure 3C, see E:T ratio of 0:1), although 
at a higher concentration of 1 μg/ml CLL1:TRAIL did induce apoptosis (data not shown). However, treatment of 
mixed leukocyte/DLD-1 cultures with CLL1:TRAIL (200 ng/ml) strongly reduced the viability of DLD-1 cells in an 
E:T ratio dependent manner (Figure 3C). Control treatment with a TRAIL-fusion protein of irrelevant specificity 
(MCSP:TRAIL; 200ng/ml) (Figure 3C), did not induce cell death, whereas MCSP:TRAIL did induce apoptosis in 
MCSP-positive melanoma cells (Supplementary Data S1A). Further, CLL1:TRAIL enhanced the cytotoxic potential 
of leukocytes (E:T-ratio=5:1) in a dose-dependent manner that was blocked by co-treatment with anti-CLL1 
minibody (Figure 3D, 2 μg/ml). The tumoricidal effect of CLL1:TRAIL (200 ng/ml) in DLD-1/leukocyte co-cultures 
(E:T-ratio 5:1) was blocked by co-treatment with TRAIL-neutralizing antibody (mab2E5; 1 μg/ml),  or caspase-8 
inhibitor (zIETDfmk; 20μM) (Figure 3E). Of note, the lactate dehydrogenase (LDH) release assay confirmed the 
results as obtained by MTS assays (Figure 3F). To confirm that granulocytes were the leukocyte population 
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responsible for the enhanced cytotoxic effect by CLL1:TRAIL, the same experiments were performed with isolated 
granulocytes. Indeed, when CLL1:TRAIL (500 ng/ml) was added to mixed cultures of isolated granulocytes and 
DLD-1 cells, DLD-1 viability was strongly reduced (Figure 3G). Similar potentiating effects of CLL1:TRAIL (200 ng/
ml) on granulocyte toxicity were observed when 3D-spheroid cultures of DLD-1 cells (E:T-ratio 10:1) were treated 
with this fusion protein (Figure 3H).
Importantly, CLL1:TRAIL (500 ng/ml) did not induce apoptosis in CLL-1 positive leukocyte populations, i.e., 
in granulocytes or monocytes (Figure 4A). Further, treatment of primary human keratinocytes, melanocytes, 
fibroblasts and hepatocytes with CLL1:TRAIL (700 ng/ml) alone (Figure 4B), or in mixed cultures with leukocytes 
(Figure 4C) did not induce apoptosis. Thus, CLL1:TRAIL armed leukocytes, particularly granulocytes have 
enhanced tumoricidal activity without toxicity toward normal cells.
CLL1:TRAIL-armed leukocytes optimize the anti-cancer activity of therapeutic antibodies
The enhanced tumoricidal activity of granulocytes armed with CLL1:TRAIL might also improve the ADCC-
activity of clinically-approved antibodies. Indeed, co-treatment of EGFR-positive FaDu cells with EGFR-specific 
antibody cetuximab (CTX; 1 μg/ml) and CLL1:TRAIL-armed leukocytes (200 ng/ml) significantly enhanced pro-
apoptotic activity compared to single-agent treatment (Figure 5A), also in established 3D-tumor cell spheres 
(Figure 5B). Similarly, co-treatment of Ramos B-cells with CLL1:TRAIL-armed leukocytes (200 ng/ml) and CD20-
specific antibody rituximab (RTX; 1 μg/ml) significantly enhanced induction of apoptosis compared to leukocyte 
or rituximab treatment alone (Figure 5C). Control treatment of FaDu cells with rituximab and Ramos cells 
with cetuximab in combination with CLL1:TRAIL-armed leukocytes did not induce ADCC (Figure 5D). Further, 
CLL1:TRAIL-armed leukocytes (200 ng/ml) optimized the therapeutic activity of a humanized anti-CD38 antibody 
and anti-CD52 antibody alemtuzumab (1 μg/ml) on Ramos cells (Figure 5E). Similar results were obtained using 
B-cell lymphoma cell line Z138 for rituximab and anti-CD38 antibody (Figure 5D, E), but not for cetuximab and 
alemtuzumab as Z138 does not express EGFR or CD52. For all antibodies, the potentiating effect of CLL1:TRAIL-
armed leukocytes was blocked by co-incubation with anti-CLL1 minibody (2,5 μg/ml) (Figure 5D,E). Importantly, 
combination treatment of primary human keratinocytes with CLL1:TRAIL-armed leukocytes and rituximab 
or cetuximab did not induce apoptosis (Figure 5F). Thus, binding of CLL1:TRAIL to CLL1-positive leukocytes 
potentiates anticancer ADCC activity of various clinically-approved antibodies without affecting normal healthy 
cells.
Figure 2. CLL1-resticted binding and apoptotic activity of CLL1:TRAIL. (A) Binding analysis of CLL1:TRAIL to Ramos (CLL1 
negative) and Ramos.CLL1 (CLL1 positive) cells, with and without blocking with aCLL1:Fc using flow cytometry. (B) Target-restricted 
induction of apoptosis by increasing doses of CLL1: TRAIL was analyzed using Ramos and Ramos.CLL1. Apoptosis was analyzed using 
flow cytometric Annexin-V staining. (C) U937 (CLL1 positive) cells were treated with CLL1:TRAIL (250 ng/ml) in the presence or absence 
of aCLL1:Fc (2.5 mg/ml) or TRAIL neutralizing mAb2E5 (1 mg/ml) and apoptosis was determined using flow cytometric analysis of 
DioC6 staining. (D) CLL1:TRAIL was stored for up to 7 d in 5% FCS at -20ºC, 4ºC, and 37ºC, after which CLL1-restricted activity was 
analyzed on the Ramos.CLL-1/Ramos cell line pair. Apoptosis was determined by Annexin-V staining. All graphs represent mean+SD. 
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Figure 3. CLL1:TRAIL selectively binds to and augments tumoricidal activity of granulocytes. (A) Flow cytometric analysis 
of CLL1:TRAIL binding to the surface of granulocytes, with and without aCLL1:Fc. (B) Within the granulocyte (CD16 positive) and 
monocyte (CD14 positive) population, the binding of CLL1:TRAIL to their cell surface was analyzed. (C) DLD-1 colon carcinoma cells 
(Target: T) were incubated with increasing amounts of leukocytes (Effector: E) (E:T ratio) in the presence or absence of CLL1:TRAIL 
(200 ng/ml) or MCSP:TRAIL (200 ng/ml) for 24 h, after which cell viability was assessed by MTS assay. (D) DLD-1 colon carcinoma cells 
were incubated with increasing concentrations of CLL1:TRAIL in the presence or absence of leukocytes (E:T = 5:1) and cell viability was 
assessed. CLL1 restricted activity of the fusion protein was evaluated by co-incubation with competing aCLL1:Fc minibody. (E) TRAIL- 
and caspase-dependent apoptosis was evaluated by co-incubating CLL1:TRAIL (200 ng/ml) and leukocytes (E:T = 5:1) with anti-TRAIL 
mab2E5 (1 mg/ml), and caspase-8 inhibitor zIETD-fmk (20 mM). (F) As in (C), but cytotoxicity was analyzed using LDH-release assay 
(G) DLD-1 colon carcinoma cells were incubated with CLL1:TRAIL (500 ng/ml) in co-cultures with increasing amounts of leukocytes or 
isolated granulocytes. Cell viability  was determined using MTS assay. (H) Apoptosis induction of leukocytes (E:T = 10:1) and CLL1:TRAIL 
(200 ng/ml) was determined on DLD-1 3D-spheroids by Annexin-V staining on trypsin dissociated DLD-1 cells. All graphs represent 




















































































































































































































In the current study, we report on fusion protein CLL-1:TRAIL that arms leukocytes, in particular granulocytes, 
with TRAIL. Hereby, CLL1:TRAIL enhanced the anti-tumor leukocyte activity per se and potentiated ADCC-activity 
of therapeutic anticancer antibodies. Thus, CLL1:TRAIL might be of clinical potential as adjuvant to optimize 
anticancer antibody-based therapy.
CLL1:TRAIL specifically augments the cytotoxic activity of granulocytes, a population of immune effector 
cells that has typically not attracted much attention for cancer therapy. However, granulocytes are an interesting 
target for immunotherapy, since they are the most abundant leukocyte population in the human blood 
(up to 60% of all leukocytes). Further, granulocytes have well-documented anticancer activity, with e.g., the 
administration of granulocytes reducing solid tumor growth and improving overall survival of tumor-bearing 
mice and rats13. Further, granulocytes are important anti-cancer immune effector cells in carcinoma, lymphoma 
and melanoma14,15, and are required for clinical activity of bladder cancer immunotherapy16.
The most important function of granulocytes is that of phagocytosis of target cells. To a far lesser extent, 
granulocytes can contribute to ADCC. Both these functions are regulated by interactions between cell-
surface FcR on granulocytes with the Fc of antibodies. Although granulocytes are very efficient phagocytes, 
their intrinsic potential to induce (tumor) cell lysis is only limited. Indeed, E:T ratios above 40:1 were needed 
to obtain significant monoclonal antibody-mediated lysis of cancer cells by granulocytes in previous studies, 
with only 20-35% cell death at an E:T ratio of 10:117,18. In contrast, CLL1:TRAIL-armed granulocytes at the same 
E:T ratio triggered ~90% apoptosis in DLD-1 cells without additional monoclonal antibodies, whereas >70% of 
Figure 4. CLL1:TRAIL has no toxicity toward normal cells. (A) The effect of CLL1:TRAIL (500 ng/ml) on CLL-1 positive leukocytes 
was determined by assessing apoptosis (Annexin-V) by flow cytometry in CD16-positive granulocytes and CD14-positive monocytes, 
after 16 h treatment (using anti-CD14-APC, anti-CD16-PE-Dy647). Of note, leukocytes were stimulated with 10 ng/ml IFNγ to reduce 
spontaneous apoptosis which normally occurs in granulocytes. (B) Primary normal human cells were treated with CLL1:TRAIL (700 ng/
















































































FaDu cells were killed when CLL1:TRAIL-armed granulocytes were combined with CTX. Thus, CLL1:TRAIL-coated 
granulocytes can eliminate targeted cells not only by virtue of their intrinsic capacity for ADCC, but also by 
virtue of the cytotoxic activity conveyed by membrane-bound TRAIL. Of note, rational choice of the therapeutic 
antibody may contribute to the efficacy of TRAIL-mediated apoptosis by inhibition of target antigen-signaling. 
In this respect, we have previously published that an anti-EGFR:TRAIL fusion protein (termed scFv425:sTRAIL) can 
simultaneously inhibit EGFR-signaling and activate TRAIL-apoptotic signaling, yielding prominent tumoricidal 
activity both in vitro and in vivo19,20. Thus, combinatorial treatment with cetuximab and CLL1:TRAIL may be an 
attractive lead candidate strategy.
Enhancing the cytotoxic potential of granulocytes has also been attempted in previous studies. For instance, 
in vivo administration of human granulocyte-colony-stimulating factor (G-CSF) in patients up-regulated the 
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Figure 5. CLL1:TRAIL-armed leukocytes enhance the anti-cancer activity of therapeutic antibodies. (A) FaDu cells (EGFR 
positive) were incubated with different ratios of leukocytes and treated with cetuximab (CTX, 1 mg/ml), CLL1:TRAIL (200 ng/ml) 
combinations thereof. (B) FaDu cells cultured in 3D-spheroids were incubated with leukocytes (E:T D 10:1) and treated with cetuximab 
(CTX, 1 mg/ml), CLL1:TRAIL (200 ng/ml) or the combination. (C) Ramos cells (CD20 positive) were incubated with different ratios of 
leukocytes and treated with rituximab (RTX, 1 mg/ml), CLL1:TRAIL (200 ng/ml) or the combination. (D) As in A and C, using FaDu, 
Ramos and Z138 cells. In addition, aCLL1:Fc was used to block the effects of CLL1:TRAIL. (E) As in D, using Ramos and Z138 cells treated 
with the anti-CD38 antibody (daratumumab analog) and anti-CD52 antibody alemtuzumab (E:T ratio = 5:1). (F) Primary normal 
human keratinocytes were treated with CLL1:TRAIL (700 ng/ml) and CTX or RTX (E:T ratio = 10:1). In all cases, apoptosis induction was 
determined using flow cytometric analysis of DioC6 staining. All graphs represent mean+SD. * p < 0.05, **p < 0.01, *** p < 0.001, n.s.: 
not significant, n.d.: not determined.
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expression of high affinity receptor FcγRI on granulocytes, and enhanced their cytotoxicity toward lymphoma 
cells21. In addition, the administration of G-CSF strongly increased the amount of circulating granulocytes in 
lymphoma bearing mice, which resulted in enhanced ADCC when combined with administration of RTX22. These 
results have led to the clinical evaluation of G-CSF and granulocyte-macrophage-colony-stimulating factor in 
the treatment of different cancer types23,24.
Notably, the current study demonstrates that CLL1:TRAIL can significantly enhance the ADCC activity of 
granulocytes when combined with therapeutic antibodies, including rituximab, cetuximab, alemtuzumab and a 
daratumumab-based minibody. Therefore, CLL1:TRAIL might be included in existing treatment protocols using 
G-CSF and therapeutic anti-cancer antibodies, e.g., by co-injection of CLL1:TRAIL and antibodies, to optimize 
therapeutic efficacy. Alternatively, activated granulocytes could be isolated and ex vivo loaded with CLL1:TRAIL 
after multiple cycles of G-CSF and anti-cancer antibody and re-infused into the patient. Of note, ex vivo loading 
of T-cells with similar scFv:TRAIL fusion proteins strongly reduced in vivo tumor growth in mice5.
In light of the in vivo use of CLL1:TRAIL it is important to note that the potentiating effect of CLL1:TRAIL on 
ADCC was target antigen specific, and will thus most likely not be associated with off-target and potentially toxic 
activity. Indeed, the application of non-binding antibodies did not enhance ADCC of TRAIL-loaded granulocytes. 
In addition, the combinational treatment of granulocytes, CLL1:TRAIL and different therapeutic antibodies was 
not cytotoxic toward primary normal human cells such as keratinocytes, melanocytes and fibroblasts. Further, 
TRAIL has proven to be safe in early clinical trials with no observations of dose-limiting toxicity25. Therefore, the 
use of CLL1:TRAIL in combination with therapeutic antibodies and possibly further combination with G-CSF may 
potentiate the anti-cancer efficacy of granulocytes in the absence of toxicity.
In conclusion, CLL1:TRAIL enhances leukocytic tumoricidal activity, particularly when combined with therapeutic 
anticancer antibodies like rituximab and cetuximab. Thus, CLL1:TRAIL might be of clinical potential as adjuvant 
to optimize anticancer antibody therapy in general.
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Supplementary Figure S1.  (A) A375M cells (MCSP+) were treated with MCSP:TRAIL (200ng/ml) for 24h, and cell viability was 
determined by MTS assay. (B) Cell death in tumor cells was determined by flow cytometry, by gating on the tumor cells based on FSC/ 
SCC. The reliability of this approach was confirmed by additional labeling of tumor cells (DLD-1) with the fluorescent dye DiD (Life 
technologies). In gate P1, all cells are positive for DiD, whereas leukocytes in gate P2, are DiD negative. Of note, the effector to target 
ratio (E:T) was determined based on this gating strategy at the start of each experiment. The induction of cell death was evaluated 
within the DiD positive cells (as also shown in Figure S1C). (C) As in B, the percentage of death tumor cells (FaDu) was analyzed within 
the DiD positive gate (R1). To exclude that dying effector cells are present within the tumor gate (P1) the percentage of DiD- cells 
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Supplementary Figure S2. To exclude that dying effector cells are bound to target cells in experiments including antibodies, an anti-
CD16 staining (anti-CD16-FITC) was performed. The different treatment conditions do not enhance the presence of CD16 positive cells 
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Chapter IV
The expedient removal of dying, damaged or altered cells by phagocytosis is essential for homeostasis. However, 
cancer cells can evade such phagocytic elimination by cell surface-upregulation of phagocyte-inhibitory signals, 
such as CD47. CD47 is a prominent ‘don’t eat me’ signal that binds to signal-regulatory protein alpha (SIRPα/
SIRPA) expressed on phagocytes1. The CD47-SIRPα interaction triggers phosphorylation of the immunoreceptor 
tyrosine-based inhibition motif (ITIM) of SIRPα and thereby potently inhibits phagocyte activity. Both solid and 
haematological malignancies hijack this inhibitory pathway by overexpression of CD472-5. 
Recent studies indicated that blocking of CD47-SIRPα interaction promotes phagocytic elimination of CD47 
overexpressing tumour cells2,6. For instance, treatment of human B-cell non-Hodgkin lymphomas (B-NHL)-
engrafted mice with CD47-blocking monoclonal antibody (MAb) B6H12 reduced lymphoma burden, improved 
survival and inhibited extranodal dissemination2,3. Further combination of this CD47-blocking antibody with 
the therapeutic antibody rituximab (RTX; a chimeric anti-CD20 IgG1) triggered synergistic anticancer activity in 
vivo2. In addition, inhibition of CD47-SIRPα interaction enhanced the killing of trastuzumab-opsonized breast 
cancer cells4. Thus, CD47-SIRPα blocking strategies can enhance the efficacy of anticancer antibodies. 
Phagocytosis induced by RTX was also enhanced by F(ab’)2 fragments of MAb B6H122. This finding opens up 
the possibility for design of immunotherapeutics that combine CD47 blockade with alternate effector moieties. 
Here, we explored this possibility by genetic fusion of a CD47-blocking antibody fragment (scFv) to the pro-
apoptotic immune effector molecule TRAIL (tumour necrosis factor [TNF]-related apoptosis-inducing ligand). 
TRAIL is a death ligand of the TNF-ligand superfamily that has pronounced tumour-selective pro-apoptotic 
activity (reviewed in7). In phase I clinical trials, TRAIL treatment triggered minimal toxicity and, when combined 
with RTX, produced clinical responses in B-NHL patients8. This new fusion protein, designated anti-CD47:TRAIL, 
was designed to 1) block CD47-SIRPa interaction and hereby potentiate phagocytosis induced by RTX, and 2) 
concurrently trigger CD47-restricted apoptotic cell death in malignant B-cells. 
To assess the effect of anti-CD47:TRAIL on RTX-induced phagocytosis, we performed mixed culture 
experiments with B-NHL cells and granulocytes as phagocytic effector cells as they are one of the most prevalent 
population of professional phagocytes. To this end, 1,10-dioctadecyl-3,3,30,30–tetramethylindodicarbocyanine 
(DiD)-labelled CD20+/CD47+ B-NHL cells (Figure S1A–B) were mixed with granulocytes and incubated in the 
presence of RTX, MAb B6H12 or anti-CD47:TRAIL and combinations thereof. Subsequently, phagocytosis 
was determined by flow cytometry (see Figure S1C for gating strategy). Treatment with RTX induced rapid 
phagocytosis of CD20+ B-NHL cells, whereas treatment with anti-CD47:TRAIL alone did not (Figure 1A). However, 
cotreatment with RTX and anti-CD47:TRAIL significantly increased tumour cell phagocytosis compared to 
RTX alone (Figure 1A, P < 0.05). These flow cytometry data were corroborated by microscopy data, which 
revealed prominent tumour cell engulfment by granulocytes upon co-treatment (Figure 1B). The potentiating 
effect of anti-CD47:TRAIL on RTX-mediated phagocytosis was dose-dependent and apparent at low  ng/ml 
concentrations of anti-CD47:TRAIL (Figure 1C). Importantly, anti-CD47:TRAIL also enhanced phagocytic removal 
of primary patient–derived B-NHL cells (Figure 1D). 
Of note, at these concentrations MAb B6H12 did not potentiate RTX-induced phagocytosis (Figure 1A-
D), which is in apparent contrast with a previous report in which MAb B6H12 did synergize RTX-mediated 
phagocytosis2. However, in our experiments we used significantly lower concentrations of both RTX and 
MAb B6H12 (RTX; 2.5 µg/ml vs. 10 μg/ml, MAb B6H12; 250 ng/ml vs. 10 µg/ml, respectively). Further, we used 
granulocytes as phagocytic effector cells, whereas Chao et al used macrophages2. Third, TRAIL forms a stable 
homotrimer in scFv:TRAIL proteins9. Hence, trivalent binding by anti-CD47:TRAIL may result in a significantly 
higher CD47 blocking capacity compared with the bivalent blocking capacity of MAb B6H12. Phagocytosis 
induction by RTX and anti-CD47:TRAIL was abrogated at 0°C, indicating that tumour cells were eliminated 
by active phagocytosis (Figure 1E). Furthermore, co-treatment of CD20- Namalwa cells with RTX and anti-
CD47:TRAIL did not enhance phagocytosis. Likewise, co-treatment of B-cell lines with anti-CD47:TRAIL and 
cetuximab (CTX; a chimeric anti-epidermal growth factor receptor IgG1) failed to enhance phagocytosis (Figure 
1F). Thus, anti-CD47:TRAIL selectively enhanced antibody-mediated phagocytosis of B-NHL cells by RTX in a 
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Figure 1. Anti-CD47:TRAIL enhances the phagocytic activity of Rituximab. (A) B cell non- Hodgkin lymphoma (B-NHL) cell lines 
(1,10 -dioctadecyl-3,3,30,30–tetramethylindodicarbocyanine [DiD]-labelled) were mixed with human granulocytes (1:1 ratio) pre-
activated for 2 h with 50 ng/ml γ-interferon (IFN-γ) and 10 ng/ml granulocyte colony-stimulating factor. Subsequently, mixed cultures 
were incubated for 2 h at 37°C in the presence of medium, rituximab, (RTX, 2.5 µg/ml), monoclonal antibody (mAb) B6H12 (250 ng/
ml), anti-CD47:TRAIL (250 ng/ml) or combinations thereof. Granulocyte-mediated phagocytosis of tumour cells was determined by 
flow cytometry. (B) Fluorescent picture of the phagocytosis assay showing engulfed DiD-labelled tumour cells inside the granulocytes. 
(C) Phagocytosis induced by RTX in the presence of increasing concentrations of anti-CD47:TRAIL or Mab B6H12 as determined by 
flow cytometry. (D) Phagocytosis induced by RTX treatment in the presence or absence of anti-CD47:TRAIL or MAb B6H12 in primary 
patient-derived malignant B-cells (n = 5) as determined by flow cytometry. (E) Phagocytosis experiment as in (A), but performed at 
37°C and 0°C to demonstrate elimination by active phagocytosis. (F) Phagocytosis in CD20+ and CD20- B-cell lines induced by RTX in 
the presence or absence of anti-CD47:TRAIL. In a control experiment, anti-CD47:TRAIL was combined with Cetuximab (CTX), a chimeric 
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Figure 2.  Anti-CD47:TRAIL induces apoptosis in B-NHL tumour cells via TRAIL-R signaling and CD47 cross-linking. (A) Direct 
apoptosis inducing activity was investigated by incubating B cell non-Hodgkin lymphoma (B-NHL) cell lines with anti-CD47:TRAIL 
(250 ng/ml) and MAb B6H12 (250 ng/ml) in a 48-well plate (3x104/well) for 20 h at 37°C in the absence of granulocytes. Apoptosis was 
determined by flow cytometry using an Annexin-V/ Propidium Iodide kit. (B) Primary tumour cells derived from B-NHL patients (n = 5) 
and peripheral blood lymphocytes from healthy volunteers were treated as in (A). (C) Granulocytes and Ramos cells were mixed (E:T 
ratio of 10:1) and treated with the different agents to determine induction of apoptosis in the presence of granulocytes. (D) Direct pro-
apoptotic activity of anti-CD47:TRAIL was investigated in the presence or absence of the pan-caspase inhibitor zVADfmk (40 µM) or the 
TRAIL neutralizing monoclonal antibody 2E5 (2 µg/ml). KillerTRAIL was used as a positive control (1 µg/ml). (E) Schematic representation 
of the proposed mode of action of anti-CD47:TRAIL. 1. binding of anti-CD47:TRAIL to CD47 blocks interaction between CD47 and SIRPα 
and thereby enhances the phagocytic activity of granulocytes as induced during treatment with RTX. 2. anti-CD47:TRAIL binding to 
CD47 cross-links CD47, which triggers caspase-independent cell death signalling in malignant B-cells. 3. binding of anti-CD47:TRAIL to 
CD47 leads to cell surface accretion of TRAIL, which allows for CD47-restricted activation of TRAIL/TRAIL-receptor caspase-dependent 
apoptotic cell death of CD47+ malignant B-cells.
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target antigen-restricted manner. 
Previously, we and others demonstrated that scFv:TRAIL fusion proteins have target antigen-restricted 
pro-apoptotic activity towards cancer cells (reviewed in7). In line with this, anti-CD47:TRAIL triggered apoptosis 
in CD47+ B-cell lines and in 4 of 5 primary malignant B-NHL  samples (Figure 2A, 2B). Importantly, normal 
blood cells were fully resistant to treatment with anti-CD47:TRAIL (Figure 2B). Furthermore, anti-CD47:TRAIL 
potentiated RTX-mediated pro-apoptotic activity in the presence of granulocytes (Figure 2C). 
In line with published data, treatment with MAb B6H12 alone did not induce apoptosis (Figure 2A)2. 
Nevertheless, CD47 cross-linking by other anti-CD47 antibodies was reported to trigger caspase-independent 
cell death. In this respect, a bivalent form of the antibody fragment used in anti-CD47:TRAIL was previously 
shown to trigger CD47-mediated apoptosis in B-NHL cells10. Thus, anti-CD47:TRAIL may have dual pro-apoptotic 
signalling capacity via CD47 cross-linking (caspase-independent) and via target-antigen restricted crosslinking 
of agonistic TRAIL-receptors (caspase-dependent). In line with this, the apoptotic activity of anti-CD47:TRAIL was 
only partly blocked by pan-caspase inhibitor zVAD-fmk, whereas the pro-apoptotic activity of a constitutively 
active TRAIL preparation was completely blocked (Fig 2D). Furthermore, TRAIL-neutralizing MAb 2E5 only partly 
inhibited apoptosis induction by anti-CD47:TRAIL (Figure 2D). Thus, anti-CD47:TRAIL appears to concurrently 
trigger apoptosis via CD47-crosslinking and TRAIL-receptor signalling. 
As CD47 is widely expressed, the use of therapeutic intact humanized or chimerized anti-CD47 antibodies 
of selected isotypes may trigger toxicity towards normal cells by antibody-dependent cellular cytotoxicity and/
or antibody-dependent cellular phagocytosis. In contrast, anti-CD47:TRAIL inhibits CD47-SIRPα interactions 
without this potential risk for Fc-mediated toxicity. 
In conclusion, anti-CD47:TRAIL effectively blocks CD47- mediated ‘don’t eat me’ signalling, promotes 
RTX-induced phagocytosis by granulocytes and triggers CD47-restricted apoptosis in malignant B-cells (for 
schematic see Figure 2E). This multifunctional therapeutic activity of anti-CD47:TRAIL may be of general use for 
optimizing antibody-based cancer therapy and serves as proof of concept for combining CD47-blockade with 
alternate effector principles that may further synergize anticancer activity.
Acknowledgements
This work was supported by Dutch Cancer Society grants RUG 2009-4355 (E.B.), RUG2009-4542 (E.B./W.H.) 
RUG2007-3784 (W.H./E.B.), RUG2012-5541 (W.H./E.B.), the Netherlands Organization for Scientific Research (E.B.), 
the Alexander von Humboldt Foundation (E.B.) and the European Community’s Seventh Framework Programme 
(FP7/2007–2013) under grant agreement [grant number 215009] (P.E.). The authors thank dr. Marco de Bruyn for 
his help in drafting the figures. 
References
1. Oldenborg, P.A., Gresham, H.D., & Lindberg, F.P. (2001) CD47-signal regulatory protein alpha (SIRPalpha) regulates 
Fcgamma and complement receptor-mediated phagocytosis. J.Exp.Med., 193, 855-862.
2. Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., Jan, M., Cha, A.C., Chan, C.K., Tan, B.T., Park, C.Y., 
Zhao, F., Kohrt, H.E., Malumbres, R., Briones, J., Gascoyne, R.D., Lossos, I.S., Levy, R., Weissman, I.L., & Majeti, R. (2010) Anti-
CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142, 
699-713.
3. Chao, M.P., Tang, C. Pachynski, R.K., Chin, R., Majeti, R & Weissman, I.L.,(2011) Extranodal dissemination of non-Hodgkin 
lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy Blood, 118, 4890-4901
4. Zhao, X.W., van Beek, E.M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M.A., Finetti, P., Van Egmond, M., 
Matozaki, T., Kraal, G., Birnbaum, D., van Elsas, A., Kuijpers, T.W., Bertucci, F & van den Berg, T.K. CD47-signal regulatory 
protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A, 108, 
18342-18347.
5. Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., Wang, J., Contreras-Trujillo, H., Martin, R., 
Cohen, J.D., Lovelace, P., Scheeren, F.A., Chao, M.P., Weiskopf, K., Tang, C., Volkmer, A.K., Naik, T.J., Storm, T.A., Mosley, A.R., 
Edris, B., Schmid, S.M., Sun, C.K., Chua, M.S., Murillo, O., Rajendran, P., Cha, A.C., Chin, R.K., Kim, D., Adorno, M., Raveh, T., 
Tseng, D., Jaiswal, S., Enger, P.O., Steinberg, G.K., Li, G., So, S.K., Majeti, R., Harsh, G.R., van de Rijn, M., Teng, N.N., Sunwoo, 
60
Chapter IV
J.B., Alizadeh, A.A., Clarke, M.F., & Weissman, I.L. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a 
therapeutic target for human solid tumors. Proc.Natl.Acad.Sci.U.S.A, 109, 6662-6667.
6. Kim, D., Wang, J., Willingham, S.B., Martin, R., Wernig, G., & Weissman, I.L. (2012) Anti-CD47 antibodies promote 
phagocytosis and inhibit the growth of human myeloma cells. Leukemia, 26, 2538-2545.
7.  Bremer, E., de Bruyn, M., Wajant, H., & Helfrich, W. (2009) Targeted cancer immunotherapy using ligands of the tumor 
necrosis factor super-family. Curr.Drug Targets., 10, 94-103.
8. Fox, N.L., Humphreys, R., Luster, T.A., Klein, J., & Gallant, G. (2010) Tumor Necrosis Factor-related apoptosis-inducing ligand 
(TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert.Opin.Biol.Ther., 10, 1-18.
9. Bremer, E., Kuijlen, J., Samplonius, D., Walczak, H., de Leij, L., & Helfrich, W. (2004) Target cell-restricted and -enhanced 
apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. 
Int.J.Cancer, 109, 281-290.
10. Kikuchi, Y., Uno, S., Yoshimura, Y., Otabe, K., Iida, S., Oheda, M., Fukushima, N., & Tsuchiya, M. (2004) A bivalent single-chain 
Fv fragment against CD47 induces apoptosis for leukemic cells. Biochem.Biophys.Res.Commun., 315, 912-918.
Supplementary Data S1: (A) Expression of CD20 and CD47 in the used cell lines as determined by flow cytometry. (B) Expression of 
CD20 and CD47  in patient derived primary B-NHL  cells as  determined by flow cytometry. (C) Gating strategy of the phagocytosis 
assay analyzed by flow cytometry. Gate P1 shows the granulocytes  determined on forward/ sideward scatter (left).  Within gate P1 
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Phagocytic removal of cancer cells upon treatment with pro-apoptotic therapeutics such as TRAIL is governed 
by a balance between anti- and pro-phagocytic molecules on the cancer cell surface. The most prominent anti-
phagocytic receptor is CD47, which is expressed on virtually all cells of the human body. Normal CD47 expression 
on healthy cells prevent untimely phagocytic removal by phagocytes, whereas down-regulation of CD47 
expression,  e.g. on damaged or aged cells, promote phagocytic removal. Cancer cells often miss-use this ‘don’t 
eat me’ checkpoint by aberrantly overexpressing CD47, which allows them to evade phagocytic clearance and 
subsequent immunogenic tumor antigen processing. A dominant pro-phagocytic signal that counterbalances 
the ‘don’t eat me activity’ of CD47 can be provided by calreticulin. Calreticulin normally resides in the lumen 
of the endoplasmic reticulum (ER) inside cells. However, upon cellular stress as induced by certain anticancer 
therapies calreticulin can translocate to the cell surface. Here, calreticulin can interact with several receptors on 
phagocytes, which promotes the engulfment by phagocytes and dendritic cells (DCs) that may promote the 
induction of an antitumor immune response. In this review, we discuss the biology of CD47 and calreticulin with 
a focus on their role in phagocytic removal. Further, the effect of the immune effector molecule tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) on this phagocytic axis is described. Moreover, we elaborate on 
several approaches that can be exploited to modulate either CD47, calreticulin or TRAIL signaling to enhance 
therapeutic cancer cell phagocytosis for cancer immunotherapy.
Key words: 
CD47, Calreticulin (CRT), tumor necrosis factor apoptosis inducing ligand (TRAIL) phagocytosis, cancer 
immunology, immunogenic cell death (ICD), therapeutic antibodies
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INTRODUCTION
Phagocytosis is an important homeostatic process that can be targeted to enhance the efficacy of cancer 
immunotherapy. The major negative regulator of phagocytosis is CD47, a 50 kDa pentaspan membrane 
glycoprotein that belongs to the immunoglobulin superfamily1. CD47 is best-known for its pivotal role in 
preventing phagocytic removal of normal cells. By binding to phagocyte-expressed signal regulatory protein 
alpha (SIRPα), CD47 triggers so-called ‘don’t eat me’ signaling in the phagocyte, which results in inhibition of 
its phagocytic activity2. Down-regulation of CD47 on damaged, aged and superfluous cells ensures their 
timely removal. This function of CD47 in cellular turn-over was first established in red blood cells almost two 
decades ago and is now considered to be a general homeostatic system2. Of note, both solid and hematologic 
malignancies overexpress CD47 and, thereby, essentially hijack this homeostatic system to evade phagocytic 
clearance3-10. One of the proteins that counterbalances anti-phagocytic CD47/SIRPα-signaling is calreticulin. 
Calreticulin normally resides in the lumen of the endoplasmic reticulum (ER) where it is, among others, involved 
in calcium homeostasis and protein folding11. However, under certain circumstances, calreticulin can translocate 
to the cell surface where it interacts with receptors of phagocytic immune cells like DCs. Here it functions as a 
so-called ”eat me signal”, that serves to promote phagocytic uptake, a function defined as a key feature of the 
process of immunogenic cell death (ICD)12. Immunogenic cell death involves a type of apoptosis that is induced 
by certain cytotoxic regimes e.g. by selected chemotherapeutics and radiation. These cytotoxic regimes appear 
to promote the phagocytic uptake of apoptotic cells by professional antigen presenting cells (APC), which may 
ultimately result in the induction of antitumor immune responses and clonal expansion of anticancer T cells13. 
This is evidenced by the fact that the prevention of extracellular calreticulin exposure, either by calreticulin 
knock-down or by inhibition of pathways required for translocation, abrogates the immunogenicity of cancer 
cells12,14. 
ICD has been reported for several cytotoxic therapies, including for a recombinant form of the Tumor 
Necrosis Factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL). Treatment with TRAIL induces cell surface 
exposure of calreticulin on cancer cells15. TRAIL is a member of the TNF superfamily that is expressed on various 
types of immune cells, including natural killer (NK) cells, T cells and natural killer T cells (NKT cells)16. Upon binding 
to its cognate receptors, TRAIL induces caspase-dependent apoptotic cell death in cancer cells, but not in normal 
healthy cells. Intriguingly, calreticulin was reported to directly interact with TRAIL as well as with other TNF family 
members such as CD40 ligand (CD40L) and FasL80. TRAIL treatment may therefore impact phagocytic uptake 
of (dying) cancer cells through modulating the balance between pro- and anti-phagocytic signals provided by 
calreticulin and CD47, respectively.
Here, we provide a concise overview on CD47, calreticulin, TRAIL and their binding partners and discuss 
their respective roles and interplay in the regulation of phagocytosis. In particular, this review focusses on how 
CD47, calreticulin and TRAIL may be therapeutically exploited to enhance the efficacy of cancer immunotherapy.
Expression of CD47 and its binding partners
Originally identified as an antigen expressed on ovarian carcinoma cells18, CD47 was found to be expressed on 
virtually all normal human cells19. CD47 occurs in four highly conserved isoforms that differ only in the length 
of their cytoplasmic domain. However, the difference in biological functions between these isoforms remains 
unclear. Of note, CD47 is overexpressed in many solid tumors and hematologic malignancies3,5-10, as well as in 
tumor-initiating bladder cancer cells and leukemic stem cells20,21. An increased level of CD47, both on the mRNA 
and protein level, is a negative prognostic factor in multiple types of cancer5,6,8,20 and is associated with poor 
clinical outcome5,6,8,20,22.
The best-characterized binding partner of CD47 is SIRPα (also termed CD172a or SHPS-1). SIRPα is a 
transmembrane protein consisting of three extracellular Ig-like domains, a transmembrane domain and an 
intracellular tail containing four immunoreceptor tyrosine-based inhibitory motifs (ITIMs)23. SIRPα belongs to 
the signal regulatory protein receptor family, which is divided in a SIRPα and SIRPβ subgroup. Expression of 
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SIRPα is restricted to phagocytes (macrophages, granulocytes and DCs) and neuronal cells24. CD47 can also bind 
to SIRPβ2 (also termed SIRPγ), among others expressed on CD3-positive T cells25, albeit with a lower affinity than 
to SIRPα26.
CD47 can also bind various other ligands, most notably thrombospondin-1 (TSP-1), a large matricellular and 
homotrimeric glycoprotein (430 kDa) comprising at least six different structural domains of which the C-terminal 
domain binds to CD4727. TSP-1 is a pleiotropic protein involved in platelet aggregation, cell-cell and cell-matrix 
interactions, and (neo)vascularization. TSP-1 overexpression decreases the number of blood vessels and tumor 
size as was shown in mouse models of squamous cell mammary carcinoma28,29. Furthermore, TSP-1 expression 
is inversely correlated with malignant progression in various types of cancer, including melanoma, breast, lung 
and bladder cancer30-33. Recently, CD47 was reported to be also directly associated with vascular endothelial 
growth factor (VEGF) receptor-2 (VEGFR-2) expression on T cells34. The interaction of VEGF with VEGFR-2 inhibits 
T cell activation, whereas the interaction of CD47 with VEGFR-2 promotes T cell activation. However, the main 
focus of this review is on the modulation of (cancer) cell phagocytosis based on the interaction between CD47 
and SIRPα . 
Inhibition of phagocytosis through CD47/SIRPα interaction
Interaction of CD47 with the N-terminal IgV domain of SIRPα promotes the  phosphorylation of its intracellular 
ITIM motifs, leading to concomitant activation of SHP-1 and SHP-2 phosphatases35-37. Subsequent downstream 
signaling events include inhibition of myosin IIA accumulation at the phagocytic synapse38 and suppression of 
respiratory burst in phagocytes39. In line with the hypothesis that CD47 overexpression suppresses phagocytosis, 
ectopic overexpression of CD47 in CD47lo MOLM-13 myeloid leukemia cells inhibited in vitro and in vivo 
phagocytosis and increased tumor outgrowth3. Reversely, dissemination of Raji NHL cells was strongly reduced 
after shRNA knockdown of CD474. In addition, disruption of CD47-SIRPα signaling by either mutagenesis of 
macrophage-expressed SIRPα or by treatment with recombinant SIRPα-Fc eliminated AML xenografts in mice40. 
Thus, cancer cells can escape from phagocytic removal by upregulation of CD47 expression, which inhibits 
myeloid cell activity by binding to SIRPα (Figure 1A).
Therapeutic targeting of CD47 activity in cancer immunity
The therapeutic potential of targeting the immunoregulatory role of CD47 has been mainly investigated using 
monoclonal antibodies that disrupt CD47/SIRPα interaction. Anti-CD47 monoclonal antibody (mAb) B6H12 
inhibited in vivo outgrowth and subsequent dissemination of xenotransplanted solid tumors and human 
primary NHL lymphoma cells4,8,10. Further, in vivo outgrowth of human leukemia cells was inhibited by both 
CD47- and SIRPα- blocking antibodies3,6,20. This therapeutic effect strictly required the presence of macrophage 
effector cells as this effect was abrogated after depletion of macrophages by clonodrate treatment3,6,20.
Nevertheless, the mechanism of CD47 antibody-mediated in in vivo tumor depletion remains debated. 
Specifically, the dominant therapeutic mode-of-action of intact CD47 IgG antibodies may come from their 
intrinsic capacity to induce antibody-dependent cellular cytotoxicity (ADCC) and FcR-dependent phagocytosis 
rather than from their capacity for blocking the CD47/SIRPα interaction. Indeed, injection of murine anti-CD47 
mAb clone MIAP410 that does not block CD47/SIRPα interaction41 also significantly inhibited tumor growth in 
immunocompetent mice8. Nevertheless, inhibition of CD47/SIRPα interaction alone can potentiate phagocytosis 
since CD47 targeted F(ab’)2 fragments did induce phagocytosis of NHL cells by mouse macrophages in vitro, 
whereas rituximab derived F(ab’)2 fragments did not5. Further, treatment of transgenic mice lacking SIRPα 
inhibitory signaling (by deletion of its cytoplasmic domain) with suboptimal concentrations of an anti-melanoma 
therapeutic antibody (mAb TA99) yielded effective anticancer activity, indicating that SIRPα-derived negative 
signaling limits antibody-mediated phagocytic elimination of target cells in vivo7.
Thus, the activity of CD47-blocking antibodies may partly be attributed to blocking of the CD47 ‘don’t 
eat me’ signal and partly to conventional antibody effector functions upon binding to CD47 on cancer cells. 
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cells with signal regulatory protein α (SIRPα) on phagocytes results in inhibition of phagocytosis. (B) The use of whole anti‐CD47 IgG 
antibodies (containing an Fc‐domain) blocks the interaction of CD47 with SIRPα, whereby phagocytosis is promoted. This may also 
partly mediated by induction of ADCC via the Fc‐domain of the IgG antibody. The application of a therapeutic antibody enhances the 
pro‐phagocytic effect induced CD47-SIRPα blockade. (C) The use of F(ab’)2 fragments derived from a CD47-blocking antibody (lacking 
the Fc‐domain) showed pro-phagocytic in some studies, whereas others required the presence of a complete functional antibody. The 
application of a therapeutic antibody enhanced the therapeutic effect of F(ab’)2-mediated CD47‐blockade
Interestingly, in the above-described SIRPα-signaling deficient mouse model, tumor outgrowth was not 
affected in the absence of therapeutic antibody mAb TA99, indicating that blocking of CD47/SIRPα signaling 
in itself is not sufficient for eliminating cancer cells7,42,43. Based on these data, the blocking of the CD47 anti-
phagocytic signal may only effectively elicit phagocytosis of target cells when combined with a prominent 
pro-phagocytic (therapeutic antibody) signal44. Preclinical data support this premise, since treatment with a 
CD47-blocking antibody or CD47 knockdown in SKBR3 breast cancer cells potentiated the antitumor activity of 
anti-Her-2 antibody trastuzumab7. Moreover, combination treatment of NHL cells with rituximab and a CD47-
blocking antibody enhanced phagocytic elimination of cancer cells compared to rituximab alone (Figure 1B)6. 
This synergistic enhancement was also observed when a F(ab’)2 fragment of CD47-blocking antibody was co-
administered with rituximab6 (Figure 1C). Thus, probably the most effective use of releasing the brake on the 
immune response by blocking CD47 is in the context of combinatorial treatment with a therapeutic anticancer 
antibody.
Expression of calreticulin and its binding partners
Calreticulin was isolated for the first time from muscle cells in 1974, where it was recognized as a high calcium 
binding protein, and therefore called ‘high affinity calcium binding protein’45. After cloning of its gene and 
subsequent deduction of its amino acid sequence, it was uncovered that this protein was identical to other 
already known calcium binding proteins and the name “calreticulin” was proposed and accepted46. Calreticulin 
normally resides in the lumen of the endoplasmic reticulum (ER) and is comprised of 3 different functional 
domains, N, P, and C. Attached to the C-domain is the KDEL sequence, which retains calreticulin in the lumen 
of the ER after post-translational modification by the Golgi apparatus47. Calreticulin is involved in many aspects 
of both normal physiology and pathology and can interact with various molecules. In particular, calreticulin 
functions as a strong calcium binder and regulator of calcium homeostasis48. Furthermore calreticulin is involved 
in correct protein folding49,50, and loading of antigenic peptides into MHC molecules51. Although normally 
residing in the lumen of the ER, calreticulin can also be found on the surface of ‘stressed’ cells12,52-56 and in serum 
of both cancer and autoimmune patients52,57,58. Extracellular calreticulin is known to affect diverse processes, via 
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e.g. binding to complement C1q53,59-61. C1q is the first subcomponent of the C1 complex of the classical pathway 
of complement activation and can interact with its Cq1 receptor as well as components of the immune system62. 
Binding C1q to the C1q receptor on phagocytes enhances their capacity to engulf cells/particles and mediates 
superoxidative bursts. Calreticulin also binds to Low Density Lipoprotein Receptor-related Protein 1 (LRP-1, 
also known as CD91)63, a receptor expressed on many different cell types involved in endocytic activity. In this 
respect, hepatocytes appear to express LRP-1 to clear certain plasma proteins, whereas phagocytes express LRP-
1 to regulate phagocytosis64. Like CD47, calreticulin can also interact with TSP-1, an interaction which is mainly 
involved in cell adhesion65. Furthermore, calreticulin can interact with different members of the tumor necrosis 
factor (TNF) family, as will be discussed later in this review.
Calreticulin is a counter receptor for CD47 in the regulation of phagocytosis
An important function of surface-expressed calreticulin is to promote phagocytosis of apoptotic cells. This 
evidenced by the fact that incubation with calreticulin-blocking antibodies decreased the phagocytic uptake 
of apoptotic fibroblasts, neutrophils and Jurkat T cells63. Furthermore, apoptotic calreticulin-deficient mouse 
embryonic fibroblasts were not phagocytosed by macrophages. Reciprocally, exogenous addition of calreticulin 
to apoptotic cells promoted their engulfment by phagocytes. Blocking of LRP-1 using antibodies or siRNA-
mediated knockdown technology, abrogated phagocytosis indicating that calreticulin-mediated removal of 
apoptotic cells occurs through this receptor63,66. Importantly, the stimulation of phagocytosis by calreticulin 
can be both via a cis interaction in which calreticulin and LRP-1 are present on the same phagocytic cell, as 
well as via a trans interaction in which calreticulin exposed on the apoptotic cell interacts with LRP-1 on the 
responding immune cell. In case of cis activation, C1q together with mannose binding lectin (MBL) bind to 
the surface of apoptotic cells that have to be cleared. Furthermore, both C1q and MBL directly interact with 
calreticulin that is expressed on the macrophage. Calreticulin then interacts with LRP-1, expressed on the same 
macrophage, which then facilitates phagocytic removal of the apoptotic cell66. Of note, cell surface expression 
of calreticulin on macrophages is controlled by the toll like receptor (TLR)- Bruton’s tyrosine kinase pathway, in 
which phosphorylation of CRT results in cleavage of its KDEL-sequence and subsequent secretion and binding to 
LRP-1 on the cell surface67. During trans activation of LRP-1 by calreticulin, surface exposed calreticulin interacts 
with LRP-1 on the phagocytic cell. However, since viable cells can also express calreticulin on their surface, there 
must be an additional signal that activates phagocytosis of dying and/ or damaged cells only. In line with this, 
the induction of surface calreticulin in the absence of apoptosis did not induce phagocytosis68. Indeed, the 
cell surface distribution pattern of calreticulin changes during apoptosis, with calreticulin co-localizing with 
phosphatidyl serine (PS) in calreticulin-PS-rich patches12,63. Importantly, PS is a very potent pro-phagocytic signal 
to which calreticulin can directly bind with high affinity (KD =1.5 x 10-5 M) in a calcium-dependent manner59. 
These calreticulin-PS-rich patches also segregate away from surface CD47, whereby the “don’t eat me” signal of 
CD47 is converted to a “eat me signal” provided by calreticulin and PS63 (Figure 2A).  However, as described above 
cancer cells often disturb this process by overexpressing CD47 to evade phagocytic removal and subsequent 
immunogenic processing3,44. 
Induction of calreticulin exposure by cancer therapeutics
Extracellular calreticulin appears essential for the induction of so-called “immunogenic cell death”, i.e. cell death 
which leads to the induction of an antitumor immune response. In this process, surface-exposed calreticulin 
facilitates the phagocytosis of dying cancer cells by myeloid dendritic cells, via trans activation, with concomitant 
DC-mediated presentation of tumor-derived antigens to T cells and clonal T cell expansion12,63,69. Interestingly, 
several anticancer therapeutics induce translocation of calreticulin to the cancer cell membrane, most notably 
anthracyclins and UV-radiation therapy12. In addition, treatment with hypericin (a photodynamic compound)70,71 
or thapsigargin (an ER-inhibitor)15 also elevated the levels of calreticulin on the cancer cell surface. Besides 
extracellular calreticulin exposure, certain other ‘danger molecules’ or damage-associated molecular patterns 
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(DAMPs) contribute to induction of ICD72,73. DAMPs normally reside inside the cell, but are released into the 
extracellular space when cells become ‘leaky’ during later stages of cell death. Among others, these include 
HMGB-1, HSP90 and ATP. The combination of pro-immunogenic signals of calreticulin and various other DAMPs 
is known to promote DC-mediated phagocytosis, DC maturation, antigen presentation, and development of T 
cell immunity (Figure 2B).
The mechanism that triggers calreticulin translocation during therapy-induced cancer cell death is not 
completely known. However, a common denominator of ICD-inducing therapeutics is that they all induce an ER 
stress response, in particular the phosphorylation of eIF2α15,74. Indeed, the expression of an inactive mutant form 
of eIF2α completely abolished calreticulin exposure upon anthracyclin therapy, whereas it did not affect the 
induction of cell death15. In addition, most therapies that promote calreticulin translocation induce the formation 
of reactive oxygen species (ROS). In line with this, ROS-scavengers decrease the exposure of calreticulin on cells 
Figure 2: Extracellular calreticulin acts as pro‐phagocytic signal that counteracts CD47 inhibitory signaling. (A) On  viable 
normal cells, CD47 and membrane calreticulin are present in clusters. In these clusters the ‘don’t eat me’ signal provided by CD47 
dominates over the pro‐phagocytic signal provided by calreticulin. Although calreticulin can interact with the LRP‐1 receptor on the 
phagocyte, the interaction CD47‐SIRPα prevents phagocytic uptake. (B) On a pre‐apoptotic cell, CD47 segregates from calreticulin 
and associates with membrane exposed phosphatidyl serine (PS). Calreticulin/PS containing patches provide a potent pro‐phagocytic 
signal which triggers the engulfment of the dying cell by phagocytes. (C) In (tumor) cells, calreticulin predominantly resides in the 
lumen of the ER. Upon induction of immunogenic cell death by, e.g.  anthracycline or radiation therapy, calreticulin translocates to the 
surface of pre‐apoptotic cells. In addition, surface-exposed calreticulin (‘eat me signal’) dissociates from CD47 (‘don’t eat me signal’), 
whereupon the apoptotic cancer cells is recognized and taken up by dendritic cells (DCs). In addition to calreticulin exposure certain 
other ‘danger molecules’ are needed for the  induction of an anticancer immune response. Among these are heat shock proteins (HSPs), 
high mobility group box‐1 (HMGB‐1) and ATP, which are released in the extracellular space when cellular integrity is lost or target cell 
become leaky in late stages of cell death.
68
Chapter V
treated with anthracyclins, radiation or hypericin15. Of note, non-immunogenic cell death can be converted 
to immunogenic cell death by co-treatment with exogenous recombinant calreticulin12. In line with this, the 
use of a whole-cell based vaccine coated with recombinant calreticulin enhanced the activation of DCs and 
induced a tumor-specific immune response in mice75. Furthermore, enhancing the expression of calreticulin on 
monocytes/ macrophages also improves cancer cell phagocytosis67.
Expression of TRAIL and its binding partners
Tumor necrosis factor (TNF) apoptosis inducing ligand (TRAIL) is a member of the TNF-superfamily expressed of 
which is detected on various types of immune cells, including natural killer (NK) cells, T cells and natural killer T 
cells (NKT cells)16. TRAIL is an important immune effector molecule that plays a role in NK cell mediated cancer 
immune surveillance in which transformed cells are killed at an early stage of their development17. TRAIL can 
bind to 5 receptors TRAILR1 (DR4), TRAILR2 (DR5), TRAIL-R3 (DcR1, TRID), TRAIL-R4 (DcR2, TRUNDD), and to the 
soluble receptor osteoprotegerin. Of these receptors, only TRAILR1 and TRAILR2 are able to convey apoptotic 
death76. The interaction between TRAIL and agonistic receptors TRAILR1 or TRAILR2 induces assembly of the 
so-called death inducing signaling complex (DISC) to the intracellular Death Domain (DD). The DISC contains 
the adaptor molecule Fas-Associated protein with Death Domain (FADD) and the pro-form of initiator caspase-8. 
Auto-proteolytic activation of caspase-8 in the DISC triggers a proteolytic caspase cascade that ultimately leads 
to the execution of apoptosis. Of note, the pro-apoptotic signaling of the DISC can be inhibited by recruitment 
of additional regulators, such as cFLIP76. The expression of TRAIL on T cells is increased upon T cell receptor 
(TCR) stimulation and in the presence of interferon-γ (IFNγ)77. Similarly, IFNγ-mediated activation of NK cells, 
monocytes and DCs enhances the expression of TRAIL on these cells78,79.
Direct interaction of calreticulin with TRAIL and TRAILR2
As described, treatment with TRAIL can induce the translocation of calreticulin to the cell membrane of tumor 
cells. Interestingly, calreticulin can also directly interact with TRAIL and other TNF family members, like CD40 
ligand (CD40L) and FasL, as was shown using a catching-type ELISA experiment80. In line with this, calreticulin 
was reported to bind to sFasL in the synovial fluid of rheumatoid arthritis patients81 and to FasL expressed on 
neuronal cells after ischemia82. Our studies confirmed a similar direct interaction of calreticulin with TRAIL83. 
Here we showed that calreticulin not only interacted with TRAIL, but also strongly co-localized with the TRAIL, 
TRAIL-R2 and the DISC. Furthermore, the interaction of calreticulin with TRAIL was necessary for its association 
with TRAILR2 as calreticulin was not co-immunoprecipitated with TRAILR2 upon treatment with agonistic 
TRAILR2 antibody. Thus, physical interaction of TRAIL with calreticulin appears to mediate its recruitment to 
the DISC of TRAILR2. In an earlier study on TNFR-signaling, surface expressed calreticulin was reported to be 
recruited to TNF receptor 1 (TNFR1) and its adaptor TNFR-associated death domain (TRADD) upon treatment 
with bacterial peptidoglycan N-acetylmuramyl-L-alanyl-D-isoglutamine (L,D-MDP)84.
The role of TRAIL-mediated cell death in phagocytosis regulation
Our results and those of others indicate that treatment of cancer cells with TRAIL can induce calreticulin 
translocation to the tumor cell surface15,83. Specifically, we demonstrated that cell surface-expressed calreticulin 
dissociates from CD47 and is subsequently recruited to the TRAIL/TRAILR/DISC complex. Of note, in some cases 
of immunogenic cell death, the activation of caspase-8 was necessary to induce calreticulin exposure on the 
cell membrane as caspase-8 depletion abrogated the translocation of calreticulin15. Together, this suggests that 
treatment with TRAIL promotes ICD by inducing caspase-8 mediated apoptotic cell death and by enhancing 
surface levels of calreticulin and PS. Simultaneously, treatment with TRAIL induces segregation of CD47 away 
from the calreticulin-PS-rich patches, which all together promotes phagocytosis (Figure 3A). On the other 
hand, the association with the TRAILR2-DISC might render calreticulin unable to effectuate pro-immunogenic 
removal of target cells by DCs. In this respect, it is tempting to speculate that upon binding to the TRAILR2-
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DISC, calreticulin is segregated from its membrane micro-domains that normally promote phagocytic uptake by 
phagocytes. As a result, a complex of TRAILR2-DISC and calreticulin may also inhibit immunogenic phagocytosis 
(Figure 3B).This speculation is in line with the non-immunogenic clearance of cells undergoing TRAIL-mediated 
programmed cell death69. To gain insight into the possible immunomodulatory role of calreticulin during TRAIL-
induced apoptosis, it will be imperative to characterize the particular complex or membrane micro-domain 
in which calreticulin resides during immunogenic cell death. Comparison of calreticulin localization upon 
treatment with typical immunogenic inducers may shed light on this issue. 
Future directions; the use of CD47, calreticulin and TRAIL in cancer therapy
In order to achieve optimal induction of cancer cell phagocytosis it may be necessary to selectively block 
CD47-mediated ‘don’t eat me’ signaling while simultaneously enhancing surface-exposure of calreticulin. 
In addition, dying cancer cells, especially those that expose PS on their membrane, are more easily engulfed 
by phagocytes as compared to viable cells. This calls for a strategy which blocks CD47, induces calreticulin 
exposure and simultaneously induces apoptotic cancer cell death. Furthermore, additional pro-phagocytic 
stimuli may be applied such as conventional therapeutic anticancer antibodies to enhance the phagocytic 
removal of cancer cells. Therefore, combination therapy using agents that induce calreticulin translocation, like 
anthracyclines or radiation, together with CD47-blocking antibodies may be of particular interest. This approach 
may be further optimized by using tumor targeting bispecific antibodies which target both CD47 and antigens 
that are selectively overexpressed on cancer cells, for instance CD20 for B-cell leukemia85, EpCAM/ EGFR on 
Figure 3: TRAIL‐mediated induction of (immunogenic) cell death and the possible effects on phagocytosis
The binding of TRAIL to its receptor (TRAILR2) results in the translocation of calreticulin to the cell surface of cancer cells, whereby a 
complex is formed between TRAIL, TRAILR2–DISC, and calreticulin. Simultaneously, calreticulin dissociates from CD47. The formation 
of the TRAIL/TRAILR2/Calreticulin complex may have different outcomes: (A) As described for the concept of immunogenic cell death, 
cell surface exposure of calreticulin and dissociation from CD47 induced by TRAIL treatment may facilitate phagocytic uptake by DCs. 
(B) the binding of calreticulin to TRAIL and TRAILR2 may impair phagocytic clearance by DCs, as calreticulin may be segregated from 
the membrane microdomains in which it can partake in the phagocytic uptake by DCs.
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Figure 4: Perspectives for the promotion of cancer cell phagocytosis by modulating CD47, calreticulin and TRAIL signaling
For optimal induction of phagocytosis, a cancer cell should expose calretiuclin and phosphatidyl serine (PS) on the cell membrane 
while simultaneously CD47‐signaling should be blocked. Certain approaches may be used to achieve this goal. (A) Anthracylin 
therapy can be used to induce calreticulin and PS‐exposure. When combined with CD47‐blocking antibodies, this will promote tumor 
cell phagocytosis. To reduce the risk of CD47‐blocking on healthy cells, CD47‐directed bispecific antibodies can be used to selectively 
block CD47‐signaling on the tumor cells. (B) Calreticulin can be artificially delivered to the membrane of cancer cells using calreticulin‐
antibody conjugates. In particular, a CD47‐blocking antibody-calreticulin conjugate (CD47xcareticulin), can be used to simultaneously 
block CD47-mediated ‘don’t eat me’ signaling and provide calreticulin-mediated ‘eat me’ signaling. However, for such conjugate there 
is a risk for unwanted side effects toward normal healthy CD47‐expressing cells. Alternatively, CD20-targeted delivery of calreticulin 
(CD20xcalretiuclin) as well as CD20-targeted CD47‐blocking (CD20xCD47) may be used to increase tumor selective therapeutic 
phagocytosis. (C) Schematic representation of the proposed mode-of-action of anti‐CD47:TRAIL. 1. binding of anti‐CD47:TRAIL to 
CD47 blocks interaction between CD47 and SIRPα and thereby enhances the phagocytic activity of granulocytes as induced during 
treatment with RTX. 2. anti‐CD47:TRAIL binding to CD47 cross‐links CD47, which triggers caspase‐independent cell death signaling 
in malignant B‐cells. 3. binding of anti‐CD47:TRAIL to CD47 leads to cell surface accretion of TRAIL, which allows for CD47‐restricted 
activation of TRAIL/TRAIL‐receptor caspase‐dependent apoptotic cell death of CD47+ malignant B‐cells.
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epithelial cancers (Figure 4A). In addition, in case of non-immunogenic therapeutic agents, the simultaneous 
administration of calreticulin together with CD47-blocking antibodies may promote phagocytic elimination of 
cancer cells. This can be achieved by fusion constructs of a CD47-blocking antibody with calreticulin (Figure 4B). 
However, it should be taken into account that this may lead to a serious risk of promoting phagocytosis of normal 
CD47-expessing cells. This problem may be overcome by the simultaneous administration of tumor targeted 
fusion proteins (e.g. anti-CD20xcalreticulin and anti-CD20xanti-CD47). In addition, a CD47-targeting antibody 
fragment can be used in fusion proteins to simultaneously deliver cytotoxic agents, such as TRAIL, to the tumor. 
Indeed, we showed that scFvCD47:TRAIL, a fusion protein comprised of a CD47-blocking antibody fragment 
and TRAIL, induced CD47-restricted apoptosis, and enhanced antibody-mediated phagocytosis (Figure 4C)86. 
Of note, a recent study showed that the inhibition of calreticulin on macrophages (cis activation) diminished 
phagocytosis, whereas blocking of calreticulin on cancer cells (trans activation) yielded no effect67. This suggests 
that cis mediated calreticulin signaling has a specific role in phagocytosis by macrophages. In line with this 
suggestion, macrophages with a higher surface calreticulin expression showed a stronger phagocytic ability67. 
Hence, modulating calreticulin exposure on immune cells may also be of interest in enhancing anticancer 
activity.
CONCLUSION
In conclusion, the importance of CD47 and calreticulin in regulating target cell phagocytosis is well-established. 
Our investigations indicate that TRAIL and other members of the TNF family may also modulate this regulatory 
axis. Further research is needed to uncover their specific role in regulating (cancer) cell phagocytosis. This 
knowledge will contribute to the design of novel/ improved therapeutic strategies to enhance therapeutic 
phagocytic uptake of cancer cells in cancer immunotherapy.
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In recent years, an important role has emerged for the glycan-binding protein Galectin-9 (Gal-9) in health and 
disease. In normal physiology, Gal-9 seems to be a pivotal modulator of T-cell immunity by inducing apoptosis in 
specific T-cell subpopulations. Because these T-cell populations are associated with autoimmunity, inflammatory 
disease, and graft rejection, it was postulated that application of exogenous Gal-9 may limit pathogenic T-cell 
activity. Indeed, treatment with recombinant Gal-9 ameliorates disease activity in various preclinical models 
of autoimmunity and allograft graft rejection. In many solid cancers, the loss of Gal-9 expression is closely 
associated with metastatic progression. In line with this observation, treatment with recombinant Gal-9 prevents 
metastatic spread in various preclinical cancer models. In addition, various hematological malignancies are 
sensitive to apoptotic elimination by recombinant Gal-9. Here, we review the biology and physiological role of 
this versatile lectin and discuss the therapeutic potential of Gal-9 in various diseases, including autoimmunity, 
asthma, infection, and cancer.
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INTRODUCTION
Originally discovered as a potent eosinophil chemoattractant, Galectin-9 (Gal-9) is currently known as a versatile 
immunomodulator that affects a host of cell types. Gal-9 is a member of the galectin family of carbohydrate-
binding proteins that comprises at least 14 members. All galectin family members are characterized by the 
presence of one or two conserved carbohydrate-recognition domains (CRD) and share binding affinity for the 
basic carbohydrate unit galactose1,2. In addition to the basic glycan structures that are generally recognized by 
galectins, each individual galectin family member preferentially binds to a selective set of glycosylated proteins 
and/or lipids that may be located in the cell, on the cell surface, or in the extracellular matrix (ECM). Furthermore, 
galectins can form protein–protein complexes independent of CRD–glycoconjugate interactions. Consequently, 
galectin family members have a wide spectrum of potential target cells and biological functions. Of note, 
depending on the cellular localization of the respective binding partner, the activity of a particular galectin 
family member may be opposite. For instance, intracellular Gal-9 triggers proinflammatory cytokine expression 
in monocytes by binding to the transcription factor NF-IL63, whereas extracellular Gal-9 triggers monocyte cell 
death4. Interestingly, secretion of galectin family members occurs via a nonclassical pathway, as galectins lack a 
signal sequence for conventional extracellular transport5,6.
Monovalent binding between a galectin and a carbohydrate is of relative low affinity. However, galectin–
carbohydrate lattices of high affinity can be formed at the cell surface as a result of polyvalent crosslinking 
of glycoconjugates7,8, as illustrated in Figure 1 for Gal-9. Indeed, cell surface-associated biological activity of 
most galectins seems to depend on multivalent interaction with glycoconjugates, which may trigger raft (re)
organization and concomitant downstream signaling events, as reported for Galectin-1, -3, -4, and -99-12.
Recombinant Gal-9 has shown promising therapeutic activity in preclinical models of various diseases, 
including autoimmunity, asthma, cancer, and transplant rejection. This review aims to provide a comprehensive 
overview of the biology of Gal-9, its role in normal (T-cell) physiology, and its role in various pathological 
processes. Moreover, we will discuss and provide perspectives for the possible therapeutic application of Gal-9.
STRUCTURE AND BINDING PARTNERS OF GALECTIN-9
Structure of Galectin-9
Gal-9 is a so-called “tandem-repeat type” galectin family member that contains an N-terminal CRD (N-CRD) 
of 148 amino acids and a C-terminal CRD (C-CRD) of 149 amino acids. X-ray crystallography revealed that the 
N-CRD of human Gal-9 is composed of six-stranded (S1–S6) and five-stranded (F1–F5) β-sheets, which form a 
β-sandwich motif13,14. More recently, another N-terminal β-strand running antiparallel to the C-terminal F1 strand 
was reported and termed F0 (Figure 2)15. The overall structure of the C-CRD of human Gal-9 is highly similar to 
the N-CRD, with two antiparallel β-sheets comprised of S1–S6 and F1–F5 β-strands with the addition of a short 
α-helix (Figure 2)16. Structural differences between the N-CRD and the C-CRD are mainly located in the loop 
regions, resulting from insertion or deletion of amino acid residues16. The carbohydrate binding pocket of both 
the N- and C-CRD is formed by the S4, S5, and S6 β-strands (Figure 2), where differences in amino acid sequence 
determine the carbohydrate binding specificity.
Three natural isoforms of human Gal-9 exist based on a difference in length of the interdomain linker 
that separates N- and C-CRD. These isoforms are termed Gal-9(S), Gal-9(M) (also known as Ecalectin or urate 
transporter), and Gal-9(L) (Figure 2)17. The expression of these isoforms is not uniform, with e.g. T-cells selectively 
expressing high levels of Gal-9(M) and Gal-9(L) but not Gal-9(S) isoforms.[5] All these Gal-9 isoforms have potent 
eosinophil chemoattractant activity17,18. However, differences in activity have also been reported, with Gal-9(L) 
inhibiting and Gal-9(S) and Gal-9(M) promoting endothelial adhesion of colon cancer cells19. In addition, the 
structure and length of the linker region can influence multivalent lattice formation, which affects the ability to 
bind glycan ligands20. On the other hand, a recombinant Gal-9 deletion mutant, from which the linker sequence 
was completely deleted (Figure 2), retained its CRD-dependent activities, i.e. eosinophil attraction and the 
induction of T-cell apoptosis, indicating that the linker is not essential for these functions21. Furthermore, this 
mutant gained resistance to proteolytic degradation.
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Figure 1. Formation of Galectin-9-carbohydrate lattices. (A) 
Crosslinking of bivalent carbohydrates, (B) trivalent carbohydrates, or (C) 
tetravalent carbohydrates by Gal-9 could lead to the formation of high-
affinity Gal-9-carbohydrate lattices on the cell surface.
Carbohydrate Specificity of Galectin-9
The N- and C-CRD of Gal-9 have a selected group of branched N-glycans and repeated oligolactosamines for 
which they have similar affinity (Figure 3)22, as well as carbohydrate binding partners that seem to require both 
the N- and C-CRD for high affinity binding (Figure 3). In addition, the N-CRD of Gal-9 has several unique binding 
partners (Figure 3). This unique carbohydrate binding profile suggests that the N- and C-CRD may differentially 
contribute to the biological effects of Gal-9. In this respect, recent reports indicate that the C-CRD of Gal-9 is the 
primary determinant of receptor recognition and death pathway signaling in T-cells23,24. On the other hand, the 
N-CRD was more effective in activation of dendritic cells (DCs)24.
Galectin-9 Glycolipid and Glycoprotein Binding Partners
Interestingly, the N-CRD of Gal-9 exhibits particular preference for the Forssman pentasaccharide14,17,22. In 
canine epithelial kidney cells, this Forssman pentasaccharide is linked to a lipid, yielding the so-called Forssman 
glycosphingolipid (FGL)25. Binding of Gal-9 to FGL regulates apical–basal cell polarity. Notably, FGL is virtually 
absent in most healthy humans, but is overexpressed in cancers of the stomach, colon, and lung26, and might 
thus be involved in Gal-9 activity in carcinoma.
Gal-9 also interacts with various glycoproteins. The best characterized binding partner of Gal-9 is the 
T-cell immunoglobulin mucin 3 (TIM-3), a protein present on specific T-cell subsets27 and cells of the innate 
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Figure 2. Galectin-9 structure and isoforms. (A) Ribbon 
model of the crystal structure of the N-terminal CRD (N-CRD) 
of Gal-9 (PDB ID:3NV2)13 and (B) ribbon model of the 
C-terminal CRD (C-CRD) of Gal-9 (PDB ID:3LSE).[16] ß-sheets 
are color coded in green and α-helix in red. (C) Surface model 
of the N-CRD of Gal-9 complexed with lactose. (D) Surface 
model of the C-CRD of Gal-9 complexed with the biantennary 
pyridylaminated oligosaccharide (BIPA). Structures were 
generated using polyview-3D (http://polyview.cchmc.org/
polyview3d.html) with PyMol rendering. Surface pockets 
were identified using CASTP. Color coded regions in C and D 
correspond to pockets with a size of >10 Å3. (E) Three natural 
Gal-9 isoforms with different interdomain linker lengths have 
been identified (Long, Medium, and Short)17. In addition, a 
recombinant form of Gal-9 with a linker length of two amino 
acids has been produced21.
immune system, such as monocytes, macrophages, and DCs28. Furthermore, Gal-9 binds to CD44, a cell surface 
glycoprotein expressed on epithelial cells that is involved in cell–cell interaction and cell adhesion29,30, the 
Epstein–Barr virus latent membrane protein-131, and the Glucose transporter 232. Of note, the Gal-9(M) isoform 
has also been reported to function as transmembrane sugar-regulated urate transporter33.
ROLE OF GALECTIN-9 IN T-CELL BIOLOGY
Galectin-9 in T-Cell Homeostasis
Gal-9 has a multifaceted role in T-cell development and homeostasis. First, Gal-9 is involved in thymic selection 
of T-cells. In particular, Gal-9 was found to be highly expressed on thymic epithelial cells in mice34 and induced 
apoptosis in both CD4/CD8 double negative and CD4/CD8 double positive thymocytes23. Second, Gal-9 
promoted the differentiation of naïve T-cells into regulatory T-cells (Tregs) by enhancing Foxp3 expression35, 
the hallmark transcription factor responsible for Treg differentiation. This finding is corroborated by the fact 
that Gal-9 knock-out mice have a reduction in the number of Tregs35,36. At the same time, the differentiation 
of naïve T-cells into T-helper 17 cells (Th17) was repressed by Gal-935. Third, Gal-9 induces apoptosis in mature 
differentiated T-cells via TIM-3 in CD4+ T-helper 1 (Th1) and Th17 cells, and to a lesser extent in CD8+/TIM-3+ 
cytotoxic T-cells (CTLs)4,23. Gal-9 did not induce apoptosis in TIM-3 negative T-helper 2 (Th2)37 or in Treg, despite 
the presence of TIM-3 on the latter cells38. A possible reason for this differential outcome of Gal-9 signaling in the 
various TIM-3+ T-cell subsets might be a differential glycosylation pattern of the respective T-cell subsets, as for 
instance reported for Galectin-1. In the case of Galectin-1, differential glycosylation of the Th2 subset conferred 
resistance to these Th2 cells for Galectin-1-mediated cell death39.
The above referred to studies collectively indicate that TIM-327, a well-established key regulatory molecule in 
the T-cell immune response, is involved in Gal-9 mediated signaling in T-cells28. However, various studies provide 
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compelling evidence for one or more alternative Gal-9 receptors on T-cells. In particular, TIM-3 deficient Th1-cells 
were incompletely protected against Gal-9-mediated cell death27. Moreover, Gal-9 activity was incompletely 
inhibited by an antagonistic TIM-3 antibody23, and TIM-3 expression did not correlate with sensitivity of T-cell 
lines to treatment with recombinant Gal-940. Furthermore, low concentrations of Gal-9 were recently reported 
to induce TIM-3 independent production of IFN-γ and TNF-α in Th1 and Th2 cells, respectively. At higher 
concentrations, Gal-9 also induced TIM-3 independent apoptosis in both Th1 and Th2 cells41. Thus, one or more 
alternative and as yet unidentified receptors for Gal-9 exist on T-cells. The presence of more receptors for Gal-9 
seems to be in line with findings for the use of multiple receptors on T-cells by e.g. Galectin-1, which is known to 
interact with CD7, CD43, and CD4542.
Taken together, Gal-9 has a host of effects on various T-cell populations that serve to alter the T-cell balance 
by negatively regulating Th1 and Th17, while at the same time increasing the number of Treg cells (for schematic, 
see Figure 4). Notably, Tregs also express Gal-9 on the cell surface43, which may contribute to the suppressive 
activity of these cells toward Th1 and Th17 cells.
Intracellular T-Cell Signaling Induced by Galectin-9
The most prominent effect of treatment of T-cells with Gal-9 is the induction of apoptotic cell death. However, 
the mechanisms of Gal-9-induced apoptotic cell death of T-cells are still poorly understood and seem to differ 
markedly between the various T-cell types studied (Figure 4). Most studies on Gal-9-induced signaling in T-cells 
used acute lymphoblastic leukemia T-cell lines, such as MOLT4 and Jurkat. Treatment of MOLT4 cells with Gal-9 
resulted in a rapid calcium flux, subsequent activation of calpains, and initiator caspase-1, followed by apoptotic 
cell death (Figure 4)4. Treatment of Jurkat similarly triggered a calcium flux, but in these cells apoptosis was due 
to caspase-3 activation and mitochondrial release of proapoptotic proteins. In addition, Gal-9 triggered caspase-
independent signaling pathways, such as mitochondrial release of Apoptosis Inducing Factor44. In human T-cell 
leukemia virus type-I (HTLV-I) infected cell lines, Gal-9 induced apoptosis via activation of initiator caspase-8 and 
-9 and caspase-340. This activation of caspase-8 by Gal-9 indicates that apoptosis is induced via Death Receptor 
(DR)-mediated signaling. Similar activation of DR-mediated signaling has been reported for Galectin-145 and 
Galectin-346. DR signaling by galectins may be due to the induction of autocrine release of the cognate death 
ligand, direct interaction of galectins with DRs, or by ligand independent activation of DRs. However, Gal-9 
induced cell death may also partly depend on necrosis, as was shown for murine Th1 T-cells27.
In addition to direct induction of T-cell death, Gal-9 suppressed the susceptibility of T-cells to mitogenic 
stimulation47. In line with this finding, inhibition of TIM-3 signaling induced a hyperproliferation of Th1 cells in 
a mouse model48. Thus, Gal-9/TIM-3 signaling may influence the strength of mitogenic T-cell stimulation and 
thereby regulate T-cell responses. However, Gal-9 did not induce active tolerance or affected basal proliferation 
levels of splenocytes, suggesting that Gal-9-mediated T-cell inhibition is activation dependent47. In this 
respect, Gal-9 treatment of HTLV-I infected T-cell lines inhibited NF-κB signaling, thereby preventing cell cycle 
progression, which ultimately lead to apoptotic demise of cells40.
THERAPEUTIC POTENTIAL OF GALECTIN-9 IN AUTOIMMUNITY
Galectin-9 Shifts Adaptive Immunity to an Anti-Inflammatory Profile in Autoimmune Disease
Autoimmune reactions are characterized by expansion/activation of Th1 and Th17 cells (See Figure 5 for an 
overview of key aspects of the autoimmune response)49. Because Gal-9 has been shown to induce apoptosis 
in both T-cell populations, recombinant Gal-9 may be of potential value to restrict acute and/or chronic 
autoimmunity. Indeed, in preclinical models of various autoimmune diseases, treatment with recombinant 
Gal-9 proved to be beneficial. For instance, the administration of recombinant Gal-9 to mice with experimental 
autoimmune encephalomyelitis resulted in the specific elimination of Th1 cells, a decrease in circulating levels 
of the cytokine IFN-γ, and a concomitant reduction in disease severity and mortality27. Similar activity of Gal-9 
was detected in models of autoimmune and immune complex-associated arthritis35,50,51, as well as autoimmune 
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Figure 3. Galectin-9 binding partners. (A) Branched N-glycans that bind both the N-CRD and C-CRD of Gal-922. (B) Glycans that 
require simultaneous binding of both CRDs of Gal-9 for high affinity interactions (22). (C) Carbohydrate groups specifically recognized 
by the N-CRD of Gal-922.
diabetes47. The therapeutic activity of recombinant Gal-9 in these models also relied on the reduction of Th1 
and Th17 cell populations and a decrease in levels of proinflammatory cytokines. In line with this, Gal-9 knock-
out mice had a higher susceptibility for autoimmune arthritis35,51. Furthermore, siRNA-mediated knock down 
of endogenous Gal-9 accelerated autoimmune encephalomyelitis progression27. In contrast, the levels of Th2 
cytokines were not affected by treatment with Gal-9, suggesting that Th2 cells are not the main target for Gal-
9-mediated apoptotic activity35. The above-described findings closely coincide with the expression pattern of 
TIM-3 on the respective T-cell subsets and are in agreement with a role for TIM-3 in autoimmunity. This aspect 
is also evident from the accelerated development of autoimmune diabetes upon treatment of mice with TIM-3 
antagonists52. Of note, TIM-3-independent interactions of Gal-9 proved to be beneficial in rheumatoid arthritis, 
although this was not due to T-cell elimination, but rather to killing of highly proliferative synovial fibroblasts50. 
Finally, mice with experimental autoimmune arthritis had reduced levels of the cytokine IL-6 in their joints 
after treatment with recombinant Gal-935. IL-6 is an important cytokine in the progression of inflammatory 
diseases53,54. In the presence of both IL-6 and TGF-β, naïve T-cells differentiate into Th17, while IL-6 inhibits TGF-β-
induced Treg differentiation55. Indeed, Gal-9 deficient mice had lower Treg numbers and were more susceptible 
to autoimmune arthritis35. Hence, application of Gal-9 may also be beneficial in other pathologies associated 
with high Th17/IL-17 levels, such as psoriasis56. Taken together, preclinical models clearly indicated that Gal-9 has 
therapeutic potential for ameliorating disease activity in autoimmunity by skewing T-cell immunity. (See Figure 
5 for an overview of Gal-9 effects on T-cell-mediated autoimmunity).
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Galectin-9 Shifts Innate Immunity to an Anti-Inflammatory Profile in Autoimmune Disease
Gal-9 has several effects on innate responses in autoimmunity. In a mouse model, human immune complex-
induced arthritis treatment with Gal-9 repressed macrophage activity51. In particular, the anti-inflammatory 
Fc receptor FcγRIIB (CD32) was upregulated. At the same time, expression of the proinflammatory Fc receptor 
FcγRIII (CD16) was decreased. Consequently, production of macrophage derived proinflammatory cytokines, 
such as TNFα and IL-1, was reduced and production of the anti-inflammatory cytokine IL-10 was upregulated51. 
Of note, upregulation of FcγRIIB on phagocytes is also observed after intravenous immunoglobulin treatment 
of autoimmune patients57,58.
Second, the expression of human Gal-9 in transgenic mice resulted in the differentiation and expansion 
of immunosuppressive granulocytes (CD11b+Ly-6G+) from the bone marrow (BM)59. These immunosuppressive 
granulocytes, also termed myeloid-derived suppressor cells (MDSCs), suppress T-cell immune responses 
by eliminating T-cells and simultaneously increasing Treg numbers (Figure 5)60,61. Correspondingly, Gal-9 
transgenic mice had reduced T-cell responses and levels of IFN-γ and were protected against autoimmune 
encephalomyelitis59.This generation of MDSCs may partly depend on Gal-9/TIM-3 signaling, because human 
TIM-3 transgenic mice also had an increased number of MDSCs, a phenotype that was reverted upon TIM-3 
knock-out59. Interestingly, monocytic MDSCs (CD11b+Ly-6C+) also appear during the induction phase of 
Figure 4. Galectin-9 modulates T-cell development and survival. (A) Gal-9 modulates thymic T-cell selection by induction of 
apoptosis in double negative as well as double positive thymocytes. In addition, Gal-9 modulates peripheral T-cell differentiation by 
inducing Treg development from naïve T-cells while repressing Th17 expansion. (B) Gal-9 induces apoptosis in Th1, 2, 17, and cytotoxic 
T-cells via the Gal-9/TIM-3 pathway or by TIM-3-independent interactions. (C) Pathways involved in Gal-9-induced T-cell death include 
caspase-dependent apoptosis, Ca2+/Calpain activation, the release of proapoptotic mitochondrial factors or the inhibition of cell cycle 
progression (references to depicted data can be found in Chapter 3).
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experimental autoimmune encephalomyelitis, possibly in an attempt to counteract disease development62. 
These immunosuppressive macrophages can also be expanded by treatment with recombinant Gal-9, as shown 
in mice with experimental lung inflammation63. Taken together, Gal-9 signaling via TIM-3 or other yet to be 
identified receptors is involved in diverse regulatory functions in autoimmunity, including direct elimination 
of proinflammatory T-cells, shifting macrophages to an anti-inflammatory state, and the induction of inhibitory 
MDSCs.
THERAPEUTIC POTENTIAL OF GALECTIN-9 IN TRANSPLANTATION
Recombinant Galectin-9 Inhibits Allograft Rejection
The inflammatory response upon acute allograft rejection shares several features with the T-cell-mediated 
autoimmune response. In particular, proinflammatory Th1 and Th17 cells are activated, whereupon CD8+ CTLs 
execute allograft rejection. Expression of endogenous Gal-9 as well as mRNA levels of TIM-3 actually correlates 
with severity of rejection, possibly implicating endogenous Gal-9 in disease progression.64 In contrast, treatment 
with exogenous recombinant Gal-9 ameliorated allograft rejection and significantly prolonged survival of 
allogeneic skin grafts in mice65,66. This increase in allograft survival was accompanied by reduced numbers of 
lymphocytes in the allograft and draining lymph nodes. In vitro characterization of CTLs showed that Gal-9 not 
only triggered apoptosis in alloreactive CD8+ CTLs, but also inhibited the proliferative response upon T-cell 
receptor crosslinking66. In addition, Gal-9 decreased the cytotoxicity of already primed/activated CD8+ T-cells. 
Consequently, CD8+ T-cell subsets were notably repressed and a diminished IFN-γ level was found in vivo.
In an analogous study, recombinant Gal-9 prolonged the survival of fully mismatched cardiac allografts 
Figure 5. Galectin-9 ameliorates autoimmune disease. (A) During autoimmune diseases, Th1 and 17 cells and cytokines contribute 
to disease progression. (B) Gal-9 ameliorates autoimmunity by eliminating Th1 and 17 cells, inducing Treg expansion while suppressing 
Th17 development. Furthermore, Gal-9 induces the expansion of immune suppressive Myeloid-derived suppressor cells (MDSCs) 
and modifies Fc receptor expression on macrophages toward an anti-inflammatory setting. Th2 cells are not affected (references to 
depicted data can be found in Chapter 4).
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in mice67. Here, the Gal-9-treated group had close to normal tissue architecture, with a decrease in CD4+ and 
CD8+ lymphocyte infiltration and proliferation, together with a reduction in circulating levels of the cytokines 
IFN-γ and IL-17. Interestingly, selective inhibition of IL-17 signaling, using an IL-17R:Fc fusion protein, prolonged 
allogeneic heart graft survival in rats68, suggesting that blockade of IL-17 signaling may partly contribute to 
the therapeutic effects of Gal-9. Based on the decrease in T-cell activity and the decrease in levels of IL-17, the 
inhibition of allograft rejection is likely partly regulated via the Gal-9/TIM-3 pathway. Indeed, the importance of 
TIM-3 in limiting acute rejection was evidenced by an accelerated allograft rejection upon treatment with TIM-3 
blocking reagents38,52. Taken together, activation of the Gal-9/TIM-3 pathway by administration of exogenous 
recombinant human Gal-9 may be applied to inhibit graft rejection in skin and cardiac transplantation. The role 
of endogenous Gal-9 in these conditions needs to be further elucidated.
Recombinant Galectin-9 Inhibits Graft vs. Host Disease
A serious complication after allogeneic BM transplantation in e.g. leukemic cancer patients is the occurrence of 
graft vs. host disease (GvHD). GvHD is characterized by the activation of donor CD8+ CTLs and an inflammatory 
‘cytokine storm’ that ultimately leads to severe damage of multiple organs of the recipient. In a murine model 
of GvHD, the expression of both endogenous Gal-9 and TIM-3 was elevated on T-cells, DCs, and macrophages69. 
Together with the finding that treatment with an anti-TIM-3 antibody accelerated GvHD by the activation of 
effector CD8+ CTLs of the BM of transplanted mice, Gal-9/TIM-3 signaling may potentially be used to ameliorate 
GvHD. In this respect, recombinant human Gal-9 suppressed a mixed leukocyte reaction by induction of T-cell 
apoptosis and inhibition of T-cell proliferation70. Furthermore, treatment with recombinant Gal-9 also reduced 
the severity of GvHD after allogeneic T-cell-depleted BM transplantation in vivo, although the survival time of 
transplanted mice was not prolonged. When GVHD was induced by transfusion of CD4+ T-cells, treatment with 
recombinant Gal-9 not only reduced the severity of GvHD, but also prolonged survival time.
THERAPEUTIC POTENTIAL OF RECOMBINANT GALECTIN-9 IN ALLERGIC ASTHMA
The expression of endogenous Gal-9 was elevated in lung tissue in animal models of asthma in mice and 
guinea pigs71,72, which was accompanied by an increase in Th2 cytokine levels and the local accumulation of 
eosinophils and lymphocytes. A similar correlation between expression of Gal-9 and eosinophil chemotactic 
activity was found in patients with acute and chronic eosinophilic pneumonia73. Thus, elevated expression levels 
of endogenous Gal-9 may contribute to disease activity. In contrast, exogenously added recombinant Gal-9 can 
ameliorate Th2-mediated asthma via TIM-3-independent interactions. For instance, Gal-9 was shown to be a 
high affinity ligand for the heavily glycosylated immunoglobulin IgE derived from both human as well as rat 
and mouse74. Gal-9 interfered with IgE/antigen complex formation, whereby degranulation of mast cells was 
suppressed and asthmatic reactions were reduced74. Recombinant Gal-9 also inhibits interactions of CD44 with 
the ECM component hyaluronic acid (HA)29. As a result, adhesion of leukocytes to endothelial cells is suppressed 
and accumulation of Th2 cells into lung tissue is reduced. Hence, Gal-9 prevents the infiltration of Th2 cells in 
the lung and limits activation of mast cells, thereby reducing disease severity in asthma. In addition, treatment 
with recombinant Gal-9 induces apoptosis in primed human eosinophils73 and in a TIM-3-independent manner 
in Th2 cells41.
ROLE OF GALECTIN-9 IN MICROBIAL INFECTIONS
Galectin-9 Expression is Induced Upon Microbial Infection
Typically, microbial infection increases endogenous Gal-9 expression in infected host cells, as shown for instance 
in endothelial cells (Dengue virus75), peritoneal macrophages (M. tuberculosis76), or lymphoid cells (Herpes 
simplex virus (HSV)36. Furthermore, Kupffer cells of livers infected with hepatitis C had markedly enhanced 
expression of Gal-9, which was accompanied by higher levels of soluble Gal-9 in the circulation77. In addition, 
mimicking viral infection using double-stranded RNA also enhanced Gal-9 expression in vascular endothelial 
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cells, which was followed by enhanced eosinophil adhesion78,70.
Similarly, bacterial infection seems to induce expression of Gal-9, as evident from an increase in Gal-9 levels 
in bacterially infected periodontal ligament cells80. Increase in Gal-9 upon bacterial infection can be caused by 
Lipopolysaccharide (LPS), the major component of the outer membrane of Gram negative bacteria. Vascular 
endothelial cells treated with LPS had strongly elevated Gal-9 mRNA and protein expression79. Analogously, 
treatment of a monocytic cell line with LPS increased the level of intracellular Gal-93. Interestingly, Gal-9 was 
found to subsequently translocate to the nucleus and induce transcription of proinflammatory cytokines3. Gal-
9 concentrations were also strongly increased in peritoneal lavage fluid of mice with LPS-induced peritoneal 
inflammation81.
Expression of Gal-9 can also be induced by IFN-γ82, a cytokine critical for immunity against viral and 
intracellular bacterial infections. Gal-9 induced by IFN-γ enhanced the adhesion of eosinophils to vascular 
endothelium82. In analogy, IFN-γ enhances levels of Gal-9 in human monocytes, macrophages77, and fibroblasts83. 
Of note, another cytokine, IL-1β, also stimulated expression of Gal-9 in astrocytes, and may thereby regulate 
eosinophil trafficking in the central nervous system84. Thus, both bacterial and viral infection upregulates Gal-9 
expression in infected cells either via viral/bacterial components or by inflammatory cytokines.
Dual Function of Galectin-9 in Antimicrobial Immunity
Gal-9 seems to have two distinct functions in antimicrobial immunity. First, Gal-9 stimulates innate immune 
responses among others by recruitment of eosinophils and subsequent enhancement of antiviral inflammatory 
reactions78. Furthermore, in the case of Leishmania major, Gal-9 acts as a L. major-specific macrophage receptor85, 
possibly contributing to macrophage-mediated clearance of this parasite. Recombinant Gal-9 also protected 
mice from tissue damage occurring upon an LPS-induced Shwartzman reaction, by inducing tissue infiltration 
with immune suppressive granulocytes. In contrast, Gal-9-deficient mice had an increased susceptibility to this 
Shwartzman reaction81. Thus, Gal-9 seems to activate innate immunity and limits tissue damage after microbial 
infection. Of interest, a recent article reported a reverse TIM-3/Gal-9 signaling pathway that limits intracellular 
bacterial replication in Mycobacterium tuberculosis (Mtb)-infected macrophages76. In brief, binding of TIM3+ Th1 
cells to infected Gal-9 positive macrophages activated innate signaling pathways, in particular IL-1ß secretion, 
leading to control of Mtb replication.
The second function of Gal-9 in antimicrobial immunity involves the inhibition of the adaptive immune 
response, in particular the T-cell response. Gal-9 knock-out mice have a better T-cell response against HSV36. 
Furthermore, treatment of wild type mice with lactose (a competitive Gal-9 inhibitor) enhanced anti-HSV 
immunity. In contrast, treatment with recombinant Gal-9 had the opposite effect and inhibited the T-cell 
response against HSV36. Gal-9 signaling in antiviral T-cell immunity is probably mediated via TIM-3, because 
blocking anti-TIM-3 antibodies restored CD8+ T-cell function and enhanced viral control in chronic lymphocytic 
choriomeningitis infection86. Furthermore, during M. tuberculosis infection, the interaction of TIM-3+ Th1-cells 
with Gal-9+ macrophages triggered apoptotic elimination of Th1-cells76. Similarly, Gal-9 expressed on hepatitis 
C infected Kupffer cells eliminated virus-specific CTLs and triggered the expansion of Tregs77. In line with this 
latter finding, Gal-9 also triggered expansion of Treg in HSV infected eyes, reducing inflammation-related 
tissue damage36. Of note, IFN-γ released by Th1 cells has been shown to induce Gal-9 expression in various cell 
types. Thus, Gal-9 is involved in the shutdown of the adaptive immune response during antimicrobial immune 
responses.
Interestingly, pathogens seem to express Gal-9 homologs to modulate the immune response of the infected 
host. For instance, the canine parasite Toxascaris leonine expresses a Gal-9 homolog that inhibits the production 
of proinflammatory cytokines by host T-cells87. Taken together, the available data indicate that Gal-9 is involved 




THERAPEUTIC POTENTIAL OF GALECTIN-9 IN HEMATOLOGIC MALIGNANCIES
T-Cell Leukemia and Lymphoma
Most studies that investigated the mechanism of T-cell death by Gal-9 were performed using leukemic T-cell 
lines. Recombinant Gal-9 induced apoptosis in various T-cell leukemic cell lines in a dose-dependent manner, 
which depended on the presence of a functional CRD4,44. Similarly, adult T-cell leukemia (ATL, caused by HTLV-I 
infection) responded well to treatment with recombinant Gal-9, both in cell lines and primary ATL samples in 
vitro, as well as in vivo in mice40. Of note, T-cells are known to express and release the Gal-9 isoforms Gal-9(M) and 
Gal-9(L)5,88. This expression was inversely correlated to Gal-9 sensitivity in T-cell lines40. Taken together, preclinical 
studies indicated that Gal-9 can selectively eliminate malignant T-cells (Figure 4), although the mechanism may 
vary between cell types from inhibition of proliferation to induction of apoptosis via different pathways.
B-Cell and Myeloid Malignancies
Although B-cells do not express TIM-3, B-cell lymphoma cell lines are sensitive to induction of cell death by 
recombinant Gal-94. In addition, Gal-9 effectively eliminated multiple myeloma (MM)89, chronic myeloid 
leukemia (CML)90, as well as Burkitt and Hodgkin lymphoma cells91, and significantly retarded tumor growth 
of myeloma xenografts in mice89. Importantly, Gal-9 also had significant therapeutic activity toward primary 
patient-derived myeloma cells, even in tumors resistant to conventional therapeutics90. The receptor(s) for Gal-
9 on these various malignant cell types as well the precise mechanism of cell death induction remains to be 
elucidated. In MM cells, apoptotic signaling was caspase dependent and induced by activation of the MAP kinases 
JNK and p3889. In Burkitt and Hodgkin lymphoma, cell death was due to selective inhibition of the Activator 
Protein-1 transcription factor complex, a complex known to be important for cell differentiation and survival91. 
Furthermore, Gal-9 treatment suppressed NF-κB signaling, which triggered cell cycle arrest and reduced the 
production of antiapoptotic proteins, such as XIAP. In addition, Gal-9 treatment induced the proapoptotic Bcl-2 
family member Noxa via activating transcription factor 3, leading to death in CML cells (Figure 6)90.
ROLE AND THERAPEUTIC POTENTIAL OF GALECTIN-9 IN SOLID TUMORS
Galectin-9 is a Prognostic Factor for Metastatic Progression of Solid Tumors
A role for Gal-9 in solid tumor biology is perhaps most evident from the finding that loss of Gal-9 expression is 
associated with tumor progression and metastasis formation in various types of cancer. Gal-9 is highly expressed 
in melanocytic lesions of low malignancy, whereas metastatic lesions are characterized by low or no expression 
of Gal-991. Similarly, primary breast carcinoma tumors were characterized by high levels of endogenous Gal-
9, whereas all distant metastasis lacked expression of Gal-993,94. Also, normal epithelium and low-grade cervix 
carcinoma had high levels of Gal-9, whereas high-grade cervix carcinoma lesions had very low levels of Gal-995. 
Therefore, the loss of Gal-9 is a negative prognostic factor in these cancer types.
In line with these clinical observations, Gal-9 transfected cancer cells formed significantly less metastases than 
parental Gal-9 negative cancer cells in mouse models of melanoma and colon cancer30. Furthermore, intravenous 
administration of recombinant Gal-9 significantly reduced the formation of metastases in mice injected with 
wild-type melanoma and colon cancer cells30. Taken together, these data indicate that endogenously expressed 
Gal-9 as well as recombinant Gal-9 inhibits formation of metastases in certain types of cancer.
Mechanism of Galectin-9-Mediated Therapeutic Activity
With the exception of sarcoma, where Gal-9 directly triggers cell death (Figure 6), the inhibitory effect of Gal-9 on 
solid cancers does not seem to rely on immediate cytotoxicity, but rather on interference with various metastatic 
features of cancer cells. A first important ability of cancer cells that is required for metastasis formation is the 
escape from the primary site by loosening cell–cell contacts (Figure 6; step 1). Cell surface-associated Gal-9 
triggered the aggregation of melanoma cells, indicative of Gal-9-mediated cellular adhesion and inhibition of cell 
detachment92. Furthermore, breast cancer cell lines with high levels of endogenous Gal-9 had a strong tendency 
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to aggregate, whereas cells with low levels of Gal-9 did not93. Importantly, ectopic expression of endogenous 
Gal-9, as well as treatment with recombinant Gal-9, triggered formation of tight cellular clusters92,93. Thus, both 
endogenous and exogenous recombinant Gal-9 trigger cancer cell aggregation, impair cell detachment, and 
prevent escape of cancer cells from the primary tumor (Figure 6).
A second feature pivotal for successful metastasis formation is the ability of circulating tumor cells to adhere 
to endothelial cells and extravasate into surrounding tissue (Figure 6; step 2). Gal-9 impairs this process by 
blocking tumor cell adhesion to endothelial cells, as evidenced by the Gal-9-mediated inhibition of vascular 
cell adhesion molecule-1 interaction with very late antigen-4 and the subsequent prevention of metastases 
formation in murine models of melanoma and colon carcinoma (Figure 6)30. Of note, it has recently been 
reported that TIM-3 expressed by endothelial cells can actually facilitate metastasis formation by melanoma 
cells96. However, this effect was not mediated by Gal-9. In this setting, recombinant Gal-9 might even reduce 
cancer cell adhesion/metastases by competitively blocking TIM-3 on endothelial cells.
A third feature required for tumor cells to acquire metastatic potential is the adhesion to ECM components 
after successful extravasation (Figure 6; step 3). Gal-9 can also inhibit this essential step of the metastatic 
process. Gal-9 is able to inhibit the binding of various cancer cell types (breast, colon, and melanoma) to ECM 
components, such as collagen, laminin, and fibronectin30,93. In addition, Gal-9 inhibits the binding of cell surface-
expressed CD44 to HA, an interaction known to contribute to metastasis formation in melanoma (Figure 6). 
Indeed, antagonistic anti-CD44 antibodies or treatment with competitive soluble CD44:Fc inhibited metastatic 
spread97,98.
Figure 6. Galectin-9 induces cancer cell death and inhibits metastasis. (A) Gal-9 induces apoptosis in B-cell and myeloid 
malignancies as well as sarcoma, which can be mediated by the inhibition of JNK/p38, Activator Protein-1 and NF-κB or activating 
transcription factor 3. (B) During metastasis, tumor cells escape from the primary tumor (1) and disseminate through blood and lymph 
vessels before finally extravasating into surrounding tissues (2). At the site of metastasis, cancer cells adhere to components of the 
extracellular matrix (ECM) to form a new tumor (3). (C) Gal-9 prevents metastasis by triggering cellular aggregation, inhibiting very 
late antigen-4/vascular cell adhesion molecule-1 interactions, as well as CD44/hyaluronic acid binding, and by blocking adhesion to 
the ECM (C) (references to depicted data can be found in Chapters 8 and 9).
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Interestingly, although E-selectin expression is normally observed in tumor endothelium, the transfection of 
Lovo-3 human colon carcinoma cells with Gal-9(S) or Gal-9(M) upregulated the expression of E-selectin, leading 
to an increase in adhesion of Lovo-3 to endothelial cells (HUVEC)19. In contrast, the Gal-9(L) isoform decreased 
E-selectin levels and Lovo-3 adhesion to endothelial cells. Thus, the various Gal-9 isoforms may differently 
regulate E-selectin expression in certain colorectal cancer cells. Of note, E-selectin expression on endothelial 
cells is a negative prognostic factor in some malignancies, including in colorectal carcinoma99.
Interestingly, recombinant Gal-9 also binds with high affinity to the Forssman glycolipid (FGL)22. FGL is 
virtually absent on normal human cells, but is strongly overexpressed on cancer cells of stomach, colon, and 
lung origin26. Data from a recent study using canine epithelial cells suggested that binding of Gal-9 to FGL 
is involved in the maintenance of apical polarity of epithelial cells25. In these epithelial cells, Gal-9 facilitated 
endosomal transport, and cycled between the Golgi apparatus and the apical membrane via endocytosis/
reverse endocytosis. In this respect, it is interesting to note that the endocytic pathway is known to be selectively 
disturbed in malignant cells, leading to loss of polarity100. Therefore, it is tempting to speculate that recombinant 
Gal-9 may affect carcinoma cells by influencing apical/basal polarity.
Galectin-9 Enhances Antitumor Immunity
Gal-9 can enhance antitumor immunity by initial CRD-independent maturation of DCs and subsequent induction 
of Th1-mediated antitumor immunity101. In particular, matured CD11+ DCs became TIM-3 positive, whereupon 
TIM-3 dependent interaction with CD8+ T-cells triggers production of IFN-γ102. In line with these in vitro findings, 
splenocytes of sarcoma-bearing mice that were treated with Gal-9 contained higher numbers of TIM3+CD8+ 
CTLs. These CTLs had higher granzyme B and perforin expression levels, indicative of higher cytolytic activity102. 
Indeed, Gal-9 augmented antitumor immunity in these mice, leading to prolonged survival. Importantly, 
although treatment with Gal-9 did not prolong survival in nude mice, transfer of naive spleen cells restored the 
protective effect of Gal-9, highlighting the involvement of the immune system102. In apparent contrast to studies 
in models of autoimmune diseases, Gal-9 did not affect the number of Tregs in these mice and induced a weak 
but significant reduction in MDSCs. In addition, treatment with recombinant Gal-9 prolonged survival in a murine 
melanoma model not only by increasing the numbers of CD8+ CTLs, but also that of Natural Killer (NK)-cells and 
macrophages103. Therefore, Gal-9 augments antitumor immunity by inducing subsets of macrophages and DCs 
and the activation of tumor-specific CTLs and NK-cells, respectively (Figure 7). In contrast to the above-described 
tumor models, Gal-9 positive exosomes released by nasopharyngeal carcinoma (NPC, caused by Epstein–Barr 
virus infection) contributed to the escape of NPC cells from antitumor immunity104. Similar NPC exosomes were 
also detected in plasma of NPC patients104. Taken together, with the exception of the NPC model, recombinant 
Gal-9 enhances antitumor immunity, and may thus be of possible use for the induction of antitumor immunity.
PERSPECTIVES: THERAPEUTIC TARGETING OF GALECTIN-9 SIGNALING PATHWAYS
As detailed in this review, Gal-9 has a broad range of biological functions in normal cell biology and in pathology, 
including autoimmune diseases, asthma, allograft rejection, infection, and cancer. The available data suggests 
that Gal-9 functions as negative regulator of the immune system in hyperimmune conditions, whereas it 
functions as an immune enhancer in immune compromised conditions, such as cancer-bearing animals. Thus, 
Gal-9 seems to function as a homeostatic regulator of normal immune responses. In light of these findings, it 
is perhaps not surprising that Gal-9 is a candidate drug for a wide array of diseases with already considerable 
preclinical proof of principle.
A possible limitation to the therapeutic applicability of recombinant Gal-9 is the need for relatively high 
concentrations to achieve relevant therapeutic activity. Strategies that increase the specific activity of Gal-9, 
by e.g. recombinant engineering of bi or multivalent Gal-9 variants, are of interest. It is well known that Gal-9 
signals upon multivalent crosslinking of receptors. Furthermore, recent reports indicate that Gal-9 can interact 
homotypically as well as heterotypically with other members of the galectin family in a CRD-dependent 
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manner105, suggesting that Gal-9 can form homo- or heteromeric complexes with increased affinity for target 
molecules. Therefore, forced dimerization or multimerization may well increase affinity and/or activity.
Furthermore, in order to minimize side effects and to optimize selective activity, target cell-selective delivery 
of Gal-9 is of interest. In this respect, a parallel can be drawn to the tumoricidal proteins soluble FasL (sFasL) 
and soluble TRAIL (sTRAIL). Both sFasL and sTRAIL have several important features in common with Gal-9. 
First, signaling of both sFasL and sTRAIL depends on multivalent crosslinking of cognate receptors, which is 
inefficiently triggered by sFasL or sTRAIL. Second, receptors for sFasL and sTRAIL are widely expressed on normal 
tissues, thus limiting both target cell specific accretion as well as increasing likelihood for off-target activity. 
In order to overcome these limitations, we and others have genetically fused sFasL and sTRAIL to an antibody 
fragment. Antibody fragment-selective binding of the resultant fusion proteins triggered selective and high-
level accretion of sFasL and sTRAIL at the target cell of choice. Furthermore, antibody fragment-specific binding 
converted the soluble death ligand into membrane-bound molecules capable of crosslinking agonistic DRs in an 
autocrine and paracrine manner. Analogous Gal-9 targeting may help improve target cell selectivity and activity. 
Of note, antibody fragment-mediated delivery of Gal-9 may result in higher affinity binding to one glycan ligand, 
and thus may cause other receptor activation, e.g. due to now higher-than-threshold binding or alteration of the 
glycan binding profile.
Gal-9 exerts many of its beneficial functions via TIM-3, which is also a bona fide target itself. Inhibition of 
autoimmune T-cell activity or allograft rejection may be achieved using agonistic TIM-3 antibodies. In contrast, 
inhibition of TIM-3 activity is of potential use in the prevention of tumor immune escape. Indeed, soluble 
decoy TIM-3:Fc inhibited tumor growth in mice both before, during, and after tumor development106. Of 
note, endothelial-expressed TIM-3 facilitated the progression of lymphoma107, which further argues for TIM-3 
inhibition as a strategy in the treatment of cancer.
CONCLUSION
As detailed in this review, Gal-9 plays a role in the regulation of various diseases, including T-cell-mediated 
diseases, such as autoimmunity and asthma. In addition, Gal-9 is involved in the control of antiviral and 
antibacterial infections and can limit tumor progression. Many of these functions, in particular T-cells, are 
regulated via TIM-3 binding, but also various TIM-3-independent effects of Gal-9 have been reported. It is 
anticipated that further studies aimed at elucidating Gal-9 binding partners, signaling pathways as well as the 
identification of novel forms of recombinant Gal-9 that are optimally suited for immunotherapy will pave the 
way for future Gal-9-based clinical strategies in various diseases.
Figure 7. Galectin-9 induces antitumor immunity. Antitumor immunity in tumor-bearing mice is augmented by Gal-9 via the 
maturation of CD11c+ dendritic cells (DCs), which can subsequently activate CD4+TIM-3+ and CD8+TIM-3+ T-cells. Gal-9 also activates 
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In recent years, a regulatory role has emerged for the glycan-binding protein galectin-9 (Gal-9) in normal 
physiology and pathology (reviewed by1). In melanoma and other malignancies, the available data suggest that 
Gal-9 has a tumor-suppressor function, with loss of Gal-9 being closely associated with metastatic progression2-5. 
In particular, melanocytic nevi and primary melanoma lesions highly express Gal-9, whereas metastatic 
melanoma lesions have no or minimal expression of Gal-92. Furthermore, ectopic expression of Gal-9 abrogates 
the formation of metastases by Gal-9-deficient B16F10 murine melanoma cells6. Similarly, treatment of Gal-
9-deficient B16F10 cells with a recombinant form of Gal-9, designated Gal-9(0), strongly reduced metastasis 
formation6.
This anti-metastatic activity of Gal-9(0) on B16F10 has been attributed mainly to inhibition of melanoma 
cell adhesion to endothelial cells and/or extracellular matrix components, such as collagen type I6. The data 
presented in the current letter suggest that within the 1-h time frame of adhesion-type assays, treatment with 
Gal-9(0) triggers early apoptotic cellular changes. In line with earlier findings, Gal-9(0) inhibits the adhesion of 
B16F10 and 7 human melanoma cell lines to collagen-I (Figure 1a). However, the morphology of Gal-9(0)-treated 
cells that had adhered to collagen-I-coated wells resembled that of dying cells (Figure 1b; illustrated for B16F10). 
Subsequent analysis of this melanoma cell line panel, as well as primary patient–derived malignant melanoma 
cells for the early apoptotic marker phosphatidyl serine (PS), revealed that treatment with Gal-9(0) induced ~90% 
cell death within the time frame used in the adhesion assay (Figure 1c). Early apoptotic PS exposure was followed 
by apoptotic cell death within 24 h of treatment, as evidenced by loss of viability (Supplementary Figure S1a), the 
presence of late apoptotic Annexin-V/PI double-positive cells (Supplementary Figure S1b and c), and an increase 
in DNA fragmentation (Supplementary Figure S1d). In primary human melanocytes, Gal-9(0) also triggered PS-
exposure, albeit to a lesser extent (Figure 1c; ~55%). More importantly, the viability of these normal cells was not 
negatively affected after 24 h (Supplementary Figure S1a). Thus, Gal-9(0) induces rapid apoptotic cell death in 
melanoma cells, but not in normal human melanocytes. PS exposure induced by Gal-9(0) was fully dependent on 
the glycan-binding specificity of Gal-9(0), as it was selectively blocked by the competitive Gal-9 inhibitor alpha-
lactose but not by the irrelevant carbohydrate sucrose (Figure1d). Sensitivity to Gal-9(0) did not or only weakly 
correlated with expression of endogenous Gal-9 (Supplementary Figure S2; r2=0.250). Time-course analysis in 
five of the human melanoma cell lines demonstrated that treatment with Gal-9(0) induced PS exposure in >60% 
of melanoma cells within 5 minutes of treatment (Figure 1e).
Furthermore, the extent of PS exposure closely correlated with the inhibitory effect of Gal-9(0) on collagen 
I binding (Figure 1f, MM-RU; r2=0.693). Together, these data suggest that the biological effect of Gal-9(0) in 
adhesion assays is mediated, at least partly, through the induction of cell death. It is noteworthy that pan-
caspase inhibition failed to block the anti-adhesive and apoptotic activity of Gal-9(0; Supplementary Figure S1e 
and f ). Thus, Gal-9(0)-mediated melanoma apoptosis does not require caspase activation, which is in line with 
e.g. reports on gal-1-mediated cell death of T cells7.
Adhesion assays are typically performed in serum-free conditions, whereas in normal physiological situations 
the presence of serum and/or plasma components may affect the biological activity of Gal-9. Indeed, it is well 
established that Gal-9 can interact with serum components8. Therefore, the biological activity of Gal-9(0) was 
next evaluated in the presence of 10% fetal calf serum (FCS), the standard serum additive in cell death assays. 
The inclusion of 10% FCS in these apoptosis experiments completely abrogated the morphological changes in 
melanoma cells, with induction of PS exposure by Gal-9(0) being abrogated in six of the seven cell lines tested 
(Figure 2a). Similarly, PS exposure by Gal-9(0) was also strongly inhibited in the primary melanoma cells (Figure 
2a). Indeed, FCS dose dependently inhibited PS exposure induced by Gal-9(0) (illustrated for cell line A2058 
in Figure 2b) and blocked the binding of Gal-9(0) to A2058 cells (Figure 2c). When using dialysed FCS or heat-
inactivated FCS, the activity of Gal-9(0) was still inhibited (Figure 2d). Thus, the inhibitory component present 
in FCS is not heat labile (i.e., complement factors) and is >10 kDa in size. Notably, FCS did not inhibit Gal-9(0) 
activity toward SK-MEL-28 cells (Figure 2a), which suggests that the inhibitory effect of FCS is not merely due 
to binding of a serum component to Gal-9(0). Possibly, a serum component may shield the receptor(s) of Gal-9 
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Figure 1. Galectin-9 (Gal-9(0)) rapidly induces apoptosis in serum-free conditions. (A). Adhesion of B16F10 and a panel of 
human melanoma cell lines to collagen-I-coated wells is inhibited by recombinant Gal-9. In brief, 3x104 melanoma cells were added 
to collagen-I-coated plates and incubated for 1 h at 37 °C in the presence or absence of 100 nm Gal-9(0). Subsequently, wells were 
washed twice with phosphate-buffered saline, and the number of adhered cells was counted in three wells per condition. Experiments 
were performed in triplicates. (B) Light microscopic pictures of B16F10 cells adhered to collagen-I-coated wells in untreated conditions 
and upon treatment with 100 nm Gal-9(0). Bar=100 μm. (C) Cells were treated for 1 h with 100 nm Gal-9(0) and subsequently analyzed 
for the early apoptotic event of phosphatidyl serine (PS) exposure using flow cytometric Annexin-V-FITC staining. The following cells 
were analyzed: B16F10, A2058, Sk-MEL-28, MM-RU, MM-WK, MM-AN, MM-EP, A375M, primary (prim.) patient–derived melanoma 
cells (n=1), and primary human melanocytes (n=1). (D) B16F10, Sk-MEL-28, A2058, and MM-RU were treated with Gal-9(0) with or 
without alpha-lactose or sucrose. (E) Sk-MEL-28, A2058, A375M, MM-AN, and MM-RU were treated with 100 nm Gal-9(0) for 5, 10, 15, 
and 20 minutes. Graph represents the average PS exposure detected in all five cell lines from three separate experiments. (F) MM-RU 
cells were treated with various Gal-9(0) concentrations (ranging from 5 to 200 nm), after which cells were simultaneously assessed for 
collagen-I adhesion and PS exposure. Statistical analysis was performed by linear regression, yielding an r2 of 0.6497. In all cell death 
assays, cell death was assessed by flow cytometry using Annexin-V-FITC, which measures the early apoptotic exposure of PS on the 
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Figure 2. Cell death induction by galectin-9 (Gal-9(0)) is blocked by fetal calf serum (FCS) but not by human pooled plasma. 
(A) A panel of melanoma cells and primary patient–derived melanoma cells (n=1) were treated for 1 h with Gal-9(0) in standard cell 
death conditions (with 10% FCS). (B) A2058 cells were treated with 100 nm Gal-9(0) in the presence of increasing concentrations of FCS 
and analyzed for the percentage of cells with phosphatidyl serine (PS) exposure. (C) A2058 cells were incubated on ice with 100 nm 
biotinylated Gal-9(0) in the presence of increasing concentrations of FCS. Cell surface binding of Gal-9(0)-biotin was evaluated using 
Streptavidin-Alexa488 by flow cytometry. (D) A2058 cells were treated with 100 nm Gal-9(0) in serum-free (SF) conditions or in the 
presence of 10% FCS, 10% dialyzed FCS (dFCS), heat-inactivated FCS (hiFCS), or human pooled plasma (HPP). (E) A panel of melanoma 
cell lines and primary patient–derived melanoma cells (n=1) were treated with 100 nm Gal-9(0) in SF conditions or in the presence of 
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on most melanoma cells. On Sk-MEL-28 cells, Gal-9(0) may interact with an alternative receptor not subject to 
binding/inhibition by FCS.
Although FCS is the standard additive in in vitro cell death assays, a better approximation of physiological 
settings is the addition of human plasma. Importantly, 10% human pooled plasma did not abrogate Gal-9(0)-
induced PS exposure in A2058 cells, with only a slight reduction in PS exposure compared with serum-free 
conditions (Figure 2d). Similar results were obtained in six melanoma cell lines and in primary patient–derived 
melanoma cells (Figure 2e).
These experiments suggest that an important biological effect of Gal-9(0) on human melanoma cells 
is the induction of apoptosis. This biological effect of Gal-9(0) is masked by as yet unidentified components 
present in FCS, but is unmasked in serum-free conditions or when human plasma is used. Indeed, in standard 
FCS-containing culture conditions, apoptotic cell death of the melanoma cell line MM-RU was only detected 
after 72 h of treatment with Gal-92. The use of FCS may similarly mask the biological activity of other gal family 
members. In this respect, gal-2, -3, -4, and -8 interact with various serum components8. Notably, plasma levels of 
several of the gal family members are increased in malignancy9. The use of human pooled serum/plasma instead 
of FCS for in vitro biological assays with members of the Gal family therefore appears prudent.
In conclusion, recombinant Gal-9 has a hitherto unrecognized cytotoxic effect toward human melanoma 
cells, which further highlights its potential therapeutic applicability for the treatment of human metastatic 
melanoma.
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FigureS1. Gal-9(0) induces cell death in melanoma cells but not melanocytes. (A) A panel of human melanoma cell and primary 
human melanocytes were treated with recombinant Gal-9 for 24h and analyzed for cell viability using MTS viability assay (Promega). 
In brief, 3x104  cells/well were seeded into 48-well plates and allowed to adhere o.n.. Subsequently, cells were treated with 100nM Gal-
9(0) for 24h. As a maximum cell death control, cells were treated for 20 minutes with 20% ethanol. Percentage viability was determined 
using the formula: (OD450medium)-(OD450ethanol)/(OD450Gal-9)- OD450ethanol)x100%. Experiments were performed in triplicates. (B) MM-EP 
cells were treated with 100nM Gal-9(0) for 24h and analyzed for cell death by Annexin-V/PI double staining. Dot-plots  represent typical 
results obtained in medium control and Gal-9(0) treated cells. (C) A panel of human melanoma cell lines was treated for 24h with 
100nM Gal-9(0) and subsequently analyzed apoptosis by Annexin-V/PI staining. (D) Cells were treated as in (C), but were now analyzed 
by flow cytometry for DNA fragmentation using standard Propidium Iodide protocol. (E) The inhibitory effect of Gal-9(0) on adhesion 
of human melanoma cell lines to Collagen-I coated wells is not blocked by pan-caspase inhibitor zVADfmk. In brief, 3x104 melanoma 
cells were added to collagen-I coated plates and incubated for 1h at 37˚C with 100nM Gal-9(0) in the presence or absence of 40μM 
zVADfmk. Subsequently, wells were washed twice with phosphate buffered saline and the number of adhered cells was counted in 
three wells per condition. Experiments were performed in triplicates. (F) Melanoma cell lines were treated with 100nM Gal-9(0) in the 
presence or absence of 40μM zVADfmk and analyzed for cell death by AnnexinV staining. All experimental values are mean + standard 





















































































































































































































































| The Glycan-Binding Protein Galectin-9 has Direct Apoptotic Activity Toward Melanoma cells
VII
FigureS2. Expression of endogenous Galectin-9 in human melanoma cell lines. Representative histograms of a flow cytometric 
staining for endogenous Galectin-9 in a panel of human melanoma cell lines. In brief, 3x105 cells were fixed and permeabilized using 
standard protocol with FIX & PERM® reagent system (Life technologies) after which cells were stained using anti-Galectin-9 antibody 
FG-9 or IgG isotype control. Cells were washed twice with PBS and then stained using secondary Alexa-488 conjugated anti-mouse 
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Oncogenic mutation of KRAS (Kirsten rat sarcoma viral oncogene homolog) in colorectal cancer (CRC) confers 
resistance to both chemotherapy and EGFR (epidermal growth factor receptor)-targeted therapy. We uncovered 
that KRAS mutant (KRASmut) CRC is uniquely sensitive to treatment with recombinant LGALS9/Galectin-9 
(rLGALS9), a recently established regulator of epithelial polarity. Upon treatment of CRC cells, rLGALS9 rapidly 
internalizes via early- and late-endosomes and accumulates in the lysosomal compartment. Treatment with 
rLGALS9 is accompanied by induction of frustrated autophagy in KRASmut CRC, but not in CRC with BRAF (B-Raf 
proto-oncogene, serine/threonine kinase) mutations (BRAFmut). In KRASmut CRC, rLGALS9 acts as a lysosomal 
inhibitor that inhibits autophagosome-lysosome fusion, leading to autophagosome accumulation, excessive 
lysosomal swelling and cell death. This antitumor activity of rLGALS9 directly correlates with elevated basal 
autophagic flux in KRASmut cancer cells. Thus, rLGALS9 has potent antitumor activity towards refractory KRASmut 
CRC cells that may be exploitable for therapeutic use.
Keywords:
autophagy, colon cancer, galectin-9, KRAS mutation, lysosomes
Abbreviations:
ATG5, autophagy related 5; BAX, BCL2-associated X protein; BECN1, beclin 1, autophagy related; BRAF, B-Raf 
proto-oncogene, serine/threonine kinase; BRAFmut, BRAF mutant; CASP3, caspase 3, apoptosis-related cysteine 
peptidase; CRC, colorectal cancer; CRDs, carbohydrate recognition domains; EGFR, epidermal growth factor 
receptor; EPCAM, epithelial cell adhesion molecule; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRASmut: 
KRAS mutant; LAMP2, lysosomal associated membrane protein 2; LC3B/MAP1LC3B, microtubule-associated 
protein 1 light chain 3 B; LGALS9/galectin-9, lectin, galactose-binding, soluble, 9; (serine/threonine kinase); 
PRKC, protein kinase C; PS, phosphatidylserine; PtdIns3K, class III phosphatidylinositol 3-kinase; RAF1/CRAF, 
Raf-1 proto-oncogene, serine/threonine kinase; rLGALS9, recombinant form of LGALS9;  RPS6KB1, ribosomal 
protein S6 kinase, 70kDa, polypeptide 1; SQSTM1/p62, sequestosome 1; TNFSF10/TRAIL, tumor necrosis factor 
(ligand) superfamily, member 10.
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INTRODUCTION
Oncogenic mutation of KRAS (Kirsten rat sarcoma viral oncogene homolog) is found in 30-45% of all colorectal 
cancer (CRC) patients and associates with poor prognosis1. Specifically, KRAS mutated CRC often poorly 
responds to chemotherapy due to an increased drug resistance and is insensitive to EGFR (epidermal growth 
factor receptor)-targeted therapeutics1,2. Unfortunately, the RAS pathway has proven an elusive target for 
cancer therapy, with the development of effective drugs targeting RAS being difficult3. Further, targeting of 
downstream effectors, such as RAF1, has yielded agents with only modest clinical activity in metastatic CRC 
patients that is associated with substantial off-target toxicity4. Therefore, the development of new therapeutic 
options for this large subset of refractory CRC patients is urgently needed. 
Oncogenic KRAS mutation (KRASmut) disrupts apical-basolateral polarity and prevents the formation of 
tight junctions in colon epithelial cells5. Loss of cellular polarity is a key factor in the acquisition of metastatic 
potential and may represent an Achilles’ heel of epithelial cancers (reviewed in6,7. Of note, selected members of 
the galectin family of carbohydrate-binding proteins have recently been recognized as important regulators 
of epithelial polarity and endocytosis. For instance, LGALS3/Galectin-3 maintains apical polarity by regulating 
clathrin-independent endocytosis of cargo proteins8-10, whereas LGALS8/galectin-8 steers endocytic and 
autophagic removal of bacteria11. 
Recently, LGALS9/Galectin-9 (lectin, galactose-binding, soluble, 9) has also emerged as an important 
regulator of endocytosis and polarity in epithelial cells12,13. In epithelial monolayers, LGALS9 undergoes a 
cyclical process of endosomal internalization and rerouting to the apical surface via the trans-Golgi network 
and recycling endosomes12,13. Upon targeted deletion of LGALS9 expression in these monolayers, polarity is 
lost and apical and basolateral proteins mislocalize12,13. Loss of expression of LGALS9 is also associated with 
metastatic progression in various epithelial cancers, including breast and colorectal cancer14-18. Taken together, 
this suggests that loss of LGALS9 promotes a metastatic tumor phenotype. Conversely, treatment of LGALS9 
deficient monolayers with exogenous recombinant LGALS9 (rLGALS9) restores epithelial polarity12,13. Further, 
rLGALS9 treatment of murine syngeneic colorectal carcinoma inhibits the formation of lung metastases19. Thus, 
treatment with exogenous rLGALS9 could potentially target the postulated Achilles’ heel of epithelial cancers.
Here, we show that in colorectal carcinoma cells, exogenous rLGALS9 is rapidly internalized via clathrin- 
and PRKC (protein kinase C)-, RAF1 (Raf-1 proto-oncogene, serine/threonine kinase)-, MAP2K1 (mitogen-
activated protein kinase kinase 1)-dependent endocytosis leading to lysosomal accumulation of rLGALS9. This 
triggers cell death in refractory KRAS mutant cancer cells, characterized by lysosomal swelling and a halt in 
the execution of autophagy at the stage of autophagosome-lysosome fusion. Thus, rLGALS9 is a lysosomal 
inhibitor with potent cytotoxic activity towards refractory KRAS mutant colon carcinoma cells that may be 
exploitable for therapeutic use.
MATERIALS AND METHODS
Cell lines and primary colorectal (cancer) cells 
MDCK, DLD-1, HCT116, HT29, LOVO, SW620, SW480, Caco-2, Colo205, HCT-8 and WiDr were obtained from the 
American Type Culture Collection (CCL-34, CCL-221, CCL-247, HTB-38, CCL-229, CCL-227, CCL-228, HTB-37, CCL-
222, CCL-244, CCL-218). Cell line authenticity was confirmed using STR profiling (Baseclear, The Netherlands and 
Idexx Radil, USA). All cell lines were cultured in RPMI or DMEM (Lonza, Biowhittaker BE12-604F and BE12-155F) 
supplemented with 10% fetal calf serum (Hyclone Thermo Scientific, SV30160.03) at 37oC, in a humidified 5% 
CO2
 atmosphere. Primary colorectal cancer cell cultures were obtained by mincing tumor tissue from surgical 
resection. Primary colonic epithelium was obtained from Tebu-Bio (The Netherlands, 2-96115). 
LGALS9 and inhibitors
Recombinant LGALS9 (rLGALS9) containing a truncated 2 amino acid interdomain linker (also known as Gal-9(0)) 
and the physiologically occurring short isoform of LGALS9, LGALS9(S)/Gal-9(S), were produced as described 
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previously20. For confocal analysis, rLGALS9 was conjugated to DyLight® 594 following the manufacturer’s 
protocol (DyLight 594 NHS Ester; Piercenet, Thermo scientific, 46412). 
The following inhibitors were used: α-lactose (Sigma Aldrich, L3625), sucrose (Merck Millipore, 107651), 
Dynasore (Sigma Aldrich, D7693), UCN-01 (Sigma Aldrich, U6508), U0126 (Sigma Aldrich, U120), GW5074 (Sigma 
Aldrich, G6416), necrostatin-1 (Sigma Aldrich, N9037), and Z-VAD-fmk (Calbiochem, 627610). Chloroquine was 
from the LC3B Antibody Kit for Autophagy (Life Technologies, L10382). LGALS9 blocking antibody was from 
GalPharma.
Cell transfection and RNA interference
Caco-2.KRASG12V, HCT-8.KRASG12V and HCT-8.BRAFV600E were generated by transfecting parental Caco-2 and HCT-
8 cells with pBabe-Puro-KRAS G12V or pBabe-Puro-BRAF-V600E plasmid (Addgene,Plasmid 46746 and Plasmid 
17544) using Fugene-HD (Promega, E2311). Stable cell lines were obtained by puromycin selection (Gibco/
Life Technologies, A11138-03). DLD-1.mCherry-GFP-LC3 was obtained by transfecting DLD-1 cells with GFP-
mCherry-LC3 (which was a kind gift of Prof. Andrew Thorburn, Dept. of Pharmacology, University of Colorado 
Cancer Center) and subsequent puromycin selection.
For RNA interference experiments, cells were precultured in a 12-well plates at a density of 1x105 cells/
well for 24 h, after which siRNA transfections were performed with Dharmafect-2 (Dharmacon, T-2002-01) 
following the manufacturer’s recommendations using a final concentration of 5 nM siRNA against BRAF 
(Origine, SR300470), RAF1/CRAF (Origene, SR303972), MAP2K1 (Origene, SR303761), BECN1 (Origene, SR305711) 
or ATG5 (Origene, SR306286). siRNA-transected cells were maintained under 80% confluence, and used 96 h 
after transfection for experiments. Cell viability was determined after long-term treatment with rLGALS9 (7 
days). Efficiency of knockdown of the target protein was evaluated (96 h after transfection) by western blotting 
(see below) using anti-BRAF (Santa Cruz Biotechnology, sc-5284), anti- RAF1/CRAF (Sigma Aldrich, R5773), 
anti-MEK1/2 (Cell Signaling Technology, 9122), anti-BECN1 (Origene, TA301471) and anti-ATG5 (Cell Signaling 
Technology, 9980), and appropriate secondary HRP-conjugated antibodies (Dako, P0447 and P0448).
 
Vacuolization experiments
Cells were precultured in a 48-well plate at a density of 2-3x104 cells/well. Subsequently cells were treated with 
rLGALS9 in the presence or absence of pre-incubated inhibitors. Imaging of cell vacuolization (minimal n=3) 
of different experimental conditions was determined by digital microscopy (Evos digital inverted microscope), 
and the degree of vacuolized cells per image was quantified. Percentages of vacuolized cells were calculated 
based on total cell counts.
Cell viability assays
For ANXA5/annexin-V staining, cells were pre-cultured in a 48-well plate at a density of 2-3x104 cells/well. 
Subsequently cells were treated with rLGALS9 for the indicated concentrations and time span, with or without 
inhibitors, and subsequently harvested using trypsin. ANXA5 staining was performed according to the 
manufacturer’s protocol (Immunotools, 31490013). In brief, cells were washed once with cold calcium binding 
buffer and resuspended in calcium buffer containing ANXA5-FITC. After incubation for 10 min at 4°C, PS 
exposure was analyzed by flow cytometry using a BD Accuri C6 flow cytometer (BD Biosciences) and accessory 
CFlow Plus analysis software (BD Biosciences).
For long-term viability assays, cells were precultured in a 48-well plate at a density of 1.5x104 cells/well. 
Subsequently, cells were treated with 300 nM rLGALS9 in the presence or absence of 40 mM α-lactose or 
sucrose, and incubated for 96 h. Then MTS (CellTiter 96® AQueous One Solution Cell Proliferation; Promega, 
G3580) was added to the culture medium (10% [v/v]) and incubated at 37oC. A maximum death control was 
induced by treating cells with 20% v/v ethanol. MTS readout was performed by measuring absorbance at 490 
nanometer (Versamax microplate reader, Molecular Devices). Absorbance of the maximum death control was 
109
| The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in 
KRAS mutant colon carcinoma that depends on elevated basal autophagic flux
VIII
subtracted from all values, and cell viability was calculated as percentage of medium control.
Colony forming and sphere assays
For colony-forming assays, cells were harvested as a single cell suspension using trypsin. BD Matrigel™ 
(Basement Membrane Matrix; BD bioscience, 354234) was thawed on ice, and RPMI medium supplemented 
with 10% v/v fetal calf serum was cooled down to 0oC. Per condition, cells were mixed to reach a final solution of 
5x103 cells in medium containing 3% v/v Matrigel and 300 nM rLGALS9 per well. All conditions were performed 
in triplicate. Then, cells were placed at 37oC resulting in solidification of the Matrigel, and incubated for 96 h. 
To quantify colony formation, pictures were taken (minimum of 3 fields of view (FOV) per well, Evos digital 
inverted microscope), and the number of colonies was counted.
For sphere-forming assays, tumor cells (2x103) were cultured in the absence or presence of the indicated 
concentrations of rLGALS9 in low adherent culture plates (96-wells; Costar, CLS3474). To quantify colony 
formation, pictures were taken after 1 week of incubation (minimum 3 FOV per well, Evos digital inverted 
microscope), and the number of spheres was counted.
Fluorescence microscopy 
To determine rLGALS9 uptake and transport, cells were precultured in 8-well borosilicate chamber slides 
(Lab-Tek II Chambered Coverglass w/Cover 1.5 8 Well; Thermo Scientific, NNU#155409-PK) at a density of 
2x104 cells/well. Subsequently, cells were transduced with Bacmam CellLight® Fluorescent Protein Constructs 
RAB5A-GFP or RAB7A-GFP (Life Technologies, C10586 and C10588), and treated with DyLight-coupled rLGALS9 
(rLGALS9-594). For other cell compartmental markers, cells were treated with rLGALS9-594 and counterstained 
with anti-LAMP2 (Abcam, Ab37024) and appropriate secondary antibodies conjugated to Alexa Fluor-488 (Life 
Technologies, A11034). For cell membrane staining, anti-EPCAM (Stem Cell Technologies, 10109) and secondary 
antibody conjugated to Alexa Fluor 488 (Life Technologies, A11029) was used. Similar protocols were used in 
combination with various inhibitors. In the case of intracellular antibody staining, cells were fixed with 4% 
w/v paraformaldehyde (PFA) and nuclei were stained with DAPI (Sigma Aldrich, D9542). Live-cell imaging was 
performed on the Solamere Nipkow Confocal Live Cell Imaging system, whereas Z-stacks were obtained using 
a Leica SP8 Confocal microscope. All fluorescence images and stacks were analyzed using ImageJ software (for 
colocalization analysis, the Pearson’s Correlation plug-in was used) or Leica application suite.
To determine the size of the nucleus, cells were precultured in a 48-well plate at a density of 2-3x104 cells/
well and treated with rLGALS9. Subsequently, cells were fixed with 4% PFA, and nuclei were stained using 
DAPI. After 3 washes with PBS, nuclei were evaluated by fluorescence microscopy (Leica) and nuclear size was 
determined using ImageJ particle analysis plug-ins.
For acridine orange, monodansylcadaverine, LysoTracker staining and cyto-ID, cells were precultured in a 
48-well plate at a density of 2-3x104 cells/well. After treatment with rLGALS9, acridine orange (1 μg/ml, Sigma 
Aldrich, A9231), monodansylcadaverine (30 μM, Sigma Aldrich, 30432), LysoTracker® Red DND-99 (1 μM, Life 
Technologies, L-7528) or cyto-IDhoechst/Hoechst (Cyto-ID autophagy detection kit; Enzo lifesciences, ENZ-
51031-0050) was added to the culture medium and subsequently incubated for 30 min at 37oC. Excess dye was 
removed by 3 repetitive washes using PBS. Each staining was visualized by fluorescence microscopy (Leica) and 
pictures of each condition were made (minimal n=3). The corrected total cell fluorescence (CTCF) of LysoTracker 
signal was determined using ImageJ software. To determine integrity of lysosomes/autophagosomes, 
cells were stained with acridine orange before rLGALS9 treatment. Of note, pseudocolors were used for all 
fluorescence microscopic images included in the paper.
Western blot analysis and ELISAs
Cells were precultured in 6-well plates at a density of 3x105. Subsequently, cells were treated with rLGALS9 
(300 nM) or chloroquine (100 µM) for the indicated time span. Cell lysates were prepared using lysis buffer 
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(150 mM NaCl, 50 mM Tris, pH 7.2, 20 nM EDTA, 20 nM EGTA, 1% NP-40 [Roche, 12879500], 0.1% SDS [Sigma, 
L6026]; containing Na3VO4 [Sigma, 450243] and protease inhibitor cocktail [Sigmafast; Sigma Aldrich, S8820]), 
and protein concentration was determined using the Bradford protein assay (Bio-Rad, 500-0006). For each 
sample, 15-30 µg total protein was loaded onto SDS-PAGE gels (10, 12 or 15%) for electrophoresis. Subsequently 
proteins were transferred to a nitrocellulose membrane (Amersham Hybond ECL; GE Healthcare, RPN303D). 
After blocking in 5% (w/v) milk powder/PBS, proteins were detected using primary antibodies against PKCs 
(Phospho-PKC Antibody Sampler Kit; Cell Signaling Technology, 9921), LC3B (LC3B Antibody Kit for Autophagy, 
Life Technologies, L10382), CASP3/Caspase-3 (Cell Signaling Technology, 9665), phospho-MTOR (serine 
2448; Abcam, Ab109268), or phospho-RPS6KB1/p70S6K1 (threonine 389, Abcam, Ab126818) and appropriate 
secondary HRP-conjugated antibodies (Dako, P0448). ACTB/β-actin (Directly HRP-conjugated; Abcam, 
Ab49900) or TUBA/α-tubulin (Acetyl-TUBA, Directly HRP-conjugated, Cell Signaling Technology, (Lys40) 
(D20G3), 5335) staining were used to assess protein loading. Blots were developed using chemiluminescent 
substrate (SuperSignal West Dura, Thermo scientific, Life Technologies, 34075), and X-ray films (Super RX, 
Fujifilm, 47410 19230) or analysis on the ChemiDoc MP system (Bio-Rad). Quantification of detected protein 
levels was performed using the ImageJ tool for gel analysis. 
The lysates used for SQSTM1 ELISAs were prepared as described for western blot analysis. The SQSTM1 
ELISAs were performed following the manufacturer’s protocol (Enzo Lifesciences, ADI-900-212-0001). 
In vivo animal experiment
Experiments involving animals were approved by the Committee for Research and Animal Ethics of the UMCG. 
Male athymic mice (Hsd:AthymicNude-Foxn1nu, Harlan, The Netherlands) were housed in individual ventilated 
cages, with ad libitum sterilized water and food, in a 12 h/12 h day and night rhythm. After an acclimatization 
period of 1 week, subcutaneous tumors were inoculated by injecting 5X105 DLD-1 cells in 100 µl BD Matrigel™. 
Tumor growth was monitored by measuring tumor volume using a caliper (l·h·w·0.5234). When the tumor 
reached a mean volume of 0.1 cm3, animals were stratified over different groups (n=5 per group), and 
rLGALS9 treatment was started. Treatments with rLGALS9 or PBS control were performed 3 times a week by 
intraperitoneal injections. When the tumor reached a size of 1.5 cm3, animals were terminated. 
Statistical analysis
Statistical analysis was performed by one-way ANOVA followed by Tukey-Kramer post-test or by two-sided 
Student’s t-test using Prism software. P<0.05 was defined as a statistically significant difference. Where 
indicated * = P<0.05; ** = P<0.01; *** = P<0.001. All graphs show average +/- standard deviation, unless stated 
otherwise.
RESULTS 
rLGALS9 internalizes into the lysosomal compartment in nonpolarized cells
LGALS9 maintains apical polarity in established epithelial monolayers through a cyclical process of LGALS9 
internalization into early endosomes, routing to the trans-Golgi network, and a resurfacing to the apical cell 
surface via recycling endosomes12. In order to follow the routing of LGALS9 in settings of disturbed polarity, 
nonpolarized MDCK cells and DLD-1 colorectal cancer cells were treated with rLGALS9/rGAL9(0), a previously 
reported recombinant form of LGALS9 containing a truncated linker for improved stability20. Surface binding 
of fluorescently labeled recombinant rLGALS9 was detected within 1 min, followed by rapid internalization 
(Figure 1A). Initially, internalized rLGALS9 was localized in close proximity to the cell membrane, but at 
later time points accumulated in enlarged vesicles more centrally located in the cytoplasm (Figure 1A). This 
internalization of rLGALS9 was dependent on its carbohydrate recognition domains (CRDs), since the CRD-
blocking sugar α-lactose, but not the irrelevant sugar sucrose, abrogated rLGALS9 internalization (Figure 1A).
The subcellular localization of rLGALS9 was determined using a panel of cell compartmental markers, 
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which demonstrated that on DLD-1 cells rLGALS9 initially colocalized with the cell surface marker EPCAM 
(epithelial cell adhesion molecule) (Figure 1B; t=5 min). In time, this was followed by colocalization of rLGALS9 
with the GFP-tagged early endosome marker RAB5A (Figure 1C; t=30 min), with the GFP-tagged late endosome 
marker RAB7A (Figure 1D; t=1 h) and with the lysosomal marker LAMP2 (lysosomal-associated membrane 
protein 2) Figure 1E; t=24 h). Similar intracellular localization of rLGALS9 was observed for MDCK (Figure 
S1A-C). Colocalization analysis (using Pearson’s correlation coefficient-Rr) confirmed that rLGALS9 very rapidly 
disappeared from the membrane (Figure 1F), with a time-dependent increase in the percentage of rLGALS9+ 
LAMP2+ lysosomes (Figure 1G). 
Figure 1. rLGALS9 is internalized via endosomes and accumulates in the lysosomes. (A) MDCK cells were treated with 
rLGALS9-594 in the presence or absence of α-lactose (40 mM) or sucrose (40 mM) and confocal images were captured at 1 min, 1 
h and 2 h. (B) Maximum association of rLGALS9-594 with the cell surface of DLD-1 cells at 5 min of incubation (arrows highlight 
colocalization). Here, DLD-1 cells were incubated with rLGALS9-594, stained with anti-EPCAM-488, fixed with 4% PFA, and 
subsequently stained with DAPI. (C) For confocal colocalization analysis with early endosomes, DLD-1 cells were transduced 
with Bacmam CellLight® Fluorescent Protein Construct RAB5A-GFP and incubated with rLGALS9-594 and Hoechst. Maximum 
colocalization was observed after 15 min (arrows highlight colocalization). (D) For confocal colocalization analysis with late 
endosomes, DLD-1 cells were transduced with Bacmam CellLight® Fluorescent Protein Construct RAB7A-GFP and incubated with 
rLGALS9-594 and Hoechst. Maximum colocalization was observed after 45 min (arrows highlight colocalization). (E) For confocal 
colocalization analysis with the lysosomes, DLD-1 cells were treated with rLGALS9-594, fixed with 4% PFA, and costaining was 
performed using anti-LAMP2-488. Maximum colocalization was observed after 24 h. (F) Colocalization analysis of EPCAM 
and rLGALS9 in DLD-1 cells, using Pearson’s correlation as determined using ImageJ. Rr=1, perfect colocalization; Rr=0, random 
localization; Rr=-1, total exclusion. (G) Time-dependent increase in lysosomal association of rLGALS9 in DLD-1 cells, determined as 
the percentage of rLGALS9-positive lysosomes of total amount of lysosomes. 
























































































rLGALS9 triggers vacuolization via PRKC-RAF1-MAP2K1-dependent clathrin-mediated internalization 
The treatment of MDCK and DLD-1 cells with rLGALS9 was characterized by the progressive formation of large 
vacuoles (Figure 2A), which affected ~95% of cells after 24 h (Figure 2B). Vacuole formation was blocked by 
cotreatment with α-lactose or blocking anti-LGALS9 antibody, but not by sucrose (Figure 2A, B). Treatment 
of MDCK or DLD-1 cells on ice, at low pH, or with the DNM/dynamin GTPase inhibitor dynasore abrogated 
rLGALS9-mediated vacuole formation (Figure 2C, D, Figure S2A). Thus, rLGALS9 internalized via active 
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Figure 2. rLGALS9 is internalized via clathrin-dependent endocytosis mediated by PRKC and MAP2K1. (A) MDCK cells 
were treated with rLGALS9 (300 nM) in the presence or absence of α-lactose (40 mM) or sucrose (40 mM) or blocking anti-LGALS9 
monoclonal antibody (mAb; 10 μg/ml). Representative light microscopy pictures were taken after 1 h of treatment. (B) Quantification 
of the percentage of cells having visible vacuoles in MDCK and DLD-1 cells upon 1 h treatment as described in (A). (C) MDCK 
and DLD-1 cells were treated with rLGALS9 (300 nM) for respectively 1 h and 6 h at 37oC versus 0oC at pH 7 or pH 5, after which 
vacuolization was quantified. (D) MDCK and DLD-1 cells were pre-incubated for 1 h with the indicated concentrations of Dynasore 
(or DMSO solvent control), after which vacuolization induced by rLGALS9 (300 nM) was determined. (E) MDCK and DLD-1 cells were 
pre-incubated for 1 h with the indicated concentrations of UCN-01 after which vacuolization induced by rLGALS9 (300 nM) was 
determined. Representative fluorescent pictures (using rLGALS9-594) illustrate the cellular distribution of rLGALS9. (F) Western blot 
detection of different PRKC isoforms in rLGALS9 (300 nM) treated MDCK cells. (G) MDCK cells were pretreated with RAF1 inhibitor 
GW5074 (50 μM, 48 h pre-incubation), BRAF inhibitor Dabrafenib (200 nM, 48 h pre-incubation), and MAP2K inhibitor U0126 (100 
μM, 2 h pre-incubation) and subsequently treated with rLGALS9 (300 nM), after which the percentage of cells with visible vacuoles 
was quantified. Representative fluorescence pictures (using rLGALS9-594) illustrate the cellular distribution of rLGALS9 with or 
without U0126 pretreatment. (H) MAP2K1-deficient DLD-1 cells were treated with rLGALS9 for 6 h after which vacuole formation 
was quantified. 
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cells were co-incubated with inhibitors of kinases involved in endocytosis. Among these, the PRKC-inhibitor 
UCN-01 dose-dependently reduced rLGALS9 uptake and vacuolization (Figure 2E, Figure S2A). UCN-01 also 
reduced colocalization of rLGALS9 with early endosomes (Figure S2B). In line with this, rLGALS9 treatment 
phosphorylated various PRKC isoforms, particularly atypical PRKC isoforms PRKCZ/PRKCζ and PRKCI/PRKCλ 
(Figure 2F). Further, inhibition of RAF1/CRAF (GW5074), but not BRAF (Dabrafenib) strongly reduced rLGALS9-
induced vacuolization in MDCK cells (Figure 2G, Figure S2A). Correspondingly, inhibition of downstream 
kinases MAP2K1 and MAP2K2 (U0126) also strongly inhibited rLGALS9 internalization and vacuolization (Figure 
2G, Figure S2A). To confirm the requirement for MAP2K-signaling, the predominant MEK isoform in DLD-1, 
MAP2K1, was knocked down by small interfering (si)RNA (Figure S2C). Treatment of MAP2K1-deficient DLD-1 
cells with rLGALS9 did not induce vacuole formation (Figure 2H, Figure S2C). Thus, rLGALS9 is internalized 
via clathrin-dependent, PRKC-RAF1-MAP2K1-mediated endocytosis in nonpolarized MDCK cells and DLD-1 
colorectal cancer cells, whereupon it triggers formation of large vacuoles. 
rLGALS9 has direct dose-dependent cytotoxic activity toward colon carcinoma in vitro and in vivo
Due to the progressive vacuolar swelling upon treatment with rLGALS9, the nuclear size of MDCK and DLD-1 
cells was reduced by ~40% within 5 h (Figure 3A, B). Treatment of MDCK and DLD-1 cells with rLGALS9 also 
dose-dependently triggered the apoptotic feature of phosphatidylserine (PS) surface exposure (Figure 3C), 
loss in cell viability (Figure 3D), reduced sphere formation (Figure 3E) and reduced colony formation (Figure 
3F). This cytotoxic effect of rLGALS9 was inhibited by α-lactose, but not sucrose as illustrated for loss of cell 
viability and PS-exposure (Figure 3G, Figure S2D). The naturally occurring short and medium LGALS9 isoforms 
(rLGALS9[S] and rLGALS9[M]) also had cytotoxic effects towards DLD-1 cells, but at higher molar concentrations 
(Figure 3H, Figure S2E). 
In primary patient-derived colon carcinoma cells, treatment with rLGALS9 also induced numerous vacuoles 
(Figure 3I), resulting in cellular detachment, PS-exposure (Figure 3J, Figure S2F) and reduced cell viability 
(Figure 3K), which was inhibited by α-lactose, but not sucrose (Figure 3I-K). Treatment of mice bearing DLD-1 
xenografts with rLGALS9 strongly inhibited tumor growth (Figure 3L) and increased overall survival (Figure 3M; 
50% for rLGALS9 vs. 0% for control animals), with no detectable signs of toxicity, such as weight loss (Figure 
3N). Corresponding to the lack of toxicity in vivo, short-term ex vivo cultures of untransformed primary normal 
human colon epithelial cells were resistant to rLGALS9, with no vacuolization (Figure 3O), PS-exposure (Figure 
3P, Figure S2F), and no loss in cell viability (Figure 3P).
rLGALS9 selectively induces cell death in KRAS mutant colon carcinoma cells
From the data above it is evident that rLGALS9 triggers prominent cytotoxic effects in DLD-1 colon carcinoma 
cells characterized by formation of large vacuoles that required RAF1 and MAP2K1 signaling. The cytotoxicity 
of rLGALS9 similarly depended on MAP2K1 and RAF1, as siRNA-mediated knockdown of either kinase strongly 
inhibited the cytotoxic effect of rLGALS9 on DLD-1 cells (Figure 4A, Figure S3A). In contrast, siRNA-mediated 
knockdown of BRAF did not affect rLGALS9 cytotoxity (Figure 4A, Figure S3A). Thus, rLGALS9-mediated RAF1, 
but not BRAF, signaling is required for cytotoxicity. Interestingly, previous studies demonstrated that RAF1 
is responsible for transmitting signals from mutated KRAS to downstream kinases MAP2K1 and MAP2K2, 
whereas BRAF is not required21. Further, knockdown of RAF1 inhibits tumorigenesis of KRAS mutant cells22. 
To investigate whether the cytotoxic activity of rLGALS9 could similarly depend on KRAS mutation, a panel of 
colon carcinoma cell lines with either oncogenic KRAS or oncogenic BRAF mutation was analyzed. Overnight 
treatment with rLGALS9 induced PS-exposure and reduced cell viability in all KRASmut BRAFWT cells (Figure 
4B, C), but did not or only minimally affected cell viability of KRASWT BRAFmut cells. Similarly, rLGALS9 reduced 
colony formation in all KRASmut BRAFWT cell lines, but not in KRASWT BRAFmut cells (Figure 4D). 
Of note, Caco-2 cells that are both KRAS and BRAF wild-type (KRASWT BRAFWT) proved resistant to rLGALS9, 
whereas another KRASWT BRAFWT cell line, HCT-8, was sensitive to rLGALS9-mediated cell death (Figure 4E). To 
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identify a causal relationship between expression of a mutant KRAS allele and rLGALS9-mediated cytotoxic-
ity, the rLGALS9 resistant KRASWT BRAFWT cell line Caco-2 was transduced with the KRASG12V oncogene (Caco-2.
KRASG12V). In these Caco-2.KRASG12V cells, treatment with rLGALS9 proved cytotoxic, with vacuole formation, 
reduced cell viability and inhibited colony formation identical to that induced in other KRASmut BRAFWT cell 
lines (Figure 4F-H). Similarly, transduction of the rLGALS9 sensitive KRASWT BRAFWT cell line HCT-8 with the 
KRASG12V oncogene (HCT-8.KRASG12V) further sensitized these cells to rLGALS9 treatment. In contrast, the onco-
genic BRAF mutant allele BRAFV600E (HCT-8.BRAFV600E) did not sensitize cells to rLGALS9 treatment (Figure 4I, J). 
rLGALS9 was previously reported to induce apoptosis in leukemic T-cells, multiple myeloma, Burkitt- and 
Hodgkin-lymphoma and melanoma cells14,23. However, rLGALS9 treatment of DLD-1 cells was not associated 
with CASP3/caspase-3 processing (Figure 4K) nor did the pan-caspase inhibitor Z-VAD-fmk inhibit rLGALS9-
induced vacuolization (Figure 4L, Figure S3B). Furthermore, cell death was not necrotic as cells displayed PS on 
the surface without membrane permeabilization after 6 h as assessed by propidium iodide (data not shown), 
nor was cell death inhibited by the necroptosis inhibitor necrostatin alone or in combination with Z-VAD-fmk 
(Figure 4L, Figure S3B). To corroborate the apoptosis-independent effect of rLGALS9, isogenic and apoptosis-
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Figure 3. (Left page) Dose-dependent cytotoxicity of rLGALS9 in vitro and in vivo (A) DAPI staining 
visualized the nucleus in medium- and rLGALS9-treated (5 h, 300 nM) MDCK cells. (B) Quantification of 
nuclear size of MDCK and DLD-1 cells after 1- to 5-h treatment with rLGALS9 (300 nM). (C) MDCK and DLD-1 cells 
were treated with the indicated concentrations of rLGALS9 and analyzed for PS exposure by flow cytometric ANXA5 
staining. (D) As in (C), but analyzed for viability after 48 h with the MTS assay. (E) MDCK and DLD-1 cells were plated 
on nonadherent plates and treated with the indicated concentrations of rLGALS9. The number of tumor spheres was 
quantified by counting 3 fields-of-view in triplicates after 1 week. (F) MDCK and DLD-1 cells were plated in Matrigel 
and treated with the indicated concentrations of rLGALS9. After 1 week, colony formation was quantified by counting 
3 fields-of-view in triplicates. (G) Analysis of cell viability after 48 h treatment of MDCK and DLD-1 cells with rLGALS9 
(300 nM) +/- α-lactose or sucrose (40 mM). (H) Cell viability of DLD-1 cells after 48 h of treatment with increasing 
doses of rLGALS9/GAL9[0], rLGALS9[S], or rLGALS9[M]. (I) Representative light microscopy pictures of primary 
patient-derived colorectal cancer cells detailing vacuole formation after 3 h treatment with rLGALS9 (300 nM). (J) 
Analysis of PS exposure after 24 h treatment of primary patient-derived colorectal cancer cells with rLGALS9 (300 
nM) in the presence or absence of α-lactose (40 mM). (K) Analysis of cell viability after 48 h treatment of primary 
patient-derived colorectal cancer cells with rLGALS9 alone or with rLGALS9 and α-lactose or sucrose (40 mM). (L) 
Tumor growth of DLD-1 xenografts treated with rLGALS9. In brief, athymic nude mice were subcutaneously injected 
with 5x105 DLD-1 cells in Matrigel. Treatment was started after tumor size reached 100 mm3 and comprised 3 times/
week intraperitoneal injection of rLGALS9 at the indicated doses. After 3 weeks, treatment was stopped and survival 
was determined. Average+/-SEM (M) Kaplan Meyer curve of survival of DLD-1 xenografted mice treated with the 
indicated concentrations rLGALS9 or solvent control. (N) Weight of rLGALS9-treated mice during the experiment. (O) 
Representative light microscopy pictures of primary normal colonic epithelial cells with rLGALS9 (300 nM) after 24 
h. (P) Analysis of PS exposure after 6 h and cell viability after 48 h of treatment of primary normal colonic epithelial 
cells with 300 nM rLGALS9.
mutation or with a deficiency in the mitochondrial apoptosis regulator BAX (BCL2-associated X protein) were 
treated with rLGALS9. Both apoptosis-resistant lines remained sensitive to rLGALS9 cytotoxicity (Figure 4M), 
but were resistant to apoptosis inducer TNFSF10/TRAIL (tumor necrosis factor [ligand] superfamily, member 
10) (Figure 4M). These data indicate that rLGALS9-induced cell death in colon cancer cells with a mutated KRAS 
allele is likely independent of apoptosis or necrosis.
rLGALS9 induced cell death depends on basal autophagic flux and is associated with lysosomal swelling 
and autophagosome formation
The progressive accumulation of rLGALS9 within the lysosomal compartment was associated with marked 
swelling of LAMP2-positive lysosomes in KRASmut cells (Figure 5A, left panels), but not BRAFmut cells (Figure S4A). 
This increase in lysosomal size was confirmed using LysoTracker-DND-99 (Figure 5A, right panels), with signal 
intensity strongly increasing upon rLGALS9 treatment. This swelling of lysosomes was detected in all rLGALS9-
sensitive, but not -resistant, cell lines (Figure 5B). Of note, in the wild-type cell lines HCT-8 and Caco-2 the 
expression of KRASG12V increased the swelling of lysosomes upon rLGALS9 treatment (Figure 5B). Conversely, 
the expression of BRAFV600E reduced lysosomal swelling in HCT-8 cells (Figure 5B). This rLGALS9-induced 
swelling of lysosomes correlated with loss in cell viability (Figure 5C). Of note, although the LysoTracker signal 
as well as the level of red fluorescence of acridine orange-stained cells increased over the first 6 h of treatment 
with rLGALS9, the signal intensity of both dyes was decreased after 24 h of treatment (Figure S4B). Analysis 
of vacuolar diameter revealed that all vacuoles with a diameter >2.5 nanometer in size lost their red acridine 
orange signal (Figure S4B), indicating that these dilated lysosomes lost functionality.  
Based on the progressive vacuolization upon rLGALS9 treatment, we reasoned that autophagy might 
be involved. A hallmark feature of autophagy is the lipidation of MAP1LC3 B/LC3B (microtubule-associated 
protein 1 light chain 3) into LC3B-II. This LC3B-II is recruited to phagophore membranes yielding a punctate 
staining pattern. In rLGALS9-treated cells such LC3B puncta were clearly visible (Figure 5D), indicative of 
autophagosome formation. Correspondingly, the staining intensity of monodansylcadaverine and Cyto-ID, 
both dyes that can be used to label autophagosomes, were increased in DLD-1 cells upon treatment with 
rLGALS9 (Figure 5D). This increase in autophagosomes correlated with a loss in cell viability upon rLGALS9 
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treatment, as illustrated for cyto-ID (Figure 5E). Upon treatment with rLGALS9, the levels of LC3B-II strongly 
increased in rLGALS9-sensitive KRASmut cell lines, MDCK and primary malignant colorectal cancer cells (Fig 5F, 
G, Figure S4C). In contrast, LC3B-II levels did not increase in rLGALS9-resistant BRAFmut cell lines or KRASWT 
BRAFWT Caco-2 cells (Figure 5F, G), whereas LC3B-II levels did increase in Caco-2.KRASG12V cells (Figure 5F, G, 
Figure S4C). Of note, the formation of autophagosomes during rLGALS9 treatment did not require the 
autophagy regulator MTOR (mechanistic target of rapamycin [serine/threonine kinase]), as rLGALS9 treatment 
induced both phosphorylation and dephosphorylation of MTOR in KRASmut and BRAFmut cell lines, with minimal 
effect on phosphorylation of the downstream MTOR target RPS6KB1 (ribosomal protein S6 kinase, 70kDa, 
polypeptide 1) (Figure 5H).
To further characterize the role of autophagy in the cytotoxic effects of rLGALS9 in KRASmut colon cancer 
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Figure 4. (left page) KRAS mutant but not BRAF mutant colon cancer cell lines are sensitive to rLGALS9 treatment. 
(A) DLD-1 cells subjected to control siRNA or siRNA-mediated knockdown of MAP2K1, RAF1 or BRAF were treated with 300 nM 
rLGALS9 for 1 week, after which cell viability was determined by the MTS assay. (B) A panel of colon carcinoma cell lines with KRAS 
mutation (KRASmut) or BRAF mutation (BRAFmut) were treated with 300 nM rLGALS9 for 24 h and analyzed for PS exposure. (C) As in 
(B), but analyzed after 48 h for cell viability with the MTS assay. (D) Colon cancer cell lines were plated in Matrigel and treated with 
300 nM rLGALS9. After 72 h, colony formation was quantified by counting 3 fields-of-view in triplicate. (E) KRASWT BRAFWT tumor cell 
lines Caco-2 and HCT-8 were treated with 300 nM rLGALS9 and analyzed for PS exposure (24 h) and cell viability (48 h). (F-H) The 
rLGALS9-resistant cell line Caco-2 (KRASWT BRAFWT) was transfected with plasmid encoding KRAS containing the G12V activating 
mutation. The resulting cell line Caco-2.KRASG12V was analyzed for (F) vacuole formation (G) cell viability and (H) colony formation 
after treatment with rLGALS9 for 3, 24, 48, and 72 h. (I-J) The rLGALS9-sensitive cell line HCT-8 (KRASWT BRAFWT) was transfected with 
plasmid encoding KRAS containing the G12V activating mutation or BRAF containing the V600E activating mutation. The resulting 
cell lines HCT-8.KRASG12V and HCT-8.BRAFV600E were analyzed for (I) vacuole formation and (J) dose-dependent reduction in cell 
viability. (K) DLD-1 cells were treated with rLGALS9 (300 nM, 24 h) and cell lysates were analyzed by western blot for CASP3 (full-
length/cleaved). (L) MDCK and DLD-1 cells were pre-incubated with the pan-caspase inhibitor Z-VAD-fmk (20 μM), the necroptosis 
inhibitor necrostatin (100 μM) or Z-VAD-fmk+necrostatin and analyzed for rLGALS9-induced vacuolization. (M) Parental HCT116, 
HCT116.PtdIns3K.WT, HCT116.PtdIns3K.MUT and HCT116.BAX-/- were treated with 300 nM rLGALS9 or 100 ng/ml recombinant human 
TNFSF10/TRAIL for 24 h, after which cells were analyzed for PS exposure using flow cytometric ANXA5 staining. 
Beclin 1 using siRNA (Figure S3A), which should block formation of autophagosomes. Indeed, in ATG5-depleted 
cells LC3B-I accumulated in the absence of conversion into LC3B-II upon rLGALS9 treatment, whereas in control 
siRNA conditions LC3B-II accumulation was detected (Figure S4D). Importantly, ATG5 depletion strongly 
inhibited the cytotoxic activity of rLGALS9 towards DLD-1 cells (Figure 5I). In line with this, siRNA-mediated 
depletion of BECN1 almost completely abrogated the cytotoxic effect of rLGALS9 treatment in DLD-1 cells 
(Figure 5J). Thus, inhibition of autophagosome formation inhibits rLGALS9-induced cell death of KRAS mutant 
colon cancer cells.
Previously, oncogenic mutation of KRAS was shown to associate with increased levels of basal 
autophagy24,25. Correspondingly, basal autophagic flux, as determined by the accumulation of LC3B-II upon 
chloroquine treatment, was high in KRASmut and low in BRAFmut cell lines (Figure 5K, Figure S4E). In addition, 
the KRASWT BRAFWT and rLGALS9-sensitive cell line HCT-8 was characterized by high autophagic flux, whereas 
the KRASWT BRAFWT and rLGALS9-resistant cell line Caco-2 was characterized by low autophagic flux. This 
basal autophagic flux strongly correlated with increases in LysoTracker signal as well as loss in cell viability 
upon rLGALS9 treatment (Figure 5L, M). Thus, the basal autophagic flux in colon cancer cells determines the 
sensitivity toward rLGALS9 treatment.
rLGALS9 induces dysfunctional autophagy halted at the stage of autophagosomal-lysosomal fusion 
During autophagy the accumulation of LC3B-II is typically transient and normalizes when autophagosomes 
fuse with lysosomes, due to degradation of the autolysosomal content. However, the progressive vacuolization 
upon rLGALS9 treatment suggested that autophagy may be incompletely executed. To assess this possibility, 
the levels of LC3B-II and the ubiquitin-binding scaffold protein SQSTM1/p62 (sequestosome 1) were determined 
over time. Upon full execution of autophagy, e.g. upon rapamycin treatment of DLD-1 cells (Figure 6A, B) and 
MDCK cells (Figure S5A), both proteins were degraded after 24 h. However, the levels of LC3B-II and SQSTM1 
remained elevated in cells treated with rLGALS9 after 24 h (Figure 6A, B). These effects of rLGALS9 resembled 
those of the lysosomal inhibitor chloroquine (Figure 6A, B) and were inhibited by α-lactose but not sucrose 
(Figure S5B). Further time course analysis of SQSTM1 levels revealed an initial small decrease in the first hours of 
rLGALS9 treatment followed by SQSTM1 accumulation at later time points (Figure 6C). This accumulation was 
observed in all KRASmut BRAFWT cell lines, with an average fold increase in SQSTM1 levels of ~2.5 (Figure 6D). In 
contrast, SQSTM1 levels did not change in KRASWT BRAFmut cells (Figure 6D). 
The accumulation of LC3B-II and SQSTM1 suggest that rLGALS9-induced cell death is likely due to inhibition 
of autophagosome-lysosome fusion. As shown in Figure 1, rLGALS9 accumulated in lysosomes. In contrast, 




























































































































































































































































































































Figure 5. rLGALS9-induced cell death is associated with lysosomal swelling and autophagosome formation. (A) Medium 
control and rLGALS9 (300 nM)-treated DLD-1 cells were stained with anti-LAMP2 (left panel) or the lysosomal marker LysoTracker® 
Red DND-99. (B) Quantification of the change in LysoTracker signal upon 6 h treatment with 300 nM rLGALS9 of KRASmut cell lines 
(n=5), BRAFmut (n=3), Caco-2WT and Caco-2.KRASG12V, HCT-8WT, HCT-8.KRASG12V and HCT-8.BRAFV600E. rLGALS9-induced lysosomal 
swelling was quantified by determining fluorescent signal induction using ImageJ (factor=rLGALS9/medium). (C) Linear correlation 
analysis of the reduction in cell viability upon rLGALS9 treatment and increases in LysoTracker signal upon rLGALS9 treatment. 
Dotted lines represent the 95% confidence interval. (D) Medium control and rLGALS9 (300 nM) treated DLD-1 cells were stained with 
anti-LC3B (left panel), monodansylcadaverine (MDC, middle panel), or Cyto-ID (left panel). All these stains detect autophagosomes. 
(E) Linear correlation analysis of the reduction in cell viability upon rLGALS9 treatment and increases in Cyto-ID signal upon rLGALS9 
treatment. Dotted lines represent the 95% confidence interval. (F) A colon cancer cell panel was treated with rLGALS9 (300 nM) for 
different time points, after which cell lysates were subjected to western blot analysis to detect the lipidated form of LC3B (LC3B-II). 
(G) Quantification of the fold increase in LC3B-II induced by rLGALS9 in KRASmut cell lines (n=5), BRAFmut (n=3), Caco-2WT and Caco-
2.KRASG12V (factor= rLGALS9/medium). (H) Western blot analysis of MTOR phosphorylation (serine 2448) and RPS6KB1/p70S6K1 
phosphorylation (threonine 389) in KRASmut and BRAFmut cell lines after treatment with 300 nM rLGALS9 for 6 h. (I) DLD-1 cells were 
subjected to control siRNA or siRNA-mediated knockdown of ATG5 and treated for 1 week with rLGALS9, after which cell viability was 
determined using the MTS assay. (J) DLD-1 cells were subjected to control siRNA or siRNA-mediated knockdown of BECN1 and treated 
for 1 week with rLGALS9, after which cell viability was determined using the MTS assay. (K) Basal autophagic flux as determined 
by LC3B-II accumulation upon chloroquine treatment (6 h, 100 µM) in KRASmut cell lines (n=3), BRAFmut (n=2), Caco-2 and HCT8. (L) 
Linear correlation analysis of the increase in LysoTracker signal upon rLGALS9 treatment and basal autophagic flux as determined by 
chloroquine treatment (6 h, 100 µM) (Fig. S3F). Dotted lines represent the 95% confidence interval. (M) Linear correlation analysis of 
the decrease in cell viability upon rLGALS9 treatment and basal autophagic flux as determined by 6 h chloroquine treatment. Dotted 
lines represent the 95% confidence interval. 
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Figure 6. Lysosomal accumulation of rLGALS9 results in halted autophagy. (A) LC3B-II levels after 24 h treatment of the 
indicated cell lines with rLGALS9 (300 nM), autophagy inhibitor chloroquine (100 μM) or autophagy inducer rapamycin (100 nM). 
(B) Analysis of SQSTM1 levels using ELISA after treatment of DLD-1 as in (A) (factor=rLGALS9/medium). (C) Time-course analysis 
of SQSTM1 levels in DLD-1 cells treated with rLGALS9 (24 h, 300 nM). (D) SQSTM1 formation induced by rLGALS9 treatment (24 h, 
300 nM) in a panel of KRASmut cell lines (n=5) and BRAFmut (n=5). (E) Confocal microscopy pictures of DLD-1 cells treated for 24 h 
with DyLight-594-labeled rLGALS9 and costained with anti-LC3B-488. (F) LC3B/rLGALS9 colocalization was analyzed by Pearson’s 
correlation. (G) Confocal microscopy pictures of DLD-1 cells treated with rLGALS9 (24 h, 300 nM) or chloroquine (24 h, 100 μM) and 
subsequently stained with anti-LAMP2 and anti-LC3B. LAMP2/LC3B colocalization was analyzed by Pearson’s correlation. (H) 
Confocal microscopy pictures of DLD-1 cells transfected with a mCherry-GFP-LC3 construct treated with rLGALS9 (24 h, 300 nM) or 
chloroquine (24 h, 100 µM). mCherry/GFP ratio was analyzed using ImageJ software. 
with LC3B was minimal in DLD-1 cells (Figure 6E), with a corresponding low level of colocalization (Figure 6F). 
Furthermore, the proteins LAMP2 and LC3B also did not colocalize in rLGALS9-treated cells, indicative of 
an arrest in the autophagic process at the stage of autophagosome-lysosome fusion (Figure 6G). Of note, 
treatment with chloroquine triggered an analogous nonoverlapping LAMP2-LC3B staining pattern and Rr 
colocalization score (Figure 6G). Arrested autophagy upon rLGALS9 treatment was confirmed using mCherry-
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GFP-LC3-transfected DLD-1 cells in which autophagosome-lysosome fusion will result in loss of GFP signal. 
Treatment of DLD-1.mCherry-GFP-LC3 with rLGALS9 did not reduce GFP-signa l intensity whereby the ratio 
of mCherry/GFP fluorescent signal did not change, similar to fluorescent LC3-signal after treatment with 
chloroquine (Figure 6H). Conversely, execution of autophagy in control settings in which DLD-1.mCherry-GFP-
LC3 cells were serum starved strongly reduced the GFP-signal intensity and thereby increased the mCherry/
GFP ratio (Figure 6H, Figure S5C). 
Taken together, rLGALS9 treatment induces lysosomal swelling and autophagosome formation in KRASmut 
colon carcinoma cells, which results in halted autophagy by the inhibition of autophagosome-lysosome fusion. 
Of note, this effect is similar as that induced by the lysosomal inhibitor chloroquine. Thus, rLGALS9 seems to 
act an oncogenic KRAS-selective lysosomal inhibitor that induces dysfunctional autophagy and cell death.
Figure 7. rLGALS9 internalization and signaling in CRC. (A) Internalization route of rLGALS9 in polarized epithelial cells. (B) Cell 



































In this study we show that oncogenic mutation of KRAS sensitizes CRC cells to autophagy-dependent cell death 
by a recombinant form of the epithelial polarity regulator LGALS9 in vitro and in vivo. We propose a mode of 
action where rLGALS9 undergoes rapid endosomal internalization in nonpolarized CRC cells and accumulates 
in the lysosomal compartment. In KRASmut CRC cells, exposure to rLGALS9 is characterized by lysosomal 
swelling, autophagosome formation and halted autophagosome-lysosome fusion, ultimately leading to cell 
death (Figure 7). This sensitivity of KRASmut CRC for rLGALS9 is of potential clinical relevance, since KRASmut CRC 
cells are notoriously refractory to available therapies, and often acquire therapy resistance by elevating basal 
levels of autophagy. 
Treatment with rLGALS9 resulted in the accumulation of rLGALS9 in the lysosomal compartment and 
lysosomal swelling in KRASmut but not BRAFmut CRC cells. Furthermore, cell death induced by rLGALS9 correlated 
with an increase in levels of autophagosomes. In line with this, rLGALS9-induced cytotoxicity depended 
on the autophagic pathway, with ATG5 and BECN1 knockdown protecting against rLGALS9 cytotoxicity. 
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However, the execution of autophagy upon treatment of KRASmut CRC with rLGALS9 was halted at the stage 
of autophagosome-lysosome fusion, leading to hallmark accumulation of LC3B-II and SQSTM1 over time. 
Such inhibition of autophagosome-lysosome fusion and LC3B-II-SQSTM1 accumulation has previously been 
reported for the lysosomal inhibitor chloroquine, leading to vacuolization and lysosomal swelling as identified 
here for rLGALS9.26,24 Colocalization analysis clearly confirmed lysosomal accumulation of rLGALS9 and lack of 
association with autophagosomes. Thus, rLGALS9 seems to act as a lysosomal inhibitor, similar to chloroquine, 
in KRASmut CRC. Of note, oncogenic KRAS mutation impairs normal lysosomal composition and function in CRC 
cells, which sensitizes these cells to lysosome-targeting drugs27. 
The differential sensitivity of KRASmut and BRAFmut cells to rLGALS9 was directly correlated with their levels 
of basal autophagic flux, with KRASmut cell lines having high and BRAFmut cells having low basal autophagic 
flux. In line with this, activated KRAS was previously shown to trigger so-called “autophagy addiction”, 
with autophagy being required for maintenance of metabolism and tumorigenesis24,25,28. Conversely, the 
low autophagic flux levels of BRAFmut cells seem to be specific for CRC, since BRAFmut cells have high basal 
autophagy levels in other types of cancer such as lung cancer29,30 and melanoma31. The correlation between 
high basal autophagic flux levels and the sensitivity toward rLGALS9 treatment may be a logical consequence 
of the inhibited autophagosome-lysosome fusion that is induced by rLGALS9. By preventing normal execution 
of autophagy, rLGALS9 induces shortness of energy, which will eventually lead to cell death in such “autophagy 
addicted” cancers. In line with this, targeting autophagy has been postulated as a promising target to treat 
(RAS mutated) cancers with high basal autophagic flux32. However, cancers which harbor RAS mutations 
are not always sensitive toward treatment with autophagy inhibitors, and the expression of oncogenic RAS 
may even promote resistance toward autophagy inhibition in lung cancer cell lines33. Therefore, the relation 
between KRASmut expression and sensitivity toward rLGALS9, may be specific for colon cancer. 
Besides the maintenance of tumorigenesis, the activation of autophagy is one of the mechanisms by which 
tumor cells acquire therapy resistance34. Indeed, high autophagic flux is associated with poor prognosis and 
drug resistance in CRC35, with KRASmut CRC cells being notoriously refractory to available therapies, including 
EGFR-targeted therapeutics2. Also in colon cancer stem cells, the autophagic pathway is responsible for the 
induction of resistance toward photodynamic therapy, which can be counteracted by the use of autophagy 
inhibitors36. Similarly, elevated levels of basal autophagic flux are found in cervical cancers compared to 
healthy tissue, which is even further enhanced by cisplatin treatment37. Interestingly, simultaneous treatment 
of ovarian cancers with cisplatin and autophagy inhibitors increases cell death37. Similar synergistic effects of 
autophagy inhibitors and standard therapies have been found in many other cancer types34. Hence, rLGALS9 
is not only of clinical relevance in its own right, but may be of particular relevance in combination therapies. 
Of note, we showed that apoptosis-resistant HCT116 strains with an oncogenic PtdIns3K mutation (found in 
~15–20% of colon cancer patients in large population-based studies38,39) or BAX-deficiency remained sensitive 
to rLGALS9 cytotoxicity, while being resistant to the typical apoptosis-inducer TNFSF10/TRAIL. Thus, the 
autophagy-inhibiting effects of rLGALS9 may be clinically relevant for the treatment of autophagy addicted 
KRASmut colon cancers and to overcome intrinsic/acquired therapy resistance.
Treatment with rLGALS9 did not negatively affect primary cultures of normal colonic epithelial cells, nor 
was treatment of xenografted mice with rLGALS9 associated with detectable signs of toxicity. This differential 
sensitivity of normal versus malignant epithelial cells to rLGALS9 provides a promising therapeutic window. 
As galectins bind to glycosylated proteins and changes in glycosylation are a hallmark of cancer40, cancer-
specific glycosylation may have altered the receptor profile for rLGALS9. For instance, short and incomplete 
glycan structures to which rLGALS9 can bind, such as the Forssman antigen12,41, have been reported in CRC42,43. 
Although rLGALS9 did not interact with this glycolipid on DLD-1 cells (data not shown), alternate cancer-
specific and de novo glycoepitopes may account for the cancer-selective activity of rLGALS9.
In contrast to the sensitivity of KRASmut CRC cells to rLGALS9, oncogenic mutation of BRAF proved to be 
associated with resistance to rLGALS9. Correspondingly, siRNA knockdown experiments in KRASmut DLD-1 cells 
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demonstrated that rLGALS9 cytotoxicity did not require BRAF signaling, but was dependent on RAF1 and 
MAP2K1 signaling. This finding is in line with the reported requirement of oncogenic RAS for RAF1-, but not 
BRAF-, mediated activation of MAP2K21,22,44,45. Indeed, although mutated KRAS and BRAF both activate MAP2K/
mitogen-activated protein kinase kinases-MAPK/mitogen-activated protein kinase-signaling and disrupt 
polarity in colon epithelial cells5, oncogenic KRAS and BRAF transformations typically occur in a mutually 
exclusive manner46. Therefore, differences in sensitivity toward rLGALS9 treatment between KRAS and BRAF 
mutant CRC may rely on their respective signaling via RAF1 and BRAF. Of note, oncogenic KRAS signaling was 
reported to require heterodimerization between RAF1 and BRAF47, whereas oncogenic BRAFV600E signaling is 
activated through monomeric BRAF48,49. It will be of interest to determine whether a differential requirement 
for homo- or heterodimerization of RAF1 proteins upon rLGALS9 treatment underlies the differential sensitivity 
of KRASmut vs. BRAFmut CRC cells.
rLGALS9 is also widely known for its immunomodulatory properties, most notably its inhibition of 
autoimmune T-cell responses (reviewed in14). However, rLGALS9 treatment also enhances antitumor immunity 
in murine sarcoma and melanoma models, leading to prolonged survival51,51. Further, rLGALS9 can induce 
activation and expansion of human T-cells ex vivo52. Conversely, rLGALS9 promotes escape from immune 
surveillance in Epstein Bar virus-infected nasopharyngeal carcinoma cells53. Thus the possible stimulatory 
or inhibitory effects of rLGALS9 on antitumor immunity in KRASmut CRC will need to be evaluated to fully 
characterize the therapeutic potential of rLGALS9. 
In conclusion, the epithelial polarity regulator rLGALS9 has potent cytotoxic activity towards KRASmut 
colon cancer by the induction of frustrated autophagy. Therefore, rLGALS9 may be exploitable for therapeutic 
use in the treatment of refractory KRASmut cancers.
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SUPPLEMENTARY DATA
Figure S1. rLGALS9 is internalized via endosomes and accumulates in the lysosomes of nonpolarized MDCK cells (A) For 
confocal colocalization analysis with early endosomes, MDCK cells were transduced with Bacmam CellLight® Fluorescent Protein 
Construct RAB5A-GFP and incubated with rLGALS9-594 and Hoechst. Maximum colocalization was observed after 15 min. (B) For 
confocal colocalization analysis with late endosomes, MDCK cells were transduced with Bacmam CellLight® Fluorescent Protein 
Construct RAB7A-GFP and incubated with rLGALS9-594 and Hoechst. Maximum colocalization was observed after 45 min. (C) For 
confocal colocalization analysis with the lysosomes, MDCK cells were treated with rLGALS9-594, fixed with 4% PFA, and costaining 
was performed using anti-LAMP2-488. Maximum colocalization was observed after 24 h. Arrows highlight colocalization of rLGALS9 
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Figure S2 (left  page). rLGALS9 triggers vacuolization via PRKC-RAF1-MAP2K1-dependent clathrin-mediated 
internalization and has no cytotoxic activity toward normal primary colonic epithelium (A) To assess active endocytosis of 
rLGALS9, MDCK cells were treated with rLGALS9 (300 nM, 6 h) under the following conditions; 37oC pH 7, 0oC pH 7 and 37oC pH 5, after 
which cellular vacuolization was determined. To determine kinases involved in the endocytic processing of rLGALS9, MDCK cells were 
pre-incubated with UCN-01 (PRKC-inhibitor), GW5074 (RAF1 inhibitor), Dabrafenib (BRAF inhibitor) or U0126 (MAP2K1/2 inhibitor), 
and subsequently treated with rLGALS9. (B) MDCK cells were transduced with the Bacmam CellLight® Fluorescent Protein Construct 
RAB5A-GFP and pre-incubated with UCN-01. Subsequently, cells were treated with rLGALS9-594, and localization of rLGALS9 was 
analyzed using fluorescent microscopy. (C) MDCK and DLD-1 cells were subjected to western blot analysis for MAP2K1 or MAP2K2 
to determine the predominant expressed isoform. MAP2K1 was knocked down in DLD-1 cells using MAP2K1 targeting siRNA, which 
was successful as determined by western blot. Light microscopy pictures were taken after 7 days of rLGALS9 treatment (300 nM) in 
ctrl- and MAP2K1 siRNA-transfected DLD-1 cells. (D) Quantification of flow cytometric analysis of PS-exposure using ANXA5-FITC, 
in rLGALS9-treated MDCK or DLD-1 cells +/- α-lactose or sucrose. (E) Analysis of PS exposure in DLD-1 cells using increasing doses 
of rLGALS9, rLGALS9[S] or rLGALS9[M]. The latter 2 are recombinant produced forms of the naturally occurring isoforms of LGALS9. 
(F) Flow cytometric dot plots of ANXA5-stained primary colorectal cancer cells and primary normal colonic epithelium with and 
without rLGALS9 treatment (6 h, 300 nM).
Figure S3. RAF1, but not BRAF, signaling is required for rLGALS9 induced cytotoxicity, which is not regulated by 
apoptosis nor necrosis (A) DLD-1 cells were transfected with siRNA targeting BRAF, RAF1, BECN1 or ATG5. Successful knock-down 
of the respective proteins was determined using western blot. Light microscopic pictures were taken after 7 days of rLGALS9 (300 
nM) treatment. (B) MDCK cells were pre-incubated with z-VAD-fmk (40 μM), necrostatin (100 μM) or a combination of both, and 
subsequently treated with rLGALS9 (300 nM). Light microscopic pictures were taken after 6 h. 
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Figure S4. rLGALS9 induces lysosomal swelling and formation of LC3B-II in KRASMUT colon carcinoma cell lines (A) DLD-1 
and HT-29 cells were treated with rLGALS9 (24 h, 300 nM), fixed and stained with anti-LAMP2 to visualize the lysosomes. Subsequently, 
lysosomal swelling was determined by measuring the lysosomal diameter. Fold increase in lysosomal diameter = diameter rLGALS9/
diameter med. (B) DLD-1 cells were prestained with acridine orange or LysoTracker before treatment with rLGALS9 (300 nM) for 6 h 
or 24 h. Bright field images were included to visualize the vacuoles in the cells. The vacuolar diameter and the fluorescence intensity 
of the red acridine orange fluorescent signal (depicted in arbitrary units (AU)), were determined using ImageJ analysis software. (C) 
Western blot analysis of LC3B-II formation upon rLGALS9 treatment (6 h, 300 nM) in the colon carcinoma cell line panel. ACTB/β-actin 
staining was performed as a protein loading control. (D) DLD-1 cells were subjected to control siRNA or siRNA-mediated knockdown 
of ATG5, and LC3B-I conversion to LC3B-II upon rLGALS9 treatment was analyzed. (E) Basal autophagic flux was determined by 6 
h treatment with chloroquine (100 μM), and subsequent western blot analysis of LC3B-II. ACTB staining was performed as protein 
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Figure S5. rLGALS9 induces dysfunctional autophagy halted at the stage of autophagosomal-lysosomal fusion (A) 
Quantification of the factor increase in SQSTM1 levels (rLGALS9/med) as determined by ELISA in MDCK cells treated for 24 h with 
medium, rLGALS9 (300 nM), chloroquine (100 μM) or rapamycin (100 nM). (B) As in (A), using the CRD-blocker α-lactose (40 mM) or 
the irrelevant sugar sucrose (40 mM) to block rLGALS9-induced effects on SQSTM1 levels. (C) Fluorescence microscopy analysis of 
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Galectin-9 (Gal-9) is known for induction of apoptosis in IFN-γ and IL-17 producing T-cells and amelioration of 
autoimmunity in murine models. On the other hand, Gal-9 induced IFN-γ positive T-cells in a sarcoma mouse 
model and in food allergy, suggesting that Gal-9 can have diametric effects on T-cell immunity. Here, we aimed 
to delineate the immunomodulatory effect of Gal-9 on human resting and ex vivo activated peripheral blood 
lymphocytes. Treatment of resting lymphocytes with low concentrations of Gal-9 (5-30 nM) induced apoptosis 
in ~60% of T-cells after 1 day, but activated the surviving T-cells. These viable T-cells started to expand after 
4 days with up to 6 cell divisions by day 7 and an associated shift from naïve towards central memory and 
IFN-γ producing phenotype. In the presence of T-cell activation signals (anti-CD3/IL-2) Gal-9 did not induce T-cell 
expansion, but shifted the CD4/CD8 balance towards a CD4-dominated T-cell response. Thus, Gal-9 activates 
resting T-cells in the absence of typical T-cell activating signals and promotes their transition to a TH1/C1 
phenotype. In the presence of T-cell activating signals T-cell immunity is directed towards a CD4-driven response 
by Gal-9. Thus, Gal-9 may specifically enhance reactive immunological memory.
Key words: 
Galectins; T-cell; IFN-γ; central memory; expansion
Abbreviations: 
carbohydrate recognition domain (CRD), galectin-9 (Gal-9), T-cell immunoglobulin and mucin domain-3 (TIM-3).
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INTRODUCTION
The galectin family is a group of glycan-binding proteins characterized by conserved carbohydrate recognition 
domains (CRDs) that bind glycosylated proteins. Galectins are involved in various processes including embryonic 
development, tumor biology and regulation of the immune system1. Within this family, Galectin-9 (Gal-9) has 
gained attention as a multifaceted player in adaptive and innate immunity, in particular in T-cell development 
and homeostasis2. The most prominent effects reported for Gal-9 are the induction of apoptosis in subsets 
of differentiated T-cells, particularly in CD4+ T-helper 1 (TH1) and T-helper 17 (TH17) cells3-7, and a stimulatory 
effect on regulatory T-cell (Treg) activity6,8. In view of these immunomodulatory effects, Gal-9 has been tested 
as a potential therapeutic agent for various autoimmune diseases. Treatment with Gal-9 ameliorated disease 
in mouse models of experimental autoimmune encephalomyelitis3, arthritis9 and diabetes10,11, by reducing 
the number of autoreactive TH1 and TH17 cells and decreasing circulating IFN-γ concentrations. In contrast, 
treatment with Gal-9 stimulated anti-tumor T-cell immune responses in a sarcoma bearing mouse model12. Here, 
recombinant Gal-9 induced cytotoxic T-cells (CTLs) and increased IFN-γ concentrations. In addition, in a recent 
study focused on food-allergy treatment of ex vivo activated human T-cells with Gal-9 promoted TH1 generation 
as well as IFN-γ production13. These data imply that Gal-9 can have a Janus-like dual activity; inhibiting immunity 
in autoimmune disease on the one side and stimulating immunity in cancer and allergy on the other side.
The immunomodulatory effects of Gal-9 were initially attributed to signaling via T-cell immunoglobulin 
and mucin domain-3 (TIM-3)3, a prominent T-cell inhibitory receptor and a marker for T-cell exhaustion that is 
currently being evaluated as a target for antibody-based therapy in cancer14. However, it has become clear that, 
aside from TIM-3, Gal-9 can signal via other receptors on T-cells15, like protein disulfide isomerase16,17, CD4018 and 
possibly other, yet unidentified receptors. Indeed, the outcome of Gal-9 signaling on T-cells likely depends on 
the specific receptor being activated by Gal-9 as well as the presence of additional (T-cell) skewing stimuli. In 
this respect, most experimental murine autoimmune models used to evaluate therapeutic effects of Gal-9 rely 
on specific antibodies or disease inducing peptides in combination with infection stimulating adjuvants and/
or bacteria3,9,19. In contrast, the CTL stimulatory effects via dendritic cell (DC) activation and induction of IFN-γ 
found in a sarcoma did not require additional skewing stimuli12. Together, this suggests that the outcome of 
Gal-9 signaling varies greatly, depending on experimental conditions and/or the balance of immunity in specific 
disease settings.
Here, we aimed to establish the effect of Gal-9 treatment on freshly isolated and non-skewed human 
peripheral blood immune cells in the absence of other stimuli. In line with current thinking, Gal-9 triggered 
cell death in >95% of T-cells at high concentrations. However, at lower doses, Gal-9 activated and strongly 
expanded surviving T-cells in a TIM-3-independent manner. In addition, the T-cell expansion induced by Gal-9 
was characterized by a shift from a naïve towards a central memory (Tcm) and IFN-γ producing TH1 phenotype. 
Further, a shift in monocytes towards a DC-phenotype was detected. However, monocyte depletion did not 
affect T-cell activation, indicating that Gal-9 had a direct effect on T-cells. In the presence of anti-CD3/IL-2 T-cell 
activation signals, Gal-9 did not trigger expansion of T-cells, but shifted the normal CD8/CD4 balance towards a 
predominant CD4+ phenotype. Taken together, these data indicate that Gal-9 has diverse immunomodulatory 
effects depending on concentration and skewing signals available and is therefore likely to have a disease-
specific role that needs to be evaluated in depth for both autoimmunity and cancer.
MATERIALS AND METHODS
Antibodies & reagents
The following fluorophore-conjugated anti-human antibodies from Immunotools (Friesoythe) were used in this 
study; anti-CD3-FITC (MEM-57), anti-CD3-Dy647 (MEM-57), anti-CD4-PE (MEM-241), anti-CD4-PE/Dy647 (MEM-
241), anti-CD8-Pe/Dy47 (MEM-31), anti-CD14-Dy647 (MEM-15), anti-CD19-APC (LT19), anti-CD25-PE (MEM-
181), anti-CD62L-FITC (LT-TD180). The following anti-human antibodies were from eBioscience; anti-CD8-PEcy7 
(RPA-T8), anti-CD45RO-APC (UCHL1), anti-CD56-APC (MEM188), anti-TIM-3-APC (F38-2E2), anti-PD-1-PERCP 
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(eBioI105), anti-CCR7-PerCP-Cy5.5 (3D12), anti-FoxP3-APC (236A/E7), anti-IL-2-PERCP-Cy5.5 (MQ1-17H12), anti-
IL-4-PE-Cy7 (8D4-8), anti-IFNy-PERCP-Cy5.5 (4S-B3), and anti-IL-17-PERCP-Cy5.5 (eBio64DEC17). The anti-CD3-
CyQ antibody was from IQ-products (IQP-519C). Streptavidin-Alexa488 was from Invitrogen. Recombinant Gal-9 
(truncated form Gal-9(0)) and the physiologically occurring short isoform of Gal-9 (Gal-9(S)) were produced as 
described before20. Gal-1, Gal-2, Gal-3, Gal-8 were purchased commercially (R&D systems).
Isolation of peripheral blood mononuclear cells (PBMCs) and activation of T-cells
Peripheral blood mononuclear cells (PBMCs) were obtained from venous blood from healthy volunteers using 
standard density gradient centrifugation (Lymphoprep). The ethics review board of the Multi- Regional Ethics 
Committee approved the study (MREC 06/Q2102/56), and all blood samples were obtained with written consent 
from the healthy subjects. Activated T-cells were generated by culturing PBMCs with anti-CD3 mAb (0.5 µg/
mL; 72 h, UCHT1, Immunotools) followed by 96 h IL-2 (100 ng/mL, Immunotools). Monocyte depletion prior to 
treatment was performed by magnetic-activated cell sorting (MACS) using anti-CD14-beads (Miltenyi Biotec), 
resulting in >99% depletion of monocytes as verified by flow cytometry (data not shown). Cells were cultured at 
37°C exposed to 21% O2/5% CO2 in X-VIVO medium (Lonza), a chemically defined and serum-free hematopoietic 
cell medium, or RPMI-1640 (Lonza) supplemented with 10% v/v FBS (Thermo Scientific). Cell numbers were 
quantified using a cell counter (Sysmex).
Flow cytometry
All flow cytometric analyses were performed on a BD Accuri C6 flow cytometer (BD Biosciences) and accessory 
CFlow Plus analysis software. Positively and negatively stained populations were calculated by quadrant dot 
plot analysis (for representative dot-plots of stainings see Figure S1–S3). For cell surface marker analysis with 
antibodies, viable cells were gated based on forward and sideward scatter plot (for example see Figure S1B).
Assessment of apoptosis and Gal-9 binding
PBMCs were treated for 1–7 days with medium with or without the indicated concentration of Gal-9 and 
analyzed for apoptosis using flow cytometric staining for phosphatidylserine exposure using an Annexin-V-
FITC staining kit according to the manufacturer’s protocol (Immunotools). In brief, cells were washed once with 
calcium binding buffer, resuspended in calcium buffer with Annexin-V, incubated for 10 min at 4°C, and analyzed 
by flow cytometry. To determine if Gal-9 bound to PBMCs in a CRD-dependent manner, competitive binding 
experiments were performed in which cells were incubated with biotinylated Gal-9 for 1 h, in the presence and 
absence of 40 mM α-lactose, followed by 3 washes to remove excess and non-bound Gal-9. Cell surface binding 
was detected using streptavidin-Alexa488.
Phenotypic analyses
Phenotype assessment was determined by immunofluorescent flow cytometric staining essentially as described 
before21. Briefly, distribution of cell populations was analyzed gating on peripheral blood lymphocytes from 
forward scatter/sideward scatter, detecting CD3+ and CD19+ populations. In addition, CD3−/CD19− cells were 
gated and analyzed for CD56-PE binding. The balance of CD4 and CD8 was analyzed within the viable cell 
population gated from forward scatter/sideward scatter using anti-CD4-PE and anti-CD8-PEcy7. TEM staining 
was performed on 0.5×106 cells per condition by incubation of PBMCs with APC-conjugated anti-CD45RO, 
PERCP-Cy5-conjugated anti-CCR7, and FITC-conjugated anti-CD3 for 30 min at room temperature in the 
dark. Alternatively, cells were stained with FITC-conjugated anti-CD62L, CyQ-conjugated anti-CD3 and APC-
conjugated CD45RO. Isotype-matched non-specific antibodies were used as negative controls. Staining was 
analyzed on viable cells on forward scatter/sideward scatter plot selected within the CD3+ cell population.
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Carboxyfluorescein succinimidyl ester (CFSE) analysis
To determine the number of cell divisions after Gal-9 treatment, a CFSE cell proliferation kit was used according 
to manufacturer’s protocol (CellTrace™ CFSE Cell Proliferation Kit, Invitrogen). In brief, harvested PBMCs were 
stained with 2.5 µM CFSE in 0.1% w/v BSA/PBS for 10 min at 37°C. Subsequently, PBMCs were incubated in 
fresh medium for 10 min on ice and excess dye was removed by 3 washes. CFSE-stained cells were then used to 
establish in vitro cell cultures. During a time course of 7 days, cells were harvested and an additional staining was 
performed, incubating CFSE-labeled PBMCs with anti-CD3-Dye647, anti-CD4-PE/Dye647, anti-CD8-PE/Dye647, 
anti-CD19-APC or CD56-APC for 30 min at 4°C. Staining was analyzed gating on the cell populations positive for 
the different phenotypic cellular markers, in which their CFSE-staining pattern was detected.
TH1, TH2, TH17 and regulatory T-cell (Treg) immunofluorescence staining
To determine the effect of Gal-9 treatment on TH1, TH2, TH17, PBMCs were treated for 7 days with medium 
supplemented with or without 15 nM Gal-9, then washed and subsequently stimulated with phorbol 
12-myristate 13-acetate (PMA) for 4 h. Subsequently, cells were washed in wash buffer (PBS, 5% v/v FBS, 0.1% 
w/v sodium azide) and stained with FITC-conjugated anti-CD3 for 15 min at room temperature. Cells were fixed 
with Reagent A (Caltag) for 10 min. After washing, cells were resuspended in permeabilization Reagent B (Caltag) 
and labeled with PERCP-Cy5-conjugated anti-IL-2, PERCP-Cy5-conjugated anti-IL-4, PERCP-Cy5-conjugated 
anti-IFN-γ, or PERCP-Cy5-conjugated anti-IL-17 for 20 min in the dark. Cells were analyzed for T-cell phenotype 
after 2 subsequent washes with PBS. Cytokine staining was performed on CD3+-gated cells. Treg staining was 
performed by cell surface staining of PBMCs with PE-conjugated anti-CD4, FITC-conjugated anti-CD3, fixation/
permeabilization as for cytokine staining above, and subsequent intracellular staining for the transcription 
factor FoxP3 with APC-conjugated anti-FoxP3. Staining for FoxP3 was assessed within the CD3 and CD4 double-
positive population of cells.
Analysis of cytokine secretion
ELISAs were used to quantify the secretion of IFN-γ and IL-17 from PBMCs treated with and without Gal-9. In brief, 
in vitro experiments were set-up as described above and supernatant of treated cells was collected at day 7. The 
IFN-γ (Immunotools) and IL-17 (Thermo Scientific) ELISAs were performed according to manufacturer’s protocol.
Statistical analysis
Statistical analysis was performed by one-way ANOVA followed by Tukey-Kramer post-test or, where appropriate, 
by two-sided unpaired Student’s t-test using Prism software. p<0.05 was defined as a statistically significant 
difference. Where indicated *  = p<0.05; **  = p<0.01; ***  = p<0.001.
RESULTS
Galectin-9 triggers cell death but also expands resting peripheral blood cells
Initial evidence suggested that the predominant effect of treatment of T-cells with Gal-9 is the induction of 
apoptotic cell death in T-helper 1 (TH1) and T-helper 17 (TH17) cells via the receptor TIM-3 ([3). However, flow 
cytometric analysis on resting PBMCs revealed that expression of TIM-3 was negligible, whereas ex vivo activated 
T-cells did express TIM-3 (Figure 1A and Figure S1A). Despite the lack of cell surface-expressed TIM-3 Gal-9 bound 
to resting PBMCs (Figure 1B). Binding of Gal-9 was inhibited in a lectin-specific manner by co-incubation with 
40 mM α-lactose (Figure 1B), but not by an anti-TIM-3 blocking antibody (data not shown). Thus, the binding of 
Gal-9 was carbohydrate recognition domain (CRD)-dependent and TIM-3-independent.
Treatment of PBMCs with Gal-9 at a concentration of 150 nM, falling within the previously published range, 
eliminated the vast majority of cells within 1 day (Figure S1B). However, a 10-fold lower concentration of Gal-9 
(15 nM) only triggered cell death in ~half of the cells (Figure S1B). Quantification of cell death during prolonged 
treatment of up to 7 days, revealed that the percentage of apoptotic cells in Gal-9 treated conditions gradually 
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declined from ~60% at day 1 to that of medium control within 4 days (Figure 1C). In line with this, treatment 
with 15 nM Gal-9 decreased cell counts compared to control at days 1–3 (Figure 1D). This initial depletion was 
followed by strong PBMC expansion, as evidenced by a 3-fold increase in cell count at day 7 from 1×106 cells/ml 
to ~3×106 cells/ml in Gal-9 treated conditions (Figure 1D). This PBMC expansion by Gal-9 was inhibited by co-
treatment with α-lactose, but not sucrose, and thus CRD-dependent (Figure 1E).
Various other immunomodulatory members of the galectin family, i.e. Galectin-8, which is a tandem-repeat 
Galectin like Gal-9, as well as Galectin-1, Galectin-2 (prototypic Galectins) and Galectin-3 (chimeric Galectin) 
did not trigger significant increase of PBMC counts at these concentrations (Figure1F), nor significant induction 
of apoptosis (data not shown). Thus, in addition to initial induction of apoptosis, Gal-9 triggers expansion of 
peripheral blood cells.
Galectin-9 and the short isoform of Gal-9 (Gal-9(S)) dose-dependently activate T-cells
To specify the stimulatory effect of Gal-9 on the PBMC fraction, the relative proportion of T-cells, B-cells and NK-
cells was analyzed in medium and Gal-9 treated PBMCs. In medium control, the percentages of all lymphocyte 
populations remained stable from day 0–7 (Figure 2A). In contrast, treatment with Gal-9 reduced the percentage 
of CD3+ positive T-cells during the first 3 days, followed by a concomitant increase in T-cells and decrease in 
B-cells and NK-cells from day 4 onwards (Figure 2B). Further, in the viable population of CD3+ T-cells, treatment 
with 15 nM Gal-9 also triggered T-cell activation, as evidenced by the upregulation of surface CD25-expression 
from ~50% at day 1 to a maximum of ~80% after 5–7 days (Figure 2C, representative dot-plots in Figure S1C). 
Activation of T-cells by Gal-9 was inhibited by co-treatment with α-lactose and thus CRD-dependent (Figure 
2D). Other galectin family members did not trigger T-cell activation (Figure S1D). Interestingly, during this time-
course, the expression of TIM-3 was induced in only 20–30% of T-cells after 4–7 days of treatment with Gal-
9 (Figure 2E). These T-cells did not become double-positive for TIM-3 and PD-1 (Figure S2E), a marker profile 
Figure 1: Gal-9 triggers TIM-3-independent cell death 
and PBMC expansion. (A) Resting PBMCs were incubated 
with anti-TIM3-APC or isotype control antibody or (B) with 
streptavidin-Alexa488, biotinylated Gal-9+streptavidin-Alexa488 
in the presence or absence of α-lactose. Cell surface staining was 
evaluated by flow cytometry. (C) Resting PBMCs (n = 3) were treated 
with medium or 15 nM of recombinant Gal-9 for up to 7 days. Cell 
death was determined by Annexin-V staining. (D) PBMCs (n = 8) 
treated as in (C) were analyzed for cell number. (E) Resting PBMCs 
(n = 8) were treated as in (C) in the presence of α-lactose or sucrose, 
and analyzed for cell number. (F) Resting PBMCs (n = 3) were treated 
with medium or 15 nM of recombinant Gal-9, Gal-1, Gal-2, Gal-3, or 
Gal-8 for up to 7 days, after which cell number was determined. All 
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associated with T-cell exhaustion22. Thus, Gal-9 interacted with T-cells via an as yet unidentified receptor, resulting 
in apoptosis of part of the T-cells. However, the remaining population of viable T-cells underwent activation as 
well as strong expansion.
In addition to lymphocytes, the isolated PBMC fraction contains monocytes. These monocytes responded 
to Gal-9 treatment with a marked stretching and loss of CD14 expression, indicative of a shift towards a DC-
phenotype (Figure S2A). Importantly, depletion of monocytes from the PBMC population prior to Gal-9 treatment 
did not affect Gal-9-induced activation of T-cells, as determined by CD3/CD25 double staining (Figure 2F). Thus, 
although Gal-9 activated monocytes, this was not required for activation and expansion of T-cells.
In addition to recombinant Gal-9, the short isoform of Gal-9 (Gal-9(S)) was included to evaluate whether 
naturally occurring isoforms of Gal-9 could have similar immunomodulatory effects. Both Gal-9 and Gal-9(S) 
dose-dependently triggered activation and expansion of T-cells, with maximal effects of recombinant Gal-9 at 
15 nM (0.5 µg/ml) and Gal-9(S) at 30 nM (1 µg/ml) (Figure 2G and 2H). Thus, both recombinant Gal-9 and Gal-9(S) 
triggered dose-dependent activation of T-cells at low concentrations.
Figure 2: Recombinant and Gal-9(s) dose dependently 
activate T-cells. (A) Resting PBMCs (n = 5) were incubated 
in medium for up to 7 days. Distribution of cell populations 
was analyzed every day by flow cytometry. (B) Similar as (A), 
but in the presence of 15 nM Gal-9. (C) Resting PBMCs (n = 5) 
treated with medium or 15 nM of recombinant Gal-9 for up 
to 7 days were analyzed for T-cell activation by staining for 
activation marker CD25. (D) Resting PBMCs were treated as in 
(C) in the presence of α-lactose, after which CD25 expression 
was analyzed at 1 day. (E) Resting PBMCs (n = 5) were treated 
as in (C) and analyzed for expression of TIM-3. (F) PBMCs or 
monocyte-depleted PBMCs were treated with Gal-9 for 7 days, 
and analyzed for CD25 expression. (G) Resting PBMCs (n = 6) 
were treated with a concentration range of recombinant 
Gal-9 or physiologically occurring isoform Gal-9(S) for 7 days 
and analyzed for cell density. (H) Resting PBMCs (n = 6) were 
treated as in G and CD25 expression was determined. All 
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Galectin-9 treatment results in expansion of CD4+ T-cells
The effect of treatment of T-cells with Gal-9 on cell division was evaluated by determining T-cell proliferation by 
CFSE staining. In control conditions, the CD3+ T-cells did not divide during the 7 day time-course, as evidenced 
by a single CFSE fluorescence peak (Figure 3A). In contrast, treatment with Gal-9 triggered up to 6 cell divisions 
within the CD3+ T-cell population (Figure 3B), with ~7% of T-cells having divided 6 times at day 7 (Figure 3C). In 
line with the data on apoptosis and cell counts, T-cell division was first detected after 3 days of Gal-9 treatment 
(Figure 3D).
Further analysis within the Gal-9 treated populations identified that most dividing T-cells were CD4+ (~76% 
of total PBMCs at day 7, Figure 3E), although the remaining CD8+ T-cells (~20%) also divided in the final days 
(Figure 3F). In line with this, Gal-9 treatment induced a steady increase in the percentage of CD4+ T-cells during 
the 7 day time-course, whereas the percentage of CD8+ T-cells initially decreased, but returned to base levels 
at day 7 (Figure 3G; representative dot-plot in Figure S2B). Again, Gal-9 induced effects were CRD-specific as 
α-lactose completely inhibited cell division in both CD4+ and CD8+ T-cells (Figure 3E and 3F).
Figure 3: Galectin-9 treatment expands CD4+ T-cells. (A) 
Representative plot of 6 independent experiments of resting 
PBMCs stained with CFSE and subsequently incubated in 
medium for up to 7 days. At Day 7, PBMCs were harvested, 
stained with the T-cell marker CD3, and CFSE peak pattern 
was analyzed within the CD3+ cells by flow cytometry. (B) 
Representative plot of 6 independent experiments of resting 
PBMCs as treated in A, but in the presence of 15 nM Gal-9. (C) 
Analysis of (A) and (B) showing percentage of CD3+ T-cells in 
the respective peak of all independent experiments (mean 
+/− SEM). (D) Analysis of (B) showing the number of CFSE 
peaks of all independent experiments. (E) Representative 
plots of 3 independent experiments of resting PBMCs 
stained with CFSE and subsequently incubated in medium 
or 15 nM Gal-9 (+/− lactose) for up to 7 days. At Day 7, 
PBMCs were harvested, stained with the T-cell marker CD4, 
and CFSE peak pattern was analyzed within the CD-3+ 
cells by flow cytometry. (F) As in (E) but stained for the T-cell 
maker CD8. G. Resting PBMCs (n = 4) were treated for up to 7 
days with medium or Gal-9 and analyzed for CD4 and CD8 
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Galectin-9 expands central memory and T-helper 1 cells
As Gal-9 clearly activated and expanded T-cells, the relative proportion of naïve, central memory (TCM), and 
effector memory (TEM) phenotypes in the PBMCs was evaluated (for representative dot-plots of staining see 
Figure S2C). As expected, the majority of T-cells in medium control were of a naïve CCR7+/CD45RO− phenotype 
(Figure 4A). However, upon treatment with Gal-9 or Gal-9(S), the percentage of naïve T-cells was strongly and 
statistically significantly reduced (Figure 4A), with the majority of T-cells acquiring a central CCR7+/CD45RO+ 
memory phenotype (Figure 4B). This dramatic shift was confirmed by a second staining for central memory 
using CD62L and CD45RO, which revealed a similar increase in CD62L+/CD45RO+ TCM (Figure S2D). In contrast, 
no significant changes were detected in the CCR7−/CD45RO+ TEM population (Figure 4C).
To characterize T-cells expanded by Gal-9 on a more functional level, cytokine profiles were determined 
in medium control and Gal-9 treated T-cells (see Figure S3 for representative dot-plots). In line with the 
immunophenotyping data, there was a marked and statistically significant increase in IL-2 producing T-cells, 
indicative of TCM cells (Figure 4D). In addition, treatment with Gal-9 resulted in a statistically significant increase 
Figure 4: Gal-9 treatment of resting PBMCs shifts T-cells towards central memory and T-helper 1 phenotype. A−C. PBMCs were 
treated for 7 days withGal-9 or Gal-9(S) after which the percentage of naïve (A), central memory (B), and effector memory (C) was 
evaluated by flow cytometry. D−G. Resting PBMCs were treated for 7 days with Gal-9 or Gal-9(S), after which T-cell cytokine production 
was analyzed by flow cytometry as described in M&M. The percentage of IL-2 (n = 11) (D), IFN-γ (E), IL-17 (F) and IL-4 (G) was determined. 
(H) Supernatants of medium and Gal-9 (15 nM) treated PBMCs was harvested at day7 after which the amount of secreted IFN-γ and IL-
17 was determined with ELISA. (I) PBMCs (n = 11) were treated for 7 days with Gal-9 or Gal-9(S) after which the percentage of regulatory 
































































































































































































































































































in IFN-γ producing T-cells (Figure 4E), but not in IL-17 and IL-4 producing T-cells (Figure 4F and 4G, respectively). 
In line with these findings, analysis of secreted cytokines within the supernatant of Gal-9 treated cells revealed an 
~100-fold increase in IFN-γ levels compared to medium control at day 7 (Figure 4H). Further, a low but significant 
increase in IL-17 was also detected upon treatment with Gal-9 (Figure 4H). In line with earlier findings, treatment 
with 15 nM Gal-9(S) but not Gal-9 also triggered a small but statistically significant increase in regulatory T-cells 
(Tregs) after 7 days (Figure 4I). Thus, in resting PBMCs the treatment with Gal-9 triggers a selective expansion of 
central memory T-cells and a predominant induction of IFN-γ-producing CD4+ T-cells.
T-cell receptor-mediated activation in the presence of Gal-9 shifts the balance towards CD4+ T-cells
The results above provide evidence that Gal-9 has a potent immunomodulatory effect on resting T-cells. This 
TH1-stimulatory effect is in line with a recent report in which CD3/CD28 co-stimulation of T-cells stimulated TH1 
development13. To further characterize the modulatory effect of Gal-9 during T-cell receptor (TCR)-stimulation, 
PBMCs were stimulated with anti-CD3 antibody for 3 days, followed by IL-2 stimulation for 4 days. In the absence 
of Gal-9, this stimulation regime led to a slight preferential induction of CD8+ T-cells compared to CD4+ T-cells 
(Figure 5A and 5B; median CD4+ 42.7% vs. median CD8+ 47%). However, treatment with Gal-9 or Gal-9(S) 
induced a dramatic shift in percentages of CD8+ and CD4+ T-cells after 7 days of activation (Figure 5A and 5B; 
median CD4+ 86.1% vs. median CD8+ 7.2%). Of note, no significant increase in apoptotic cells or cell counts was 
detected upon treatment with Gal-9 or Gal-9(S) after 7 days of treatment (data not shown). TCR/IL-2 mediated 
activation of T-cells in the presence of Gal-9 shifted T-cells toward a central memory phenotype, as defined by 
immunophenotyping for CD45RO/CCR7 or CD45RO/CD62L (Figure 5C), and intracellular cytokine staining for 
IL-2 (Figure 5D). In contrast to treatment of resting PBMCs, treatment of anti-CD3/IL-2 activated T-cells with Gal-9 
did not trigger an increase in the percentage of IFN-γ producing cells (Figure 5E). Similarly, no increase in IL-17 or 
Figure 5: Gal-9 treatment of TCR-activated T-cells reverses CD8/CD4 distribution and shifts T-cells towards a central memory 
phenotype. A−B. T-cells were activated by anti-CD3/IL-2, or additionally with 15 nM Gal-9 or Gal-9(S). After 7 days the percentage 
of CD4 (A) and CD8 (B) were determined by flow cytometry. (C) T-cells were activated as in (A) and percentage of T-cells with central 
memory phenotype was determined. D−G. T-cells were activated as in (A), after which T-cell cytokine production was analyzed by 
flow cytometry as described in M&M. The percentage of IL-2 (n = 11) (D), IFN-γ (E), IL-17 (F) and IL-4 (G) was determined. H. T-cells were 
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IL-4 producing T-cells or regulatory T-cells was observed (Figure 5F−H). Taken together, TCR-mediated activation 
and IL-2 induced expansion of T-cells in the presence of Gal-9 shifts the T-cell response towards a CD4+ helper 
response that is further characterized by a central memory phenotype.
DISCUSSION
Gal-9 is a strong modulator of T-cell immunity known for its apoptotic effects on TH1 and TH17 cells in 
autoimmunity, but also for its stimulatory activity on CTLs and TH1 cells in cancer and food allergy. These apparent 
diametrical outcomes of Gal-9 signaling on T-cell immunity suggests that the balance of immunomodulatory 
signals is crucial for Gal-9 signaling. Data presented in the current study indicate that single-agent treatment 
of resting PBMCs with low Gal-9 doses is, after initial apoptotic elimination, accompanied by activation and 
subsequent expansion of CD4+ T-cells. Furthermore, Gal-9 treatment shifts T-cells from a naïve to a central 
memory phenotype and increases the percentage of IFN-γ producing T-cells. In activated (anti-CD3/IL-2) T-cells, 
Gal-9 skews the CD4+/CD8+ balance towards a CD4+ phenotype.
As evident from the data, the reported differences in T-cell responses upon Gal-9 treatment can be partly 
ascribed to the amount of Gal-9 that is used. In particular, a concentration of 150 nM eliminated the vast majority 
of T-cells within one day, whereas a dose-response analysis demonstrated that 15-30 nM Gal-9 is the optimal 
concentration for T-cell stimulatory effects. In previous reports, T-cell apoptosis was induced with relatively high 
doses of up to 1000 nM Gal-93,23. Furthermore, a recent study using murine T-cell clones also required high Gal-9 
concentrations to induce T-cell apoptosis (400 nM), whereas non-lethal doses had T-cell stimulatory effects15. In 
addition to concentration, most studies were designed to evaluate Gal-9 activity at relatively short incubation 
periods varying from 1h to 4 days3,4,7,23,24. In the current study, Gal-9 effects were evaluated for up to 7 days. 
Notably, significant T-cell expansion in the current study was only seen after 4 days of treatment, whereas the 
induction of apoptosis occurred rapidly within 1 day. Of note, these effects were independent of TIM-3, as 
freshly isolated T-cells lacked TIM-3 expression, and only ~35% of T-cells became TIM-3+ after 4-7 days of Gal-
9 treatment. Such TIM-3 independent binding has been described earlier3,6,7,15, and several alternate binding 
partners have been reported, e.g. CD4018, several adhesion molecules25,26, immunoglobulin E (IgE)27, and protein 
disulfide isomerase16,17. Whether the TIM-3 independent binding observed in the current study can be attributed 
to binding of Gal-9 to one of these alternate receptors, or an as yet unidentified receptor, is subject of an ongoing 
study.
Binding of Gal-9 to resting blood lymphocytes activated T-cells and shifted T-cell phenotype from naïve 
toward IL-2 producing central memory T-cells (CD62+/CCR7+/CD45R0+) and IFN-γ producing TH1 cells. This 
single-agent stimulatory effect of Gal-9 on resting T-cells has not been reported before and appears to contrast 
with published studies that describe predominant elimination of TH1 cells by Gal-9. However, our findings are 
in line with several recent reports on the stimulatory effect of Gal-9 on activated TH1 cells13,15, and the induction 
of central memory cytokines by Gal-9 upon CD3/CD40 co-stimulation in murine T-cells18. The mechanism by 
which Gal-9 induces T-cell activation and proliferation is currently unknown. However, other lectins, such as 
concanavalin A, also potently stimulate T-cell proliferation. Concanavalin A does so by directly interacting with 
activating receptors, like CD328. Within the Galectin family of lectins, it has been reported that Galectin-1 can 
directly bind to CD3 on T-cells29. It was suggested that Galectin-1 mediated ligation of the CD3-complex mimics 
antigen-induced TCR signaling, which induces early events in T-cell activation comparable to those elicited by 
agonistic anti-CD3 antibodies. Therefore, it is tentative to speculate that Gal-9 interacts with activating receptors 
such as CD3 on the T-cell surface. This is currently subject for further study in our laboratory.
Besides direct Gal-9 effects on T-cells, indirect T-cell stimulation by Gal-9 via the activation of DCs and DC-like 
macrophages was reported in sarcoma and melanoma bearing mouse models12,25. Furthermore, Gal-9 induced 
the maturation of human monocyte-derived dendritic cells, resulting in IL-12, IL-2 and IFN-γ secretion30. In line 
with these findings, monocytes did undergo phenotypic changes towards DC-phenotype in the current study. 
However, monocyte depletion did not affect the activity of Gal-9 towards resting T-cells, which suggests that 
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Gal-9 has a direct immunostimulatory effect on T-cells. Gal-9 was also reported to enhance production of IFN-γ 
by NK-cells31, but our analysis of lymphocyte distribution/activation in the current study showed only an increase 
in T-cells and a decrease in NK-cells. Further, a clear increase in IFN-γ producing T-cells was detected. Thus, our 
data suggest that IFN-γ is secreted by T-cells and not NK-cells. In addition to TH1 cells, a statistically significant 
increase in Treg cells by Gal-9(S) was detected, which is in line with recent murine studies32,33.
The here reported activating effect of low dose Gal-9 on resting T-cells may be of relevance in certain 
human diseases. For instance, elevated Gal-9 serum levels were detected in patients with type 2 diabetes and 
chronic kidney disease34. Here, serum Gal-9 levels negatively correlated with renal function and increased 
along with disease progression. Of note, aberrant recruitment and activation of T-cells has been described in 
diabetic nephropathy35. Hence, Gal-9 may be involved in T-cell activation, which contributes to kidney damage 
in diabetes type 2. In addition, dietary supplementation of pre-biotic oligosaccharides and Bifidobacterium breve 
reduced allergic symptoms in a murine model of food allergy and in infants with atopic dermatitis, as an effect of 
increased serum Gal-9 levels and subsequent TH1 and Treg responses13. Thus, depending on type of disease and 
immunological environment, serum Gal-9 can have both positive and negative effects on disease progression 
by the activation of T-cells.
In conclusion, treatment of human resting blood T-cells with Gal-9 induces apoptosis in a substantial 
proportion of the cells, but also activates and expands IFN-γ producing TH1 cells and central memory 
T-cells in surviving population. In the presence of activating signals (anti-CD3/IL2), the treatment with Gal-
9 does not expand T-cells, but skews the CD4+/CD8+ balance towards a CD4+ phenotype. This study thus 
uncovers the stimulatory effect of Gal-9 treatment on resting lymphocytes and highlights the complexity of 
immunomodulatory signaling by Gal-9 on human T-cells. Indeed, in various diseases settings the influence of 
Gal-9 on T-cell immunity will be determined by micro-environmental concentrations of Gal-9 and other immune 
modulators as well as the activation status of T-cells.
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Figure S1: (A) T-cells were activated with anti-CD3 (72h) and IL-2 (96h), after which cell surface expression of TIM-3 was analyzed by 
flow cytometry. (B) Resting PBMCs were treated with medium, 15 nM or 150 nM of Gal-9 for 1 day. Representative fsc/ssc dot-plots of 
lymphocytes demonstrate that treatment with 150 nM of Gal-9 shifts cells from a viable population (see medium; left panel) to dead/
fragmented distribution (150 nM Gal-9; right panel), whereas at 15 nM ∼50% of cells remain viable (15 nM Gal-9; middle panel). (C) 
Representative flow cytometric dot-plots of CD3/CD25 staining. (D) Resting PBMCs were treated with 0-15 nM Gal-1, Gal-2, Gal-3, 
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Figure S2 (A) Resting PBMCs were treated with Gal-9 for 7 days after which cell surface expression of CD14 in adhered monocytic cells 
was analyzed by flow cytometry. (B) Representative flow cytometric dot-plots of CD4/CD8 staining, (C) CCR7/CD45RO staining, (D) 














































































































 SUMMARY AND PERSPECTIVES
SUMMARY:
Despite significant and important improvements in cancer therapy, the overall 5-year survival rate for cancer 
patients in the Netherlands has only moderately increased from 51% in 1995 to 62% in 20131, highlighting the 
need for further breakthroughs. There are a number of reasons that underlie these somewhat disappointing 
results, two of which have been the focus of this thesis. Firstly, it has become increasingly evident that the 
tumor microenvironment critically suppresses the successful execution of anticancer immune responses. This 
suppression is both evident for immune effector cells of the innate as well as the adaptive immune system 
and leads to immune escape of cancerous cells2. Nevertheless, the presence of existing antitumor immunity as 
quantified by the presence of so-called tumor infiltrating lymphocytes (TILs) does associate with an improved 
prognosis in many types of cancer3-6. Correspondingly, new immunotherapeutic strategies that augment 
TIL activity have recently yielded exciting breakthroughs in the treatment of hard-to-treat cancers, such as 
melanoma, with even cure in a small percentage of patients7,8.
Secondly, many patients relapse after initial seemingly successful treatment due to acquired resistance 
of cancer cells to cytotoxic treatment. These recurrent cancer cells typically contain mutations in cell death 
pathways, such as apoptosis, that confer resistance to existing therapeutic agents relying on these pathways9. 
Therefore, a second  important research focus is the identification of novel anticancer strategies that exploit 
alternative cell death pathways that are not affected in recurrent disease. 
Part I of this thesis describes the pre-clinical development of a novel strategy that can help to reactivate 
antitumor immunity. In brief, we developed so-called scFv:sTRAIL fusion proteins that contain a high affinity 
antibody fragment (scFv) genetically fused to the pro-apoptotic and tumoricidal protein TRAIL (tumor necrosis 
factor-related apoptosis-inducing ligand). The guiding principle is to selectively deliver the cytotoxic effector 
molecule TRAIL to the surface of immune effector cells and, thereby, equip these cells with additional tumoricidal 
potential. This approach can be applied to both innate and adaptive immune effector cells. Further, targeting of 
an immunomodulatory antigen with the scFv domain can confer additional immunological functions. 
Part II of this thesis describes the characterization of the tumoricidal and immunomodulatory effects of the 
carbohydrate binding protein Galectin-9 (Gal-9). Most notably, we uncovered that Gal-9 triggered cell death in 
various types of cancers via a cytotoxic pathway that is independent of pathways frequently mutated in drug 
resistant cancer cells. In addition and in contrast, Gal-9 was found to have potent immunostimulatory effects on 
T cells that, depending on the dose, can either kill or activate T cells.
In the section below, a more detailed summary of each of the chapters is provided.
PART I: TARGETED DELIVERY OF TRAIL FOR CANCER IMMUNE THERAPY
TRAIL is an important immune effector molecule that is physiologically expressed on the membrane of natural 
killer (NK) and NKT cells. Here, TRAIL contributes to cancer-immunosurveillance by inducing apoptosis in 
circulating cancer cells10. Correspondingly, TRAIL knock-out mice have an increased risk of developing tumors 
and metastatic disease11,12. Moreover, in wild-type mice the formation of metastases increased when tumor-
bearing mice were treated with a TRAIL neutralizing antibody10. Thus, TRAIL is an immune effector molecule with 
prominent antitumor activity. However, TRAIL is typically detected on NK cells whereas its expression on T cells 
as well as other (innate) effector cells is low or even absent. In chapter 2, we designed a strategy to increase 
the amount of TRAIL present on the cell surface of T cells with the aim of enhancing antitumor T cell activity. 
In brief, we constructed two TRAIL fusion proteins, designated scFvCD3:sTRAIL and K12:sTRAIL, which target T 
cell surface markers CD3 and CD7, respectively. Incubation of (resting) T cells with either of these TRAIL fusion 
proteins strongly increased the display of TRAIL molecules on the surface of T cells. As a consequence, the in vitro 
tumoricidal activity of these TRAIL-armed T cells was increased up to 500-fold. Furthermore, in vivo application 
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of scFvCD3:TRAIL and K12:TRAIL inhibited the outgrowth of human colorectal carcinoma xenografts in mice, 
with 4 out of 5 mice treated with scFvCD3:TRAIL remaining tumor free for the duration of the experiment. 
Of note, scFvCD3:sTRAIL not only armed T cells with sTRAIL, but also activated T cells via the CD3 scFv, with 
concomitant release of cytolytic granzymes and perforins. In contrast, targeting of CD7 with K12:sTRAIL did not 
additionally activate T cells, but solely induced cancer cell death via its TRAIL domain by the activation of initiator 
caspase-8/-9 and effector caspases. Thus, targeted delivery of TRAIL via CD3 and CD7 potently enhances the 
tumoricidal activity of T cells and choice of targeting antigen can yield bifunctional activity. 
In chapter 3, we expanded this TRAIL-arming approach to myeloid immune effector cells, specifically 
granulocytes. Granulocytes or polymorphonuclear leukocytes (PMNs) comprise approximately 60% of all 
leukocytes in the human blood and are important for the removal of antibody-opsonized cells13. Granulocytes 
interact with the Fc domain of therapeutic antibodies via surface expressed Fc receptors (FcRs), whereupon 
antibody-dependent cellular phagocytosis (ADCP) is induced. However, although granulocytes are potent ADCP 
effector cells, they are relatively inefficient in the execution of antibody-dependent cell-mediated cytotoxicity 
(ADCC). To improve the tumoricidal activity of granulocytes, we generated scFvCLL1:sTRAIL, a TRAIL-based 
fusion protein that binds to C-type lectin-like molecule-1 (CLL-1), a lectin that is selectively expressed on 
myeloid cell types. Fusion protein scFvCLL1:sTRAIL bound to granulocytes, leading to the display of high levels 
of surface TRAIL. Consequently, in mixed cultures of granulocytes and cancer cells, treatment with scFvCLL-
1:TRAIL strongly increased apoptotic cancer cell death. Of note, scFvCLL-1:TRAIL treatment of granulocytes also 
potentiated ADCC of therapeutic anticancer antibodies such as rituximab and cetuximab. Thus, scFvCLL1:sTRAIL 
may be used as an adjuvant in anticancer antibody therapy to augment the tumoricidal activity of granulocytes.
Of note, the antibody fragment in the TRAIL fusion protein is not only a ‘targeting device’, but can also be 
exploited to block or activate signaling by its target antigen. In chapter 4 we provided proof of concept for the 
use of a functional antibody fragment by targeting sTRAIL to CD47. CD47 is a crucial ‘don’t eat me’ glycoprotein 
that binds to signal-regulatory protein alpha (SIRPα) on phagocytes and, thereby, inhibits phagocytic activity14. 
Cancer cells hijack this regulatory pathway and typically overexpress CD47 to evade phagocytic elimination. 
Interestingly, CD47-blocking antibodies restore phagocytic activity of immune cells and augment the efficacy 
of therapeutic anticancer antibodies15-17. Therefore, we constructed scFvCD47:sTRAIL, which simultaneously 
blocks CD47 signaling and delivers the cytotoxic molecule TRAIL to CD47 overexpressing tumor cells. Indeed, 
scFvCD47:sTRAIL induced CD47-restricted cancer cell death in B-cell lymphoma cell lines as well as in primary 
patient-derived lymphoma cells. Furthermore, scFvCD47:sTRAIL enhanced phagocytosis induced by the anti-
CD20 antibody rituximab. Thus, scFvCD47:TRAIL effectively blocks CD47-mediated ‘don’t eat me’ signaling, 
promotes rituximab-induced phagocytosis and triggers CD47-restricted apoptosis in malignant B cells. This 
multifunctional therapeutic activity of scFvCD47:TRAIL may be of general use for optimizing antibody-based 
cancer therapy and serves as proof of concept for combining CD47-blockade with alternate effector principles 
that may further synergize anticancer activity. 
In chapter 5, a comprehensive overview of the interplay between ‘don’t eat me’ receptor CD47 and the ‘eat 
me’ molecule calreticulin is provided, specifically in the context of TRAIL-based immunotherapy. The balance 
between the expression of ‘eat me’ versus ‘don’t eat me’ signals on the cell surface ultimately determines whether 
a cell is removed by phagocytes or not. In cancer, this balance is disturbed and driven towards ‘don’t eat me’. 
Calreticulin is a pro-phagocytic protein that normally resides in the endoplasmic reticulum (ER), but can rapidly 
translocate to the cell surface of dying cells, e.g. upon radiation, anthracycline and TRAIL treatment18. Once 
on the cell membrane, calreticulin interacts with phagocytes and promotes the engulfment of the dying cell. 
Translocation of calreticulin is a prerequisite for induction of a process termed ‘immunogenic cell death’, i.e. the 
induction of cancer cell death that triggers an anticancer immune response19. As we demonstrated in chapter 
4, the simultaneous blockade of CD47 and the induction of TRAIL-mediated cancer cell death, enhanced the 
phagocytic uptake of rituximab-treated leukemia cells. Further, we identified that treatment with TRAIL triggered 
the cell surface association of calreticulin with TRAIL and the TRAIL-R2 death inducing signalling complex in 
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melanoma cells. This data is in line with previous reports that showed that TRAIL and other members of the TNF 
superfamily can directly interact with calreticulin. Hence, calreticulin recruitment to TRAIL/TRAIL-receptor, and 
possibly other TNF members, may represent a way of regulating (cancer) cell phagocytosis.
Part II: Evaluation of Galectin-9 as novel agent for cancer therapy
The second part of this thesis is dedicated to exploratory studies into the tumoricidal and immunomodulatory 
activities of the glycan-binding protein Galectin-9 (Gal-9), with an introductory review on the biology and effect 
of Gal-9 in cancer and autoimmunity in chapter 6. Gal-9 is a versatile protein best known for its cytotoxic effects 
toward specific T cell subsets and its inhibitory effects on cell adhesion. In line with literature, we in chapter 
7 identified that Gal-9 indeed reduced adhesion of melanoma cells to components of the extracellular matrix 
(ECM), i.e. collagen-I. However, careful analysis of cell morphology revealed that these Gal-9-treated melanoma 
cells exhibited features of dying cells. Correspondingly, we identified that Gal-9 induced melanoma cell death 
through a caspase-independent pathway. The percentage of cell death induced by Gal-9 strongly correlated 
with the reduction in collagen-I adhesion by melanoma cells, indicating that the primary effect of Gal-9 is the 
induction of cell death rather than blocking of cell adhesion. Of note, whereas melanoma cells proved sensitive 
to cell death induction by Gal-9, treatment of primary normal melanocytes with Gal-9 did not have any cytotoxic 
effects, suggesting that this cytotoxic effect of Gal-9 is tumor-selective.
In chapter 8 we identified that Gal-9 also had prominent cytotoxic activity towards colorectal carcinoma, 
both towards cell lines and primary patient-derived colon cancer cells in vitro. Further, Gal-9 treatment strongly 
reduced tumor growth and prolonged overall survival in a mouse model of human colon cancer with no 
evidence of cytotoxicity toward normal mouse tissues. Correspondingly, treatment of normal human colon 
epithelial cells with Gal-9 did not induce any cytotoxicity, again highlighting an apparent tumor-selective 
cytotoxic effect of Gal-9. Interestingly, cell death as induced by Gal-9 was neither apoptotic nor necrotic and was 
characterized by the formation of large vacuoles. Internalization studies revealed that Gal-9 was taken-up via 
endocytosis and in time accumulated in the lysosomes, leading to excessive lysosomal swelling. In addition, Gal-
9 induced the accumulation of so-called autophagosomes, organelles important in the execution of autophagy. 
This autophagy pathway proved to be essential for the cytotoxic activity of Gal-9, since siRNA mediated knock-
down of essential autophagy proteins (i.e. ATG-5 and Beclin-1) abrogated Gal-9-mediated induction of cancer 
cell death. 
During the normal execution of autophagy, autophagosomes fuse with lysosomes, leading to degradation 
of the autophagosomal content20. In our studies, we identified that Gal-9 treatment blocked the execution of 
autophagy by inhibiting fusion of autophagosomes with lysosomes. Consequently, Gal-9 treatment leads to the 
progressive and massive accumulation of autophagosomes and lysosomes, even to the point of suppressing 
nuclear size by up to 40%. These phenotypical effects of Gal-9 are reminiscent of those observed with lysosomal 
inhibitors such as chloroquine. Interestingly, colon cancer cells that harbor an activating k-Ras mutation were 
uniquely sensitive to Gal-9. This enhanced sensitivity of k-Ras mutated colon cancer cells correlated with their 
elevated basal levels of autophagic flux. This finding is of particular therapeutic interest since k-Ras mutated 
colon cancers poorly respond to conventional therapies and, moreover, are resistant toward epidermal growth 
factor receptor (EGFR)-targeted antibody therapy21. Thus, Gal-9 may be a potential new therapeutic for the 
treatment of k-Ras mutated colon carcinoma.
In addition to its cytotoxic effect towards cancer cells, Gal-9 is well-known for its immunomodulatory 
effects. Most notably, Gal-9 has been described to induce cell death in IFN-y producing T helper 1 (Th1) cells by 
binding to the checkpoint inhibition receptor T cell immunoglobulin and mucin domain–containing-3 (TIM-3). 
However, in chapter 9 we identified that at low doses of Gal-9, treatment triggered cell death but also induced 
strong proliferation and survival of Th1 cells. This T cell stimulatory effect was most prominent at low nanomolar 
concentrations and was, in contrast to earlier published reports, independent of TIM-3 expression. Gal-9 
predominantly induced proliferation of CD4+ T cells and promoted their differentiation into central memory T 
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cells with an IFNγ-secreting Th1 phenotype. When pre-activated PBMCs were treated with Gal-9, this treatment 
did not induce further cell proliferation but skewed the CD4+ /CD8+ balance towards a CD4+ Th1 phenotype. 
These divergent effect at distinct Gal-9 doses indicate that the outcome of Gal-9 mediated signaling upon T cell 
responses depends on micro-environmental concentrations of Gal-9 as well as the activation status of T cells.
PERSPECTIVES:
PART I: TARGETED DELIVERY OF TRAIL FOR CANCER IMMUNE THERAPY
Arming immune cells with TRAIL: strengthening T cell-mediated antitumor immune responses via co-
stimulation
The data presented in the first part of this thesis clearly demonstrates that TRAIL-based fusion proteins can 
potentiate the antitumor activity of T cells. As referred to before, by selecting an antibody fragment that affects 
a specific biological function itself, dual or multipurpose therapeutic fusion proteins can be generated. In this 
respect, crosslinking of CD3 using the scFvCD3:sTRAIL fusion protein provided a strong activation signal to 
T cells. This proof of concept study can be exploited for further rational design of dual function TRAIL-based 
therapeutics. Among these, T cell co-stimulatory receptors are of special interest as appropriate co-stimulation 
after antigen recognition by the T cell receptor (TCR) is essential for the generation of functional antitumor 
immune responses, with lack of co-stimulation leading to induction of T cell anergy22. Several co-stimulatory 
receptors expressed on T cells are of special interest, including 4-1BB, CD27, CD28 and CD40 (reviewed by23). 
By selecting a specific T cell antigen, specific T cell subsets can be targeted. For instance, by choosing a target 
antigen that is highly expressed by CD8+ cytotoxic T cells, optimal anticancer activity may be achieved. Further, a 
prerequisite for the design of such a TRAIL-based approach is a relatively high expression level on T cells in order 
to deliver sufficiently high quantities of bioactive TRAIL to the cell surface. 
Taking these selection criteria in consideration, perhaps one of the most promising co-stimulatory TRAIL 
fusion protein would be a CD27-targeting TRAIL fusion protein. CD27 is a member of the tumor necrosis factor 
super family that is highly and constitutively expressed on various T cell subsets. Binding of CD27 by its ligand 
CD70 regulates T cell dependent immunity24, with  several reports showing that CD27 signaling promotes 
survival and proliferation of CD8+ T cells25-27. Further, CD27 signaling promotes the differentiation of naïve 
CD4+ T cells into immunostimulatory effector T cells28 and is required for the long-term maintenance of T cell 
immunity29. In line with these functions of CD27, high levels of intratumoral CD27+ TILs were associated with 
a better prognosis in ovarian cancer patients30, and a high frequency of CD27+ CD8+ in bulk TILs associated 
with tumor regression following adoptive T cell transfer in melanoma patients31. To exploit CD27-mediated 
co-stimulation for cancer immunotherapy, agonistic antibodies have been produced that proved to potently 
activate anticancer T cell immunity with concomitant tumor regression in mouse models32,33. Subsequently, a fully 
human anti-CD27 antibody (1F5) was generated34, which induced in vitro proliferation and cytokine production 
of CD27+ T cells, and showed potent antitumor efficacy in mice35,36. Of note, this antibody (Varlilumab, CDX-
1127) is currently being tested in various clinical trials as single treatment (NCT01460134) or in combination with 
other anticancer (immunomodulatory) agents (NCT02386111, NCT02413827, NCT02270372, NCT02335918). 
Based on the potent T cell activating potential of CD27 agonistic antibodies, scFvCD27:sTRAIL is expected to 
activate T cells via its antibody fragment, which will result in T cell-mediated killing of cancer cells. Further, as 
we showed for scFvCD3:sTRAIL, binding of TRAIL to TRAILR2 resulted into cross-linking and activation of the 
TCR via CD3. Analogously, CD27-signaling will be likely stimulated via TRAIL/TRAILR-mediated cross-linking. The 
anticancer effect of scFvCD27:sTRAIL will be further enhanced by simultaneously induction of TRAIL-mediated 
cancer cell apoptosis. Therefore, scFvCD27:sTRAIL will have dual anticancer activity. In addition, scFvCD27:sTRAIL 
may be used to treat CD27-expressing lymphoma and leukemia where the antibody fragment of the fusion 
protein is used to deliver TRAIL to the cancer cells. Of note, the use of an agonistic CD27 antibody did not induce 
proliferation in these hematological cancer cells in previous studies34.
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However, there are some potential drawbacks of activating CD27 co-stimulation that need to be carefully 
analyzed. First, targeting of co-stimulation in the immune system always carries the risk of unwanted (auto-
immune like) overstimulation. Case in point here is the CD28-targeted super agonist (TGN1412), which 
despite a good safety profile in pre-clinical models induced cytokine storm and multiple organ failure 
in human volunteers37. Later it was discovered that whereas T cells of macaques lost expression of CD28 
upon CD28-mediated differentiation into effector cells, this downregulation did not occur in human T cells 
leading to continued CD28-mediated signalling38. In this respect, it has been shown that CD27 expression is 
downregulated on human T cells after strong activation24 and by pro-inflammatory cytokines such as IL-231. 
Secondly, CD27 signalling has been associated with the promotion of Tregs. Specifically, tumor bearing CD27-
deficient mice had lower levels of intra-tumoral Tregs with a concomitant reduction in tumor growth compared 
to wildtype animals39. However, although CD27-CD70 interactions suppressed the anticancer response of T cells 
in the presence of established solid tumors in this model, it increased the antitumor response against tumor 
cells injected as single-cell suspension. This data suggests that chronic CD27 stimulation may yield inhibitory 
T cell signalling instead of T cell activation by the induction of Tregs. On the contrary, during transient CD27 
co-stimulation, the activation of cytotoxic T cell functions dominates over the induction of Tregs (reviewed 
by40). Therefore, anticancer immunotherapy using anti-CD27 agonistic antibodies should be used transiently 
to predominantly activate T cell responses and prevent Treg promotion. Of note, a recent paper showed that 
Varlilumab did not activate purified Tregs35. Furthermore, the use of the proposed scFvCD27:sTRAIL fusion 
protein may also (at least partly) circumvent the problem with Tregs, as it will coat these cells with TRAIL, thereby 
converting suppressor cells into tumor killer cells. In addition, Treg stimulation by CD70 over-expressing DCs 
reduced their suppressive capacity and promoted their differentiation into Th1 cells41. Therefore, CD27 co-
stimulation in tumors with infiltrated Tregs may also promote anticancer immune responses by suppressing 
Treg functions. So taken together, the concept of TRAIL fusion proteins can be applied to obtain many different 
immune stimulating formats, among which scFvCD27:sTRAIL is a promising one.
Arming immune cells with TRAIL: converting immune suppressors into tumor killers by blocking immune 
checkpoints
On the flip side of the T cell activation balance are the so-called inhibitory immune checkpoints. These immune 
checkpoints normally ensure the timely shut-down of an immune response to prevent collateral damage. 
Among others, T cells express Programmed Death-1 (PD-1) upon activation, which will dampen T cell activation 
upon binding to its ligand Programmed Death Ligand 1 (PD-L1)42. However, in the tumor microenvironment the 
expression of inhibitory immune checkpoint ligands and receptors is often enhanced, tilting the immunological 
balance towards inhibition of immunity. For instance, PD-L1 is expressed on various tumor types43,44, whereas 
TILs commonly express high levels of PD-1 and PD-L1 as determined by our own lab (unpublished data,45) and 
reported by others46. As a result, the interaction between PD-1 and PD-L1 dampens the antitumor immune 
response. Releasing the immunological break by use of blocking PD-1 or PD-L1 monoclonal antibodies can 
stimulate anticancer immune responses in cancer patients with advanced disease7,8. Furthermore, combinations 
of PD-1 blockade (Nivolimab) with radiotherapy47,48 or chemotherapy49 further improved therapeutic outcome 
of cancer patients. Together, these findings suggest that simultaneous inhibition of immune checkpoints 
and the induction of cancer cell death improves anticancer activity. Thus, targeting of immune check-points 
using TRAIL-based fusion proteins, such as scFvPD-L1:sTRAIL or scFvPD-1:sTRAIL, may yield bifunctional and 
synergistic antitumor therapeutics. Indeed, we recently published on the scFvPD-L1-sTRAIL fusion protein which 
induced PD-L1-directed cancer cell death in PD-L1-expressing cancer cell lines and simultaneously enhanced T 
cell activity and proliferation when combined with a CD3 agonist50. Furthermore, scFvPD-L1:TRAIL had similar 
activity in mixed cultures of melanoma cells and TILs derived from melanoma patients. Of note, PD-1 and PD-L1 
are also highly expressed on so called myeloid-derived suppressor cells (MDSCs)51,52, which are commonly found 
in the patients tumor micro-environment where they suppress T cell mediated anticancer immune responses. 
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In line with the inhibitory function of MDSCs, the presence of high levels of these immune cells is associated 
with poor survival and clinical outcome53-55. Interestingly, by use of scFvPD-L1 sTRAIL, these PD-L1-expressing 
MDSCs could be converted into pro-apoptotic tumoricidal effector cells. Taken together, scFvPD-L1:TRAIL yields 
promising  multi-fold  and  mutually  reinforcing anticancer  activity  that  may  be  exploited  to  enhance  the 
efficacy  of  therapeutic  PD-L1/PD-1  checkpoint inhibition. 
The scFvPD-L1:sTRAIL fusion protein provides proof of concept for the design of several other TRAIL-
fusion proteins that contain a checkpoint inhibitory moiety. An example may be scFvCTLA-4:sTRAIL. Cytotoxic 
T-Lymphocyte Associated Protein 4 (CTLA-4) is expressed on activated T cells56 and inhibits T cell activity by 
binding its ligand B7 (CD80/ CD86), thereby preventing the T cell activating interaction between B7 and CD28. 
In addition, CTLA-4 is continuously expressed on Tregs57 and highly upregulated on TILs58-60, rendering these T 
cells in an inactive state. Antibodies that block CTLA-4 have proved to induce T cell activation leading to tumor 
regression in pre-clinical settings59,61. Also in clinical settings, the use of anti-CTLA-4 (Ipilimumab) improved 
clinical outcome of cancer patients62, especially when combined with chemotherapy63. Therefore, combining 
TRAIL-mediated tumor cell killing with checkpoint inhibition via CTLA-4 is expected to increase anticancer 
activity as compared to CTLA-4 blockade alone. In addition, scFvCTLA-4:sTRAIL can be used to coat the CTLA-4-
expressing Tregs to convert these suppressor cells into tumor killer cells. However, it should be noticed that on 
resting T cells, most of the CTLA-4 molecules are present in intracellular vesicles, which are transported to the cell 
membrane upon T cell activation64,65. Therefore, the levels of TRAIL that can be coated on the surface of T cells 
using scFvCTLA-4:sTRAIL is likely not as high as achieved with scFvCD3:sTRAIL or K12:sTRAIL. 
Interestingly, CTLA-4 has also been found to be constitutively expressed on both haematological as well 
as solid cancer cell lines and patient derived material66,67. Therefore, scFvCTLA-4:sTRAIL is also useful to deliver 
TRAIL to CTLA-4 expressing cancer cells to induce cancer cell death. Further, multiple clinical studies showed 
that combining CTLA-4 blockade with PD-1 blockade outperforms monotherapy68-70, and that CTLA-4 inhibition 
therapy can induce clinical responses in patients who previously failed PD-1 inhibition therapy71. Indeed, PD-1 
and CTLA-4 receptors use distinct mechanisms to dampen T cell activity72,73, which argues for synergistic effects 
when blocking both receptors. Therefore, scFvCTLA-4:sTRAIL and scFvPDL-1:sTRAIL may be simultaneously 
applied to obtain optimal anticancer activity.
Of note, a general disadvantage of all immune activating TRAIL fusion proteins is the risk of unwanted 
side effects by ubiquitously activating immune cells throughout the human body. To circumvent this problem, 
bispecific antibodies may be developed that can stimulate the immune system only at the site of the tumor. 
Examples for this approach are EGFRxPD-L1, MCSPxPD-L1 (melanoma), or CLL-1xPD-L1 (AML), which are 
currently being developed in our laboratory. To also include the TRAIL part into these agents, novel triplebodies 
may be constructed which contain one arm against an immune checkpoint/ co-stimulatory molecule, one arm 
against a tumor antigen and one arm that has agonistic TRAIL receptor (TRAILR) activity. In addition, also TRAILR 
activating bispecifics can be designed to selectively kill tumor cells. Among these we recently published the 
bispecific MCSPxDR5, which selectively kills MCSP+ melanoma cells by activating the agonistic TRAILR-DR574.
In conclusion, blocking immune check point inhibition is a promising approach to boost anticancer 
immunity. The efficiency of this type of therapy may be further improved by combining it with TRAIL, and/ or 
specifically target the molecules to the tumor using antibody fragments, or bispecific formats. 
Eat me versus don’t eat me signaling: skew the balance toward engulfment in a tumor selective way 
In this thesis we reported that scFvCD47:sTRAIL simultaneously induced target antigen-restricted tumor cell 
death and promoted phagocytosis by blocking CD47-mediated ‘don’t eat me’ signaling. This inhibition of ‘don’t 
eat me’ signaling was particularly effective when combined with therapies that promote the surface display of 
‘eat me’ signals that promote tumor cell engulfment. In this respect, scFvCD47:sTRAIL enhanced phagocytosis of 
tumor cells when combined with clinically used anticancer antibodies that trigger pro-phagocytic FcR signaling 
in phagocytes. In addition, we showed that the ‘eat me’ signal calreticulin associated with the TRAILR upon 
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TRAIL treatment. Therefore, it is possible that scFvCD47:sTRAIL treatment stimulates cancer cell phagocytosis by 
inducing cell death, blocking CD47 and simultaneously recruiting the pro-phagocytic protein calreticulin to the 
cell membrane. Importantly, since apoptotic cells are more easily engulfed then viable cells, scFvCD47:sTRAIL 
also has increased activity toward cancer cells. Specifically, TRAIL only induces cell death in cancer cells, and not 
in healthy cells. Hereby scFvCD47:sTRAIL induces a pro-phagocytic signal selectively at the site of the tumor, 
which is enhanced by the simultaneous blockade of CD47. Taken together, scFvCD47:sTRAIL may be generally 
used to optimize efficacy of anticancer monoclonal antibody therapy. 
As CD47 is expressed on virtually every cell in the human body, CD47-targeted therapy has a clear risk of 
toxicity toward normal CD47-expressing cells. Therefore, to fully exploit CD47 as a target for cancer therapy 
the development of bispecific antibodies that comprise of one arm against CD47 and one arm against a tumor 
antigen appears warranted. The use of such CD47 bispecific antibodies will ensure the accretion of the CD47-
blocking antibody domain to the site of the tumor, which should both enhance tumor-localized accretion and 
activity as well as limit unwanted side effects toward healthy tissues. Suitable and prominent targets in this 
respect are EGFR (cetuximab) to target epithelial cancers and CD20 (rituximab) to target B cell leukemia. Indeed, 
a bispecific IgG1 antibody which targets both CD20 and CD47 was recently published75. This bispecific antibody 
was shown to bind to each of its target antigens, thereby inducing phagocytosis predominantly of dual antigen 
expressing lymphoma cells. Furthermore, the treatment of lymphoma bearing mice with the CD20xCD47 
bispecific reduced tumor burden and prolonged overall survival. To reduce the problem of binding of the 
bispecific to normal CD47-expressing cells, the anti-CD47 antibody was modified to yield several bispecific 
antibodies with reduced affinity for CD47. Hereby, the predominant binding of a certain CD20xCD47 bispecific 
will be via its anti-CD20 domain, specifically targeting the bispecific to the CD20-overexpressing lymphoma 
cells. Indeed, these engineered bispecific antibodies showed reduced binding to red blood cells, which are 
highly CD47 positive. 
However, several other adaptations could be made in these kind of bispecifics to obtain optimal functionality 
and/ or specificity. For instance, the choice of the isotype of the bispecific antibody will influence its activity76. 
Whereas IgG1 antibodies have a high affinity for Fc-receptors on phagocytes, IgG4 has a relatively low affinity. 
Therefore, IgG1 antibodies or IgG1 containing bispecifics are typically strong inducers of ADCC and/ or CDC. 
Thus, besides blocking CD47 mediated don’t eat me signaling, a CD47-blocking (bispecific) antibody in an IgG1 
format will also result in activation of FcR-mediated phagocyte effector functions, which may increase the risk 
for  unwanted side-effects. In contrast, the therapeutic functionality of an IgG4 antibody format will mainly rely 
on its antigen specific domain, and not on its Fc-domain. Further rational selection of antibody isotype may be 
used to pre-select for which immune cell subset is recruited and activated by the antibody. In this respect, the 
majority of the current clinically used therapeutic antibodies is of the IgG1 isotype, which is an isotype that does 
not very potently activate neutrophils. However, it has been shown that neutrophils are very potent effector cells 
in inducing antibody-induced anticancer effects in a mouse model77. Since neutrophils comprise ~60% of all 
the leukocytes in the human blood, it may be of interest to target these immune effector cells with therapeutic 
antibodies. This can be achieved by use of IgA isotype antibodies, which are known to very potently activate 
neutrophils78,79. Thus constructing an IgA containing RTXxCD47 may also be a potential interesting approach to 
potentiate tumor cell phagocytosis.
In Fc-containing ‘full’ antibodies the Fc domain recruits immune effector cells, which may trigger unwanted 
side-effects. A potentially more selective approach is the sole removal of the CD47 inhibitory signal using 
antibody-derivative that lacks an Fc-domain, like a F(ab’)2 preparation. F(ab’)2 variants are typically produced 
by protease-mediated digestion methods, but can also be recombinantly produced. Such a F(ab)’2 would be 
particularly useful in an adjuvant, whereby a therapeutic mAb is used to redirect immune effector cells to 
cancerous cells while the F(ab)’2 CD47 construct ensures tumor-selective removal of CD47 inhibitory signaling. 
In our laboratory we are currently evaluating such a construct for the B cell target CD20, with preliminary results 
demonstrating that this format does induce phagocytosis when co-treated with therapeutic mAbs, but not in 
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the absence of an ‘eat me’ signal. In addition, tumor cells in general already have a more ‘stressed’ phenotype 
compared to normal healthy cells that already promotes the uptake by phagocytes and induction of an immune 
response80,81. Therefore, F(ab)’2 CD47 will predominantly favor the uptake of cancer cells over normal healthy 
cells.
CD47-blocking bispecific antibodies or F(ab)’2 may also be rationally combined with cell death inducing 
strategies, such as chemotherapy. In this setting, the cytotoxic drug will trigger cancer cell death and exposure 
of the ‘eat me’ signal phospatidyl serine, which in combination with CD47 blocking should synergistically 
trigger phagocytic removal of cancer cells82. In addition, certain chemotherapeutic drugs are known to induce 
the membrane exposure of calreticulin whereby immunogenic cell death is induced. Indeed, the combination 
of anti-CD47 antibodies (B6H12) with doxorubicin was much stronger in reducing tumor growth then single 
treatments in a patient derived xenograft mouse model of liver cancer83. 
An interesting recent finding indicates that the therapeutic effects of anti-CD47 antibodies in mice to a large 
extent depended on the activation of T cell-mediated immunity, with no anti-tumor activity in T cell-deficient mice 
or mice selectively depleted for CD8+ T cells84. In addition, the depletion of DCs abrogated the therapeutic effects 
of CD47-blocking antibodies, which suggest the need for DC/CD8+ T cell cross priming. When chemotherapy was 
administrated after anti-CD47 treatment this prevented tumor growth via ‘natural vaccination’, an effect that was 
abrogated when chemotherapy was given before anti-CD47 treatment. Furthermore, chemotherapy after anti-
CD47 therapy also prevented tumor rejection upon re-challenge, whereas animals treated with anti-CD47 alone 
or chemotherapy before anti-CD47 were not protected. Taken together, this suggests that T cells are necessary 
to obtain long-term anticancer immune responses. Therefore, inhibition of the innate immune checkpoint CD47 
may well and rationally be combined with inhibition of T cell checkpoints (e.g. PD-1 or PD-L1 antagonist) or 
selective T cell co-stimulation (e.g. CD27 agonist) to further boost (long-term) anticancer immune responses
Taken together, phagocytosis of cancer cells can be enhanced by blocking ‘don’t eat me’ signaling or 
providing ‘eat me’ signaling. As with all (immuno)therapeutics, tumor selectivity is a critical aspect to consider 
in the design of these approaches. Therefore, most promising strategies will comprise a bispecific format that 
targets tumor cells, thereby promoting phagocytosis at the site of the tumor. Additional properties like affinity 
for the antigen, isotype of the antibody or even the absence of the Fc-domain can be selected based on the 
desired mode of action of the bispecific antibody.
PART II: EVALUATION OF GALECTIN-9 AS NOVEL AGENT FOR CANCER THERAPY
Galectin-9 as novel therapeutic agent to overcome autophagy-induced therapy resistance in cancer
As detailed in this thesis the glycan-binding protein Gal-9 triggered cell death in melanoma as well as colon 
cancer cells. In addition, yet unpublished data by our laboratory shows that Gal-9 has similar cytotoxic potential 
toward ovarian cancer, hypopharyngeal cancer and acute myeloid leukemia (AML). Also our collaborators 
recently published several papers that showed the induction of cell death upon Gal-9 treatment of hepatocellular 
carcinoma, gallbladder carcinoma, cholangiocarcinoma and gastric cancer85-88. This data collectively suggests 
that Gal-9 is a widely applicable agent for the treatment of various human cancers. Interestingly, especially 
certain hard-to-treat cancers may be very suitable targets for Gal-9 therapy. In this respect, we showed in chapter 
8 of this thesis that Gal-9 killed k-Ras mutated colorectal cancer by the induction of fatal frustrated autophagy. We 
discovered that Gal-9 induced cell death by inhibiting the proper execution of autophagy, which predominantly 
affected k-Ras mutant cancers likely due to their increased basal levels of autophagic flux. From literature it is 
evident that oncogenic mutations such as k-Ras can induce a state of so-called “autophagy addiction”, whereby 
cancer cells rely on autophagy for their energy supply89. Therefore, inhibition of autophagy execution, by agents 
like Gal-9, may cut off the energy supply in these cancers and promotes cell death. Furthermore, elevated 
autophagic flux is increasingly being recognized as an important cause of therapy resistance in many types of 
human cancer (reviewed in89). For instance, treatment with the first line chemotherapeutic cisplatin in ovarian and 
lung cancer generally fails due to therapy resistance resulting from activation of cytoprotective autophagy90-93. 
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Correspondingly, co-treatment of cancer cells with cisplatin and autophagy inhibitors (e.g. chloroquine) 
increased the induction of cancer cell death91,92. Similar correlations between autophagy and therapy resistance 
in solid cancers have been described for other chemotherapeutics like taxol94-96 and doxorubicin97-99, but also 
for photodynamic therapy100-102 and radiation therapy103-105. Analogously, TRAIL-resistant tumor cells that harbor 
defects in the apoptotic cell death pathways are characterized by elevated levels of autophagy106 and may thus 
be sensitive to Gal-9. Indeed, as also described in this thesis, apoptosis-resistant HCT116 colon carcinoma cell 
lines remained sensitive to Gal-9 while being fully resistant toward TRAIL. In addition, preliminary data from our 
laboratory shows that TRAIL-resistant primary patient derived ovarian cancer cells are sensitive toward Gal-9. 
Induction of autophagy has also been described to mediate therapy resistance in various hematological 
cancers, including in acute myeloid leukemia (AML), multiple myeloma (MM) and B-chronic lymphocytic leukemia 
(B-CLL). Autophagy appears particularly relevant for AML, which has a limited overall 5-year survival rate after 
diagnosis of only 20%1 due to therapy-resistant relapses. AML cells resistant to the standard chemotherapeutic 
drug cytarabine are characterized by elevated levels of autophagy107,108. Similarly, AML cells that have survived 
treatment with histone deacetylase inhibitors (HDACis) or mTOR inhibitors have elevated levels of cytoprotective 
autophagy109,110. Furthermore, autophagy contributes to AML cell survival under hypoxia, as may be present in 
the bone marrow111, and is involved in the maintenance of leukemia-initiating cells112. Therefore, strategies to 
inhibit autophagy are being explored for AML therapy. For instance, blocking autophagy using chloroquine 
reduces the cell viability of cytarabine resistant AML cells108. Furthermore, treatment of therapy resistant AML 
cells with chloroquine together with cytarabine107,108 or HDACis109, strongly improved cytotoxic anti-AML effects, 
also under hypoxia111. Therefore, AML may be a suitable cancer type to be treated with Gal-9. Indeed, preliminary 
results from our laboratory shows potent cytotoxic activity of Gal-9 toward AML cell lines as well as patient 
derived cells.
Thus, in both solid and hematological cancers, the induction of cytoprotective autophagy can contribute 
to therapy resistance. Therefore, in my opinion, inhibiting autophagy is a promising approach to improve 
therapeutic outcome. In this respect it is important to mention that the current FDA-approved autophagy 
inhibitor chloroquine, has dosing issues which hampers its clinical implication. Specifically, high doses up 
to 50 mg/ kg chloroquine were needed to observe autophagy inhibition in a mouse model of colon cancer, 
only leading to moderate inhibition of tumor growth113. Since the maximum tolerated dose of chloroquine for 
humans is 10 mg/ kg, chloroquine can probably not be given at a sufficient dose. In addition, in a study where 
chloroquine was combined with doxorubicine for the treatment of dogs with spontaneous non-Hodgskin’s 
lymphoma it was shown that chloroquine has a poor biodistribution profile114. Specifically, levels of chloroquine 
in the blood were much higher than in the tumor, which suggests that there is a need for better autophagy 
inhibitors with improved biodistribution and preferably the ability to specifically target tumor cells. 
For Gal-9, the acquired dosing for the inhibition of autophagy may be well achieved in vivo. As described in 
this thesis, Gal-9 did not affect various normal healthy cell types, i.e. melanocytes or colon epithelium (even at 
a high dose of 600nM), whereas it did eliminate malignant melanoma cells and colon cancer cells. In addition, 
we have by now verified that Gal-9 is also not toxic to normal bronchial epithelial cells, breast epithelial cells, 
fibroblasts and cord blood stem cells (unpublished data). These data suggest that Gal-9 therapy is not harmful 
for various types of normal healthy cells, and therefore may have a therapeutic window. Indeed, treatment with 
Gal-9 did not show any signs of adverse side-effects in our in vivo mouse model (even at doses up to 8 mg/kg), 
whereas it strongly inhibited colon cancer growth and significantly prolonged survival of tumor bearing mice. 
However, in spite of these prominent anti-tumor effects of recombinant Gal-9, the use of this protein in cancer 
therapy needs to take the well-established pleiotropic activity profile of Gal9 in consideration, especially its well-
established immunomodulatory effects. In this respect, the induction of apoptosis in T cells by Gal-9 is one of the 
best known and most-widely published effects of Gal-9. Hence, the treatment of cancer patients with Gal-9 has 
the risk of knocking out large subsets of T cells, especially when high(er) doses are used. On the other hand, as 
shown in chapter 9 Gal-9 can also facilitate induction of T helper 1-mediated immune responses at lower doses, 
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an effect that may be beneficial and contribute to antitumor immune responses.
However, a potential possibility to circumvent the risk for unwanted side-effects on the immune system 
during Gal-9 treatment is by using it in patients that undergo stem cell transplantation. Stem cell transplantation 
is part of the treatment protocol for certain hematological cancers, but can also be applied in patients with 
solid tumors115. In both cases, stem cells are harvested from the patient (autologous) or a healthy donor 
(allogeneic), after which the cancer patient will receive a high dose chemotherapy (with Gal-9) to kill the cancer 
cells. Subsequently, stem cells are given back to the patient to restore the patient’s immune system. Another 
possibility is to use Gal-9 therapy in isolated body compartments where there is a reduced risk of affecting the 
immune system. For instance, patients with cancers in the abdomen may develop metastases at the peritoneum 
(peritoneal carcinomatosis), as most seen with colon carcinoma. These patients are currently treated with 
hyperthermic intraperitoneal chemotherapy, whereby a high dose of heated chemotherapy is directly applied 
to the abdomen116. Similarly the abdomen can be infused with a high concentration of Gal-9 to locally kill the 
metastasized cancer cells. Of note, Gal-9 is a thermostable protein and may easily be incorporated into the HiPEC 
procedure. Finally, it is possible to produce antibody-based Gal-9 fusion proteins (like the TRAIL-fusion proteins 
described in this thesis) to target Gal-9 to the tumor. This targeting approach can both reduce the unwanted 
immunomodulatory effects as well as improve the biodistribution (a main problem for in vivo chloroquine use). 
In the next paragraph the design of such targeted-Gal-9 constructs is discussed in more detail.
Taken together, the inhibition of autophagy is a promising approach that may help improve current 
treatment protocols and reduce autophagy-induced therapy resistance. Since current available autophagy 
inhibitors have some dosing issues, it will be of interest to further delineate the potential therapeutic activity of 
Gal-9 in relevant models. 
Increasing the selectivity of Gal-9 therapy: antibody targeted Gal-9 fusion proteins and
selected Gal-9-CRD constructs 
Analogous to the TRAIL-based scFv-targeting strategy described in this thesis, an scFv-targeting approach can 
be used to selectively deliver Gal-9 to target cells of choice. Based on the target cell of choice, different antigens 
can be selected with prominent and established marker on epithelial cancers being EGFR and EpCAM. Especially 
the use of an antagonistic EGFR-targeting antibody (fragment) may be of interest, as EGFR-signaling promotes 
tumor growth and the inhibition of this pathway is associated with induction of cytoprotective autophagy117-119. 
Treatment with scFvEGFR:Gal-9 would therefore 1. target Gal-9 to EGFR overexpressing tumors, 2. block EGFR 
mediated tumorigenic signaling and 3. prevent the activation of cytoprotective autophagy that is induced upon 
EGFR inhibition. Furthermore, growth factor receptors like EGFR are rapidly transported to the lysosomes for 
degradation upon ligand interaction120,121. Since, Gal-9 needs to accumulate into the lysosomes for its tumoricidal 
activity, it is likely that an internalizing receptor is required to retain full activity of the Gal-9 fusion protein. 
Of note, a recent paper reported on collagen binding protein (CBP):Gal-9 fusion proteins in which Gal-9 
was redirected to collagen matrices in order to induce local, contact-dependent immune suppression122. 
However, the Gal-9-mediated activity of these fusion proteins was markedly reduced compared to ‘free’ Gal-
9, with a reduction in Jurkat proliferation to only 10% of the effect of non-targeted Gal-9. Also the collagen-
binding activity of CBP was reduced upon fusion to Gal-9. This data suggests that coupling Gal-9 to another 
protein may severely hamper its activity, which may be a problem for the here proposed scFvEGFR:Gal-9 as well. 
A possible way to overcome this problem is by rational design of the linker that separates both effector domains 
(reviewed by123. In this respect, the linker should not be too short linker as this may prevent that both domains 
can simultaneously bind to their target. On the other hand, a too long linker can enhance the vulnerability of 
the fusion protein to be proteolytically cleaved124. The distance between the Gal-9 and scFvEGFR domain may be 
adapted by choosing for a flexible (increases spatial separation) or a rigid (maintains distance) linker. In addition, 
it may be necessary that the Gal-9 domain is released once bound to the tumor cell via EGFR. This can be achieved 
by the incorporation of a cleavable site between the antibody fragment and the Gal-9 fragment. This approach 
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has already been successfully applied to locally release TNF and FasL using matrix metalloprotease (MPP) and 
urokinase plasminogen activator (uPa) cleavable linkers125-127. In this way, the antibody fragment will target Gal-9 
to the cell membrane of tumor cells, whereupon Gal-9 is locally released in the tumor micro-environment due 
to tumor overexpressed proteases. The construction and pre-clinical evaluation of such scFv-based Gal-9 fusion 
proteins (with cleavable linker) is currently being explored in our laboratory.
Another aspect that has to be considered during the design of Gal-9-based fusion proteins is which 
carbohydrate recognition domain (CRD) of Gal-9 will be incorporated. Gal-9 is a “tandem repeat” galectin with 
two distinct CRDs that although sharing many carbohydrate partners, have difference in affinity for certain 
sugar moieties128. Therefore, the N-CRD and C-CRD of Gal-9 may have different functions, something that can be 
exploited to make the scFv:Gal-9 even more specific in activity. Indeed, the Gal-9 C-CRD more potently induced T 
cell apoptosis compared to the N-CRD of Gal-9, whereas the N-CRD outperformed the C-CRD in DC activation129. 
Similarly, it is well possible that one of the CRDs is mainly responsible for internalization of Gal-9, whereas the 
other CRD might be necessary for induction of cancer cell death as described in this thesis. Therefore, studies 
that are ongoing in our laboratory use Gal-9 CRD constructs to delineate the differences in function of the two 
CRDs. Specifically, we produced several mutant forms of Gal-9 which contain a single CRD (C-CRD, N-CRD) or two 
times the same CRD (Gal-9-CC, Gal-9-NN). These Gal-9 mutants are tested for their activity towards cancer cells 
and immune cells. Detailed functional information on these Gal-9 mutants will be used to rationally optimize 
the design Gal-9 mutants or Gal-9 based antibody fusion proteins with predefined CRD-mediated therapeutic 
activity, e.g. tumoricidal or immunostimulatory, which may be more efficient than wild-type Gal-9 and/ or lack 
unwanted side-effects.
    
Unraveling the ‘Gal-9 death inducing receptor’: opportunities for the development of Gal-9-based 
therapeutics 
Thus far, several binding partners for Gal-9 have been described on various types of human cells, including TIM-
3, CD44, protein disulfide isomerase and 4-1BB on T cells130-134. In addition Gal-9 may interact with glycolipids like 
the Thomsen Friedenreich antigen, as has been shown for the N-CRD of mouse Gal-9135. However, the receptor on 
cancer cells that triggers the cytotoxic effect as described in this thesis here has yet to be identified. Analogously, 
the receptor responsible for the stimulatory effect of low doses of Gal-9 on T cell activation identified by us and 
others is also unknown, although we have clearly shown this effect to be independent of TIM-3. Lectins like 
galectins bind to carbohydrate structures that may be present on a broad diversity of glycoproteins as well as 
glycolipids. Therefore, it is highly likely that Gal-9 binds to several structures on different cell types or even on 
one cell type. This pleiotropic binding profile makes it particularly challenging to pinpoint which receptor may 
be responsible for the effects induced by Gal-9 as described in this thesis. However, preliminary data shows that 
several different human tumor types (colon cancer, ovarian cancer, hypopharyngeal cancer, and melanoma) 
are all sensitive toward Gal-9 therapy with all showing characteristic formation of vacuoles. This similarity in 
phenotype suggests that the cytotoxic effects of Gal-9 are mediated by a single receptor or family of receptors. 
On the other hand, since Gal-9-induced cell death seems to need Gal-9 accumulation in the lysosomes, it is also 
tempting to speculate that all receptors that are translocated to the lysosomes upon ligand binding can be 
Gal-9 receptors. Of note, differential glycosylation in cancer cells may have yielded a unique receptor profile for 
Gal-9 on cancer cells, with glycosylation pathways often being deregulated in cancers, yielding both over- and 
under- glycosylated receptors (reviewed by136. Indeed, Gal-9 strongly binds to CD34+ primary AML cells, whereas 
it hardly interacts with CD34+ cord blood cells (preliminary data from our laboratory).
Obviously, highly glycosylated proteins are main suspects for being a binding partner of Gal-9, especially 
LAMP1 and LAMP2137, since Gal-9 accumulates in the lysosomes of cancer cells. In addition, the interaction 
with LAMPs has been published for other galectin members, i.e. Gal-1 and Gal-3138,139. The identification of the 
receptor and the epitope to which Gal-9 binds would enable the development of Gal-9-derived therapeutics. 
Specifically, one might think about the development of Gal-9 mimetic proteins or chemicals that specifically 
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bind to the identified receptor. In addition, specific antibodies may be produced that induce the same effects 
as Gal-9 upon receptor binding, which ideally would limit off-target activity towards other glycoproteins/lipids. 
CONCLUSION
In conclusion, targeted delivery of TRAIL to the surface of immune effector cells enhances the tumoricidal 
potential of such cells, both of the innate and adaptive immune system. Simultaneously, depending on the 
antibody fragment exploited for targeted delivery of TRAIL, immune inhibitory signaling may be abrogated 
or immune co-stimulatory signaling may be activated. Thus, scFv:TRAIL fusion proteins can have bifunctional 
potentiating effects on antitumor immune responses. Secondly, the carbohydrate-binding protein Gal-9 has a 
hitherto unrecognized cytotoxic activity towards melanoma as well as k-Ras mutated colon carcinoma, which 
does not affect normal cells. This induction of cell death was mediated by the inhibition of autophagy, a process 
that is important for the energy supply in certain (therapy resistant) cancers. Hence, Gal-9 or derivatives thereof 
may be potential new candidates for the treatment of human cancers, particularly therapy-resistant cancers 
characterized by high autophagic activity.
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Kanker is een verzamelnaam voor meer dan honderd verschillende kwaadaardige ziektes met als belangrijke 
overeenkomst de ongeremde deling van lichaamscellen en op enig moment uitzaaiing van de ziekte naar elders 
in het lichaam. Ondanks vele verbeteringen in de behandeling van kanker is de gemiddelde kans om deze ziekte 
te overleven de afgelopen jaren nog onvoldoende toegenomen. Dit komt naar voren in de overlevingscijfers 
van kankerpatiënten in Nederland, waarbij 5-jaar na de diagnose 51% van de patiënten nog in leven was in 1995 
tegen 62% in 2013. 
Er zijn uiteenlopende redenen waarom de behandeling van bepaalde vormen van kanker nog steeds 
ontoereikend is. Reeds lang is bekend dat in een gezwel kankercellen aanwezig zijn en/of ontstaan met 
toenemende resistentie tegen de huidige antikanker therapieën. Daarnaast is het de afgelopen jaren steeds 
duidelijker geworden dat kankercellen in staat om te ontsnappen aan vernietiging door het immuunsysteem. 
Enerzijds zijn kankercellen instaat zich bijna ‘onzichtbaar’ te maken voor cellen van het immuunsysteem, 
anderzijds zijn ze instaat het immuunsysteem actief tegen te werken. Ondanks deze ontsnappingsmechanismen 
bestaat er in verschillende kankertypes een duidelijke positieve correlatie tussen de mate van aanwezigheid 
van T-cellen in de tumor (TILs) en de prognose. Aanwezigheid van TILs draagt kennelijk nog wel bij aan het 
remmen van de tumorgroei, maar hun antikankeractiviteit is blijkbaar ontoereikend om de ziekte effectief te 
bestrijden. Daarom zijn verschillende immuuntherapeutische strategieën ontwikkeld om de antikankeractiviteit 
van de TILs te (her-)activeren. Deze aanpak heeft recent geleid tot doorbraken in moeilijk te behandelen kankers, 
zoals uitgezaaide ziekte bij melanoom (huidkanker), niercelkanker en niet-kleincellig longkanker. Dergelijke 
therapeutische effecten wordt echter waargenomen in een relatieve kleine subgroep van kankerpatiënten. Het 
(her-)activeren van een antikankerrespons is een veelbelovende strategie die nog verder doorontwikkeld moet 
worden.
Ondanks de bovengenoemde nieuwe ontwikkelingen blijven conventionele behandelingsmethodes als 
chirurgie, chemotherapie en/of radiotherapie essentieel bij de bestrijding van kanker. Helaas treedt daarbij 
vaak therapieresistentie op. Therapieresistentie kan het gevolg zijn van reeds aanwezige (intrinsieke) resistentie 
in (sommige) kankercellen of van resistentie die ontstaat tijdens de behandeling. Dit heeft tot gevolg dat, 
na een op het eerste gezicht succesvolle eerste behandeling, een resistente vorm van kanker terugkeert. 
Deze resistente kankercellen bevatten vaak mutaties in signaleringsroutes die celdood door conventionele 
behandelingsmethodes blokkeert. Daarom is het van groot belang om nieuwe antikankermiddelen te 
identificeren en/of te ontwikkelen die deze resistentie kunnen omzeilen. 
Deel I van dit proefschrift beschrijft de ontwikkeling van een nieuwe therapeutische strategie die kan 
bijdragen aan de (her-)activatie van een antikanker immuunresponse. Hier hebben wij een aantal zogenaamde 
scFv:sTRAIL fusie-eiwitten ontworpen en geproduceerd die bestaan uit een antilichaamfragment (scFv) dat 
genetisch is gefuseerd aan een oplosbare vorm van TRAIL (tumor necrosis factor-related apoptosis-inducing 
ligand), een molecuul dat selectief celdood induceert in kankercellen. Het algemene principe van deze strategie 
is dat het antilichaamfragment in een dergelijk scFv:sTRAIL fusie-eiwit een target herkent dat tot expressie komt 
op immuuncellen. Via dit antilichaamfragment bindt het TRAIL fusie-eiwit vervolgens specifiek aan een bepaalde 
immuuncel. Hierdoor wordt een immuuncel als het ware ‘bewapend’ met extra TRAIL moleculen, waardoor deze 
extra antikankeractiviteit krijgt. Tegelijkertijd draagt binding van het antilichaamfragment van het fusie-eiwit 
bij aan een verdere versterking van de antikanker immuunrespons, bijvoorbeeld door gerichte stimulatie van 
activatiesignalen of blokkade van inhibitiesignalen in deze immuuncellen. 
Deel II van dit proefschrift beschrijft de biologische en therapeutische effecten van het suiker-bindende 
eiwit Galectine-9 (Gal-9) op kankercellen en immuuncellen. Wij hebben ontdekt dat Gal-9 celdood induceert 
in verschillende kankertypes die verloopt via een alternatieve celdoodroute, waardoor therapieresistente 
kankercellen mogelijk toch gedood kunnen worden. Bovendien heeft Gal-9 verschillende effecten op het 
immuunsysteem. Wij ontdekten dat, afhankelijk van de dosering, Gal-9 T-cellen activeert of juist doodt.
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DEEL I: HET BEWAPENEN VAN IMMUUNCELLEN MET TRAIL
TRAIL is een eiwit dat behoort tot de tumor necrose factor (TNF) superfamilie. TRAIL komt tot expressie op de 
celmembraan van de zogenaamde ’natuurlijke killer’ (NK) cellen van het aangeboren immuunsysteem. TRAIL op 
NK cellen is essentieel voor de zogenaamde ‘kanker immuunsurveillance’ door dat het selectief apoptotische 
celdood induceert in kankercellen. Op deze wijze draagt TRAIL bij aan het voorkomen van de ontwikkeling van 
kanker. Apoptose komt van het Griekse Apo=af en ptosis=vallen, hetgeen dus vrij vertaald het ‘wegvallen’ van 
cellen door celdood betekent. Het belang van TRAIL voor kanker immuunsurveillance blijkt uit studies in muizen 
waarbij de expressie van TRAIL kunstmatig werd uitgeschakeld. Muizen zonder bescherming door TRAIL hadden 
een veel grotere kans om tumoren te ontwikkelen en een sterk toegenomen kans op uitzaaiingen. 
Vergelijkbare effecten werden waargenomen in normale (wildtype) muizen die behandeld werden met een 
TRAIL-neutraliserend antilichaam. TRAIL is dus een belangrijk molecuul voor het immuunsysteem met een sterke 
antikankeractiviteit. TRAIL komt ook tot expressie op andere essentiële immuuncellen zoals T-cellen, maar dan 
met een veel lagere expressie. In hoofdstuk 2 hebben wij daarom een strategie ontwikkeld om de hoeveelheid 
TRAIL op het celoppervlak van T-cellen te verhogen om zo hun antikankeractiviteit aanzienlijk te versterken. 
Om dit te bewerkstelligen hebben wij twee TRAIL fusie-eiwitten gemaakt, scFvCD3:sTRAIL en K12:sTRAIL, welke 
respectievelijk gericht zijn tegen de T-cel celmembraan eiwitten CD3 en CD7. Behandeling van (rustende) 
T-cellen met deze TRAIL fusie-eiwitten resulteerde in een sterke verhoging van het aantal TRAIL-moleculen 
op hun celoppervlak. In laboratoriumexperimenten vertoonden de met TRAIL-bewapende T-cellen een tot 
500 keer sterkere antikankeractiviteit in vergelijking met normale ‘onbewapende’ T-cellen. In een muis model 
voor darmkanker lieten wij zien dat behandeling met T-cellen die bewapend waren met scFvCD3:sTRAIL of 
K12:sTRAIL een sterke remming gaf in de uitgroei van tumoren, waarbij 4 van de 5 muizen in de scFvCD3:sTRAIL 
behandelde groep zelfs geheel tumorvrij bleven. Bewapening van T-cellen met scFvCD3:sTRAIL leidde tevens tot 
extra activatie van T-cellen via het anti-CD3 antilichaamfragment deel van dit fusie-eiwit. Het pro-apoptotische 
antikankereffect van scFvCD3:sTRAIL werd daarbij versterkt met de uitscheiding van celafbrekende enzymen 
door deze T-cellen. Bewapening van T-cellen met K12:sTRAIL vertoonde dit extra activatie effect niet en 
induceerde celdood uitsluitend via de activatie van apoptose. Samengevat zorgt het specifiek afleveren van 
TRAIL naar T-cellen door middel van scFvCD3:sTRAIL of K12:sTRAIL voor een toename in de antikankeractiviteit 
van T-cellen, waarbij de keuze van target op T-cel bepaalt welke antikankerfunctionaliteit wordt gestimuleerd.
In hoofdstuk 3 wordt voortgeborduurd op bovengenoemde strategie door ook granulocyten te bewapenen 
met TRAIL. De granulocyt is het meest voorkomende witte bloedceltype (60% van alle witte bloedcellen) en is 
belangrijk bij het opruimen van afwijkende (microbiële) cellen die zijn herkend door antilichamen (opsonisatie). 
De granulocyt gaat hierbij een interactie aan met antilichamen via antilichaamreceptoren die aanwezig zijn op 
hun celoppervlak. Vervolgens kan de granulocyt de tumorcel opeten via zogenaamde ‘antilichaam-afhankelijke 
fagocytose’. Fagocytose komt van het Griekse phagein=eten, kytos=holte en thans=cel, waarbij fagocytose 
dus het opeten van cellen betekent door ze in een holte van de etende cel (=fagocyt) op te nemen. Hoewel 
granulocyten erg effectief zijn in het opeten van tumorcellen, zijn ze vrij zwak in het direct doden van tumorcellen 
via zogenaamde ‘antilichaam-afhankelijke celdood’ (ADCC). Om de effectiviteit van ADCC van granulocyten 
te versterken hebben wij TRAIL fusie-eiwit scFvCLL1:sTRAIL ontworpen. ScFvCLL1:sTRAIL bindt aan C-type 
lectin-like molecule-1 (CLL-1), een eiwit dat aanwezig is op het celoppervlak van granulocyten. Het binden 
van scFvCLL1:sTRAIL aan granulocyten resulteerde in grote hoeveelheden TRAIL op het celoppervlak van deze 
immuuncellen. Wanneer granulocyten, kankercellen en scFvCLL1:sTRAIL tezamen werden geïncubeerd leidde 
dit vervolgens tot een sterke inductie van apoptotische kankerceldood. De behandeling van granulocyten 
met scFvCLL1:sTRAIL zorgde ook voor een toename van de ADCC activiteit van therapeutische antikanker 
antilichamen die reeds in de kliniek worden gebruikt, zoals rituximab en cetuximab. scFvCLL1:sTRAIL kan 
daarom mogelijk gebruikt worden als toevoeging aan bestaande antikanker antilichaambehandelingen. 
Het antilichaamfragment in de TRAIL fusie-eiwitten kan behalve voor targeting tevens gebruikt worden om 
signaalroutes van het betreffende targeteiwit naar wens te activeren of blokkeren. In hoofdstuk 4 hebben wij 
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de werkzaamheid van dit concept aangetoond door TRAIL te koppelen aan een antilichaamfragment dat gericht 
is tegen CD47. CD47 is een cruciaal ‘eet mij niet’ eiwit dat bindt aan SIRPα (signal-regulatory protein alpha) op 
fagocyten, wat leidt tot remming van fagocytose activiteit. Kankercellen misbruiken deze immuun checkpoint 
door extra veel CD47 op hun celmembraan tot expressie te brengen. Op deze wijze kunnen kankercellen 
voorkomen dat ze door fagocyten worden opgegeten. Uit eerdere studies is gebleken dat CD47-blokkerende 
antilichamen in staat zijn om de fagocytose van kankercellen te her-activeren. Bovendien versterkten CD47-
bokkerende antilichamen de werking van andere therapeutische antikanker antilichamen zoals rituximab en 
cituximab. Fusie-eiwit scFvCD47:sTRAIL werd ontworpen om enerzijds CD47 te blokkeren en anderzijds het 
TRAIL molecuul af te leveren op tumorcellen. Zoals verwacht induceerde scFvCD47:sTRAIL celdood in CD47-
positieve B-cel kankercellijnen en kwaadaardige cellen afkomstig van kankerpatiënten. Bovendien versterkte 
scFvCD47:sTRAIL de fagocytose werking van rituximab. Samengevat; scFvCD47:sTRAIL is in staat om de ‘eet mij 
niet’ signalering van CD47 op kankercellen te blokkeren, de fagocytose geïnduceerd door rituximab te versterken 
en om CD47-specifieke celdood te activeren in B-cel kankercellen. scFvCD47:sTRAIL heeft dus meerdere functies 
die gezamenlijk bijdragen aan het doden en opruimen van kankercellen. Fusie-eiwit scFvCD47:sTRAIL zou 
daarmee een goede toevoeging kunnen zijn om de effectiviteit van huidige antilichaamtherapieën bij kanker 
verder te optimaliseren. 
Hoofdstuk 5 bevat een overzichtsartikel over de onderlinge balans tussen het ‘eet mij niet’ eiwit CD47 en 
het ‘eet mij’ molecuul calreticuline, specifiek in de context van op TRAIL gebaseerde immuuntherapie. De balans 
tussen ‘eet mij’ en ‘eet mij niet’ signalen op het cel oppervlak van cellen bepaalt of een cel wordt opgeruimd 
door fagocyten of niet. In kanker is deze balans verstoord en slaat daardoor meer uit naar de ‘eet mij niet’ 
kant. Calreticuline is een fagocytose-bevorderend eiwit dat zich onder normale omstandigheden bevindt in 
bepaalde compartimenten binnen in een cel, al waar het verschillende functies heeft zoals het reguleren van 
intracellulaire calcium niveaus. Tijdens behandeling met bestraling, bepaalde soorten chemotherapie en TRAIL 
ontstaat een vorm van stress in de kankercel. Als gevolg hiervan wordt calreticuline naar het celoppervlak 
getransporteerd. Hier heeft calreticuline een ‘eet mij’ functie, waarbij het de fagocyten aanzet om de stervende 
kankercel op te eten. Het opeten van kankercellen is een belangrijke eerste stap in de activatie van een 
antikanker immuunrespons. De aanwezigheid van calreticuline op de buitenkant van stervende kankercellen is 
daarom een belangrijke vereiste voor de inductie van zogenaamde ‘immunogene celdood’, celdood die leidt tot 
de activatie van een immuunrespons. Bovendien blijkt uit onze data dat na behandeling met TRAIL calreticuline 
een interactie aangaat met dit immunologische effectormolecuul. Deze data is in overeenstemming met 
eerdere studies die lieten zien dat TRAIL (en andere leden van de TNF superfamilie) direct kunnen binnen aan 
calreticuline. De interactie van calreticuline met TRAIL/TRAIL-receptoren (en mogelijke andere TNF familie leden) 
zou daarom een mechanisme kunnen zijn waarmee de fagocytose van (kanker) cellen kan worden gereguleerd.
DEEL II: VERKENNING VAN DE ANTIKANKER EN IMMUNOMODULATOIRE WERKINGEN VAN GALECTINE-9 
Het tweede deel van dit proefschrift is gewijd aan verkennende studies naar de antikanker en 
immuunmodulatoire effecten van het suiker-bindende eiwit Galectine-9 (Gal-9). Hoofdstuk 6 bestaat uit een 
overzichtsartikel over de biologie van Gal-9, waarbij wordt ingegaan op de reeds bekende effecten van Gal-9 in 
kanker en auto-immuunziekten. Gal-9 is een veelzijdig eiwit dat het meest bekend is vanwege zijn remmende 
effecten op specifieke T-celtypes en remmende werking op celhechting. In hoofdstuk 7 beschrijven wij dat Gal-
9 de hechting van melanoom (huidkanker) cellen aan collageen-I (belangrijk eiwit in bindweefsel) inderdaad 
verminderd. Echter, nadere inspectie toonde aan dat dit fenomeen vooral het gevolg was van het feit dat Gal-9 
apoptotische celdood induceerde in deze melanoom cellen. Het percentage dode melanoom cellen na Gal-9 
behandeling correleerde sterk met de mate van afname in celhechting aan collageen-I. Dit toonde aan dat het 
primaire effect van Gal-9 de inductie van celdood is en niet remming van celhechting. Een andere belangrijke 
vinding is dat, in tegenstelling tot melanoomcellen, normale gezonde melanocyten niet gevoelig zijn voor deze 
effecten van Gal-9. Dit suggereert dat het celdood-inducerend effect van Gal-9 tumor-selectief is en mogelijk 
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zonder bijwerkingen is voor normale gezonde cellen.
In hoofdstuk 8 wordt beschreven dat Gal-9 een sterke antikankeractiviteit heeft tegen darmkankercellen, 
waarbij zowel cellijnen als cellen afkomstig van patiënten gevoelig waren voor deze behandeling. Behandeling 
met Gal-9 gaf een duidelijke toename in de overleving van muizen die waren getransplanteerd met 
menselijke darmkankercellen. Deze behandeling gaf geen zichtbare bijwerkingen in deze muizen. Ook in 
laboratoriumproeven liet Gal-9 geen toxische effecten zien op normale gezonde darmcellen. Een belangrijk 
punt in dit onderzoek was dat het type celdood dat door Gal-9 geïnduceerd werd niet via de standaard 
celdood routes verliep, zoals bij bijvoorbeeld apoptose. Apoptose routes zijn vaak gemuteerd in kankercellen 
hetgeen ze resistentie verschaft. De behandeling met Gal-9 resulteerde in de vorming van grote ‘bellen’ binnen 
in de kankercellen. Nadat Gal-9 in de kankercellen werd opgenomen hoopte Gal-9 selectief op in bepaalde 
organellen, de zogenaamde lysosomen, die daardoor enorm opzwollen. Daarnaast zorgde de opname van Gal-9 
voor de ophoping van autofagosomen, organellen die belangrijk zijn bij het uitvoeren van autofagie. Autofagie 
komt van het Griekse auto=zelf en fagie=eten. Autofagie is een cellulaire respons die leidt tot ‘zelf eten’, een 
gereguleerde manier om oude en beschadigde producten van de cel af te breken en te hergebruiken. Tijdens 
dit proces vindt een fusie plaats tussen autofagosomen en lysosomen, waarbij de autofagosomen dienen als 
vangnet voor de te recyclen producten en de lysosomen zorgen voor hun afbraak. Omdat bij autofagie energie 
wordt vrijgemaakt is deze route erg belangrijk voor celoverleving tijdens perioden van stress, zoals ook vaak 
in kankercellen voorkomt. Daarnaast is aangetoond dat therapie-resistente kankercellen vaak afhankelijk zijn 
van de autofagie route om te kunnen overleven. Dat autofagie inderdaad belangrijk was voor de werking van 
Gal-9 bleek uit studies waarbij wij de autofagie route blokkeerden met selectieve inhibitors. De blokkade van 
de autofagie route zorgde er voor dat de effecten van Gal-9 sterk werden verminderd. Na verder onderzoek 
ontdekten we dat de behandeling met Gal-9 de normale uitvoering van autofagie blokkeerde. Gal-9 blokkeert 
met name de fusie tussen autofagosomen en lysosomen. Een consequentie hiervan is dat de lysosomen en 
autofagosomen ophopen en opzwellen (hetgeen de vorming van de eerder genoemde ‘bellen’ verklaart) wat 
uiteindelijk resulteerde in celdood van de kankercel. Deze effecten van Gal-9 lijken sterk op die van chloroquine, 
een bekende autofagie remmer die tevens ophoopt in lysosomen. Een interessant feit is dat darmkankercellen die 
een bepaalde mutatie hebben in het zogenaamde k-Ras gen het meest gevoelig zijn voor Gal-9. Deze toename 
in gevoeligheid werd veroorzaakt door de hogere basale levels autofagie in deze kankercellen. Kankercellen 
die vooral gebruik maken van deze autofagie route (en er dus meer van afhankelijk zijn) zijn logischerwijs 
ook meer gevoelig voor de remming ervan. Deze vinding is vanuit therapeutisch oogpunt erg interessant, 
omdat darmkankers met een k-Ras mutatie over het algemeen slecht reageren op standaard therapieën en 
vaak resistent zijn tegen antilichaamtherapie. Daarnaast is aangetoond dat therapie-resistente kankers vaak 
afhankelijk zijn van autofagie voor hun overleving. Gal-9 is daarom een potentieel nieuw antikankermiddel om 
darmkankers met een k-Ras mutatie te behandelen en kan mogelijk therapie-resistente kankercellen doden 
door autofagie te remmen.
Naast de celdodende eigenschappen van Gal-9 (zoals beschreven in dit proefschrift) is Gal-9 in de literatuur 
vooral bekend vanwege zijn immuunmodulerende eigenschappen. Zo induceert Gal-9 celdood in een specifiek 
type T-cellen, de T-helper 1 (Th1) cellen door te binden aan TIM-3 (T-cell immunoglobulin and mucin domain–
containing-3). Echter, wij rapporteren in hoofdstuk 9 dat bij een lage dosering Gal-9 naast celdood tevens T-cel 
activatie werd geïnduceerd, welke gekarakteriseerd werd door een toename in celdelingen en overleving van 
T-cellen. In tegenstelling tot eerdere publicaties van andere onderzoekers bleek dit effect van Gal-9 op T-cellen 
onafhankelijk van TIM-3 te zijn. Gal-9 induceerde vooral voor celdeling van de zogenaamde CD4+ T-cellen en 
stimuleerde de ontwikkeling van deze cellen tot Th1 cellen. Wanneer vooraf geactiveerde T-cellen werden 
behandeld met Gal-9 had dit geen invloed op hun celdeling, maar zorgde er wel voor dat deze T-cellen zich 
hoofdzakelijk ontwikkelden tot het CD4+ Th1 type. Deze verschillende effecten van Gal-9 bij verschillende 
doseringen geven aan dat het effect van Gal-9 behandeling afhangt van de concentratie die beschikbaar is en 




Het selectief afleveren van TRAIL naar immuuncellen met behulp van op antilichaam gebaseerde TRAIL fusie-
eiwitten versterkt de antikankeractiviteit van deze cellen. Tegelijkertijd kan er, afhankelijk van het gebruikte 
antilichaamfragment, extra antikankeractiviteit aan het fusie-eiwit worden meegegeven door signaleringsroutes 
die het immuunsysteem remmen te blokkeren of juist door immuunstimulerende signaleringsroutes te 
activeren. scFv:sTRAIL fusie-eiwitten die gericht zijn tegen immuuncellen zijn dus in staat om de antikanker 
immuunrespons op meerdere manieren tegelijkertijd te versterken en zouden dus een goede toevoeging 
kunnen zijn aan de huidige antikanker therapieën. Daarnaast hebben wij aangetoond dat Gal-9 een voorheen 
onbekend effect op kankercellen heeft, namelijk het induceren van kankerceldood. Daarnaast heeft Gal-9 geen 
negatief effect op normale gezonde cellen. Behandeling met Gal-9 zorgt voor de inductie van kankerceldood 
door het remmen van de autofagie route, een route die belangrijk is voor de overleving van (therapie-resistente) 
kankercellen. Gal-9 is daarom een mogelijk nieuw geneesmiddel om kankercellen die therapie resistent zijn 







En dan nu het dankwoord, waarschijnlijk het meest gelezen hoofdstuk van een proefschrift en misschien ook 
wel het meest moeilijke, je zou maar iemand vergeten!? Daarnaast ook een belangrijk hoofdstuk, want hoe 
hard je ook werkt, hoe slim je ook soms denkt te zijn, onderzoek doe je nooit alleen! Omdat ik ‘pas’ na 6 jaar 
ga promoveren is de lijst van mensen die ik moet bedanken ook behoorlijk lang geworden. Laat ik dus maar 
gewoon beginnen, dan zien we wel waar ik strand!
Om te beginnen natuurlijk mijn promotor Prof. Dr. Wijnand Helfrich. Beste Wijnand, ik weet nog goed 
dat ik bij jou op het chirurgisch onderzoekslab stage kwam lopen. Destijds waren we nog een ‘mannen groepje’ 
met Edwin, Douwe, Yunwei, Marco en Marco. Ik had het erg naar mijn zin bij jullie en aan het einde van mijn 
stage vroeg jij of ik ook promotieonderzoek bij jou in de groep zou willen doen. Promoveren? Daar had ik nog 
nooit over nagedacht en mijn eerste reactie was dan ook “maar dat kan ik toch helemaal niet?”. Ik ben jou erg 
dankbaar dat je mij dit aanbod destijds gedaan hebt, want ik kon het blijkbaar toch, en vond het echt meer 
dan leuk! Dit kwam natuurlijk ook mede dankzij jouw enthousiasme voor de wetenschap! Je hebt altijd goede, 
vernuftige ideeën en ook meestal een oplossing wanneer het even wat minder gaat. Zo heeft jouw uitspraak 
“de natuur liegt nooit, die doet geen gekke dingen!” mij vaak geholpen om door te zetten wanneer er in mijn 
optiek vreemde en onverklaarbare resultaten uit mijn experimenten kwamen. Dat er momenteel nog steeds 
mooie papers gepubliceerd worden over TRAIL fusie-eiwitten die altijd ‘improved, novel, superior’ zijn (van jou 
leerde ik dat je best een beetje mag opscheppen in je abstract), bewijst wel dat dit een erg goed idee van 
jou was. Ook het eerste deel van mijn proefschrift bestaat uit onderzoek naar TRAIL fusie-eiwitten, in dit geval 
ingezet om immuunresponsen tegen kankercellen te versterken; de mogelijkheden lijken eindeloos. Ook na de 
4 jaar van mijn promotie onderzoek ben ik nog 2 jaar bij het COL ‘blijven hangen’, gezellig op mijn vertrouwde 
stekkie. Ook fijn dat ik in deze periode samen met jou je benoeming tot hoogleraar heb kunnen vieren. Vooral 
het optreden met je band vond ik erg leuk, super om dat eens te zien! Ik wens jou nog vele wetenschappelijke 
jaren als professor met veel en mooi onderzoek! 
Vervolgens natuurlijk mijn co-promotor Dr. Edwin Bremer. Beste Edwin, als er iemand slim is, dan ben jij het 
wel! Waarschijnlijk begin je nu weer te lachen wanneer je dit leest, want dat doe je altijd als ik zeg dat je slim bent. 
Maar neem nou maar eens van mij aan, het is toch echt zo! Ik heb echt heel veel van jou geleerd over proeven 
doen en verzinnen, maar ook over alle dingen die je daarnaast allemaal nog moet kunnen als wetenschapper, 
zoals data uitwerken, papers schrijven, praatjes geven, samenwerkingen opzetten en grants schrijven. Je houdt 
van hard werken en de experimenten gaan je nooit snel genoeg. Heb ik 5 experimenten gedaan, dan vraag jij 
waarom ik de 6e niet gedaan heb. Oké, dat was soms best wel vervelend, maar met zo’n houding kom je wel 
het snelst tot een complete paper! Ook spreekt het voor je enorme enthousiasme. Vaak als ik na 17:00 nog 
experimenten aan het doen was had ik al ruim voor ik thuis was een email van jou ontvangen met slechts één 
woord: “en!?”. Dit heeft mij altijd enorm aangemoedigd om de data meteen netjes uit te werken en het dezelfde 
avond nog naar je te versturen. Ook wist ik als ik mooie data had niet hoe snel ik naar je kantoor moest rennen, 
blij zijn met de resultaten en dan weer nieuwe plannen smeden. Of in het geval van Galectine-9, vaak weer een 
hypothese verwerpen. Vooral die receptor, hoeveel mogelijke kandidaten we daar al niet voor hebben gehad? 
Hopelijk vinden we die ooit in de toekomst. Ik wens je veel succes met je eigen groep ‘immunohematologie’ die 
je in mei 2016 begonnen bent, waarvan ik hopelijk nog een tijdje deel uit zal maken.
Eén van de beste analisten die er is, Douwe Samplonius. Zoals ik vaak zeg “iedereen wil wel een Douwe op 
het lab”. Van jou leerde ik alle basisvaardigheden die ik nodig had om mijn experimenten te doen. En de oh zo 
belangrijke les: vergeet de juiste controles niet! Daarnaast kon jij mij altijd vertellen waar ik bepaalde reagentia 
kon vinden. Hoewel onze koelkasten en vriezers er vaak wat chaotisch uitzagen (laten we het daar maar op 
houden) wist jij toch altijd waar een bepaald antilichaam stond, of welke kleur en vorm het potje had, hetgeen 
ook al enorm scheelt met zoeken. Ook wist jij mij altijd te helpen met het maken van de juiste keuzes tijdens een 
experiment. “Ik denk dat …. wel goed is om te checken, wat denk jij!?”. Als Douwe het ook een goed idee vond, 
nou dan was het een goed idee en werd het experiment zo ingezet. Hoewel het al een paar jaar terug is herinner 
ik mij nog goed die keer dat Edwin een library van inhibitors had aangeschaft, of we die even allemaal konden 
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testen. Platen en platen vol met cellen hebben we behandeld. Ik denk dat toen mijn ‘pipeteer-eelt’ gevormd is. 
Ook hadden we altijd veel lol in de celkweek, getuige ook een van mijn stellingen “you can not count on the cell 
counter”. Hoe vaak we dat ding wel niet hebben moeten spoelen en ontstoppen!? En gezellig liedjes zingen, ook 
altijd leuk, “pico bello pico bello”… Of meer in de draaiorgel stijl? Ik bewaar het draaiorgel diploma dat ik door 
het hanteren van jouw ‘Sientje’ heb verkregen met trots! Dingen die ik het vaakst tegen je gezegd heb zijn denk 
ik wel: “koffietijd!?” (elke ochtend), “moet jij nog FACSen?” (elke middag), “oant moarn!” (elk einde van de dag) en 
“beugels met patat” (elke vrijdag). Dag in dag uit in de celkweek, ja ik woonde ongeveer in de celkweek. Het is 
dan ook niet meer dan terecht dat jij mijn paranimf bent bij mijn promotie en ik vind het dan ook geweldig dat 
je dat wilt zijn. Heel erg bedankt voor alles!
Dr. Marco de Bruyn, beste Marco, toen ik als student bij het COL kwam was jij daar al druk bezig met 
je promotie onderzoek. Ik kijk altijd met een erg goed gevoel terug op die tijd bij het COL, met z’n allen vol 
enthousiasme hard werken, als een hecht team. Samen deden we de muisexperimenten van de T-cel paper en 
ook de eerste experimenten van Galectine-9 deden we in die tijd. Het werken met de fluorescentie microscoop, 
en dan vooral de confocal, leerde ik van jou. Ook al heb ik best wat aardige plaatjes gemaakt, jij blijft toch wel de 
confocal man! Over plaatjes gesproken, jij bent ook de beste in het maken van mooie figuren bij reviews en het 
‘alles omvattende conclusie plaatje’ in papers. Vele artikelen waaraan ik heb gewerkt zijn door jou figuren stukken 
mooier geworden, waarvoor dank! In de kweek was naast pipeteren het zingen van liedjes wat jij het meeste 
deed. Altijd wist je het weer voor elkaar te krijgen om één of ander deuntje in mijn geheugen te planten, ja ik heb 
vaak met ‘oorwurmen’ rondgelopen door jouw toedoen. Hierbij heb ik ook van jou geleerd dat kerstliedjes altijd 
kunnen, zelfs wanneer het hoogzomer is! Inmiddels zit je alweer een aantal jaar bij de gynaecologie, maar we 
komen elkaar natuurlijk nog regelmatig tegen. Ik hoop dat wij in de toekomst ook samen zullen blijven werken 
en wens jou veel succes en plezier in de wetenschap voor de toekomst!
Dan de PhD studenten waarmee ik de afgelopen jaren veel gepipetteerd heb; Yuan, Djoke, Peter, Iris en 
Ilona. Dr. Yuan He, Dear Yuan, I clearly remember when you came to the Netherlands and gave your first talk 
to our group. You kept repeating (at least that is how I remember it) that you were “very eager to learn new 
techniques and to become a good scientist”. Well, you did it! You managed to learn all kinds of techniques, and 
in October last year you successfully obtained your PhD degree. I really enjoyed working with you in the flow 
cabinet, but also outside working hours we had lots of fun. Like that time that you cooked Chinese food for the 
whole group to have dinner at Edwin’s place. I assisted you with preparing the food and you asked me to cut 
some vegetables. I will never forget the huge knife you gave me to complete my task and that you told me you 
took it from China (I am still wondering how you travelled with such a big knife…). And of course we had some 
drinks (and some more) during the dinner. Having drinks with you was always fun! You were always the first one 
admitting feeling a little dizzy, but in the end it was always you, me and Edwin who had to finish the bottles 
of wine. Therefore, I am very happy that you are still in the Netherlands, so we can do some more experiments 
and have some more drinks together. Maybe it is also time to learn some more Dutch now? It is very funny you 
already started to use ‘nee’ instead of ‘no’. Good luck with all your future experiments!
Beste Djoke Hendriks, jou kwam ik voor het eerst tegen op de gang samen met Wijnand die jou aan 
het rondleiden was. Snel daarna kon je dan daadwerkelijk bij ons aan de slag op het melanoom project. We 
begonnen met het afmaken van een paper over ‘the-protein-that-must-not-be-named’ (even een verwijzing 
naar je grote liefde voor Harry Potter!). Het ging allemaal best voorspoedig, al kregen we uiteindelijk toch de 
nodige tegenslagen te verwerken. Echter lieten wij ons niet uit het veld slaan en begon jij vol goede moed aan 
het onderzoek naar scFvPDL1:sTRAIL. Dit was een groot succes en twee weken voor mijn promotie zal jij dan ook 
jouw proefschrift verdedigen! Naast pipeteren houden wij beide ook van dwarsfluit spelen. Zo zijn we samen 
naar de houtblazers dagen van het Prins Claus Conservatorium geweest. Wat was het eng om voor een hele zaal 
individueel te spelen, maar we hebben dat toch maar even gedaan! Inmiddels ben je naar Leiderdorp verhuisd. 
Ik wens jou een goede toekomst in het westen des lands!
“Kijk wie ik gevonden heb op de introductieochtend?”. Terwijl Djoke dit zei stapte jij, Peter van Bommel, 
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mijn kantoor binnen, onze nieuwe PhD student. Vanzelfsprekend hebben we veel samen op het lab gezeten. 
Dit was het leukste wanneer we a capella klassieke muziek ‘zongen’. Zo hard mogelijk alle partijen van ‘eine 
kleine nachtmusik’ ten gehore brengen terwijl we de maat aangaven door tegen de flow aan te slaan. Allebei 
bespelen we een blaasinstrument, al is de jouwe toch ietsje groter dan de mijne, en we konden dan ook tijden 
praten over muziekstukken en hoe je iets zou moeten spelen (in ieder geval niet zo stompzinnig hard als de 
buurman doet tijdens een pianissimo stuk, haha!). En ja, waar konden we het eigenlijk niet over hebben? Ik heb 
bewondering voor jouw enorme hoeveelheid aan kennis. Welk onderwerp je ook aansnijdt, jij hebt altijd wel wat 
wetenswaardigheden paraat. Daarnaast ben je dol op eten. Peter heeft altijd honger en ik ken jou dan ook als 
iemand die rondloopt met een compleet bruin brood en een pakje kokosbrood om de boel te beleggen. Op het 
moment dat ik zal promoveren is jouw promotietijd ook zo ongeveer achter de rug. Ik wens je veel succes met 
het afronden van je proefschrift!
Iris Koopmans, jij begon met je project iets voor de kerst weet ik nog. Dat was meteen erg gezellig zodat 
ik niet alleen in de flow zat tijdens de vakantiedagen. Toen we net een beetje aan je gewend waren vertrok je 
voor een tijdje naar Nijmegen om daar interessante experimenten te doen. Je kwam terug met een bak data 
en enthousiasme, waarna we weer vrolijk verder werkten in de celkweek. Een echt gezamenlijk project hebben 
we niet echt gehad, maar we deelden wel heel veel materialen. “Wie haalt er vandaag bloed? Mag ik ook wat 
PBMCs? Gebruik je de pellets ook? Wil je met of zonder CFSE”? Hoewel er veel Friezen zaten in de groep, was het 
bij jou wel het duidelijkste te merken. “Ien, twa, trije, en dan dizze derby”. Door jou ‘hardop nadenken’ kwam ik 
er achter dat ik tegenwoordig niet meer in het Fries denk, een best vreemde gewaarwording! Op het moment 
dat ik dit schrijf zal het wel een beetje onwennig zijn in de kweek nadat zoveel collega’s kort na elkaar klaar en 
vertrokken zijn. In ieder geval (tijdelijk) meer werkplek voor jou! Ik wens je veel succes en plezier bij het voltooien 
van je project!
De laatste PhD student die in de groep werd aangenomen toen ik er zat was Ilona Schepel. We hadden 
het altijd erg gezellig in de flow en kletsten wat af. Zo hebben we vele B-cel leukemie patiënten samples 
samen opgewerkt om vervolgens fagocytose experimenten te doen. Vaak kwamen die samples laat op de dag, 
waardoor er nog ver na 17:00 gemeten moest worden. Om elkaar aan te moedigen schreven we briefjes voor bij 
de FACS: “Succes met meten en onthoud: je hebt WEL zin!!”. Ook was jij mijn mede ‘tukkel’ op het lab. Ik ben altijd 
vrij onhandig qua inschatten waar mijn eigen ledematen zijn, vergeet dat ik schouders heb wanneer ik door 
de deur loop en struikel nog over mijn eigen voeten. Jij begreep dit en showde dan ook regelmatig de blauwe 
plekken die jij had opgedaan door het ‘tukkel’ zijn. Helaas heb jij door omstandigheden besloten jouw project 
niet af te maken. Ik vond dit natuurlijk erg jammer, maar wel een moedige beslissing. Ik wens jou dan ook heel 
erg veel succes en plezier met je nieuwe baan en veel geluk voor de toekomst.
Naast de directe collega’s had ik mijn werk niet kunnen doen zonder Jacco Zwaagstra. Beste Jacco, mijn 
eerste indruk van jou was niet zo best, haha. Ik kwam als masterstudent bij jou op het lab, net nadat ik een 
HBO opleiding had afgerond. Zoals iedereen moest ik de pipeteercursus doen. Steeds week dezelfde waarde 
af in mijn ijklijn. Volgens mij was de oplossing ervan dus niet goed, maar volgens jou kon ik niet pipeteren. 
Laten we maar in het midden houden waaraan het lag. Uiteindelijk slaagde ik voor de cursus (na het maken 
van een nieuwe ijkoplossing, zie je wel!?) en kon ik aan de slag. Als hoofdanalist had jij de touwtjes in handen 
op het ‘grote lab’  en die hield je meestal goed strak! “Wil je de blot tafel opruimen? Van wie is die zooi in de 
zuurkast? Hoe vaak moet ik nog zeggen dat je niet met twee handschoenen mag pipeteren”? Tsja, je was soms 
best wel irritant. Maar eerlijk is eerlijk, het COL lab is altijd netjes en overzichtelijk, zeker als je het vergelijkt met 
andere labs, hetgeen ook prettig werken is. Ook verzorgde jij altijd de bestellingen, echt super fijn! Je kiest een 
antilichaam, mailt Jacco en vervolgens wordt het product geleverd. Niet op tijd? Jacco belt er achteraan. Heel 
erg bedankt voor deze goede service! Daarnaast wil ik jou ook bedanken dat je mij zo netjes en rustig bij de SEH 
hebt gebracht toen ik een hoofdwond opliep na een botsing met de incubator. Terwijl de collega’s die bij het 
voorval aanwezig waren allemaal lichtelijk in paniek raakten, bleef jij kalm. Ook al zal ik straks op een andere 
afdeling werken, ik hoop dat ik altijd welkom blijf op het COL!
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Dan nog de andere ‘stamgasten’ van het COL, Janneke, Jelle, Petra en Suzanne. Hoewel we niet echt bij 
dezelfde groep zaten hadden we natuurlijk wel dagelijks met elkaar te maken en kon ik altijd bij jullie terecht voor 
vragen. Janneke Wiersema, jij weet alles van coupes kleuren. Zo ging je ook aan de slag met mijn weefsels als 
projectje voor een student bij ons op het lab. Hoewel we de kleuringen tot op heden nog niet hebben afgemaakt 
wil ik je zeker bedanken voor de pilotstudie die je gedaan hebt. Jelle Adelmeijer, jij hoort voor mij ook echt 
bij het COL. Vrijwel altijd als ik op het ‘grote lab’ aan het werk was liep jij er ook rond. Hoewel ik meestal in de 
kweek zat kwam dit niet erg vaak voor. Je vroeg dan ook wel eens gekscherend of ik ontsnapt was, of misschien 
een dagje buiten mocht spelen van de baas? Bedankt voor de gezelligheid! Petra Ottens, onze experimentele 
wegen kruisten elkaar niet zo vaak. Wel heb jij mij meerdere keren uit de brand geholpen met PCR platen en 
dergelijke wanneer ik één van mij sporadische PCR experimentjes deed, waarvoor dank! Suzanne Veldhuis, 
jij bent het ‘dierenmeisje’ van het COL. Jij hebt mij dan ook geholpen bij mijn muisexperimenten tijdens het 
verzamelen van de weefsels, waarvoor dank!
Ook zeker nog een woord van dank aan de oudmedewerkers van onze groep. Hoewel ze het niet zo lang vol 
hebben gehouden bij het COL als ik, hebben ze zeker bijgedragen aan mijn experimenten. Let’s start with Prof. 
Dr. Yunwei Wei. Dear Yunwei, when I came as a student to the lab, you were already there. Together we worked 
a lot in the flow cabinet, but also did many Western blots. At that time we still had to develop our films in the 
dark room and I remember you were always joking that you could smell the bands. Also the very first Galectin-
9-related Western blots were made with your help. Thanks for your help and I wish you all the best with you 
research group in China. Dr. Marco Verkaik, beste Marco, jij gaf altijd de voorkeur om Fries met mij te praten, dus 
laat ik dan ook mijn dank aan jou in het Fries uitspreken (mijn excuses alvast voor de eventuele spellingsfouten/ 
flaters). Doe’t ik op syk wie nei in stage plak wêr ik wurkje koe yn it kanker ûndersyk yn kombinaasje mei in vivo 
wurk, kaam ik by Wijnand terjocht. Hy fertelde my dat ik krekt op it goeie momint kaam wie, der soe gauw in 
mûzen eksperiment begjinne ûnderlieding fan dy. Do waarst dus myn stage begelieder en tegeare wurken we 
oan it Foscan project. Dat wie al wat siz! De mûzen moasten yn it tsjuster ferblieuwe en ek it in vitro wurk waard 
dien mei alle ljochten út. Gauw nei myn stage hawsto in carrière switch makke, en bist begûn as ûnderwizer yn 
Ljouwert. Neffens my in goeie keuze west, do hast it no bêst nei it sin! Ast wer ris op it UMCG bist foar in studint 
drinke we wol wer ris in bakje thee! Dan de analist die ik altijd ‘mijn analist’ noemde, omdat je op hetzelfde 
KWF project zat als ik; Jurjen Gerssen. Beste Jurjen, dat ik jou altijd graag commandeerde had je geheel aan 
jezelf te danken. Ik leerde jou namelijk kennen op het HBO biotechnologie op het van Hall waar jij meehielp bij 
de introductieweek van de eerstejaars. De hele nacht moest ik met mijn nieuwe studiegenoten door het bos 
ploegen tijdens een soort van dropping/speurtocht, bang om gepakt te worden door de mannen in het busje, 
waarvan jij er dus één was. We sprongen zelfs in greppels om aan jullie te ontkomen, niet wetende dat jullie een 
nachtkijker hadden, flauw hoor! Omdat jij toen baasje speelde over mij heb ik dat vervolgens 4 jaar gedaan over 
jou. Oké, dat viel natuurlijk reuze mee. We konden het goed vinden en ook nadat ‘ons’ project was afgelopen 
hebben we contact gehouden. Je hebt in je tijd op het lab vooral heel veel constructen gemaakt. Of nee niet 
heel veel, super veel, ontelbaar veel. Ik zei vaak dat je wel een museum kon beginnen met de verzameling 
verschillende constructen die je had. Vele zijn getest in het lab, maar er liggen waarschijnlijk ook nog wel een 
aantal mooie fusie-eiwitten te wachten tot hun tijd daar is. Toen we samen op dat KWF project zaten beloofde 
ik jou dat jij mijn paranimf zou zijn. Hoewel je nu al een hele tijd bij de gynaecologie werkt, houd ik mij graag 
aan mijn woord. Ik vind het dan ook erg leuk dat jij als ‘mijn analist’ ook mijn paranimf bent, zodat ik je nog één 
dagje extra kan commanderen! Een andere analist die veel constructen heeft gemaakt is Marleen Rinket. Beste 
Marleen, dat wij samen pipeteerden lijkt een eeuwigheid geleden. Het is dan ook al bijna 6 jaar terug dat jij de 
groep verliet en naar de gynaecologie ging (waar je nu samen met Jurjen zit). Toch herinner ik mij vooral onze 
gesprekken nog goed. We hadden beide nieuwe ontwikkelingen in de liefde en konden elkaar daarin helemaal 
vinden. Hoe grappig is het dan om nu terug te kijken en te zien dat de hoofdrolspelers in onze ‘soap’ (zoals we 
het zelf gekscherend noemden) nu nog steeds onze partners zijn en we inmiddels beide een zoontje hebben! 
Bedankt voor je hulp, zowel op wetenschappelijk als op liefdesgebied! En dan als laatste, Hans Westra. Toen jij 
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bij ons op het lab kwam waren we net bezig met het afronden van de scFvCLL1:sTRAIL paper. Er moesten nog 
wat chromatografie experimentjes gedaan worden en laat dat nou net iets zijn waar jij heel goed in bent! Al 
gauw hadden we de benodigde data, waarvoor dank. Zoals velen op het COL lab had ook jij een passie voor 
muziek. Zo was jij vroeger de drummer van de Kast. Zij oefenden altijd op een steenworp afstand van mijn 
ouderlijk huis in Feanwâlden dus wie weet heb ik je wel eens gehoord!? Je bleef echter niet lang op ons lab en 
na een jaar ging je terug naar je oude stekkie. Ik hoop dat je het daar naar je zin hebt!
Dan wil ik ook graag alle PhD studenten bedanken met wie ik de afgelopen jaren flow, labtafel of kantoor 
heb gedeeld. Aangezien het bij het COL altijd een drukte van jewelste is, durf ik het niet aan om alle namen hier 
één voor één te noemen, ik zou er teveel vergeten. Daarom dank aan iedereen die in de periode 2010-2016 PhD 
student was op het COL. Als laatste betreffende het COL wil ik nog een aantal studenten bedanken die in de 
loop der tijd bij ons in de groep hebben gezeten. Beste Evelien Boerma, Emily Sigar, Lizanne Wiegers, Mark 
Slotemaker, Jan Otto Schutte, Maria Piecuch en Naomi Hofsink. Naast dat jullie experimenten voor de groep 
uitvoerden, heb ik dankzij jullie ook vaardigheden weten te verkrijgen op het gebied van begeleiding. Hartelijk 
dank daarvoor!
Naast Marco wil ik nog een aantal andere mensen van de gynaecologie bedanken. Om te beginnen Prof. 
Dr. Hans Nijman. Beste Hans, na mijn 4 jaar als PhD student kon ik aan de slag als postdoc op het project 
dat Edwin en jij samen hadden op het gebied van T-cel co-stimulatie. Hoewel het een tijdje duurde voor de 
resultaten naar believen waren is het ons uiteindelijk toch gelukt! Ook had ik tijdens deze periode van 2 jaar de 
tijd om een aantal papers die nu ook in dit proefschrift staan af te maken. Bedankt dat ik hiervoor de tijd kreeg 
en bedankt voor de samenwerking! Dr. Marloes Gooden, beste Marloes, dit jaar is het alweer 4 jaar geleden dat 
ik jouw paranimf was tijdens jouw promotie. Voordat het zover was hebben we samen veel tijd doorgebracht 
in de kweek die door ons was omgetoverd tot ‘karaoke kweek’. Seven nation army van de White stripes was één 
van onze favorieten al kon niks tippen aan het bananenlied. Om jouw zenuwen te bedwingen hebben we deze 
zelfs nog ten gehore gebracht in het zweetkamertje vlak voor jouw promotieceremonie. Momenteel ben je je 
aan het specialiseren tot patholoog. Ik wens je veel plezier met alle weefsels! Bij de samenwerking tussen het 
COL en de gynaecologie heb ik ook experimenten gedaan en data geanalyseerd met Dr. Maartje Wouters. 
Beste Maartje, jij bent echt het meisje van de kleuringen, TMA’s en Kaplan Meijer curves, bedankt voor je hulp 
daarbij. Inmiddels zit je in Canada waar je het hopelijk erg naar je zin hebt! Daarnaast wil ik van de gynaecologie 
verder nog bedanken Annechien Plat, Fenne Komdeur, Florine Eggink en Kim Merkus-Brunekreeft voor 
de samenwerking, hoofdzakelijk betreffende de primaire ovariumcarcinoom samples. In dit opzicht ben ik ook 
dank verschuldigd aan Harry Klip en Harry Pijper voor het logistieke gedeelte van de samples. Allen bedankt!
Veel van mijn experimenten waren ook niet mogelijk geweest zonder de hulp van een aantal facilitaire afdelingen 
van het UMCG. Ik wil van het flow cytometry center bedanken Henk Moes, Geert Mesander en Roelof Jan van 
der Leij. Beste Roelof Jan, ik kende jou al een hele tijd, omdat we samen de opleiding biotechnologie op het 
van Hall hebben gedaan. Bedankt voor het sorten van mijn celletjes! Beste Henk, ik wil jou vooral bedanken 
voor de leuke gesprekken die we hadden tijdens het sorten, dat maakte het wachten een stuk minder saai! 
Daarnaast staat mijn aanbod om je hetzelfde kapsel als Daan te geven nog steeds. Verder wil ik Klaas Sjollema 
van het UMIC center bedanken. Beste Klaas, zonder jouw hulp waren de confocal plaatjes in dit proefschrift niet 
zo mooi geworden als ze nu zijn. Daarnaast wil ik iedereen van het CDP bedanken die heeft bijgedragen aan het 
succesvol verlopen van mijn in vivo experimenten.
Naast collega’s van het UMCG wil ik ook nog een aantal mensen bedanken van buiten dit instituut. Let’s start 
by thanking our Japanese colleagues from Kagawa University Prof. Dr. Mitsuomi Hirashima, Prof. Dr. Toshiro 
Niki and Prof. Dr. Nozomu Nishi. By supplying us with the recombinant and stable form of Galectin-9 you were 
quite important for the work involving this lectin. In addition, your Galectin-9 expertise was very helpful during 
all the discussions we had about our data. I want to thank all of you for your help and hope we can continue 
our collaboration. I also want to thank Dr. Paul Eggleton from Exeter university, United Kingdom. Dear Paul, 
we first met during the thesis defense of Marco de Bruyn and talked some about the first Galectin-9 paper I was 
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drafting at that time. Now, five years later, we have worked together on papers involving Galectin-9, calreticulin 
and CD47, for which I want to thank you for your input. Currently we are still working on some papers together 
and I hope we will successfully complete them in the near future! For the calreticulin work, we also worked a 
lot together with Prof. Dr. Marek Michalak from Alberta University, Canada. Dear Marek, thank you for your 
expertise regarding calreticulin and for your help with the calreticulin review we wrote together. 
Uiteraard wil ik ook mijn dank uitspreken aan de leden van de leescommissie die mijn manuscript hebben 
doorgespit en goedgekeurd; Prof. dr. Tanja de Gruijl, Prof. dr. Gerwin Huls en Prof. dr. Frank Kruyt. Ik hoop 
dat jullie van mijn proefschrift hebben genoten en nu net zo erg Galectine-9 fan zijn als ik dat ben!
Ook al was mijn eigenlijke promotieperiode al verlopen ten tijde dat ik bij de hematologie kwam, toch wil 
ik een aantal mensen bedanken. Dit vooral voor de hulp bij het onderzoek dat is voortgevloeid uit het werk als 
beschreven in dit proefschrift en de mogelijkheid om mijn proefschrift daadwerkelijk af te ronden. Ik beschouw 
de komende alinea dan zowel als een dankwoord als een aanmoediging voor de toekomstige research. Hoewel 
ik Prof. Dr. Gerwin Huls net al genoemd heb voor de beoordeling van mijn manuscript, wil ik ook graag nog 
een persoonlijk woord tot hem richten. Beste Gerwin, jij was vrijwel meteen enthousiast over het Galectine-9 
werk dat ik gedaan had. Ook voor de behandeling van hematologische kankers zou deze lectine een oplossing 
kunnen zijn, hetgeen ik graag ga onderzoeken de komende tijd. Ook bedankt voor de klinische input die je aan 
ons onderzoek geeft. Ik denk dat het erg belangrijk is dat onderzoekers en clinici veel samenwerken om tot 
optimale ideeën en resultaten te komen. Ik verheug mij dan ook op onze samenwerking in de toekomst. Dan 
wil ik het woord nog even richten tot Harm Jan Lourens, Martijn Vlaming en Renée Bouwstra, mijn huidige 
collega’s die samen met Yuan en Edwin de groep ‘immunohematologie’ vormen. Beste Harm Jan, jou kennen 
we natuurlijk al een hele tijd. Toen ik begon op het COL als student was jij daar ook bezig met je stage. Samen 
hebben we destijds heel wat uurtjes in de flow doorgebracht! Ik hoop dat we dat de komende tijd ook met veel 
plezier zullen doen. Daarnaast is het super fijn om iemand in de groep te hebben die dol op Western-blotten is, 
daar zal ik vast nog wel eens gebruik van maken. Beste Martijn, sinds september 2016 ben jij PhD student op 
het co-stimulatie project. Aangezien ik mij ook 2 jaar heb bezig gehouden met hetzelfde onderwerp vind ik het 
natuurlijk erg leuk dat jij deze lijn voortzet. Uiteraard ga ik er vanuit dat je fantastische resultaten zult behalen. 
Je hebt nog een hele lange tijd pipeteren voor je, geniet er van, want voor je het weet zijn de 4 jaar voorbij! 
Beste Renée, momenteel ben jij student, een heel enthousiaste mag ik wel zeggen! Ik denk daarom dan het ook 
helemaal goed zal komen met de MD/PhD aanvraag die je wilt gaan doen. Hopelijk kun je dan nog een aantal 
jaar bij ons blijven pipeteren! 
In niet mindere mate wil ik een aantal van mijn vrienden bedanken. Om goed te kunnen functioneren is een 
beetje ontspanning op zijn tijd wel belangrijk! Om te beginnen wil ik Welmer Boiten bedanken. Beste Welmer, 
toen ik aan mijn promotie traject begon waren wij nog meer dan gewoon vrienden. Hoewel je vaak geen idee 
had wat ik op dat lab aan het doen was heb je mij destijds altijd gesteund en mijn gang laten gaan als ik op gekke 
tijden naar het lab moest of iets moest uitwerken op de computer. Inmiddels zijn we al 6 jaar gewoon vrienden, 
waar ik nog altijd erg blij mee ben (en ook wel een beetje trots). Onze manier van bierdrinken is de afgelopen 
jaren wel iets veranderd. Was het eerst nog zoveel mogelijk halve liter blikken naar binnen werken, zijn we nu 
toch meer van de speciaal biertjes. Naast dat ik hoop dat we onze vriendschap kunnen behouden, hoop ik ook 
dat je zo nu en dan met Daan en mij mee blijft gaan naar metalconcerten. Echt waar Welmer, dat is goed voor 
je, haha! En neem vooral Brigit mee, ze vond het zo leuk op het bruiloftsfeest! Daarnaast moet, speciaal voor 
jou, het volgende nog gezegd worden: Der is hjir gjin retjinder, aant mar in bierke út de kjeller, want tjaskers 
hawwe de takomst! Ook wil ik het woord richten tot Dr. Wilfred Poppinga. Beste Wilfred, wie jouw proefschrift 
heeft gelezen weet hoe lang wij elkaar al kennen. Sinds Havo 4 zaten we bij elkaar in de klas, vervolgens 
deden we samen de opleiding Biotechnologie op het HBO, stroomden we in bij het schakelprogramma van 
de RUG om vervolgens de master Medisch Farmaceutische Wetenschappen te volgen. Nu, 15 jaar later, zijn 
we beide getrouwd en straks ook gepromoveerd, ja er is veel veranderd de afgelopen tijd. Eén ding is echter 
niet veranderd en dat is dat wij nog altijd contact hebben en ik hoop dat dit de komende jaren zo zal blijven! 
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Dan mijn vrienden uit Dedemsvaart (en omgeving) die ten tijde van mijn promotietraject bestond uit; Rick de 
Leeuw, Mark Kreule, Marjolein Brummer, Yvonne Wolters, Erwin en Joanie Aufderhaar, David Hoorn en 
Jos Bakker. Ik heb jullie leren kennen als de vrienden van Daan, maar al gauw zag ik jullie ook als mijn eigen 
vrienden. Vele weekenden heb ik de afgelopen jaren met jullie doorgebracht. Meestal (altijd!?) onder het genot 
van een drankje en veel geouwehoer. Bedankt dat jullie voor de nodige ontspanning zorgden in het leven van 
‘de professor’ (zoals Rick Daan altijd noemt) en zijn vriendin. Na de promotie zal er ook een feest zijn, laten we 
daar ook iets moois van maken; “tafel d’r uit!!!”.
Zoals de meesten inmiddels wel zullen weten is metal de favoriete muziek stijl van Daan en mij. Muziek is 
erg belangrijk voor ons, het is een echte uitlaatklep. We bezochten dan ook regelmatig live optredens van bands 
in kroegen en poppodia en festivals. Tijdens al deze bezoekjes hebben we ook veel vrienden gemaakt, laat ik 
jullie mijn metal vrienden noemen. Jullie zijn met teveel om allemaal bij naam te noemen, maar degene die 
mijn proefschrift zullen krijgen zullen weten dat zij hiermee bedoeld worden. Bedankt dat jullie er altijd waren 
(en zijn), voor de mooie feestjes met veel gitaren, bier, paint en lang haar! Om in muzikale sferen te blijven wil ik 
ook graag mijn vrienden van Showband Oerterp bedanken. Hoewel ik inmiddels al een tijdje niet meer lid ben 
van jullie vereniging heb ik toch een groot deel van mijn promotie traject met veel plezier bij jullie gespeeld. 
Omdat het soms best lastig was om repetities en optredens te combineren met labwerk en artikelen schrijven 
heb ik uiteindelijk moeten stoppen. Ik wil jullie bedanken voor de vele muzikale jaren! Wie ik in muzikale zin 
ook zeker wil bedanken is Jeanette Kappelhof. Beste Jeannette, lieve fluit juf, inmiddels heb ik bijna drie jaar 
dwarsfluitles van jou. Hoewel ik zo ongeveer al mijn hele leven speel valt er altijd nog wat bij te leren! Bedankt 
voor het fijne samenspel (ook bij Syrinx) en dat je naast fluiten ook altijd geïnteresseerd bent in wat mij verder 
zoal bezighoudt. Het ‘zwangerschapsfluiten’ van de afgelopen maanden was ook een groot succes, daar moet 
je wat mee doen!
En natuurlijk mijn familie. Als eerst uiteraard mijn ouders, Gurbe en Sophia Wiersma. Leave heit, leave mem, 
bedankt dat jullie er altijd voor mij zijn. Dankzij jullie steun kon ik ook altijd doorgaan wanneer ik het even iets 
moeilijker had. Jullie hebben mij zien opgroeien, en nu ik zelf moeder ben weet ik pas hoe bijzonder dit is. Jullie 
vonden het tijdens mijn promotietraject altijd interessant om op de hoogte te zijn van wat ik aan het doen was. 
Dit heeft mijn vaardigheden om Galectine-9 en TRAIL fusie-eiwitten in ‘Jip en Janneke taal’ uit te leggen absoluut 
verbeterd. In dit licht wil ik heit ook bedanken voor het lezen van mijn Nederlandse samenvatting. Ook heb ik 
van jullie geleerd om altijd door te zetten, ‘kop der foar’, wat zeker helpt bij zoiets als promoveren. En natuurlijk 
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